<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.0 Transitional//EN">
<HTML>
<HEAD>
<!-- Created by: EDGAR Online, Inc. EDGAR Filing HTML Converter, Version: 4.66, http://www.edgar-online.com -->
<TITLE> ADMA BIOLOGICS, INC. (Form: 10-K, Received: 02/24/2017 17:04:48) </TITLE>
<META NAME="TABLES" CONTENT="FIS_FORM **FIS_PART_I **FIS_PART_II **FIS_PART_III **FIS_PART_IV **FIS_BUSINESS **FIS_RISK_FACTORS **FIS_UNRESOLVED_STAFF_COMMENTS **FIS_PROPERTIES **FIS_LEGAL_PROCEEDINGS **FIS_MINE_SAFETY_DISCLOSURE **FIS_MARKET **FIS_FINANCIAL_DATA **FIS_MANAGEMENTS_DISCUSSION **FIS_RESULTS_OF_OPERATIONS **FIS_LIQUIDITY_CAPITAL **FIS_MARKET_RISK **FIS_FINANCIAL_STATEMENTS **FIS_ACCOUNTING_CHANGES **FIS_CONTROL_AND_PROCEDURES **FIS_OTHER_INFORMATION **FIS_DIRECTORS_AND_OFFICERS **FIS_COMPENSATION **FIS_SECURITY_OWNERS **FIS_OFFICER_TRANSACTIONS **FIS_ACCOUNTANT_FEES **FIS_EXHIBITS **FIS_SIGNATURES **FIS_AUDITORS_OPINION **FIS_BALANCE_SHEET **FIS_BALANCE_SHEET_2 **FIS_INCOME_STATEMENT **FIS_STOCKHOLDERS_EQUITY **FIS_CASH_FLOW **FIS_NOTES_TO_FINANCIAL_STATEMENT **FIS_INCOME_STATEMENT_2 **FIS_EXHIBIT_INDEX FIS_EXHIBIT_10 FIS_EXHIBIT_23 **FIS_EXPERTS_CONSENT FIS_EXHIBIT_31 **FIS_CERTIFICATION FIS_EXHIBIT_31_2 **FIS_CERTIFICATION_2 FIS_EXHIBIT_32 **FIS_CERTIFICATION_3 FIS_EXHIBIT_32_2 **FIS_CERTIFICATION_4 ">
<META NAME="DETECTED PAGES" CONTENT="146">
<STYLE TYPE="text/css">
<!--
	body          { background-color: white; color: black }
	.eolNewPage   { page-break-after: always; line-height: 0; height: 0; margin: 0; padding: 0 }
	.eolLeftAlign { text-align: left; margin-left: auto; margin-right: auto }
	.eolCenter    { text-align: center }
	a:link        { color: blue }
	a:active      { color: red }
	a:visited     { color: purple }
	
	@media print
	{
		@page           { margin: 0.25in }
		body            { font-size: 10pt }
		a               { text-decoration: none }
		thead           { display: table-header-group }
		tfoot           { display: table-footer-group }
		hr.eolPageBreak { display: none }
		.eolPrint50pt   { font-size: 5pt }
		.eolPrint55pt   { font-size: 5.5pt }
		.eolPrint60pt   { font-size: 6pt }
		.eolPrint65pt   { font-size: 6.5pt }
		.eolPrint70pt   { font-size: 7pt }
		.eolPrint75pt   { font-size: 7.5pt }
		.eolPrint80pt   { font-size: 8pt }
		.eolPrint85pt   { font-size: 8.5pt }
		.eolPrint90pt   { font-size: 9pt }
		.eolPrint95pt   { font-size: 9.5pt }
	}
-->
</STYLE>
</HEAD>
<BODY>
<A NAME="eolPage1"></A>
<A NAME="FIS_TOP_OF_DOCUMENT"></A>

<A NAME="E615811_10K-ADMA_HTM"></A>
<EFX_FORM>
<A NAME="FIS_FORM"></A>
<P STYLE="MARGIN: 0">
	&nbsp;
</P>
<P STYLE="MARGIN: 0">
</P>
<P STYLE="FONT: 11PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	UNITED STATES
</B>
	&nbsp;
</P>
<P STYLE="FONT: 11PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	SECURITIES AND EXCHANGE COMMISSION
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
</P>
<P STYLE="FONT: 11PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	Washington, D.C. 20549
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: 14PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	FORM 10-K
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	(Mark One)
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: WINGDINGS">
<B>
	x
</B>
</FONT>
<B>
	ANNUAL
	REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	For the fiscal year ended December 31, 2016
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	or
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: WINGDINGS">
<B>
	&uml;
</B>
</FONT>
<B>
	TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	For the transition period from&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;to
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	Commission File Number: 001-36728
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: 18PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	ADMA BIOLOGICS, INC.
</B>
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	(Exact Name of Registrant as Specified in
	Its Charter)
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-RIGHT: 0; MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT">
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 48%; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
<B>
	Delaware
</B>
</TD>
<TD STYLE="WIDTH: 4%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: CENTER; WIDTH: 48%">
<B>
	56-2590442
</B>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="TEXT-ALIGN: CENTER">
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
	(State or Other Jurisdiction of Incorporation or Organization)
</P>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&#9;(I.R.S. Employer Identification No.)
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
	&nbsp;&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-RIGHT: 0; MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 48%; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	465 State Route 17, Ramsey,
	New Jersey
</B>
</P>
</TD>
<TD STYLE="WIDTH: 4%; FONT-SIZE: 10PT; TEXT-DECORATION: NONE">
<B>
	&nbsp;
</B>
</TD>
<TD STYLE="WIDTH: 48%; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	07446
</B>
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
</P>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD NOWRAP STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	(Address of Principal Executive Offices)
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	(Zip Code)
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	Registrant&rsquo;s telephone number, including
	area code:
<B>
	(201) 478-5552
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	Securities registered pursuant to Section
	12(b) of the Act:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	&nbsp;&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 48%">
<P STYLE="MARGIN: 0PT 0">
<U>
	Title of each class
</U>
</P>
<P STYLE="MARGIN: 0PT 0">
</P>
</TD>
<TD STYLE="WIDTH: 4%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 48%">
<P STYLE="MARGIN: 0PT 0">
<U>
	Name of each exchange on which registered
</U>
</P>
<P STYLE="MARGIN: 0PT 0">
</P>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD>
<P STYLE="MARGIN: 0PT 0">
<B>
	Common stock, par value $0.0001 per share
</B>
</P>
<P STYLE="MARGIN: 0PT 0">
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<P STYLE="MARGIN: 0PT 0">
<B>
	NASDAQ Stock Market LLC
</B>
</P>
<P STYLE="MARGIN: 0PT 0">
</P>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
	&nbsp;&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; TEXT-ALIGN: CENTER">
	Securities registered pursuant to Section
	12(g) of the Act:
<B>
	None
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Indicate by check mark if the registrant is a well-known seasoned
	issuer, as defined in Rule 405 of the Securities Act.&nbsp; Yes
<FONT STYLE="FONT-FAMILY: WINGDINGS">
	&uml;
</FONT>
	No
<FONT STYLE="FONT-FAMILY: WINGDINGS">
	x
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Indicate by check mark if the registrant is not required to
	file reports pursuant to Section 13 or 15(d) of the Act. Yes
<FONT STYLE="FONT-FAMILY: WINGDINGS">
	&uml;
</FONT>
	No
<FONT STYLE="FONT-FAMILY: WINGDINGS">
	x
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Indicate by check mark whether the registrant (1) has filed
	all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or
	for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements
	for the past 90 days. Yes&#9;
<FONT STYLE="FONT-FAMILY: WINGDINGS">
	x
</FONT>
	&#9;No
<FONT STYLE="FONT-FAMILY: WINGDINGS">
	&uml;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Indicate by check mark whether the registrant has submitted
	electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant
	to Rule 405 of Regulation S-T (&sect;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the
	registrant was required to submit and post such files). Yes
<FONT STYLE="FONT-FAMILY: WINGDINGS">
	x
</FONT>
	No
<FONT STYLE="FONT-FAMILY: WINGDINGS">
	&uml;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Indicate by check mark if disclosure of delinquent filers pursuant
	to Item 405 of Regulation S-K (&sect;229.405) is not contained herein, and will not be contained, to the best of registrant&rsquo;s
	knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment
	to this Form 10-K.
<FONT STYLE="FONT-FAMILY: WINGDINGS">
	x
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Indicate by check mark whether the registrant is a large accelerated
	filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company.&nbsp;&nbsp;See the definitions of &ldquo;large
	accelerated filer,&rdquo; &ldquo;accelerated filer&rdquo; and &ldquo;smaller reporting company&rdquo; in Rule 12b-2 of the Exchange
	Act.&nbsp;&nbsp;(Check one):
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
<FONT STYLE="FONT-FAMILY: WINGDINGS">
	&uml;
</FONT>
	Large
	Accelerated Filer
<FONT STYLE="FONT-FAMILY: WINGDINGS">
	&uml;
</FONT>
	Accelerated Filer
<FONT STYLE="FONT-FAMILY: WINGDINGS">
	&uml;
</FONT>
	Non-accelerated Filer
<FONT STYLE="FONT-FAMILY: WINGDINGS">
	x
</FONT>
	Smaller Reporting Company
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Indicate by check mark whether the registrant is a shell company
	(as defined in Rule 12b-2 of the Act). Yes&#9;
<FONT STYLE="FONT-FAMILY: WINGDINGS">
	&uml;
</FONT>
	No
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	The aggregate market value of the registrant&rsquo;s voting
	and non-voting common stock held by non-affiliates was $40,899,598 as of June 30, 2016 (the last business day of the registrant&rsquo;s
	most recently completed second fiscal quarter), based on a total of 6,873,882 shares of common stock held by non-affiliates and
	a closing price of $5.95 as reported on the Nasdaq Capital Market on June 30, 2016.&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	The number of shares of the registrant&rsquo;s common stock,
	par value $0.0001 per share, outstanding as of February 24, 2017 was 12,886,741.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	DOCUMENTS INCORPORATED BY REFERENCE
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Portions of the registrant&rsquo;s definitive proxy statement
	for its 2017 annual meeting of stockholders or annual report on Form 10-K/A, to be filed on or before May 1, 2017, are incorporated
	by reference into Part III of this annual report on Form 10-K.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 1 -->
<DIV STYLE="MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage2"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<P STYLE="MARGIN: 0PT; TEXT-ALIGN: RIGHT; FONT-SIZE: 8PT">
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
<A NAME="E615811_10K-ADMA_HTM_TOC">
</A>
	ADMA BIOLOGICS, INC.
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<SUP>
</SUP>
</FONT>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<EFX_PART_I>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 9%; FONT-SIZE: 10PT">
<A NAME="FIS_PART_I"></A>
	PART I
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 79%">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; WIDTH: 10%">
	&nbsp;
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="VERTICAL-ALIGN: TOP; FONT-SIZE: 10PT">
	Item 1.
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; FONT-SIZE: 10PT">
<A HREF="#E615811_10K-ADMA_HTM_ITEM1">
	Business
</A>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	3
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD STYLE="VERTICAL-ALIGN: TOP; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="VERTICAL-ALIGN: TOP; FONT-SIZE: 10PT">
	Item 1A.
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; FONT-SIZE: 10PT">
<A HREF="#E615811_10K-ADMA_HTM_ITEM1A">
	Risk Factors
</A>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	21
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD STYLE="VERTICAL-ALIGN: TOP; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="VERTICAL-ALIGN: TOP; FONT-SIZE: 10PT">
	Item 1B.
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; FONT-SIZE: 10PT">
<A HREF="#E615811_10K-ADMA_HTM_ITEM1B">
	Unresolved Staff Comments
</A>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	44
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD STYLE="VERTICAL-ALIGN: TOP; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="VERTICAL-ALIGN: TOP; FONT-SIZE: 10PT">
	Item 2.
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; FONT-SIZE: 10PT">
<A HREF="#E615811_10K-ADMA_HTM_ITEM2">
	Properties
</A>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	44
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD STYLE="VERTICAL-ALIGN: TOP; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="VERTICAL-ALIGN: TOP; FONT-SIZE: 10PT">
	Item 3.
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; FONT-SIZE: 10PT">
<A HREF="#E615811_10K-ADMA_HTM_ITEM3">
	Legal Proceedings
</A>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	44
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD STYLE="VERTICAL-ALIGN: TOP; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="VERTICAL-ALIGN: TOP; FONT-SIZE: 10PT">
	Item 4.
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; FONT-SIZE: 10PT">
<A HREF="#E615811_10K-ADMA_HTM_ITEM4">
	Mine Safety Disclosures
</A>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	44
</TD>
</TR>
</EFX_PART_I>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD STYLE="VERTICAL-ALIGN: TOP; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
<EFX_PART_II>
<TR STYLE="BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="VERTICAL-ALIGN: TOP; FONT-SIZE: 10PT">
<A NAME="FIS_PART_II"></A>
	PART II
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="VERTICAL-ALIGN: TOP; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
<EFX_UNIDENTIFIED_TABLE>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD STYLE="VERTICAL-ALIGN: TOP; FONT-SIZE: 10PT">
<A NAME="FIS_UNIDENTIFIED_TABLE"></A>
	Item 5.
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; FONT-SIZE: 10PT">
<A HREF="#E615811_10K-ADMA_HTM_ITEM5">
	Market For Registrant&rsquo;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities
</A>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	45
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="VERTICAL-ALIGN: TOP; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD STYLE="VERTICAL-ALIGN: TOP; FONT-SIZE: 10PT">
	Item 6.
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; FONT-SIZE: 10PT">
<A HREF="#E615811_10K-ADMA_HTM_ITEM6">
	Selected Financial Data
</A>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	46
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="VERTICAL-ALIGN: TOP; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD STYLE="VERTICAL-ALIGN: TOP; FONT-SIZE: 10PT">
	Item 7.
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; FONT-SIZE: 10PT">
<A HREF="#E615811_10K-ADMA_HTM_ITEM7">
	Management&rsquo;s Discussion and Analysis of Financial Condition and Results of Operations
</A>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	46
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="VERTICAL-ALIGN: TOP; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD STYLE="VERTICAL-ALIGN: TOP; FONT-SIZE: 10PT">
	Item 7A.
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; FONT-SIZE: 10PT">
<A HREF="#E615811_10K-ADMA_HTM_ITEM7A">
	Quantitative and Qualitative Disclosures About Market Risk
</A>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	61
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="VERTICAL-ALIGN: TOP; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD STYLE="VERTICAL-ALIGN: TOP; FONT-SIZE: 10PT">
	Item 8.
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; FONT-SIZE: 10PT">
<A HREF="#E615811_10K-ADMA_HTM_ITEM8">
	Financial Statements and Supplementary Data
</A>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	61
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="VERTICAL-ALIGN: TOP; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD STYLE="VERTICAL-ALIGN: TOP; FONT-SIZE: 10PT">
	Item 9.
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; FONT-SIZE: 10PT">
<A HREF="#E615811_10K-ADMA_HTM_ITEM9">
	Changes in and Disagreements With Accountants on Accounting and Financial Disclosure
</A>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	61
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="VERTICAL-ALIGN: TOP; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD STYLE="VERTICAL-ALIGN: TOP; FONT-SIZE: 10PT">
	Item 9A.
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; FONT-SIZE: 10PT">
<A HREF="#E615811_10K-ADMA_HTM_ITEM9A">
	Controls and Procedures
</A>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	61
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="VERTICAL-ALIGN: TOP; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD STYLE="VERTICAL-ALIGN: TOP; FONT-SIZE: 10PT">
	Item 9B.
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; FONT-SIZE: 10PT">
<A HREF="#E615811_10K-ADMA_HTM_ITEM9B">
	Other Information
</A>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	62
</TD>
</TR>
</EFX_UNIDENTIFIED_TABLE>
</EFX_PART_II>
<TR STYLE="BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="VERTICAL-ALIGN: TOP; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
<EFX_PART_III>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD STYLE="VERTICAL-ALIGN: TOP; FONT-SIZE: 10PT">
<A NAME="FIS_PART_III"></A>
	PART III
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="VERTICAL-ALIGN: TOP; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD STYLE="VERTICAL-ALIGN: TOP; FONT-SIZE: 10PT">
	Item 10.
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; FONT-SIZE: 10PT">
<A HREF="#E615811_10K-ADMA_HTM_ITEM10">
	Directors, Executive Officers and Corporate Governance
</A>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	63
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="VERTICAL-ALIGN: TOP; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD STYLE="VERTICAL-ALIGN: TOP; FONT-SIZE: 10PT">
	Item 11.
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; FONT-SIZE: 10PT">
<A HREF="#E615811_10K-ADMA_HTM_ITEM11">
	Executive Compensation
</A>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	63
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="VERTICAL-ALIGN: TOP; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD STYLE="VERTICAL-ALIGN: TOP; FONT-SIZE: 10PT">
	Item 12.
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; FONT-SIZE: 10PT">
<A HREF="#E615811_10K-ADMA_HTM_ITEM12">
	Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters
</A>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	63
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="VERTICAL-ALIGN: TOP; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD STYLE="VERTICAL-ALIGN: TOP; FONT-SIZE: 10PT">
	Item 13.
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; FONT-SIZE: 10PT">
<A HREF="#E615811_10K-ADMA_HTM_ITEM13">
	Certain Relationships and Related Transactions, and Director Independence
</A>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	63
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="VERTICAL-ALIGN: TOP; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD STYLE="VERTICAL-ALIGN: TOP; FONT-SIZE: 10PT">
	Item 14.
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; FONT-SIZE: 10PT">
<A HREF="#E615811_10K-ADMA_HTM_ITEM14">
	Principal Accountant Fees and Services
</A>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	64
</TD>
</TR>
</EFX_PART_III>
<TR STYLE="BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
</TR>
<EFX_PART_IV>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD STYLE="VERTICAL-ALIGN: TOP; FONT-SIZE: 10PT">
<A NAME="FIS_PART_IV"></A>
	PART IV
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD STYLE="VERTICAL-ALIGN: TOP; FONT-SIZE: 10PT">
	Item 15.
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; FONT-SIZE: 10PT">
<A HREF="#E615811_10K-ADMA_HTM_ITEM15">
	Exhibits and Financial Statement Schedules
</A>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	65
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="VERTICAL-ALIGN: TOP; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD STYLE="VERTICAL-ALIGN: TOP; FONT-SIZE: 10PT">
	Item 16.
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; FONT-SIZE: 10PT">
<A HREF="#E615811_10K-ADMA_HTM_ITEM16">
	Form 10-K Summary
</A>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	65
</TD>
</TR>
</TABLE>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
</P>
<!-- FIELD: PAGE; SEQUENCE: 2 -->
<DIV STYLE="MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
	i
</P>
</DIV>
<A NAME="eolPage3"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<P STYLE="MARGIN-TOP: 0PT; MARGIN-RIGHT: 0PT; MARGIN-BOTTOM: 0PT; FONT-SIZE: 8PT; TEXT-ALIGN: RIGHT">
<A HREF="#E615811_10K-ADMA_HTM_TOC" STYLE="FONT-STYLE: ITALIC">
	Table of Contents
</A>
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	Special Note Regarding Forward-Looking
	Statements
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	Some of the information in this annual report
	on Form 10-K contains forward-looking statements within the meaning of the federal securities laws.&nbsp;&nbsp;These statements
	include, among others, statements about:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	our ability to successfully consummate and close our proposed acquisition of certain assets from Biotest
	Pharmaceuticals Corporation, the expected closing date of which is conditioned upon several
	factors, including stockholder approval;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	our ability to successfully leverage the anticipated benefits and synergies of our proposed acquisition of certain assets from
	Biotest Pharmaceuticals Corporation, including maximizing the anticipated future combined
	businesses, operations, products and services, and liquidity, debt repayment and capital return expectations;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	our ability to successfully resubmit to the U.S. Food and Drug Administration, or FDA, our Biologics License Application, or
	BLA, for our lead product candidate, RI-002, once the deficiencies identified in the July 2016 Complete Response Letter, or CRL,
	have been resolved by us and/or our third party vendors to the satisfaction of the FDA, and other requests for information included
	therein have been provided by us;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	our plans to develop, market, launch and build our own commercial infrastructure and commercialize RI-002 and the success of
	such efforts;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	the expected timing of and our ability to obtain and maintain regulatory approvals for our product candidates, including the
	timeframe within which we may receive approval from the FDA, if at all, of our BLA for RI-002 and the labeling or nature of any
	such approvals;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	the achievement of or expected timing, progress and results of clinical development, clinical trials and potential regulatory
	approvals;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	our dependence upon one manufacturer for RI-002 and the effect any adverse events on such manufacturer could have on us or
	our business;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	our dependence upon our third-party contract manufacturers and vendors;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	our ability to obtain adequate quantities of FDA-approved normal source plasma and Respiratory Syncytical Virus, or RSV, high-titer
	plasma with proper specifications;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	our plans to increase our supplies of plasma;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	the potential indications for our product candidates;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	potential investigational new product applications;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	the acceptability of RI-002 for any purpose by physicians, patients or payers;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	concurrence by FDA with our conclusions and the satisfaction by us of its guidance;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	the comparability of results of RI-002 to other comparably run injectable immune globulin clinical trials;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	the potential of RI-002 to provide meaningful clinical improvement for patients living with Primary Immune Deficiency Disease,
	or PIDD;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	our intellectual property position, including our expectations of the scope of patent protection with respect to RI-002, or
	other future pipeline product candidates;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
</P>
<!-- FIELD: PAGE; SEQUENCE: 3; OPTIONS: NEWSECTION -->
<DIV STYLE="MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	1
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage4"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<P STYLE="MARGIN: 0PT; TEXT-ALIGN: RIGHT; FONT-SIZE: 8PT">
<A HREF="#E615811_10K-ADMA_HTM_TOC" STYLE="FONT-STYLE: ITALIC">
	Table of Contents
</A>
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	our manufacturing capabilities, third-party contractor capabilities and strategy;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	our plans relating to manufacturing, supply and other collaborative agreements;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	our estimates regarding expenses, capital requirements and needs for additional financing;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	possible or likely reimbursement levels, if any, if and when RI-002 is approved for marketing;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	estimates regarding market size, projected growth and sales as well as our expectations of market acceptance of RI-002; and
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	expectations for future capital requirements.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	These statements may be found under the
	&ldquo;Risk Factors,&rdquo; &ldquo;Management&rsquo;s Discussion and Analysis of Financial Condition and Results of Operations&rdquo;
	and &ldquo;Business&rdquo; sections of this annual report on Form 10-K.&nbsp;&nbsp;Forward-looking statements typically are identified
	by the use of terms such as &ldquo;anticipates,&rdquo; &ldquo;believes,&rdquo; &ldquo;can,&rdquo; &ldquo;continue,&rdquo; &ldquo;could,&rdquo;
	&ldquo;estimates,&rdquo; &ldquo;expects,&rdquo; &ldquo;intends,&rdquo; &ldquo;may,&rdquo; &ldquo;plans,&rdquo; &ldquo;potential,&rdquo;
	&ldquo;predicts,&rdquo; &ldquo;should,&rdquo; or &ldquo;will&rdquo; or the negative of these terms, although some forward-looking
	statements are expressed differently.&nbsp;&nbsp;You should be aware that our actual results could differ materially from those
	contained in the forward-looking statements due to the factors referenced above.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	In addition to the foregoing, you should
	also consider carefully the statements under the section entitled &ldquo;Risk Factors&rdquo; and other sections of this annual
	report on Form 10-K, which address additional factors that could cause our actual results to differ from those set forth in the
	forward-looking statements.&nbsp;&nbsp;We expressly disclaim any obligation or undertaking to release publicly any updates or revisions
	to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions
	or circumstances on which any such statement is based, except as required by law.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
</P>
<!-- FIELD: PAGE; SEQUENCE: 4 -->
<DIV STYLE="MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	2
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage5"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<P STYLE="MARGIN: 0PT; TEXT-ALIGN: RIGHT; FONT-SIZE: 8PT">
<A HREF="#E615811_10K-ADMA_HTM_TOC" STYLE="FONT-STYLE: ITALIC">
	Table of Contents
</A>
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	PART I
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<EFX_BUSINESS>
<A NAME="FIS_BUSINESS"></A>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
<A NAME="E615811_10K-ADMA_HTM_ITEM1">
</A>
	Item 1. Business
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: ITALIC 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Unless the context otherwise requires, references
	in this Business section to &ldquo;ADMA,&rdquo; &ldquo;ADMA Biologics,&rdquo; the &ldquo;Company,&rdquo; &ldquo;we,&rdquo;
	&ldquo;us&rdquo; and &ldquo;our&rdquo; refer to ADMA Biologics, Inc., a Delaware corporation, as well as its subsidiary, ADMA
	Plasma Biologics, Inc., a Delaware corporation, including its wholly-owned subsidiary, ADMA Bio Centers Georgia Inc., or ADMA
	BioCenters, a Delaware corporation, taken as a whole.
</P>
<P STYLE="FONT: ITALIC 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Business of ADMA
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Overview
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	ADMA Biologics is a late-stage biopharmaceutical
	company that develops, manufactures and intends to commercialize specialty plasma-based biologics for the proposed treatment of
	immune deficiencies and prevention of certain infectious diseases. Our targeted patient populations include immune-compromised
	individuals who suffer from an underlying immune deficiency disorder or who may be immune-suppressed for medical reasons. Our product
	candidates are intended to be used by physician specialists focused on caring for immune-compromised patients with or at risk for
	certain infectious diseases.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<I>
	Our Lead Product Candidate &ndash; RI-002
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	We are currently developing our lead product
	candidate, RI-002, for the treatment of Primary Immune Deficiency Disease, or PIDD, and have completed a pivotal Phase III clinical
	study. RI-002 is derived from human plasma blended from normal donors and donors tested to have high levels of neutralizing titers
	to Respiratory Syncytical Virus, or RSV. RI-002 is manufactured using a process called fractionation, which purifies immune globulins,
	or IgG, from this blended plasma pool resulting in a final IVIG product enriched with naturally occurring polyclonal anti-pathogen
	antibodies (e.g., streptococcus pneumonia, H. influenza type B, Cytomegalovirus or CMV, measles, tetanus, etc.). We use our proprietary
	RSV microneutralization assay to test for standardized levels of neutralizing antibodies to RSV in the final drug product.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	In the third quarter of 2015, the
	U.S. Food and Drug Administration, or FDA, accepted for review our Biologics License Application, or BLA, for RI-002 for
	the treatment of PIDD. In July 2016, the FDA issued a Complete Response Letter, or CRL. The CRL did not cite any concerns
	with the clinical safety or efficacy data for RI-002 submitted in the BLA, nor did the FDA request any additional clinical
	studies be completed prior to FDA approval of RI-002. The FDA identified in the CRL, among other things, certain
	outstanding inspection issues and deficiencies relating to Chemistry, Manufacturing and Controls, or CMC, at our
	third-party contract manufacturers and vendors and requested documentation of corrections for a number of those issues. The
	FDA indicated in the CRL that it cannot grant final approval of the BLA until, among other things,&nbsp;these deficiencies
	are resolved. Since receiving the CRL, we have worked diligently with our contract fill and finisher as well as the contract
	testing laboratory. We have also continued to work with our third-party contract manufacturer, Biotest Pharmaceuticals
	Corporation, or Seller or BPC, and on January 23, 2017 we announced the signing of a definitive acquisition agreement to
	acquire certain manufacturing and therapy-related assets from BPC in Boca Raton, Florida, a wholly-owned subsidiary of
	Biotest AG, or Biotest, in efforts to address the CRL and remediate the outstanding warning letter and other matters at the
	manufacturing facility.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	We continue to collaborate with
	our third-party manufacturers and vendors to identify solutions to outstanding issues identified in the CRL. We are
	currently preparing documentation for an additional submission to the FDA to address the CRL. We, along with our vendors, are
	awaiting certain feedback from the FDA regarding previous submissions and we intend to provide a timeline for resubmission of
	our BLA for RI-002 as soon as practicable. If RI-002 is approved by the FDA for PIDD, we intend to commercialize RI-002 for the
	treatment of PIDD and explore alternative regulatory processes to evaluate and seek approval for RI-002 for additional
	indications, patient populations and uses.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
</P>
<!-- FIELD: PAGE; SEQUENCE: 5 -->
<DIV STYLE="MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	3
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage6"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<P STYLE="MARGIN: 0PT; TEXT-ALIGN: RIGHT; FONT-SIZE: 8PT">
<A HREF="#E615811_10K-ADMA_HTM_TOC" STYLE="FONT-STYLE: ITALIC">
	Table of Contents
</A>
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<I>
	Evaluation of PIDD Patients
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	PIDD, a genetic disorder that causes a deficient
	or absent immune system, is caused by hereditary or genetic defects and can affect anyone regardless of age or gender. PIDD patients
	are more vulnerable to infections and more likely to suffer complications from these infections. IVIG is a plasma derived product
	that is used to prevent serious infections in patients with PIDD. It is comprised of polyclonal antibodies, which are proteins
	produced by B-cells that are used by the body&rsquo;s immune system to neutralize foreign objects such as bacteria and viruses.
	It is estimated that there are about 250,000 diagnosed PIDD patients in the U.S., approximately half of whom are treated
	with IVIG regularly. In the U.S., sales of immune globulin products for all its uses were reported to be approximately
	$4.8 billion in 2014.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	The RI-002 pivotal Phase III clinical trial
	was conducted as a single arm study in which patients were treated approximately once per month for a period of 12 months plus
	90 days for follow up. Fifty-nine patients were enrolled in nine treatment centers in the U.S. The pivotal Phase III primary
	endpoint followed published FDA industry guidance, which provides for a reduction in the incidence of serious infections to less
	than one per year in each subject receiving IVIG. The secondary outcome was safety and included other pharmacokinetic, or PK, data
	collection points including antibody titers for certain agents, including RSV antibody levels at various time points after infusion.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	RI-002 demonstrated positive results in
	the Phase III study in patients with PIDD, meeting its primary endpoint, of no&nbsp;Serious Bacterial Infections, or SBI,&nbsp;reported.
	RI-002 was administered a total of 793 infusions with zero serious adverse events to 59 patients in nine treatment centers throughout
	the U.S. These results, included in the BLA, more than meet the requirement specified by FDA guidance of&nbsp;&le; 1
	SBI per patient-year.&nbsp;&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	On February 22, 2015, at the 2015 American
	Academy of Allergy, Asthma &amp; Immunology Annual Meeting, scientific investigators reported on the secondary outcomes that included:
	a total of 93 days, or 1.66 days per patient per year lost from work or school due to infection; one hospitalization due to an
	infection of only five days duration in the entire study and IgG trough levels above those required by the FDA for IVIG products.
	Additionally, there was a marked increase in all of the measured specific anti-pathogen antibodies in PK subjects (n=31). The mean
	of maximum fold increases in specific antibody levels after infusion of RI-002 ranged from 1.9 fold (S. pneumonia type 19A) to
	5.3 fold (RSV), which were statistically significant fold increases from the pathogen's specific measured baselines. The safety
	profile of RI-002 is comparable to that of other immunoglobulins.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<I>
	Rationale for the Potential Evaluation in RSV Infected Patients
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	RSV is a common virus that ordinarily leads
	to mild, cold-like symptoms in healthy adults and children. In high-risk groups, such as the PIDD population and the other immune-compromised
	populations, RSV can lead to a more serious infection and may even cause death. The polyclonal antibodies which are present in
	RI-002 are expected to prevent infections in immune-compromised patients.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	We previously conducted a randomized, double-blind,
	placebo-controlled Phase II clinical trial to evaluate RI-001, RI-002&rsquo;s predecessor product candidate, in immune-compromised,
	RSV-infected patients. This trial was conducted with 21 patients in the U.S., Canada, Australia, and New Zealand. The
	Phase II dose-ranging trial demonstrated a statistically significant improvement in the change from baseline RSV titers to day
	18 in the high dose and low dose treatment groups when compared with placebo (p=0.0043 and p=0.0268, respectively). The mean fold
	increase for high dose was 9.24 (95% CI 4.07, 21.02) and the observed mean fold increase for low dose was 4.85 (95% CI 2.22, 10.59).
	The mean fold change for placebo treated patients was 1.42 (95% CI 0.64, 3.17). In addition, more patients in the high dose (85.7%)
	and low dose (42.9%) groups experienced greater than a four-fold increase from baseline to day 18 in RSV titer levels compared
	to placebo (0%). There were no serious drug-related adverse events reported during the trial.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	From April 2009 through February 2011, RI-001
	was also administered to 15 compassionate use patients where physicians requested access to the product for treating their patients
	with documented lower respiratory tract RSV infections due to the fact that these patients had failed conventional therapeutic
	interventions. Serum samples were obtained from 13 patients. Samples showed that patients demonstrated a four-fold or greater rise
	in RSV antibody titers from baseline. Serum samples were not obtained from two patients that received Palivizumab. All 11 patients
	who received RI-001 within 4.2 days after the onset of the diagnosis of RSV survived. The drug was well-tolerated in all 15 patients
	and there were no reports of serious adverse events attributable to RI-001. Data from our Phase II clinical trial, compassionate
	use experience and data obtained from the evaluation of RI-002 in the infected cotton rat animal model has been presented at various
	conferences during 2014, 2015 and 2016.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
</P>
<!-- FIELD: PAGE; SEQUENCE: 6 -->
<DIV STYLE="MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	4
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage7"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<P STYLE="MARGIN: 0PT; TEXT-ALIGN: RIGHT; FONT-SIZE: 8PT">
<A HREF="#E615811_10K-ADMA_HTM_TOC" STYLE="FONT-STYLE: ITALIC">
	Table of Contents
</A>
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	Based on these results, we intend to evaluate
	RI-002 for the treatment of RSV patients following FDA approval, if received, for treatment of PIDD.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<I>
	Commercialization
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	While we are working
	towards remediating the Warning Letter and other deficiencies and eventually filing the BLA resubmission for RI-002, we
	expect to continue our commercialization efforts and plan to increase our initiatives by hiring a small, specialty sales
	force to market Nabi-HB&trade; (Hepatitis B Immune Globulin, Human) upon closing the BPC acquisition anticipated during the
	first half of 2017, and Bivigam&trade; (Immune Globulin Intravenous, Human) upon its relaunch and RI-002 once approved by the
	FDA, to hospitals, physician offices/clinics, and other specialty treatment organizations.&nbsp;&nbsp;We anticipate staffing
	our company with additional personnel for patient support, medical affairs, quality assurance, regulatory affairs,
	scientific affairs, reimbursement, inventory and logistics, human resources, and financial and operational
	management.&nbsp;&nbsp;If and when we receive FDA approval, we may also use a network of national distributors to assist with
	order fulfillment for RI-002 for use by healthcare professionals and hospitals.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<I>
	Intellectual Property
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	During the second quarter of 2015, we received
	a notice of allowance from the U.S. Patent Office, or USPTO, for our RI-002 patent filed under U.S. patent application
	14/592,721 entitled &lsquo;Compositions and Methods for the Treatment of Immunodeficiency,&rsquo; which extends through January
	2035. &nbsp;During the third quarter of 2015, our U.S. Patent 9,107,906 was issued by the USPTO. This patent describes methods
	by which the blending of plasma obtained from normal donors with plasma obtained from donors selected to have high levels of neutralizing
	titers to RSV form a unique antibody enriched plasma pool and provide for the standardization of the levels of anti-RSV antibodies
	in the RI-002 final product. Our proprietary microneutralization assay allows us to effectively identify and isolate donor plasma
	with high-titer RSV antibodies and to standardize RI-002&rsquo;s antibody profile, which we believe may enable us to garner a premium
	price.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<I>
	Plasma Collection Facilities
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	Our wholly-owned subsidiary, ADMA BioCenters,
	operates two FDA-licensed, German Health Authority, or GHA, and Korean Ministry of Food and Drug Safety, or MFDS, certified source
	plasma collection facilities located in Norcross, Georgia and Marietta, Georgia, which provide us with a portion of our blood plasma
	for the manufacture of RI-002. Our plasma collection center in Marietta, Georgia received FDA approval in the third quarter of
	2015. A typical plasma collection center, such as those operated by&nbsp;ADMA BioCenters, can collect approximately 30,000 to 50,000
	liters of source plasma annually, which may be sold for different prices depending upon the type of plasma, quantity of purchase,
	and market conditions at the time of sale. Plasma collected from ADMA BioCenters' two Georgia facilities that is not used for making
	RI-002 is sold to third-party customers in the U.S.,&nbsp;and other locations&nbsp;where we are approved globally under
	supply agreements or in the open &quot;spot&quot; market. We have entered into long-term manufacturing and licensing agreements
	with Biotest&nbsp;and its U.S. subsidiary, BPC, that provide for the exclusive manufacture of RI-002. At the same
	time, we granted Biotest an exclusive, royalty-bearing license to market and sell RSV antibody-enriched IVIG in Europe and in
	other selected territories in North Africa and the Middle East.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-RIGHT: 0; MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: ITALIC 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Leadership
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	The founders of ADMA have combined greater
	than 60 years of experience marketing and distributing blood plasma products and devices. With our executive team, members of the
	board of directors and our commercial team, we collectively possess over 200 years of deep medical, technical, development and
	commercial experience in the biologics and pharmaceutical industry.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
</P>
<!-- FIELD: PAGE; SEQUENCE: 7 -->
<DIV STYLE="MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	5
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage8"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<P STYLE="MARGIN: 0PT; TEXT-ALIGN: RIGHT; FONT-SIZE: 8PT">
<A HREF="#E615811_10K-ADMA_HTM_TOC" STYLE="FONT-STYLE: ITALIC">
	Table of Contents
</A>
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	Our mission is to develop and commercialize
	plasma-derived, human immune globulins targeted to niche immune-compromised patient populations. We intend to accomplish our mission
	by achieving the following:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	obtain FDA approval to manufacture and market RI-002 for the treatment of patients with PIDD;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	establish a specialty sales force to commercialize RI-002;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	explore other possible indications (label expansion) for RI-002;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	develop additional plasma-derived products for the treatment and/or prevention of infectious diseases in immune-compromised
	patient populations; and
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	expand our network of ADMA BioCenters facilities, both to maintain control of a portion of our raw material supply and to generate
	additional revenue through the collection and sale of source plasma to third party customers.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0IN">
<B>
	Our Strategy
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	Our goal is to be a leader in developing
	and commercializing specialized, targeted, plasma-derived therapeutics to extend and enhance the lives of individuals who are naturally
	or medically immune-compromised.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	The key elements of our strategy for achieving
	this goal are as follows:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
<B>
<I>
	Obtain FDA approval of RI-002 as a treatment for PIDD
</I>
</B>
	.&nbsp;&nbsp;In the third quarter of 2015, the FDA
	accepted for review a BLA for RI-002 for the treatment of PIDD. In July 2016, the FDA issued a CRL. The CRL did not cite any
	concerns with the clinical safety or efficacy data for RI-002 submitted in the BLA, nor did the FDA request any additional
	clinical studies be completed prior to FDA approval of RI-002. The FDA identified in the CRL, among other things, certain
	outstanding inspection issues and CMC deficiencies at our third-party contract manufacturers and vendors and requested
	documentation of corrections for a number of those issues. Since receiving the CRL, we have worked diligently with our
	contract fill and finisher as well as the contract testing laboratory. We have also continued to work with our third-party
	contract manufacturer, BPC, and on January 23, 2017 we announced the signing of a definitive acquisition agreement to
	acquire
	certain
	manufacturing and therapy-related assets from BPC in Boca Raton, Florida, a wholly-owned subsidiary of Biotest, in
	efforts to address the CRL and remediate the outstanding Warning Letter and other deficiencies at the manufacturing
	facility.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.75IN; TEXT-INDENT: 0IN">
	We continue to collaborate
	with our third-party manufacturers and vendors to identify solutions to outstanding issues identified in the CRL. We are
	currently preparing documentation for an additional submission to the FDA to address the CRL. We, along with our vendors, are
	awaiting certain feedback from the FDA regarding previous submissions and we intend to provide a timeline for resubmission of
	our BLA for RI-002 as soon as practicable. If RI-002 is approved by the FDA for PIDD, we intend to commercialize RI-002 for
	the treatment of PIDD and explore alternative regulatory processes to evaluate and seek approval for RI-002 for additional
	indications, patient populations and uses. The FDA indicated in the CRL that it cannot grant final approval of the BLA until,
	among other things,&nbsp;these deficiencies are resolved.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.75IN; TEXT-INDENT: 0IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 36PT">
</TD>
<TD STYLE="WIDTH: 13.5PT">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
<B>
<I>
	Commercialize RI-002 as a treatment for PIDD
</I>
</B>
	.&nbsp;&nbsp;We plan to increase our hiring initiatives of a small,
	specialty sales force to market RI-002 to hospitals, physician offices/clinics, and other specialty treatment and infusion center
	organizations.&nbsp;&nbsp;We anticipate staffing our company with additional personnel for patient support, medical affairs, quality
	assurance, regulatory affairs, scientific affairs, reimbursement, inventory and logistics, human resources, and financial and operational
	management.&nbsp;&nbsp;We may also use a network of national distributors to fulfill orders for RI-002.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
</P>
<!-- FIELD: PAGE; SEQUENCE: 8 -->
<DIV STYLE="MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	6
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage9"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<P STYLE="MARGIN: 0PT; TEXT-ALIGN: RIGHT; FONT-SIZE: 8PT">
<A HREF="#E615811_10K-ADMA_HTM_TOC" STYLE="FONT-STYLE: ITALIC">
	Table of Contents
</A>
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 36PT">
</TD>
<TD STYLE="WIDTH: 13.5PT">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
<B>
<I>
	Expand RI-002&rsquo;s FDA-approved uses
</I>
</B>
	.&nbsp;&nbsp;If RI-002 is approved by the FDA as a treatment for PIDD,
	we plan to evaluate the clinical and regulatory paths to grow the RI-002 franchise through expanded FDA-approved uses.&nbsp;&nbsp;We
	believe that there may be patient populations beyond PIDD that would derive clinical benefit from RI-002 some of which may be eligible
	for orphan status.&nbsp;&nbsp;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 36PT">
</TD>
<TD STYLE="WIDTH: 13.5PT">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
<B>
<I>
	Develop additional plasma-derived products
</I>
</B>
	.&nbsp;&nbsp;Our core competency is in the development and commercialization
	of plasma-derived therapeutics.&nbsp;&nbsp;We believe there are a number of under addressed medical conditions for which plasma-derived
	therapeutics may be beneficial.&nbsp;&nbsp;Utilizing our intellectual property patent, which includes our proprietary testing assay
	and other standardization methods and technologies, we have identified potential new product candidates that we may advance into
	preclinical activities in the near term.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 36PT">
</TD>
<TD STYLE="WIDTH: 13.5PT">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
<B>
<I>
	Develop and expand ADMA BioCenters
</I>
</B>
	.&nbsp;&nbsp;In order to maintain partial control of our raw material supply
	as well as generate revenues in advance of RI-002&rsquo;s commercialization, we formed ADMA BioCenters, a subsidiary that operates
	plasma collection facilities in Norcross and Marietta, Georgia.&nbsp;&nbsp;The Norcross and Marietta facilities hold FDA licenses,
	along with GHA and MFDS certifications.&nbsp;&nbsp;Under the FDA licenses, ADMA BioCenters may collect normal source plasma and
	high-titer RSV plasma.&nbsp;&nbsp;We sell a portion of our normal source plasma to buyers in the open &ldquo;spot&rdquo; market.&nbsp;&nbsp;We
	also plan to use the high-titer RSV plasma collected by ADMA BioCenters in the commercial manufacturing of RI-002.&nbsp;&nbsp;We
	may initiate other hyperimmune plasma collection programs at the Norcross and Marietta facilities.&nbsp;&nbsp;These programs would
	be initiated during the normal course of business and are expected to cost approximately $2 million to implement.&nbsp;&nbsp;We
	may also consider growth through the creation and licensing of additional ADMA BioCenters facilities in various regions of the
	U.S.&nbsp;&nbsp;Additional ADMA BioCenters may allow us to cost-effectively secure additional high-titer RSV plasma for
	RI-002, and potentially increase revenues through the collection and sale of normal source plasma and other hyperimmune plasma
	to third parties.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	Summary of Proposed Acquisition of Certain Assets of BPC
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	On January 21, 2017, we and
	our wholly-owned subsidiary, ADMA BioManufacturing, LLC, a Delaware limited liability company (&ldquo;Buyer&rdquo;), entered
	into a definitive Master Purchase and Sale Agreement (as amended, restated, supplemented or otherwise modified from time to
	time, the &ldquo;Purchase Agreement&rdquo;) with Seller, and for certain limited purposes set forth in
	the Purchase Agreement, Biotest and Biotest US Corporation, a Delaware corporation and subsidiary of Biotest (together with
	Biotest AG, the &ldquo;Biotest Guarantors&rdquo;), pursuant to which Buyer has agreed to acquire certain assets and assume
	certain liabilities constituting the therapy business of Seller (the &ldquo;Business&rdquo;). We refer to the foregoing
	transactions and the other transactions contemplated by the Purchase Agreement collectively as the &ldquo;Proposed
	Acquisition.&rdquo; The Business includes (a) a FDA-licensed immune globulin manufacturing and plasma products production
	facility of two buildings of approximately 126,000 square feet located on approximately 15 acres of land in Boca Raton,
	Florida, and the associated real property, (b) all exclusive rights to FDA licensed biologics products Nabi-HB&reg;,
	BIVIGAM&reg; and the investigational product CIVACIR&reg;, (c) in-process inventory with an agreed-upon value of at least
	$5.0 million, (d) certain other properties and assets used exclusively in the Business, and (e) certain additional assets
	which relate to both the Business and Biotest&rsquo;s plasma business, the arrangement with respect to which will be
	documented in a transition services agreement to be mutually agreed by the parties between the signing of the Purchase
	Agreement and the closing of the Proposed Acquisition.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	Subject to the terms and conditions of
	the Purchase Agreement, (i) upon the closing, Buyer has agreed to assume certain liabilities of Seller related to the
	Business, including, without limitation, related to (x) product liabilities, breach of warranty, product complaints, product
	returns, post-market commitments, recalls, adverse event reporting, product deviation reporting, lookbacks, market
	withdrawals and field corrections or similar claims for injury to person or property with respect to the Business or any
	product of the Business to the extent such liabilities relate to products manufactured and sold by Buyer after the
	closing (other than inventory transferred to us at the closing, which will be allocated 50% to Buyer and 50% to Seller if not
	traceable to acts or omissions of a particular party); and (y) other regulatory matters, whether related to the pre-closing
	or post-closing period and including any liabilities related to the products of the Business, the FDA warning letter (the
	warning letter issued by the FDA to Seller in connection with outstanding issues requiring remediation at the manufacturing
	facility in Boca Raton, Florida), noncompliance with applicable laws and legal proceedings related to the foregoing, but
	excluding such liabilities that arise out of any fraud, willful misconduct or intentional misrepresentation by Seller prior
	to the closing (the &ldquo;Assumed Liabilities&rdquo;); (ii) upon the closing, we have agreed to deliver to Seller an
	aggregate equity interest in us equal to 50%, less one share, of our issued and outstanding capital stock (calculated as
	of immediately following the closing and on a post-closing issuance basis) (the &ldquo;Biotest Equity Interest&rdquo;), consisting of (x)
	common stock representing 25% of our issued and outstanding common stock, equal to 4,295,580 common shares and (y) non-voting
	common stock equal to 8,591,160 shares of our common stock representing the balance of the Biotest Equity Interest which is
	convertible into our common stock upon the occurrence of certain specified events; (iii) upon the closing, we agreed to issue
	to Seller warrants, if any, necessary to acquire additional shares of our capital stock equal to the excess, if any, of (x)
	the number of shares represented by rights, options and warrants issued by us between September 12, 2016 until the closing,
	over (y) 184,000 shares; and (iv) on January 1, 2019, pursuant to the terms of a separate purchase agreement to be entered
	into by the parties at the closing, we have agreed to sell, transfer and convey to Seller for no additional consideration,
	all of our right, title and interest in and to our certain biocenter located in Norcross, Georgia and our certain biocenter
	located in Marietta, Georgia, which are subject to a repurchase right in favor of us if within five years after January 1,
	2019, the Biotest stockholders and its related entities own less than 20% of our issued and outstanding capital stock. As
	part of the consideration, upon the closing, Seller will also be granted the right to designate one director and one
	observer to our board of directors, and under certain circumstances, Seller will be granted the right to designate an
	additional director.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
</P>
<!-- FIELD: PAGE; SEQUENCE: 9 -->
<DIV STYLE="MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	7
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage10"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<P STYLE="MARGIN: 0PT; TEXT-ALIGN: RIGHT; FONT-SIZE: 8PT">
<A HREF="#E615811_10K-ADMA_HTM_TOC" STYLE="FONT-STYLE: ITALIC">
	Table of Contents
</A>
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	Additionally, on the closing
	date, Seller has agreed to (i) deliver to us a capital contribution of $12.5 million in respect of the Biotest Equity
	Interest, which capital contribution will be contributed by Seller to Buyer; and (ii) fund a $15.0 million unsecured
	subordinated loan to us, which (a) will bear interest at a rate of 6% per annum, payable semiannually in arrears, (b) has a
	term of five years and (c) will not be subject to any prepayment penalty or other breakage costs. Such loan will be
	subordinated to our existing indebtedness as of the signing of the Purchase Agreement and any additional
	indebtedness approved by our board of directors which is secured only by a mortgage on the owned real property acquired in
	connection with the transaction. Such loan will rank pari passu with all additional indebtedness approved by our board of
	directors that is not secured only by a mortgage on such owned real property and if such additional indebtedness is secured,
	the loan from Seller will be secured on a pari passu basis with such additional indebtedness. At any time after the closing,
	if we undertake an underwritten equity financing or a Private Investment in Public Equity, or PIPE, offering involving at
	least one unrelated third party, Biotest and/or Seller have agreed to participate pro rata in accordance with the Biotest
	Equity Interest up to an aggregate amount equal to $12.5 million.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	Upon the closing, the parties will also
	enter into a ten-year plasma supply agreement, pursuant to which (x) Seller will sell to us high titer Hepatitis B plasma at a
	specified price (indexed by inflation), and (y) we will purchase from Seller all Hepatitis B plasma necessary to produce Nabi-HB&reg;
	unless we require more than a specified amount, in which case we may use alternative sources for the excess quantity. Additionally,
	the parties have agreed to a mutual release with respect to any claims relating to or arising from any breach or default under
	the existing Manufacturing Supply and License Agreement and Master Services Agreement between Buyer and Seller. The mutual release
	is effective as of the signing of the Purchase Agreement conditioned on the closing of the Proposed Acquisition at which time the
	Manufacturing Supply and License Agreement and Master Services Agreement will terminate and the mutual release will no longer be
	conditional.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	The Purchase Agreement contains customary
	representations and warranties of the parties, including, without limitation, with respect to: organization; power and authority;
	due authorization; enforceability; capitalization; no conflict; no consents required; no actions; no orders; financial statements;
	indebtedness; no undisclosed liabilities; absence of certain changes; taxes; contracts; customers and suppliers; intellectual property;
	title to properties; real property; employee benefit plans; employees; insurance; compliance with laws; environmental; material
	permits; inventory; affiliate transactions; and no brokers.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	The Purchase Agreement also
	contains customary covenants and agreements, including covenants and agreements of: Seller to conduct the Business in the
	ordinary course until the Proposed Acquisition is completed or terminated and to not take certain actions relating to the
	Business during the interim period between signing and closing, without our prior consent not to be unreasonably withheld,
	conditioned or delayed; our conduct of our business in the ordinary course until the Proposed Acquisition is completed or
	terminated and to not take certain actions relating to its business during the interim period between signing and closing,
	without Seller&rsquo;s prior consent not to be unreasonably withheld, conditioned or delayed; Seller not to compete with us
	in certain lines of business for a period of five years following the closing date; Seller and the Biotest Guarantors not to
	solicit our employees for one year following the closing date; we and Buyer not to solicit Seller&rsquo;s employees for
	one year following the closing date; and Seller not to interfere with the our customers for five years following the closing
	date.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
</P>
<!-- FIELD: PAGE; SEQUENCE: 10 -->
<DIV STYLE="MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	8
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage11"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<P STYLE="MARGIN: 0PT; TEXT-ALIGN: RIGHT; FONT-SIZE: 8PT">
<A HREF="#E615811_10K-ADMA_HTM_TOC" STYLE="FONT-STYLE: ITALIC">
	Table of Contents
</A>
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	Subject to certain limitations, Buyer or Seller
	may terminate the Purchase Agreement if the Proposed Acquisition has not been consummated by September 30, 2017. A termination
	of the Purchase Agreement under certain customary circumstances relating to (i) our board of directors exercising their fiduciary
	out will entitle Seller to receive from us a termination fee in an amount equal to $2.5 million; or (ii) our failure to obtain the
	requisite stockholder approval will entitle Seller to receive expense reimbursement in an amount up to $2.5 million. In no event
	will Seller be entitled to both a termination fee and expense reimbursement.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	We and Seller will each indemnify the
	other party after the closing for any losses arising from breaches of its representations, warranties, covenants and
	agreements in the Purchase Agreement. In addition, Buyer will indemnify Seller after the closing for any assumed liability, and
	Seller will indemnify us after the closing for any excluded asset or excluded liability. The representations, warranties and
	pre-closing covenants generally survive for 15 months following the closing of the transaction and each party&rsquo;s
	indemnification obligations with respect to (a) its representations and warranties (other than its fundamental
	representations, which include representations related to taxes, organization, due authorization, organizational documents,
	no conflicts, enforceability, title, sufficiency, the Amended and Restated Product Distribution Agreement, effective as of
	January 19, 2016, by and between Seller and
<FONT STYLE="BACKGROUND-COLOR: WHITE">
	Kedrion Biopharma Inc., or the Kedrion
	Contract
</FONT>
	, brokers, etc. and ownership of our securities) are subject to a $25,000 mini-basket and $750,000 true
	deductible; and (b) its representations and warranties (other than fundamental) and pre-closing covenants are subject to a
	$25.0 million cap.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	Seller will be entering into a
	standstill with ADMA, which will limit Seller&rsquo;s ability to control the Company. Seller will also agree to a six (6)
	month lock-up of the sale of ADMA securities.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	The consummation of the Proposed
	Acquisition is subject to the satisfaction of certain conditions, including approval of the Proposed Acquisition by the
	stockholders of ADMA and approval of the amended and restated certificate of incorporation of the Company by the stockholders
	of ADMA. The Proposed Acquisition is not subject to any financing conditions. There can be no assurance as to when the closing
	conditions will be satisfied, if at all.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	Upon consummation and closing of the Proposed
	Acquisition, we believe we will be uniquely positioned to offer a fully vertically integrated plasma products and immune globulin
	platform in the U.S.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	The Plasma Industry
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<I>
	Primary Immunodeficiency Disease
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	PIDD is a class of&nbsp;hereditary disorders
	characterized by defects in the immune system, due to either a lack of necessary antibodies or a failure of these antibodies to
	function properly.&nbsp;&nbsp;According to the World Health Organization, there are over 150 different presentations of PIDD.&nbsp;&nbsp;As
	patients suffering from PIDD lack a properly functioning immune system, they typically receive monthly, outpatient infusions of
	IVIG therapy.&nbsp;&nbsp;Without this exogenous antibody immune support, these patients would be susceptible to a wide variety
	of infectious diseases.&nbsp;&nbsp;PIDD has an estimated prevalence of 1:1,200 in the U.S., or approximately 250,000 people.&nbsp;&nbsp;Of
	these 250,000 people diagnosed with PIDD in the U.S., approximately 125,000 receive monthly infusions of IVIG and it is
	estimated that over 300,000 patients worldwide receive monthly IVIG infusions for PIDD.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	As most&nbsp;patients with PIDD present
	with infections, the differential diagnosis and initial investigations for an underlying immune defect are typically guided by
	the clinical presentation.&nbsp; In subjects with PIDD, individual infections are not necessarily more severe than those that occur
	in a normal host.&nbsp; Rather, the clinical features suggestive of an immune defect may be the recurring and/or chronic nature
	of infections with common pathogens that may result in end organ damage, such as bronchiectasis.&nbsp; In addition, subjects with
	PIDD will often respond poorly to standard antimicrobial therapy or they may have repeated infections with the same pathogen.&nbsp;
	The virulence of the infecting organism should also be considered, and a subject&rsquo;s immune competence should be questioned
	when invasive infections are caused by low virulence or opportunistic pathogens.&nbsp; For example, infection with the opportunistic
	pathogens Pneumocystis jiroveci (previously Pneumocystis carinii) or atypical mycobacteria should prompt an investigation for underlying
	immunodeficiency. Typical clinical presentations for subjects with PIDD are:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
</P>
<!-- FIELD: PAGE; SEQUENCE: 11 -->
<DIV STYLE="MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	9
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage12"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<P STYLE="MARGIN: 0PT; TEXT-ALIGN: RIGHT; FONT-SIZE: 8PT">
<A HREF="#E615811_10K-ADMA_HTM_TOC" STYLE="FONT-STYLE: ITALIC">
	Table of Contents
</A>
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 48PX; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;&nbsp;Antibody deficiency and recurrent bacterial infections;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
</TR>
</TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 48PX; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;&nbsp;T-lymphocyte deficiency and opportunistic infections;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
</TR>
</TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 48PX; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;&nbsp;Other lymphocyte defects causing opportunistic infections;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
</TR>
</TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 48PX; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;&nbsp;Neutrophil defects causing immunodeficiency; and
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
</TR>
</TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 48PX; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;&nbsp;Complement deficiencies.
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	PIDD can present at any age from birth to
	adulthood, posing a considerable challenge for the practicing physician to know when and how to evaluate a subject for a possible
	immune defect. &nbsp;Subjects with marked antibody deficiencies are generally&nbsp;dependent on IVIG therapy for survival.&nbsp;
	Benefits of adequate IVIG therapy in subjects not able to produce antibodies normally include a reduction of the severity and frequency
	of infections, prevention of chronic lung disease and prevention of enteroviral meningoencephalitis.&nbsp; Several immune globulin
	products have already been approved by the FDA.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	RI-002, our IVIG product candidate, contains
	polyclonal antibodies against various infectious agents (e.g., streptococcus pneumoniae, H. influenza type B, CMV, measles, tetanus,
	etc.) including standardized antibodies against RSV.&nbsp;RSV is a common respiratory virus that often presents during the winter
	months.&nbsp;&nbsp;Nearly all children will have been infected with RSV by three years of age; however, the immune systems of most
	healthy children prevent significant morbidity and mortality.&nbsp;&nbsp;Conversely, in patients who are immune-compromised, such
	as those with PIDD or who have undergone a hematopoietic stem cell or solid organ transplant and may be on immunosuppressive drugs
	or chemotherapy, RSV infection can be associated with significant morbidity and mortality.&nbsp;&nbsp;Immune-compromised patients
	historically have a 5% to 15% rate of RSV infection, and, if left untreated, lower respiratory tract RSV infections in immune-compromised
	patients can result in a mortality rate of up to 40% of infected patients.&nbsp;&nbsp;In hematopoietic stem cell transplant, or
	HSCT, patients, a subset of the immune-compromised patient population with approximately 25,000 transplants being performed annually
	in the U.S., it is estimated that about 25% of patients treated with the current standard of care (aerosolized Ribavirin)
	will progress to lower respiratory tract infection, or LRTI, while 41% of patients untreated with the current standard of care
	will progress to LRTI.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<I>
	Plasma - Background, Composition and Manufacturing
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	Human blood contains a number of components
	including:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 48PX; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	Red blood cells &ndash; Used to carry oxygen from the lungs to the body;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
</TR>
</TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 48PX; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	White blood cells &ndash; Used by the immune system to fight infection;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
</TR>
</TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 48PX; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	Platelets &ndash; Used for blood clotting; and
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
</TR>
</TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 48PX; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;&nbsp;
</FONT>
</TD>
<TD>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Plasma &ndash; Used to carry the aforementioned components throughout
	the body and provide support in clotting and immunity.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
</P>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	Plasma is the most abundant blood component,
	representing approximately 55% of total blood volume.&nbsp;&nbsp;Plasma, which is 90% water, is rich in proteins used by the human
	body for blood clotting and fighting infection.&nbsp;&nbsp;These proteins account for approximately 7% of plasma&rsquo;s volume.&nbsp;&nbsp;As
	plasma contains these valuable proteins, plasma collection and the manufacturing of human plasma-derived therapeutics provide therapeutic
	benefits for ill patients.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	In order to produce plasma-derived therapeutics
	that can be administered to ill patients, raw material plasma must be collected from human donors and then manufactured into specialized
	products.&nbsp;&nbsp;Plasma is collected from healthy donors at FDA-licensed plasma donation centers.&nbsp;&nbsp;To ensure safety
	of the collected plasma, all plasma donations are tested using FDA-approved methods of Nucleic Acid Testing, or NAT, for various
	infectious diseases, such as human immunodeficiency virus, or HIV, and hepatitis C virus, or HCV.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
</P>
<!-- FIELD: PAGE; SEQUENCE: 12 -->
<DIV STYLE="MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	10
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage13"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<P STYLE="MARGIN: 0PT; TEXT-ALIGN: RIGHT; FONT-SIZE: 8PT">
<A HREF="#E615811_10K-ADMA_HTM_TOC" STYLE="FONT-STYLE: ITALIC">
	Table of Contents
</A>
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	Plasma is collected using a process called
	&ldquo;plasmapheresis.&rdquo; During plasmapheresis, a donor&rsquo;s blood is drawn into a specialized medical device that separates
	the plasma component through centrifugation, and then returns the other blood components back into the donor&rsquo;s bloodstream.&nbsp;&nbsp;Plasmapheresis
	is performed utilizing an FDA-approved, automated device with a sterile, self-contained collection kit.&nbsp;&nbsp;The plasma that
	is collected is known as &ldquo;normal source plasma.&rdquo; There are over 500 plasma donation centers in the U.S. As
	noted in a variety of plasma industry trade reports and related conferences, approximately 35 million liters of source plasma were
	collected in the U.S. in 2015.&nbsp;&nbsp;In the U.S., a donor may donate plasma a maximum of two times during
	any seven-day period, with at least two days in between donations.&nbsp;&nbsp;Plasma donation centers in the U.S. typically
	pay donors $25 to $50 per donation and some donors with rare or high antibody levels can be paid more.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	In order to isolate the desired therapeutic
	elements in normal source plasma, it must initially undergo a manufacturing process called &ldquo;fractionation.&rdquo;&nbsp;&nbsp;The
	process of fractionation was invented in the 1940&rsquo;s by E.J. Cohn and is referred to as the Cohn method or cold ethanol fractionation.&nbsp;&nbsp;First,
	the source plasma undergoes a process called pooling, in which the individual plasma donations are combined into a pooling tank.&nbsp;&nbsp;Second,
	the Cohn fractionation method, which is a combination of time, temperature, pH, alcohol concentration, and centrifugation, is used
	to separate the desired plasma protein components, or &ldquo;fractions.&rdquo; After fractionation, the separated proteins are
	then re-suspended and are treated with a solvent detergent treatment process for viral inactivation.&nbsp;&nbsp;Next, other forms
	of filtration (e.g., nanofiltration) are performed as an additional viral removal and viral reduction step.&nbsp;&nbsp;Finally,
	with the various components separated and purified, the bulk product is formulated and filled into final, finished vials.&nbsp;&nbsp;During
	these various steps of manufacturing, each lot is reviewed and tested for potency and purity prior to being approved for release.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	The proteins in human plasma fall into four
	categories: albumin (60% of protein volume), immune globulins (15% of protein volume), coagulation factors (1% of protein volume),
	and other proteins (24% of protein volume) such as alpha-1 proteinase inhibitor, C1 esterase inhibitor, fibrin sealants and fibrinogen.&nbsp;&nbsp;Many
	of the other proteins in plasma have yet to be developed into commercial therapies.&nbsp;&nbsp;In the U.S., not only are
	the plasma collection centers subject to FDA licensure, but each plasma protein product that is derived and fractionated from plasma
	must undergo an approval process with FDA&rsquo;s Center for Biologics Evaluation and Research, or CBER.&nbsp;&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<I>
	Immune Globulins
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	In June 2008, the FDA published the FDA
	Guidance for Industry outlining the regulatory pathway for the approval of IVIG, for the treatment of PIDD
<I>
	(Guidance for Industry:
	Safety, Efficacy, and Pharmacokinetic Studies to Support Marketing of Immune Globulin Intravenous (Human) as Replacement Therapy
	for Primary Humoral Immunodeficiency)
</I>
	.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	Immune globulins can be administered in
	three ways: intramuscularly, intravenously or subcutaneously.&nbsp;&nbsp;IVIG principally contains antibodies and, as such, provides
	passive immunization for individuals who are immune-deficient or who have been exposed to various infectious agents.&nbsp;&nbsp;IVIG
	is used therapeutically in a variety of immunological diseases/deficiencies, such as PIDD, idiopathic thrombocytopenic purpura,
	Guillain-Barr&eacute; syndrome, Kawasaki disease, bone marrow transplant, and chronic inflammatory demyelinating polyneuropathy.&nbsp;&nbsp;We
	are aware that other companies are also evaluating IVIG in a clinical study for the treatment of Alzheimer&rsquo;s disease. Additionally,
	IVIG is also used as therapy in a variety of other diseases that do not involve primary or secondary immune deficiencies, such
	as multiple sclerosis, skin disease, and asthma.&nbsp;&nbsp;These latter uses are referred to as &ldquo;off-label&rdquo; or evidence-based
	uses because the FDA has not approved their use in these indications and promotion of such uses is not permitted by FDA unless
	a BLA or BLA supplement with additional data is approved.&nbsp;&nbsp;Among the various IVIG products, there are only 14 labeled
	indications approved by the FDA.&nbsp;&nbsp;However, medical literature identifies at least 150 evidence based uses for IVIG, of
	which approximately 60 are currently included on lists of reimbursable uses by Medicare and other healthcare plans.&nbsp;&nbsp;This
	provides opportunities for new product development and submissions.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
</P>
<!-- FIELD: PAGE; SEQUENCE: 13 -->
<DIV STYLE="MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	11
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage14"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<P STYLE="MARGIN: 0PT; TEXT-ALIGN: RIGHT; FONT-SIZE: 8PT">
<A HREF="#E615811_10K-ADMA_HTM_TOC" STYLE="FONT-STYLE: ITALIC">
	Table of Contents
</A>
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	There are two types of immune globulins,
	standard and hyperimmune.&nbsp;&nbsp;The difference between standard immune globulins and hyperimmune globulins is that the latter
	are manufactured using plasma obtained from donors who have elevated amounts (high-titers) of specific antibodies.&nbsp;&nbsp;These
	high-titer products can be used to treat and prevent diseases that present those specific antigens that are reactive with the high-titer
	antibodies.&nbsp;&nbsp;Hyperimmune products currently available include hepatitis B, tetanus, rabies cytomegalovirus and RhoD immune
	globulins.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	As of the date of this annual report on
	Form 10-K, the worldwide market for plasma-derived therapeutic drug products was approximately $15 billion and the U.S.
	market for all plasma-derived products was approximately $7.8 billion.&nbsp;&nbsp;IVIG products accounted for approximately $4.8
	billion of sales in the U.S. in 2014.&nbsp;&nbsp;IVIG products are used to treat primary immune deficiencies, certain
	autoimmune diseases, and other illnesses for immune-compromised patients and certain neuropathy indications.&nbsp;&nbsp;New research
	and data, additional labeled indications, an aging population and emerging countries with new markets are all adding to the worldwide
	growth of IVIG utilization.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<I>
	Our Lead Product Candidate &ndash; RI-002
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	We are currently developing our lead product
	candidate, RI-002, for the treatment of PIDD, and have completed a pivotal Phase III clinical study. RI-002 is derived from human
	plasma blended from normal donors and donors tested to have high levels of neutralizing titers to RSV. RI-002 is manufactured using
	a process called fractionation, which purifies immune globulins, or IgG, from this blended plasma pool resulting in a final IVIG
	product enriched with naturally occurring polyclonal anti-pathogen antibodies (e.g., streptococcus pneumonia, H. influenza type
	B, Cytomegalovirus or CMV, measles, tetanus, etc.). We use our proprietary RSV microneutralization assay to test for standardized
	levels of neutralizing antibodies to RSV in the final drug product.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	In the third quarter of 2015, the FDA accepted
	for review a BLA for RI-002 for the treatment of PIDD. In July 2016, the FDA issued a CRL. The CRL did not cite any concerns with
	the clinical safety or efficacy data for RI-002 submitted in the BLA, nor did the FDA request any additional clinical studies be
	completed prior to FDA approval of RI-002. The FDA identified in the CRL, among other things, certain outstanding inspection issues
	and deficiencies at our third-party contract manufacturers and vendors and requested documentation of corrections for a number
	of those issues. The FDA indicated in the CRL that it cannot grant final approval of the BLA until, among other things,&nbsp;these
	deficiencies are resolved.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	We continue to collaborate with our third-party
	manufacturers and vendors to identify solutions to outstanding issues identified in the CRL. We are currently preparing documentation
	for an additional submission to the FDA to address the CRL. We, along with our vendors, are awaiting certain feedback from the
	FDA regarding previous submissions and we intend to provide a timeline for resubmission of our BLA for RI-002 as soon as practicable.
	If RI-002 is approved by the FDA, we intend to commercialize RI-002 for the treatment of PIDD and explore alternative processes
	to evaluate and seek approval for RI-002 for additional indications, patient populations and uses.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<I>
	Evaluation of PIDD Patients
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	PIDD, a genetic disorder that causes a deficient
	or absent immune system, is caused by hereditary or genetic defects and can affect anyone regardless of age or gender. PIDD patients
	are more vulnerable to infections and more likely to suffer complications from these infections. IVIG is a plasma derived product
	that is used to prevent serious infections in patients with PIDD. It is comprised of polyclonal antibodies, which are proteins
	produced by B-cells that are used by the body&rsquo;s immune system to neutralize foreign objects such as bacteria and viruses.
	It is estimated that there are about 250,000 diagnosed PIDD patients in the U.S., approximately half of whom are treated
	with IVIG regularly. In the U.S., sales of immune globulin products for all its uses were reported to be approximately
	$4.8 billion in 2014.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	The RI-002 pivotal Phase III clinical
	trial was conducted as a single arm study in which patients were treated approximately once per month for a period of 12
	months plus 90 days for follow up. Fifty-nine patients were enrolled in nine treatment centers in the U.S. The pivotal Phase
	III primary endpoint followed published FDA industry guidance, which provides for a reduction in the incidence of serious
	infections to less than one per year in each subject receiving IVIG. The secondary outcome was safety and included other
	pharmacokinetic, or PK, data collection points including antibody titers for certain agents, including RSV antibody levels at
	various time points after infusion.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
</P>
<!-- FIELD: PAGE; SEQUENCE: 14 -->
<DIV STYLE="MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	12
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage15"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<P STYLE="MARGIN: 0PT; TEXT-ALIGN: RIGHT; FONT-SIZE: 8PT">
<A HREF="#E615811_10K-ADMA_HTM_TOC" STYLE="FONT-STYLE: ITALIC">
	Table of Contents
</A>
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	RI-002 demonstrated positive results in
	the Phase III study in patients with PIDD, meeting its primary endpoint, of no&nbsp;Serious Bacterial Infections, or SBI,&nbsp;reported.
	RI-002 was administered a total of 793 infusions with zero serious adverse events to 59 patients in nine treatment centers throughout
	the U.S. These results, included in the BLA, more than meet the requirement specified by FDA guidance of&nbsp;&le; 1
	SBI per patient-year.&nbsp;&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	On February 22, 2015, at the 2015 American
	Academy of Allergy, Asthma &amp; Immunology Annual Meeting, scientific investigators reported on the secondary outcomes that included:
	a total of 93 days, or 1.66 days per patient per year lost from work or school due to infection; one hospitalization due to an
	infection of only five days duration in the entire study and IgG trough levels above those required by the FDA for IVIG products.
	Additionally, there was a marked increase in all of the measured specific anti-pathogen antibodies in PK subjects (n=31). The mean
	of maximum fold increases in specific antibody levels after infusion of RI-002 ranged from 1.9 fold (S. pneumonia type 19A) to
	5.3 fold (RSV), which were statistically significant fold increases from the pathogen's specific measured baselines. The safety
	profile of RI-002 is comparable to that of other immunoglobulins.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<I>
	Rationale for the Potential Evaluation in RSV Infected Patients
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	RSV is a common virus that ordinarily leads
	to mild, cold-like symptoms in healthy adults and children. In high-risk groups, such as the PIDD population and the other immune-compromised
	populations, RSV can lead to a more serious infection and may even cause death. The polyclonal antibodies which are present in
	RI-002 are expected to prevent infections in immune-compromised patients.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	We previously conducted a randomized, double-blind,
	placebo-controlled Phase II clinical trial to evaluate RI-001, RI-002&rsquo;s predecessor product candidate, in immune-compromised,
	RSV-infected patients. This trial was conducted with 21 patients in the U.S., Canada, Australia, and New Zealand. The
	Phase II dose-ranging trial demonstrated a statistically significant improvement in the change from baseline RSV titers to day
	18 in the high dose and low dose treatment groups when compared with placebo (p=0.0043 and p=0.0268, respectively). The mean fold
	increase for high dose was 9.24 (95% CI 4.07, 21.02) and the observed mean fold increase for low dose was 4.85 (95% CI 2.22, 10.59).
	The mean fold change for placebo treated patients was 1.42 (95% CI 0.64, 3.17). In addition, more patients in the high dose (85.7%)
	and low dose (42.9%) groups experienced greater than a four-fold increase from baseline to day 18 in RSV titer levels compared
	to placebo (0%). There were no serious drug-related adverse events reported during the trial.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	From April 2009 through February 2011, RI-001
	was also administered to 15 compassionate use patients where physicians requested access to the product for treating their patients
	with documented lower respiratory tract RSV infections due to the fact that these patients had failed conventional therapeutic
	interventions. Serum samples were obtained from 13 patients. Samples showed that patients demonstrated a four-fold or greater rise
	in RSV antibody titers from baseline. Serum samples were not obtained from two patients that received Palivizumab. All 11 patients
	who received RI-001 within 4.2 days after the onset of the diagnosis of RSV survived. The drug was well-tolerated in all 15 patients
	and there were no reports of serious adverse events attributable to RI-001. Data from our Phase II clinical trial, compassionate
	use experience and data obtained from the evaluation of RI-002 in the infected cotton rat animal model has been presented at various
	conferences during 2014, 2015 and 2016.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	Manufacturing and Supply
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	In order to produce plasma-derived therapeutics
	that can be administered to patients, raw material plasma is collected from healthy donors at plasma collection facilities licensed
	by the FDA.&nbsp;&nbsp;ADMA BioCenters operates two FDA-licensed, GHA and MFDS-certified source plasma collection facilities located
	in Norcross and Marietta, Georgia, which facilities provide us with a portion of our plasma requirements.&nbsp;&nbsp;By using our
	patented proprietary assay, we can identify plasma donors with elevated amounts of RSV antibodies and formulate RI-002 with an
	appropriate RSV titer level to ensure the final product is standardized to contain high levels of RSV antibodies.&nbsp;&nbsp;Once
	source plasma has been collected, it is then fractionated and purified into specialized therapies, which are used by patients who
	require them.&nbsp;&nbsp;We have agreements with independent third parties for the sourcing of blood plasma and for the fractionation
	and purification stages of manufacturing.&nbsp;&nbsp;The contracts are with well-regarded facilities that are fully licensed to
	manufacture biologics.&nbsp;&nbsp;We are dependent upon our third party suppliers for the manufacture of RI-002.&nbsp;&nbsp;Our
	principal supplier of source plasma is BPC.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
</P>
<!-- FIELD: PAGE; SEQUENCE: 15 -->
<DIV STYLE="MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	13
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage16"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<P STYLE="MARGIN: 0PT; TEXT-ALIGN: RIGHT; FONT-SIZE: 8PT">
<A HREF="#E615811_10K-ADMA_HTM_TOC" STYLE="FONT-STYLE: ITALIC">
	Table of Contents
</A>
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	In December 2012, we entered into
	our Manufacturing, Supply and License Agreement with BPC.&nbsp;&nbsp;Under the agreement, we agreed to purchase
	exclusively from BPC our worldwide requirements of RSV immune globulin manufactured from human plasma containing
	RSV antibodies.&nbsp;&nbsp;The term of the agreement is for a period of ten years from January 1, 2013, renewable for
	two additional five year periods at the agreement of both parties. We are obligated under this agreement to purchase a
	minimum of at least one lot of product during each calendar year after the finished product is approved by the
	FDA.&nbsp;&nbsp;This number is subject to increase at our option.&nbsp;&nbsp;As consideration for BPC&rsquo;s obligations
	under the agreement, we are obligated to pay a dollar amount per lot of RSV immune globulin manufactured from human plasma
	containing RSV antibodies, as well as a percentage royalty on the sales thereof and of RI-002, up to a specified cumulative
	maximum amount.&nbsp;&nbsp;The agreement may be terminated by either party (a) by reason of a material breach if the
	breaching party fails to remedy the breach within 120 days after receiving notice of the breach from the other party, (b)
	upon bankruptcy, insolvency, dissolution, or winding up of the other party, or (c) if the other party is unable to fulfill
	its obligations under the agreement for 120 consecutive days or more as a result of (a) or (b) above. Additionally, the
	parties have agreed to a mutual release with respect to any claims relating to or arising from any breach or default under
	the existing Manufacturing Supply and License Agreement and Master Services Agreement between us and BPC. The mutual
	release is effective as of January 21, 2017 conditioned on the closing of the Proposed Acquisition anticipated during the
	first half of 2017 at which time the Manufacturing Supply and License Agreement and Master Services Agreement will terminate
	and the mutual release will no longer be conditional.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	Pursuant to the terms of a Plasma
	Purchase Agreement with BPC, we have agreed to purchase from BPC an annual minimum volume of source plasma containing
	antibodies to RSV to be used in the manufacture of RI-002.&nbsp;&nbsp;This volume will increase at the earlier of our receipt
	of a BLA from the FDA, or March 31, 2016.&nbsp;&nbsp;We must purchase a to-be-determined and agreed upon annual minimum
	volume from BPC, but may also collect high-titer RSV plasma from up to five wholly-owned ADMA
	BioCenters.&nbsp;&nbsp;During 2015, BPC and ADMA amended its plasma supply agreement to allow ADMA the ability to collect
	its raw material RSV high-titer plasma from other third party collection organizations, thus allowing ADMA to expand its
	reach for raw material supply as we approach commercialization for RI-002. Unless terminated earlier, the agreement expires
	in November 2021, after which it may be renewed for two additional five-year periods if agreed to by the
	parties.&nbsp;&nbsp;Either party may terminate the agreement if the other party fails to remedy any material default in the
	performance of any material condition or obligation under the agreement following notice.&nbsp;&nbsp;Either party may also
	terminate the agreement, after providing written notice, if a proceeding under any bankruptcy, reorganization, arrangement of
	debts, insolvency or receivership law is filed by or against the other party, and is not dismissed or stayed, or a receiver
	or trustee is appointed for all or a substantial portion of the assets of the other party, or the other party makes an
	assignment for the benefit of its creditors or becomes insolvent.&nbsp;&nbsp;We may also terminate the agreement upon written
	notice if the clinical development of our product candidate is halted or terminated, whether by the FDA, a Data Safety
	Monitoring Board, or any other regulatory authority.&nbsp;&nbsp;Upon termination of the agreement, we must pay for any source
	plasma already delivered to us and for any source plasma collected under the terms of the agreement. As part of the closing
	of the Proposed Acquisition, we will amend the Plasma Purchase Agreement to extend BPC&rsquo;s annual minimum purchase
	requirements of plasma containing antibodies to RSV for ten years through the closing date of the Proposed Acquisition, which
	is anticipated during the first half of 2017.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	On June 22, 2012, we entered into a
	Plasma Supply Agreement with BPC for the purchase of normal source plasma from our ADMA BioCenters, Norcross, Georgia
	facility to be used in&nbsp;BPC's proprietary products&rsquo; manufacturing, which was subsequently amended on February
	25, 2014 and then amended and restated on March 23, 2016.&nbsp;&nbsp;After the initial term, the agreement may be renewed on
	an annual basis upon the mutual consent of the parties.&nbsp;&nbsp;In addition to any other remedy it may have, either party
	has the right to terminate the agreement if the other party fails to remedy any material default in the performance of a
	material condition or obligation under the agreement following written notice.&nbsp;&nbsp;In addition, upon giving the
	appropriate written notice, either party may terminate the agreement upon the occurrence of any of the following events: a
	proceeding under bankruptcy, reorganization, agreement of debts, insolvency or receivership law is filed by or against the
	other party, and is not dismissed or stayed, or a receiver or trustee is appointed for all or a substantial portion of the
	assets of the other party, or the other party makes an assignment for the benefit of its creditors or becomes
	insolvent.&nbsp;&nbsp;Neither party can assign the agreement or any of its right or obligations there under without the
	express written consent of the other party.&nbsp;&nbsp;However, with notice to the other party, either party without the
	other party&rsquo;s consent may assign the agreement to (i) its affiliate, or (ii) a successor to all or substantially all of
	the assets relating to the business of that party which is involved in the fulfillment of its obligations under the
	agreement.&nbsp;&nbsp;Under the agreement, BPC applied to the GHA for, and we have subsequently obtained, GHA
	certification. The Manufacturing, Supply and License Agreement with BPC will be terminated upon the closing
	the Proposed Acquisition anticipated during the first half of 2017.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
</P>
<!-- FIELD: PAGE; SEQUENCE: 16 -->
<DIV STYLE="MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	14
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage17"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<P STYLE="MARGIN: 0PT; TEXT-ALIGN: RIGHT; FONT-SIZE: 8PT">
<A HREF="#E615811_10K-ADMA_HTM_TOC" STYLE="FONT-STYLE: ITALIC">
	Table of Contents
</A>
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	For the fiscal year ended December 31, 2016,
	two of our customers, SK Plasma Co., Ltd., or SK, and BPC, represented greater than 95% of our total revenues, with SK representing
	approximately 14% of our total revenues and BPC representing approximately 82% of our total revenues. We believe SK will represent
	approximately less than 10% of our total revenues for 2017.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	On June 7, 2012, we entered into a Testing
	Services Agreement with Quest Diagnostics Clinical Laboratories, Inc., or Quest, in which Quest agreed to provide biomarker testing
	and related support services for protocol screening and recertification which are exclusive to us.&nbsp;&nbsp;If either party believes
	the other party is in material breach of any of their obligations under the agreement, the non-breaching party has the right to
	terminate the agreement by providing the breaching party with written notice specifying the material breach(es) and indicating
	clearly its intention to terminate the agreement.&nbsp;&nbsp;If the breaching party cures such breach, the non-breaching party&rsquo;s
	notice is void.&nbsp;&nbsp;In addition, either party can terminate the agreement without cause upon written notice.&nbsp;&nbsp;All
	data, test results, studies and other information generated by Quest in performing services under the agreement will be our sole
	property.&nbsp;&nbsp;Neither party can assign the agreement or any of its right or obligations under the agreement without the
	express written consent of the other party, except under specified circumstances.&nbsp;&nbsp;Quest agreed and acknowledged that
	we paid for the development and validation of the testing assay and as such, the assay is our sole property and shall only be utilized
	for our benefit.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	Marketing, Sales and Market Research
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	We intend to market and sell our product
	through a small specialty sales force, distribution relationships and other customary industry methods.&nbsp;&nbsp;We will focus
	our efforts specifically on the easily identifiable treatment centers which specialize in the care and management of immune compromised
	individuals.&nbsp;&nbsp;We estimate that there are approximately 500 leading specialty programs in the U.S. which have
	significant patient populations for PIDD, suitable for treatment with RI-002.&nbsp;&nbsp;We plan to hire our own specialty sales
	force which will consist of account managers, medical science liaisons and other normal and customary scientific, medical and detail
	representatives.&nbsp;&nbsp;Our management and board of directors has substantial prior direct marketing, sales and distribution
	experience with plasma derived drugs, specialty immune globulins and other biological products.&nbsp;&nbsp;We anticipate staffing
	the company with additional personnel for patient support, medical affairs, quality assurance, regulatory affairs, scientific affairs,
	reimbursement, supply chain and logistics, human resources, financial and other operational management positions.&nbsp;&nbsp;As
	is normal and customary in the plasma products industry, we may also use a network of national distribution organizations that
	have specialty divisions that focus on plasma products to fulfill orders for RI-002. We anticipate that due to certain recent events,
	including our Proposed Acquisition, our current and anticipated plans and intentions will evolve and change. For a discussion of
	forward-looking statements, see the section entitled &ldquo;Special Note Regarding Forward-Looking Statements&rdquo; on page 1
	of this annual report on Form 10-K and the section entitled &ldquo;Item 1A &ndash; Risk Factors&rdquo; beginning on page 21 of
	this annual report on Form 10-K.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	In our Manufacturing, Supply and License
	Agreement, we granted BPC an exclusive license to market and sell RSV antibody-enriched IVIG in Europe and in selected countries
	in North Africa and the Middle East, collectively referred to as the Territory, to have access to our testing services for testing
	of BPC&rsquo;s plasma samples using our&nbsp;proprietary RSV assay, and to reference (but not access) our proprietary information
	for the purpose of BPC seeking regulatory approval for the RSV antibody-enriched IVIG in the Territory.&nbsp;&nbsp;As consideration
	for the license, BPC agreed to provide us with certain services at no charge and also compensate us with cash payments upon
	the completion of certain milestones.&nbsp;&nbsp;BPC is also obligated to pay us an adjustable royalty based on a percentage
	of revenues from the sale of RSV antibody-enriched IVIG in the Territory for 20 years from the date of first commercial sale.
	Additionally, BPC has agreed to grant us an exclusive license for marketing and sales in the U.S. and Canada for BPC&rsquo;s
	Varicella Zoster Immune Globulin, or VZIG, of which terms are expected to be terminated upon the closing of the Proposed Acquisition,
	anticipated during the first of 2017. The mutual release is effective as of January 21, 2017 conditioned on the closing of the
	Proposed Acquisition anticipated during the first half of 2017 at which time the Manufacturing Supply and License Agreement and
	Master Services Agreement will terminate and the mutual release will no longer be conditional.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
</P>
<!-- FIELD: PAGE; SEQUENCE: 17 -->
<DIV STYLE="MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	15
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage18"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<P STYLE="MARGIN: 0PT; TEXT-ALIGN: RIGHT; FONT-SIZE: 8PT">
<A HREF="#E615811_10K-ADMA_HTM_TOC" STYLE="FONT-STYLE: ITALIC">
	Table of Contents
</A>
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	Competition
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	Although blood plasma and its derivative
	proteins are not subject to patent protection, the FDA recognizes each immune globulin product as unique and generally requires
	a separate Investigational New Drug, or IND, clinical trial and BLA for each as a condition to approval.&nbsp;&nbsp;Regardless
	of whether competitors are able to develop an assay that can achieve our level of consistency and reproducibility in providing
	RSV antibody titer data, we believe they would still be required to validate and qualify such an assay as well as conduct clinical
	trials and undergo an FDA review prior to marketing an immune globulin product.&nbsp;&nbsp;The plasma products industry is highly
	competitive.&nbsp;&nbsp;We face, and will continue to face, intense competition from both U.S.-based and foreign producers
	of plasma products, some of which have lower cost structures, greater access to capital, direct ownership of manufacturing facilities,
	greater resources for research and development, and sophisticated marketing capabilities.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	These competitors may include: CSL Behring,
	Grifols Biologicals, Shire, Octapharma and Kedrion.&nbsp;&nbsp;In addition to competition from other large worldwide plasma products
	providers, we face competition in local areas from smaller entities.&nbsp;&nbsp;In Europe, where the industry is highly regulated
	and health care systems vary from country to country, local companies may have greater knowledge of local health care systems,
	more established infrastructures and have existing regulatory approvals or a better understanding of the local regulatory process,
	allowing them to market their products more quickly.&nbsp;&nbsp;Moreover, plasma therapy generally faces competition from non-plasma
	products and other courses of treatments.&nbsp;&nbsp;For example, recombinant Factor VIII products compete with plasma-derived
	products in the treatment of Hemophilia A.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	Intellectual Property
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	During the second quarter of 2015, we received
	a notice of allowance from the U.S. Patent Office, or USPTO, for our RI-002 patent filed under U.S. patent application
	14/592,721 entitled &lsquo;Compositions and Methods for the Treatment of Immunodeficiency,&rsquo; which extends through January
	2035. &nbsp;During the third quarter of 2015 our U.S. Patent 9,107,906 was issued by the USPTO. This patent describes methods by
	which the blending of plasma obtained from normal donors with plasma obtained from donors selected to have high levels of neutralizing
	titers to RSV form a unique antibody enriched plasma pool and provide for the standardization of the levels of anti-RSV antibodies
	in the RI-002 final product. Our proprietary microneutralization assay allows us to effectively identify and isolate donor plasma
	with high-titer RSV antibodies and to standardize RI-002&rsquo;s antibody profile, which we believe may enable us to garner a premium
	price.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	We also rely on a combination of patents,
	trade secrets and nondisclosure and non-competition agreements to protect our&nbsp;proprietary intellectual property and will continue
	to do so.&nbsp;&nbsp;We also seek to enhance and ensure our competitive position through a variety of means including our unique
	and proprietary plasma donor selection criteria, our proprietary formulation methodology for plasma pooling, and the proprietary
	reagents, controls, testing standards, standard operating procedures and methods we use in our anti-RSV microneutralization assay.&nbsp;&nbsp;While
	we intend to defend against threats to our intellectual property, litigation can be costly and there can be no assurance that our
	patent will be enforced or that our trade secret policies and practices or other agreements will adequately protect our intellectual
	property.&nbsp;&nbsp;We seek to preserve the integrity and confidentiality of our data and trade secrets by maintaining physical
	security of our premises and physical and electronic security of our information technology systems.&nbsp;&nbsp;These processes,
	systems, and/or security measures may be breached, and we may not have adequate remedies as a result of any such breaches.&nbsp;&nbsp;Third
	parties may also own or could obtain patents that may require us to negotiate licenses to conduct our business, and there can be
	no assurance that the required licenses would be available on reasonable terms or at all.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	In addition, our trade secrets may otherwise
	become known or be independently discovered by competitors.&nbsp;&nbsp;We also seek to protect our proprietary technology and processes,
	in part, by confidentiality agreements with our employees, consultants, scientific advisors and contractors.&nbsp;&nbsp;Although
	we rely, in part, on confidentiality, nondisclosure and non-competition agreements with employees, consultants and other parties
	with access to our proprietary information to protect our trade secrets, proprietary technology, processes and other proprietary
	rights, there can be no assurance that these agreements or any other security measures relating to such trade secrets, proprietary
	technology, processes and proprietary rights will be adequate, will not be breached, that we will have adequate remedies for any
	breach, that others will not independently develop substantially equivalent proprietary information or that third parties will
	not otherwise gain access to our trade secrets or proprietary knowledge.&nbsp;&nbsp;To the extent that our consultants, contractors
	or collaborators use intellectual property owned by others in their work for us, disputes may arise as to the rights in related
	or resulting know-how and inventions.&nbsp;&nbsp;We have filed for other provisional patent applications with the U.S.
	which are pending relating to expanded hyperimmune globulin products.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
</P>
<!-- FIELD: PAGE; SEQUENCE: 18 -->
<DIV STYLE="MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	16
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage19"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<P STYLE="MARGIN: 0PT; TEXT-ALIGN: RIGHT; FONT-SIZE: 8PT">
<A HREF="#E615811_10K-ADMA_HTM_TOC" STYLE="FONT-STYLE: ITALIC">
	Table of Contents
</A>
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	Government Regulation and Product Approval
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<SUP>
</SUP>
</FONT>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	The FDA and comparable regulatory agencies
	in state and local jurisdictions and in foreign countries impose substantial requirements upon the testing (preclinical and clinical),
	manufacturing, labeling, storage, recordkeeping, advertising, promotion, import, export, marketing and distribution, among other
	things, of products and product candidates.&nbsp;&nbsp;If we do not comply with applicable requirements, we may be fined, the government
	may refuse to approve our marketing applications or allow us to manufacture or market our products, and we may be criminally prosecuted.&nbsp;&nbsp;We
	and our manufacturers may also be subject to regulations under other federal, state, and local laws.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<I>
	U.S. Government Regulation
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	In the U.S., the FDA regulates products
	under the Federal Food, Drug, and Cosmetic Act, or FDCA, and related regulations. Our current and anticipated future product candidates
	are considered &ldquo;biologics&rdquo; under the FDA regulatory framework. FDA's regulatory authority for the approval of biologics
	resides in the PHS Act. However, biologics are also subject to regulation under the FDCA because most biological products also
	meet the FDCA&rsquo;s definition of &quot;drugs.&quot; Most pharmaceuticals or &ldquo;conventional drugs&rdquo; consist of pure
	chemical substances and their structures are known. Most biologics, however, are complex mixtures that are not easily identified
	or characterized. Biological products differ from conventional drugs in that they tend to be heat-sensitive and susceptible to
	microbial contamination. This requires sterile processes to be applied from initial manufacturing steps.&nbsp;&nbsp;The process
	required by the FDA before our product candidates may be marketed in the U.S. generally involves the following (although the FDA
	is given wide discretion to impose different or more stringent requirements on a case-by-case basis):
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 48PX; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 48PX; FONT-SIZE: 10PT">
	1.
</TD>
<TD>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	completion of extensive preclinical laboratory tests, preclinical
	animal studies and formulation studies performed in accordance with the FDA&rsquo;s good laboratory practice regulations and other
	regulations;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
</P>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	2.
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	submission to the FDA of an IND application which must become effective before clinical trials may begin;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
</TR>
</TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 48PX; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 48PX; FONT-SIZE: 10PT">
	3.
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	performance of adequate and well-controlled clinical trials meeting FDA requirements to establish the safety and efficacy of the product candidate for each proposed indication;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
</TR>
</TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 48PX; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 48PX; FONT-SIZE: 10PT">
	4.
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	manufacturing (through an FDA-licensed contract manufacturing organization) of product in accordance with current Good Manufacturing Practices, or cGMP, to be used in the clinical trials and providing manufacturing information need in regulatory filings;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
</TR>
</TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 48PX; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 48PX; FONT-SIZE: 10PT">
	5.
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	submission of a BLA to the FDA;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
</TR>
</TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 48PX; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 48PX; FONT-SIZE: 10PT">
	6.
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	satisfactory completion of an FDA pre-approval inspection of the manufacturing facilities at which the product candidate is produced, and potentially other involved facilities as well, to assess compliance with cGMP regulations and other applicable regulations; and
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
</TR>
</TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 48PX; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 48PX; FONT-SIZE: 10PT">
	7.
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	the FDA review and approval of the BLA prior to any commercial marketing, sale or shipment of the product.
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	The testing and approval process requires
	substantial time, effort and financial resources, and we cannot be certain that any approvals for our product candidates will be
	granted on a timely basis, if at all.&nbsp;&nbsp;See the section entitled &ldquo;Item 1A &ndash; Risk Factors&rdquo; beginning
	on page 21 of this annual report on Form 10-K.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	We submit manufacturing and analytical data,
	among other information, to the FDA as part of an IND application.&nbsp;&nbsp;Subject to certain exceptions, an IND becomes effective
	30 days after receipt by the FDA, unless the FDA, within the 30-day time period, issues a clinical hold to delay a proposed clinical
	investigation due to concerns or questions about the product or the conduct of the clinical trial, including concerns that human
	research subjects will be exposed to unreasonable health risks.&nbsp;&nbsp;In such a case, the IND sponsor and the FDA must resolve
	any outstanding concerns before the clinical trial can begin.&nbsp;&nbsp;Our submission of an IND, or those of our collaboration
	partners, may not result in the FDA allowance to commence a clinical trial.&nbsp;&nbsp;A separate submission to an existing IND
	must also be made for each successive clinical trial conducted during product development.&nbsp;&nbsp;The FDA must also approve
	certain changes to an existing IND, such as certain manufacturing changes.&nbsp;&nbsp;Further, an independent institutional review
	board, or IRB, duly constituted to meet FDA requirements, for each medical center proposing to conduct the clinical trial must
	review and approve the plan for any clinical trial before it commences at that center and it must monitor the safety of the study
	and study subjects until completed.&nbsp;&nbsp;The FDA, the IRB or the sponsor may suspend a clinical trial at any time on various
	grounds, including a finding that the subjects or patients are being exposed to an unacceptable health risk.&nbsp;&nbsp;Clinical
	testing also must satisfy extensive Good Clinical Practice, or GCP, requirements and regulations for informed consent.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
</P>
<!-- FIELD: PAGE; SEQUENCE: 19 -->
<DIV STYLE="MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	17
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage20"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<P STYLE="MARGIN: 0PT; TEXT-ALIGN: RIGHT; FONT-SIZE: 8PT">
<A HREF="#E615811_10K-ADMA_HTM_TOC" STYLE="FONT-STYLE: ITALIC">
	Table of Contents
</A>
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<I>
	Clinical Trials
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	For purposes of BLA submission and approval,
	clinical trials are typically conducted in the following three sequential phases, which may overlap (although additional or different
	trials may be required by the FDA as well):
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 48PX; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 48PX; FONT-SIZE: 10PT">
	1.
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	Phase I clinical trials are initially conducted in a limited population to test the product candidate for safety, dose tolerance, absorption, metabolism, distribution and excretion in healthy humans or, on occasion, in patients, such as cancer patients.
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
</TR>
</TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 48PX; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 48PX; FONT-SIZE: 10PT">
	2.
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	Phase II clinical trials are generally conducted in a limited patient population to identify possible adverse effects and safety risks, to determine the efficacy of the product candidate for specific targeted indications and to determine tolerance and optimal dosage.&nbsp;&nbsp;Multiple Phase II clinical trials may be conducted by the sponsor to obtain information prior to beginning larger and more expensive Phase III clinical trials.&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
</TR>
</TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 48PX; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 48PX; FONT-SIZE: 10PT">
	3.
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	Certain Phase III clinical trials are referred to as pivotal trials.&nbsp;&nbsp;When Phase II clinical trials demonstrate that a dose range of the product candidate is effective and has an acceptable safety profile, Phase III clinical trials are undertaken in large patient populations to provide substantial evidence of reproducibility of clinical efficacy results and to further test for safety in an expanded and diverse patient population at multiple, geographically dispersed clinical trial sites.
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	In addition, under the Pediatric Research Equity Act of 2003 (PREA), a BLA application or supplement for
	a new active ingredient, new indication, new dosage form, new dosing regimen, or new route of administration must contain data
	that are adequate to assess the safety and effectiveness of the drug for the claimed indications in all relevant pediatric subpopulations,
	and to support dosing and administration for each pediatric subpopulation for which the product is safe and effective, unless the
	applicant has obtained a waiver or deferral. In 2012, the FDASIA amended the FDCA to require that a sponsor who is planning to
	submit such an application submit an initial Pediatric Study Plan (PSP), within sixty days of an end-of-phase 2 meeting or as may
	be agreed between the sponsor and the FDA. The FDA may, on its own initiative or at the request of the applicant, grant deferrals
	for submission of data or full or partial waivers. The FDA and the sponsor must reach agreement on the PSP.
</P>
<P STYLE="MARGIN: 0PT 0">
	&nbsp;&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	In some cases, the FDA may condition continued approval of a BLA on
	the sponsor&rsquo;s agreement to conduct additional clinical trials, or other commitments.&nbsp;&nbsp;Such post-approval studies
	are typically referred to as Phase IV studies.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<I>
	Biological License Application
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	The results of product candidate development,
	preclinical testing and clinical trials, together with, among other things, detailed information on the manufacture and composition
	of the product and proposed labeling, and the payment of a user fee, are submitted to the FDA as part of a BLA.&nbsp;&nbsp;The
	FDA reviews all BLAs submitted before it accepts them for filing and may reject the filing as inadequate to merit review or may
	request additional information to be submitted in a very short time frame before accepting a BLA for filing.&nbsp;&nbsp;Once a
	BLA is accepted for filing, the FDA begins an in-depth review of the application.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	During its review of a BLA, the FDA
	may refer the application to an advisory committee of experts for their review, evaluation and recommendation as to whether
	the application should be approved, which information is taken into consideration along with FDA&rsquo;s own review
	findings.&nbsp;&nbsp;The FDA may refuse to approve a BLA and issue a&nbsp;CRL&nbsp;if the applicable regulatory criteria are
	not satisfied.&nbsp;&nbsp;In a CRL, it may also require additional clinical or other data, including one or more additional
	pivotal Phase III clinical trials.&nbsp;&nbsp;Even if such requested data are submitted, the FDA may ultimately decide that
	the BLA does not satisfy the criteria for approval and issue a denial of the BLA.&nbsp;&nbsp;Data from clinical trials are
	not always conclusive and the FDA may interpret data differently than we do.&nbsp;&nbsp;If the FDA&rsquo;s evaluations of the
	BLA and the clinical and manufacturing procedures and facilities are favorable, the FDA may issue an approval letter or a
	CRL, which contains the conditions that must be met in order to secure final approval of the BLA.&nbsp;&nbsp;If a CRL is
	issued, a company has up to twelve months to resubmit or withdraw the BLA, unless the FDA allows for an extension. If a CRL is
	issued, if and when those items have been resolved to the FDA&rsquo;s satisfaction, the FDA will issue an approval letter,
	authorizing commercial marketing of the product for certain indications.&nbsp;&nbsp;The FDA may withdraw product approval if
	ongoing regulatory requirements are not met or if safety problems occur after the product reaches the market.&nbsp;&nbsp;In
	addition, the FDA may require testing, including Phase IV clinical trials, and surveillance programs to monitor the effect of
	approved products that have been commercialized, and the FDA has the power to prevent or limit further marketing of a product
	based on the results of these post-marketing programs.&nbsp;&nbsp;Products may be marketed only for the FDA-approved
	indications and in accordance with the FDA-approved label.&nbsp;The FDA generally does not allow drugs to be promoted for
	&ldquo;off-label&rdquo; uses &ndash; that is, uses that are not described in the product&rsquo;s approved labeling and that
	differ from those that were approved by the FDA. Furthermore, the FDA generally limits approved uses to those studied in
	clinical trials. If there are any modifications to the product, including changes in indications, other labeling changes, or
	manufacturing processes or facilities, we may be required to submit and obtain FDA approval of a new BLA or BLA supplement,
	which may require us to develop additional data or conduct additional preclinical studies and clinical trials, and/or require
	additional manufacturing data.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
</P>
<!-- FIELD: PAGE; SEQUENCE: 20 -->
<DIV STYLE="MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	18
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage21"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<P STYLE="MARGIN: 0PT; TEXT-ALIGN: RIGHT; FONT-SIZE: 8PT">
<A HREF="#E615811_10K-ADMA_HTM_TOC" STYLE="FONT-STYLE: ITALIC">
	Table of Contents
</A>
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	Satisfaction of the FDA regulations and
	approval requirements or similar requirements of foreign regulatory agencies typically takes several years, and the actual time
	required may vary substantially based upon the type, complexity and novelty of the product or disease.&nbsp;&nbsp;Typically, if
	a product candidate is intended to treat a chronic disease, as is the case with RI-002, safety and efficacy data must be gathered
	over an extended period of time.&nbsp;&nbsp;Government regulation may delay or prevent marketing of product candidates for a considerable
	period of time and impose costly procedures upon our activities.&nbsp;&nbsp;The FDA or any other regulatory agency may not grant
	approvals for changes in dose form or new indications for a product candidate on a timely basis, or at all.&nbsp;&nbsp;Even if
	a product candidate receives regulatory approval, the approval may be significantly limited to specific disease states, patient
	populations and dosages.&nbsp;&nbsp;Further, even after regulatory approval is obtained, later discovery of previously unknown
	problems with a product may result in restrictions on the product or even complete withdrawal of the product from the market.&nbsp;&nbsp;Delays
	in obtaining, or failures to obtain, regulatory approvals for any of our product candidates would harm our business.&nbsp;&nbsp;In
	addition, we cannot predict what adverse governmental regulations may arise from future U.S. or foreign governmental action.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	Upon the resubmission of a
	BLA application, the FDA will classify the resubmission as Class 1 (triggering a 2-month review goal for the FDA) or Class
	2 (triggering a 6-month review goal for the FDA).
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<I>
	Other Regulatory Requirements
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	Biological drug products manufactured
	or distributed pursuant to FDA approvals are subject to extensive and continuing regulation by the FDA, including, among other
	things, requirements relating to recordkeeping (including certain electronic record and signature requirements), periodic reporting,
	product sampling and distribution, advertising and promotion and reporting of certain adverse experiences, deviations, and other
	problems with the product. After approval, most changes to the approved product, such as adding new indications or other labeling
	claims are subject to prior FDA review and approval. There also are continuing, annual user fee requirements for any marketed products
	and the establishments at which such products are manufactured, as well as new application fees for supplemental applications with
	clinical data.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1IN; TEXT-INDENT: -1IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	Manufacturers must continue to comply
	with cGMP requirements, which are extensive and require considerable time, resources and ongoing investment to ensure compliance.
	In addition, changes to the manufacturing process generally require prior FDA approval before being implemented and other types
	of changes to the approved product, such as adding new indications and additional labeling claims, are also subject to further
	FDA review and approval.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1IN; TEXT-INDENT: 0IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	Manufacturers and certain other entities
	involved in the manufacturing and distribution of approved products are required to register their establishments with the FDA
	and certain state agencies, and are subject to periodic unannounced inspections by the FDA and certain state agencies for compliance
	with cGMP and other laws. The cGMP requirements apply to all stages of the manufacturing process, including the production, processing,
	sterilization, packaging, labeling, storage and shipment of the product. Manufacturers must establish validated systems to ensure
	that products meet specifications and regulatory standards, and test each product batch or lot prior to its release. For biologics
	products in particular, for each product lot the applicant must submit materials relating to that lot to the FDA before the lot
	can be released for distribution.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1IN; TEXT-INDENT: 0IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	Changes to the manufacturing process
	are strictly regulated and often require prior FDA approval before being implemented. FDA regulations also require investigation
	and correction of any deviations from cGMP and impose reporting and documentation requirements upon the sponsor and any third-party
	manufacturers that the sponsor may decide to use. Accordingly, manufacturers must continue to expend time, money, and effort in
	the area of production and quality control to maintain cGMP compliance.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1IN; TEXT-INDENT: 0IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	The FDA may impose a number of
	post-approval requirements as a condition of approval of an application. The FDA may withdraw a product approval if
	compliance with regulatory requirements is not maintained or if problems occur after the product reaches the market. Later
	discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency,
	problems with manufacturing processes, or failure to comply with regulatory requirements, may result in restrictions on the
	product or even complete withdrawal of the product from the market. Failure to comply with the statutory and regulatory
	requirements can subject a manufacturer to possible legal or regulatory action, such as warning letters, suspension of
	manufacturing, sales or use, seizure of product, injunctive action or possible fines and other penalties.&nbsp;&nbsp;We
	cannot be certain that we or our present or future third-party manufacturers or suppliers will be able to comply with the
	cGMP regulations and other ongoing FDA regulatory requirements.&nbsp;&nbsp;If we or our present or future third-party
	manufacturers or suppliers are not able to comply with these requirements, the FDA may halt our clinical trials, require us
	to recall a product from distribution, or withdraw approval of the BLA for that product.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	The FDA closely regulates the post-approval
	marketing and promotion of products, including standards and regulations for direct-to-consumer advertising, off-label promotion,
	industry-sponsored scientific and educational activities and promotional activities involving the Internet.&nbsp;&nbsp;A company
	can make only those claims relating to safety and efficacy that are approved by the FDA.&nbsp;&nbsp;Failure to comply with these
	requirements can result in adverse publicity, warning and/or other regulatory letters, corrective advertising and potential major
	fines and other penalties.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	In addition, the distribution of
	prescription drug products (including biological drug products) is subject to the Prescription Drug Marketing Act (PDMA), which
	regulates the distribution of drugs and drug samples at the federal level, and sets minimum standards for the registration and
	regulation of drug distributors by the states. Both the PDMA and state laws limit the distribution of prescription product samples
	and impose requirements to ensure accountability in distribution.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1IN; TEXT-INDENT: -1IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	From time to time, legislation is drafted, introduced and passed in Congress that could significantly
	change the statutory provisions governing the approval, manufacturing and marketing of products regulated by the FDA. In addition
	to new legislation, FDA regulations, guidance, and policies are often revised or reinterpreted by the agency in ways that may
	significantly affect our business and our product candidates. It is impossible to predict whether further legislative or FDA regulation
	or policy changes will be enacted or implemented and what the impact of such changes, if any, may be.
</P>
<P STYLE="MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
</P>
<!-- FIELD: PAGE; SEQUENCE: 21 -->
<DIV STYLE="MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	19
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage22"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<P STYLE="MARGIN: 0PT; TEXT-ALIGN: RIGHT; FONT-SIZE: 8PT">
<A HREF="#E615811_10K-ADMA_HTM_TOC" STYLE="FONT-STYLE: ITALIC">
	Table of Contents
</A>
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<I>
	Regulation of ADMA BioCenters
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	All blood and blood product collection and
	manufacturing centers which engage in interstate commerce must be licensed by the FDA.&nbsp;&nbsp;In order to achieve licensure,
	the organization must submit a BLA and undergo pre-licensure inspection.&nbsp;&nbsp;Our ADMA BioCenters, located in Norcross and
	Marietta, Georgia, have completed these requirements and hold FDA licenses along with GHA and MFDS certifications.&nbsp;&nbsp;In
	order to maintain the license, the facilities operated by ADMA BioCenters will be inspected at least every two years.&nbsp;&nbsp;ADMA
	BioCenters is also required to submit annual reports to the FDA.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	Blood plasma collection and manufacturing
	centers are also subject to the Clinical Laboratory Improvement Amendments, or CLIA, state licensure, and compliance with industry
	standards such as the International Quality Plasma Program, or IQPP. Compliance with state and industry standards is verified by
	means of routine inspection.&nbsp;We believe that both of our&nbsp;ADMA BioCenters facilities are currently in compliance with
	state and industry standards.&nbsp;&nbsp;Delays in obtaining, or failures to obtain, regulatory approvals for any facilities operated
	by ADMA BioCenters would harm our business.&nbsp;&nbsp;In addition, we cannot predict what adverse federal and state regulations
	and industry standards may arise in the future.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<I>
	Foreign Regulation
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	In addition to regulations in the U.S., if we choose to pursue clinical development and commercialization in the European Union, we will be subject to a variety
	of foreign regulations governing clinical trials and commercial sales and distribution of any future product.&nbsp;&nbsp;Whether
	or not we obtain FDA approval for a product, we must obtain approval of a product by the comparable regulatory authorities of foreign
	countries before we can commence clinical trials or marketing of the product in those countries.&nbsp;&nbsp;The approval process
	varies from country to country, and the time may be longer or shorter than that required for FDA approval.&nbsp;&nbsp;The requirements
	governing the conduct of clinical trials, product licensing, pricing and reimbursement vary greatly from country to country.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	Under European Union regulatory systems,
	marketing authorizations may be submitted either under a centralized or mutual recognition procedure.&nbsp;&nbsp;The centralized
	procedure provides for the grant of a single marketing authorization that is valid for all European Union member states.&nbsp;&nbsp;The
	mutual recognition procedure provides for mutual recognition of national approval decisions.&nbsp;&nbsp;Under this procedure, the
	holder of a national marketing authorization may submit an application to the remaining member states.&nbsp;&nbsp;Within 90 days
	of receiving the applications and assessment report, each member state must decide whether to recognize approval, refuse it or
	request additional information.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1IN; TEXT-INDENT: -1IN">
<I>
	Product Coverage, Pricing and
	Reimbursement
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1IN; TEXT-INDENT: -1IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	Significant uncertainty exists as
	to the coverage and reimbursement status of any products for which we may obtain regulatory approval. In the U.S., sales
	of any products for which we may receive regulatory approval for commercial sale will depend in part on the availability of coverage
	and reimbursement from third-party payors. Third-party payors include government authorities, managed care providers, private health
	insurers and other organizations. The process for determining whether a payor will provide coverage for a drug product may be separate
	from the process for setting the reimbursement rate that the payor will pay for the drug product. Third-party payors may limit
	coverage to specific drug products on an approved list, or formulary, which might not include all of the FDA-approved drugs for
	a particular indication. Moreover, a payor&rsquo;s decision to provide coverage for a drug product does not imply that an adequate
	reimbursement rate will be approved. Adequate third-party reimbursement may not be available to enable us to maintain price levels
	sufficient to realize an appropriate return on our investment in product development.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1IN; TEXT-INDENT: 0IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	Third-party payors are increasingly
	challenging the price and examining the medical necessity and cost-effectiveness of medical products and services, in addition
	to their safety and efficacy. In order to obtain coverage and reimbursement for any product that might be approved for sale, we
	may need to conduct expensive pharmacoeconomic studies in order to demonstrate the medical necessity and cost-effectiveness of
	any products, in addition to the costs required to obtain regulatory approvals. Our product candidates may not be considered medically
	necessary or cost-effective. If third-party payors do not consider a product to be cost-effective compared to other available therapies,
	they may not cover the product after approval as a benefit under their plans or, if they do, the level of payment may not be sufficient
	to allow a company to sell its products at a profit.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1IN; TEXT-INDENT: 0IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	The U.S. government and state legislatures
	have shown significant interest in implementing cost containment programs to limit the growth of government-paid health care costs,
	including price controls, restrictions on reimbursement and requirements for substitution of generic products for branded prescription
	drugs. For example, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation
	Act, collectively, the Healthcare Reform Law, contains provisions that may reduce the profitability of drug products, including,
	for example, increased rebates for drugs reimbursed by Medicaid programs, extension of Medicaid rebates to Medicaid managed care
	plans, mandatory discounts for certain Medicare Part D beneficiaries and annual fees based on pharmaceutical companies&rsquo; share
	of sales to federal health care programs. Adoption of government controls and measures, and tightening of restrictive policies
	in jurisdictions with existing controls and measures, could limit payments for pharmaceuticals.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1IN; TEXT-INDENT: 0IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	The marketability of any products for which we receive regulatory approval for commercial sale may suffer
	if the government and third-party payors fail to provide adequate coverage and reimbursement. In addition, an increasing emphasis
	on cost containment measures in the U.S. has increased and we expect will continue to increase the pressure on pharmaceutical
	pricing. Coverage policies and third-party reimbursement rates may change at any time. Even if favorable coverage and reimbursement
	status is attained for one or more products for which we receive regulatory approval, less favorable coverage policies and reimbursement
	rates may be implemented in the future.
</P>
<P STYLE="MARGIN: 0PT 0">
	&nbsp;&nbsp;
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Research and Development
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	ADMA&rsquo;s expenditures on research and
	development were approximately $7.7 million and $7.0 million for the fiscal years ended December 31, 2016 and 2015, respectively.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	Employees
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	ADMA Biologics, Inc., together with its
	subsidiaries ADMA Plasma Biologics, Inc. and ADMA BioCenters, Inc., has a total of 92 employees, which include 5 part-time employees,
	as well as additional full and part-time consultants and temporary staff.&nbsp;&nbsp; Over the course of the next year, we anticipate
	hiring additional full-time employees devoted to sales and marketing, medical and scientific affairs, general and administrative,
	as well as hiring additional staff to the plasma collection centers as appropriate.&nbsp;&nbsp;We intend to use Clinical Research
	Organizations, or CROs, third parties and consultants to perform our clinical studies and manufacturing, regulatory affairs and
	quality control services in addition to corporate marketing, branding and commercialization activities.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	Corporate Information
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN; BACKGROUND-COLOR: WHITE">
	ADMA Biologics,
	Inc. was founded&nbsp;on June 24, 2004 as a New Jersey corporation and re-incorporated in Delaware on July 16, 2007 (&ldquo;Former
	ADMA&rdquo;). On February 13, 2012,&nbsp;Former ADMA merged&nbsp;into a subsidiary of R&amp;R Acquisition VI, Inc., a Delaware&nbsp;&ldquo;blank
	check&rdquo; company, which had been incorporated in 2006 and&nbsp;which&nbsp;subsequently changed its name to ADMA Biologics,
	Inc. upon completion of the merger.&nbsp;&nbsp;
<FONT STYLE="BACKGROUND-COLOR: WHITE">
	For accounting purposes, the merger was accounted
	for as a reverse acquisition, with&nbsp;Former ADMA as the accounting acquiror (legal acquiree) and&nbsp;R&amp;R Acquisition VI,
	Inc. (now ADMA Biologics, Inc.)&nbsp;as the accounting acquiree (legal acquiror), effectively a recapitalization of&nbsp;Former
	ADMA.
</FONT>
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN; BACKGROUND-COLOR: WHITE">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN; BACKGROUND-COLOR: WHITE">
</P>
<!-- FIELD: PAGE; SEQUENCE: 22 -->
<DIV STYLE="MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	20
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage23"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<P STYLE="MARGIN: 0PT; TEXT-ALIGN: RIGHT; FONT-SIZE: 8PT">
<A HREF="#E615811_10K-ADMA_HTM_TOC" STYLE="FONT-STYLE: ITALIC">
	Table of Contents
</A>
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN; BACKGROUND-COLOR: WHITE">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN; BACKGROUND-COLOR: WHITE">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	The Company maintains a website at
	www.admabiologics.com; however, the information on, or that can be accessed through, our website is not part of this annual
	report on Form 10-K. This annual report on Form 10-K and all of the Company's filings under the Exchange Act, including
	copies of annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K, and any amendments to
	those reports, are available free of charge through our website on the date we file those materials with, or furnish them to,
	the U.S. Securities and Exchange Commission, or the SEC. Such filings are also available to the public on the internet at the
	SEC's website at www.sec.gov. The public may also read and copy any document that we file at the SEC's Public Reference Room
	located at 100 F Street, NE, Washington, D.C. 20549 on official business days during the hours of 10 a.m. to 3 p.m. For
	further information on the Public Reference Room, the public is instructed to call the SEC at 1-800-SEC-0330.
</P>
</EFX_BUSINESS>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<EFX_RISK_FACTORS>
<A NAME="FIS_RISK_FACTORS"></A>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
<A NAME="E615811_10K-ADMA_HTM_ITEM1A">
</A>
	Item 1A. Risk Factors
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<I>
	There are numerous and varied risks that may prevent us from
	achieving our goals.&nbsp;&nbsp;We believe that the following are the material risks that we face.&nbsp;&nbsp;If any of the following
	risks actually occurs, our business, financial condition or results of operations may be materially adversely affected.&nbsp;&nbsp;In
	such case, the trading price of our common stock could decline and investors in our common stock could lose all or part of their
	investment.
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Risks Relating to our Business
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
<I>
	To date, we have generated limited product revenues, we
	have a history of losses and will need to raise additional capital to operate our business, which may not be available on favorable
	terms, if at all
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	To date, we have generated nearly all of
	our revenues from our plasma collections facilities derived from the sale of plasma, as well as our other plasma inventory sales.
	Unless and until we receive approval from the FDA and other regulatory authorities for our RI-002 product candidate, we do not
	expect to sell and generate revenue from the commercialization of RI-002 and we will be required to raise additional funds through
	the sale of equity and/or debt securities or otherwise to, among others, establish a commercial salesforce, infrastructure and
	recognize any significant sales.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	Our long term liquidity will depend upon
	our ability to raise additional capital, fund our research and development and commercial programs, establish and build out a commercial
	sales force and commercial infrastructure and meet our ongoing obligations.&nbsp;&nbsp;If we are unable to successfully raise additional
	capital during the second half of 2017, we will likely not have sufficient cash flow and liquidity to fund our business operations
	as we currently operate, forcing us to curtail our activities and&nbsp;potentially significantly reduce, or potentially cease operations.
	Even if we are able to raise additional capital, such financings may only be available on unattractive terms, resulting in significant
	dilution of stockholders' interests and, in such event, the value and potential future market price of our common stock may decline.
	In addition, if we raise additional funds through license arrangements or through the disposition of any of our assets, it may
	be necessary to relinquish potentially valuable rights to our product candidates or assets or grant licenses on terms that are
	not favorable to us.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	Based upon the our projected revenue and
	expenditures for 2017, including regulatory and consulting fees for RI-002 associated with third-party manufacturers and ongoing
	discussions with the FDA, continuing implementation of our commercialization and expansion activities and certain other assumptions,
	management currently believes that its cash, cash equivalents, short-term investments, projected revenue and accounts receivable
	are sufficient to fund our operations, as currently conducted, into the second half of 2017. These estimates may change based upon
	whether or when the FDA approves RI-002, the timing of any required commercial manufacturing scale up activities or if any of our
	other assumptions change. These estimates may also change based upon the timing of the completion of the Proposed Acquisition which
	is anticipated during the first half of 2017. Upon the closing of the Proposed Acquisition, BPC will be providing funds to
	us consisting of: $12.5 million in funding, $15.0 million in debt financing and an additional $12.5 million commitment towards
	a future equity financing is expected to be sufficient to fund operations into the first quarter of 2018. There is no assurance
	that we will be able to successfully close on the Proposed Acquisition. Other than the funding to be provided by BPC, we currently
	do not have arrangements to obtain additional financing. Any such financing could be difficult to obtain or only available on unattractive
	terms and could result in significant dilution to stockholders. Failure to secure necessary financing in a timely manner and on
	favorable terms could have a material adverse effect on our business plan and financial performance and could delay, discontinue
	or prevent product development, clinical trial or commercialization activities, or the approval of any of our potential products.
	In addition, we could be forced to reduce or forego sales and marketing efforts and forego attractive business opportunities.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
</P>
<!-- FIELD: PAGE; SEQUENCE: 23 -->
<DIV STYLE="MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	21
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage24"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<P STYLE="MARGIN: 0PT; TEXT-ALIGN: RIGHT; FONT-SIZE: 8PT">
<A HREF="#E615811_10K-ADMA_HTM_TOC" STYLE="FONT-STYLE: ITALIC">
	Table of Contents
</A>
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
<I>
	We are not currently profitable and may never become profitable.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	We have a history of losses and expect to
	incur substantial losses and negative operating cash flow for the foreseeable future, and we may never achieve or maintain profitability.
	For the years ended December 31, 2016 and 2015, we incurred net losses of $19.5 million and $18.0 million, respectively, and from
	our inception in 2004 through December 31, 2016, we have incurred an accumulated deficit of $106.9 million. Even if we succeed
	in developing and commercializing one or more of our product candidates, we expect to incur substantial losses for the foreseeable
	future and may never become profitable. We also expect to continue to incur significant operating and capital expenditures and
	anticipate that our operating expenses will increase substantially in the foreseeable future as we
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	:
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	seek regulatory approval(s);
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	initiate commercialization and marketing efforts;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	implement additional internal systems, controls and infrastructure;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	hire additional personnel;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	expand and build out of our plasma center network; and
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	integrate the assets which we intend to acquire in the Proposed Acquisition
	into our business post-closing.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	We also expect to experience negative cash
	flow for the foreseeable future as we fund our operating losses and capital expenditures. As a result, we will need to generate
	significant revenues in order to achieve and maintain profitability. We may not be able to generate these revenues or achieve profitability
	in the future. Our failure to achieve or maintain profitability could negatively impact the value of our securities.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
<I>
	Relying exclusively on third-parties to manufacture and
	commercialize our product candidates exposes us to risks that may delay: testing, development, regulatory approval, commercialization
	and overall manufacturing of our product candidates.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	We currently lack the internal resources
	to manufacture RI-002, our lead product candidate. Although we have agreements pertaining to the manufacture, testing, supply,
	storage and distribution of product supplies of RI-002, upon commercialization, it is possible that our manufacturing requirements
	may exceed the available supply allotments under our existing agreements. We rely on one third-party contractor to manufacture
	RI-002. Our anticipated future reliance on a limited number of third-party manufacturers exposes us to the following risks:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 48PX; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX; FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	we may be unable to identify manufacturers on acceptable terms or at all because the number of potential manufacturers is limited and the FDA must approve any replacement contractor. This approval would require new testing and compliance inspections. In addition, a new manufacturer would have to be educated in, or develop substantially equivalent processes for, production of our products after receipt of FDA approval, if any;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	third-party manufacturers might be unable to manufacture our products in the volume and of the quality required to meet our clinical and commercial needs, if any;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
</TR>
</TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 48PX; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX; FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	contract manufacturers may not perform as agreed, and operate their business independently from ADMA.&nbsp;&nbsp;Contract manufacturers are directly responsible for their own FDA cGMP interactions and ADMA may not be privy to all ongoing discussions and information concerning products or process unrelated to ADMA.&nbsp;&nbsp;Additionally, contract manufacturers may not remain in the contract manufacturing business for the time required to successfully produce, store and distribute our products;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 24 -->
<DIV STYLE="MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	22
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage25"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<P STYLE="MARGIN: 0PT; TEXT-ALIGN: RIGHT; FONT-SIZE: 8PT">
<A HREF="#E615811_10K-ADMA_HTM_TOC" STYLE="FONT-STYLE: ITALIC">
	Table of Contents
</A>
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 48PX; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX; FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	product manufacturers are subject to ongoing periodic unannounced inspection by the FDA, the Drug Enforcement Administration, and corresponding state agencies to ensure strict compliance with cGMP and other government regulations and corresponding foreign standards. We do not have control over third-party manufacturers' compliance with these regulations and standards and our manufacturers may be found to be in noncompliance with certain regulations, which may impact our ability to manufacture our drug product candidates and may impact the regulatory status of ADMA and its product candidates; and
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	if any third-party manufacturer makes improvements in the manufacturing process for our products, we may not own, or may have to share, the intellectual property rights to the innovation. We may be required to pay fees or other costs for access to such improvements and additional clinical trials or other studies may be required.
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	Each of these risks could delay the approval,
	if any, of our product candidates by the FDA or the commercialization of our product candidates or result in higher costs or deprive
	us of potential product revenues. Our contract manufacturer announced in November 2014 that it received a warning letter from the
	FDA relating to an inspection at its Boca Raton, Florida location, which, we are informed, does not prevent the manufacturing or
	distribution of any of our contract manufacturer&rsquo;s commercial products. Failure to resolve any outstanding issues or any
	administrative actions or changes taken by FDA toward our contract manufacturers, vendors or us, could impact our ability to receive
	approval, including the timing thereof, for RI-002, disrupt our business operations and the timing of our commercialization efforts,
	and may have a material adverse effect on our financial condition and operating results.&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	If we do not achieve one or more of these
	factors in a timely manner or at all, we could experience significant delays or an inability to successfully commercialize our
	product candidates, which would materially harm our business.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
<I>
	Although our financial statements have been prepared on
	a going concern basis, we must raise additional capital during the second half of 2017 to fund our operations in order to continue
	as a going concern.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	CohnReznick LLP, our independent registered
	public accounting firm for the fiscal year ended December 31, 2016, has included an explanatory paragraph in their opinion that
	accompanies our audited consolidated financial statements as of and for the year ended December 31, 2016, indicating that our current
	liquidity position raises substantial doubt about our ability to continue as a going concern. If we are unable to improve our liquidity
	position we may not be able to continue as a going concern.&nbsp; If we are unable to continue as a going concern, we may have
	to liquidate our assets and may receive less than the value at which those assets are carried on our financial statements. We may
	also be forced to make reductions in spending, including delaying or curtailing our clinical development, trials or commercialization
	efforts, or seek to extend payment terms with our vendors and licensing partners. Our ability to raise or borrow the capital needed
	to improve our financial condition may be hindered by a variety of factors, including market conditions and the availability of
	such financing on acceptable terms, if at all. If we are unable to obtain sufficient funding, our business, prospects, financial
	condition and results of operations will be materially and adversely affected and we may be unable to continue as a going concern.
	The accompanying consolidated financial statements do not include any adjustments that might result if we are unable to continue
	as a going concern and, therefore, be required to realize our assets and discharge our liabilities other than in the normal course
	of business which could cause our security holders to suffer the loss of all or a substantial portion of their investment in our
	company.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 24.5PT">
	We anticipate that our principal sources
	of liquidity will only be sufficient to fund our activities as currently conducted and financial obligations into the second half
	of 2017. In order to have sufficient cash to fund our operations thereafter, we will need to raise additional equity or debt capital
	by the end of the second half of 2017 in order to continue as a going concern, and we cannot provide any assurance that we will
	be successful in doing so. This time frame may change based upon the timing of our commercial manufacturing scale up activities
	and the timing of the closing of the Proposed Acquisition. If our assumptions underlying our estimated expenses prove to be wrong,
	we may have to raise additional capital sooner than the second half of 2017. These assumptions may also change based upon the timing
	of the completion of the Proposed Acquisition, anticipated during the first half of 2017, of which funds received from BPC
	at the closing of the Proposed Acquisition are expected to be sufficient to fund operations into the first quarter of 2018.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 24.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 24.5PT">
</P>
<!-- FIELD: PAGE; SEQUENCE: 25 -->
<DIV STYLE="MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	23
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage26"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<P STYLE="MARGIN: 0PT; TEXT-ALIGN: RIGHT; FONT-SIZE: 8PT">
<A HREF="#E615811_10K-ADMA_HTM_TOC" STYLE="FONT-STYLE: ITALIC">
	Table of Contents
</A>
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 24.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 24.5PT">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
<I>
	We have a limited operating history upon which to base
	an investment decision.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	We have not demonstrated an ability to perform
	the functions necessary for the successful commercialization of RI-002. The successful development and commercialization of any
	product candidate will require us or our collaborators to perform a variety of functions, including:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	undertaking product development and clinical trials;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	participating in regulatory approval processes;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	formulating and manufacturing products; and
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	conducting sales and marketing activities once authorized.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	Our operations thus far provide a limited
	basis for you to assess our ability to commercialize our product candidates and the advisability of investing in our securities.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
<I>
	Our lead product candidate, RI-002, requires extensive
	clinical data analysis and regulatory review and may require additional testing. Clinical trials and data analysis can be very
	expensive, time-consuming and difficult to design and implement. If we are unsuccessful in obtaining regulatory approval for RI-002,
	or any of our product candidates don't provide positive results, we may be required to delay or abandon development of such product,
	which would have a material adverse impact on our business.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	Continuing product development requires
	additional and extensive clinical testing. Human clinical trials are very expensive and difficult to design and implement, in part
	because they are subject to rigorous regulatory requirements. The clinical trial process is also time consuming. We cannot provide
	any assurance or certainty regarding when we might complete the clinical trial process or receive regulatory approval for our BLA
	for RI-002. Furthermore, failure can occur at any stage of the process, and we could encounter problems that cause us to abandon
	or repeat clinical trials. The commencement and completion of clinical trials may be delayed by several factors, including:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	unforeseen safety issues;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	determination of dosing issues;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	lack of effectiveness during clinical trials;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	slower than expected rates of patient recruitment;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	inability to monitor patients adequately during or after treatment;
	and
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	inability or unwillingness of medical investigators to follow our
	clinical protocols.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	In addition, the FDA or an IRB may suspend
	our clinical trials at any time if it appears that we are exposing participants to unacceptable health risks or if the FDA finds
	deficiencies in our IND submissions or the conduct of these trials. Therefore, we cannot provide any assurance or predict with
	certainty the schedule for future clinical trials. In the event we do not ultimately receive regulatory approval for RI-002, we
	may be required to terminate development of our only product candidate. Unless we acquire or develop other product candidates that
	are saleable, our business will be limited to plasma collection and sales.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
<I>
	If the results of our clinical trials do not support our
	product candidate claims, completing the development of such product candidate may be significantly delayed or we may be forced
	to abandon development of such product candidate altogether.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	Even though our clinical trials have been
	completed as planned, we cannot be certain that their results will support our product candidate claims. Success in preclinical
	testing and early clinical trials does not ensure that later clinical trials will be successful, and we cannot be sure that the
	results of later clinical trials will replicate the results of prior clinical trials and preclinical testing. The clinical trial
	process may fail to demonstrate that our product candidates are safe for humans and effective for indicated uses. This failure
	would cause us to abandon a product candidate and may delay development of other product candidates. Any delay in, or termination
	of, our clinical trials will delay our ability to commercialize our product candidates and generate product revenues. In addition,
	our clinical trials involve a relatively small patient population. Because of the small sample size, the results of these clinical
	trials may not be indicative of future results. In addition, certain portions of the clinical trial and product testing for RI-002
	were performed outside of the U.S., and therefore, may not have been performed in accordance with standards normally required
	by the FDA and other regulatory agencies.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
</P>
<!-- FIELD: PAGE; SEQUENCE: 26 -->
<DIV STYLE="MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	24
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage27"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<P STYLE="MARGIN: 0PT; TEXT-ALIGN: RIGHT; FONT-SIZE: 8PT">
<A HREF="#E615811_10K-ADMA_HTM_TOC" STYLE="FONT-STYLE: ITALIC">
	Table of Contents
</A>
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
<I>
	Currently, our only viable product candidate is RI-002.
	If we do not obtain the necessary U.S. or worldwide regulatory approvals to commercialize RI-002, we will not be able to sell RI-002.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	At the present time, our entire focus is
	obtaining regulatory approval for RI-002, our only product candidate. If we cannot obtain regulatory approval for RI-002, our only
	source of revenue will be plasma collection and sales. We cannot assure you that we will receive the approvals necessary to commercialize
	RI-002 or any other product candidate we may acquire or develop in the future. In order to obtain FDA approval of RI-002 or any
	other product candidate requiring FDA approval, our clinical development must demonstrate that the product candidate is safe for
	humans and effective for its intended use, and we must submit a BLA. To obtain required FDA approval of any other product candidate
	generally requires significant research and testing, referred to as preclinical studies, as well as human tests, referred to as
	clinical trials. Satisfaction of the FDA's regulatory requirements typically takes many years, depends upon the type, complexity
	and novelty of the product candidate and requires substantial resources for research, development and testing. We cannot predict
	whether our research and clinical approaches will result in products that the FDA considers safe for humans and effective for indicated
	uses. The FDA has substantial discretion in the product approval process and may require us to conduct additional preclinical and
	clinical testing or to perform post-marketing studies. The approval process may also be delayed by changes in government regulation,
	future legislation or administrative action or changes in FDA policy that occur prior to or during our regulatory review. Delays
	in obtaining regulatory approvals may:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	delay commercialization of, and our ability to derive product revenues
	from, our product candidate;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	impose costly procedures on us; and
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	diminish any competitive advantages that we may otherwise enjoy.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	Even if we comply with all FDA requests,
	the FDA may ultimately reject our BLA. Our BLA is dependent upon our third party manufacturer continuing operations and maintaining
	compliance with rules and regulations. In addition, the FDA could determine that we must test additional subjects and/or require
	that we conduct further studies with more subjects.&nbsp;We may never obtain regulatory approval for RI-002, or any other potential
	product candidate. Failure to obtain FDA approval of any of our product candidates will severely undermine our business by leaving
	us without a saleable product beyond the plasma collected by ADMA BioCenters, and therefore without any source of additional revenues
	if and until another product candidate can be developed and commercialized. There is no guarantee that we will ever be able to
	develop or acquire another product candidate. In foreign jurisdictions, we must receive approval from the appropriate regulatory
	authorities before we can commercialize any products. Foreign regulatory approval processes generally include all of the risks
	associated with the FDA approval procedures described above. We cannot assure you that we will receive the approvals necessary
	to commercialize any product candidate for sale outside the U.S.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
<I>
	Even if we receive approval from the&nbsp;FDA to market
	RI-002, our ability to market RI-002 for alternative applications could be limited.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	The FDA strictly regulates marketing, labeling,
	advertising and promotion of prescription drugs. These regulations include standards and restrictions for direct-to-consumer advertising,
	industry-sponsored scientific and educational activities, promotional activities involving the Internet and off-label promotion.
	The FDA generally does not allow drugs to be promoted for &ldquo;off-label&rdquo; uses&thinsp;&mdash;&thinsp;that is, uses that
	are not described in the product&rsquo;s labeling and that differ from those that were approved by the FDA. Generally, the FDA
	limits approved uses to those studied by a company in its clinical trials. In addition to the FDA approval required for new formulations,
	any new indication for an approved product also requires FDA approval. We have sought approval from FDA to market RI-002 for the
	treatment of PIDD and, even if approved, we cannot be sure whether we will be able to obtain FDA approval for any desired future
	indications for RI-002.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
</P>
<!-- FIELD: PAGE; SEQUENCE: 27 -->
<DIV STYLE="MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	25
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage28"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<P STYLE="MARGIN: 0PT; TEXT-ALIGN: RIGHT; FONT-SIZE: 8PT">
<A HREF="#E615811_10K-ADMA_HTM_TOC" STYLE="FONT-STYLE: ITALIC">
	Table of Contents
</A>
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	While physicians in the U.S. may choose,
	and are generally permitted to prescribe drugs for uses that are not described in the product&rsquo;s labeling, and for uses that
	differ from those tested in clinical studies and approved by the regulatory authorities, our ability to promote our products is
	narrowly limited to those indications that are specifically approved by the FDA. &ldquo;Off-label&rdquo; uses are common across
	medical specialties and may constitute an appropriate treatment for some patients in varied circumstances. Regulatory authorities
	in the U.S. generally do not regulate the behavior of physicians in their choice of treatments. Regulatory authorities do, however,
	restrict communications by pharmaceutical companies on the subject of off-label use. Although recent court decisions suggest that
	certain off-label communications (e.g., truthful and non-misleading speech) may be protected under the First Amendment, the scope
	of any such protection is unclear, and there are still significant risks in this area as it is unclear how these court decisions
	will impact the FDA&rsquo;s enforcement practices, and there is likely to be substantial disagreement and difference of opinion
	regarding whether any particular statement is truthful and not misleading. Moreover, while we intend to promote our products
	consistent with what we believe to be the approved indication for our drugs, the FDA may disagree. If the FDA determines that
	our promotional activities fail to comply with the FDA&rsquo;s regulations or guidelines, we may be subject to warnings from,
	or enforcement action by, these authorities. In addition, our failure to follow FDA rules and guidelines relating to promotion
	and advertising may cause the FDA to issue warning letters or untitled letters, bring an enforcement action against us, suspend
	or withdraw an approved product from the market, require a recall or institute fines or civil fines, or could result in disgorgement
	of money, operating restrictions, injunctions or criminal prosecution, any of which could harm our reputation and our business.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
<I>
	We depend on third-party researchers, developers and vendors
	to develop RI-002, and such parties are, to some extent, outside of our control.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	We depend on independent investigators and
	collaborators, such as universities and medical institutions, contract laboratories, clinical research organizations and consultants
	to conduct our preclinical and clinical trials under agreements with us. These collaborators are not our employees and we cannot
	control the amount or timing of resources that they devote to our programs. These investigators may not assign as great a priority
	to our programs or pursue them as diligently as we would if we were undertaking such programs ourselves. If outside collaborators
	fail to devote sufficient time and resources to our product-development programs, or if their performance is substandard, the approval
	of our FDA application(s), if any, and our introduction of new products, if any, will be delayed. These collaborators may also
	have relationships with other commercial entities, some of whom may compete with us. If our collaborators assist our competitors
	at our expense, our competitive position would be harmed.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
<I>
	A single customer accounts for a significant amount of
	our revenues and, together with a second customer represent greater than 95% of our total revenues, and, therefore, the loss of
	such single customer could have a material adverse effect on our business, results of operations and financial condition.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	A significant amount of our revenues are
	attributed to a single customer, BPC. For the fiscal year ended December 31, 2016, two of our customers, SK and BPC, represented
	greater than 95% of our total revenues, with BPC representing approximately 82% of our total revenues and SK representing approximately
	14% of our total revenues. We believe SK will represent approximately less than 10% of our total revenues for 2017.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	Our relationships with BPC and SK are
	arm's length commercial relationships. The loss of either or both of BPC and SK as a customer or a material change in the revenue
	generated by either or both of Biotest and SK could have a material adverse effect on our business, results of operations and financial
	condition. Factors that could influence our relationships with our customers include, among other things:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	our ability to sell our products at prices that are competitive with
	our competitors;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	our ability to maintain features and quality standards for our products
	sufficient to meet the expectations of our customers; and
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	our ability to produce and deliver a sufficient quantity of our products
	in a timely manner to meet our customers&rsquo; requirements.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	Additionally, an adverse change in the financial
	condition of either or both of BPC and SK could have a material adverse effect on our business and results of operations.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
</P>
<!-- FIELD: PAGE; SEQUENCE: 28 -->
<DIV STYLE="MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	26
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage29"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<P STYLE="MARGIN: 0PT; TEXT-ALIGN: RIGHT; FONT-SIZE: 8PT">
<A HREF="#E615811_10K-ADMA_HTM_TOC" STYLE="FONT-STYLE: ITALIC">
	Table of Contents
</A>
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
<I>
	Relying exclusively on third parties to manufacture and
	commercialize&nbsp;our product candidates exposes us to risks that may delay: testing, development, regulatory approval, commercialization
	and overall manufacturing of our product candidates.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	We have limited internal experience in manufacturing
	operations and have not historically established our own manufacturing facilities. We currently lack the internal resources to
	manufacture RI-002. Although we have agreements pertaining to the manufacture, testing, supply, storage and distribution of product
	supplies of RI-002, upon commercialization, it is possible that our manufacturing requirements may exceed the available supply
	allotments under our existing agreements. We currently rely on one third-party contractor to manufacture RI-002. Our anticipated
	future reliance on a limited number of third-party manufacturers exposes us to the following risks:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	we may be unable to identify manufacturers on acceptable terms or
	at all because the number of potential manufacturers is limited and the FDA must approve any replacement contractor. This approval
	would require new testing and compliance inspections. In addition, a new manufacturer would have to be educated in, or develop
	substantially equivalent processes for, production of our products after receipt of FDA approval, if any;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	third-party manufacturers might be unable to manufacture our products
	in the volume and of the quality required to meet our clinical and commercial needs, if any;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	contract manufacturers may not perform as agreed or may not remain in the contract manufacturing business for the time required
	to successfully produce, store and distribute our products;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 38.25PT">
</TD>
<TD STYLE="WIDTH: 18PT">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	product manufacturers are subject to ongoing periodic unannounced inspection by the FDA, the Drug Enforcement Administration,
	and corresponding state agencies to ensure strict compliance with good manufacturing practice (cGMP) and other government regulations
	and corresponding foreign standards. We do not have control over third-party manufacturers' compliance with these regulations and
	standards and our manufacturers may be found to be in noncompliance with certain regulations, which may impact our ability to manufacture
	our drug product; and
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 38.25PT">
</TD>
<TD STYLE="WIDTH: 18PT">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	if any third-party manufacturer makes improvements in the manufacturing process for our products, we may not own, or may have
	to share, the intellectual property rights to the innovation. We may be required to pay fees or other costs for access to such
	improvements.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	Each of these risks could delay&nbsp;the
	approval, if any, of our product candidates by the FDA or the commercialization of our product candidates or result in higher costs
	or deprive us of potential product revenues. Our contract manufacturer has announced that it received a warning letter from the
	FDA relating to an inspection at its Boca Raton, Florida location in August 2014 and that the warning letter does not prevent the
	manufacturing or distribution of any of its products. The receipt of the warning letter has not affected the manufacture or delivery
	to us of RI-002 by our contract manufacturer.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-RIGHT: 0; MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT">
<B>
<I>
	Issues with product quality
	could have a material adverse effect upon our business, subject us to regulatory actions and cause a loss of customer confidence
	in us or our products.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1IN; TEXT-INDENT: -1IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	Our success depends upon the quality of our products. Quality management plays an essential role in meeting
	customer requirements, preventing defects, improving our products and services and assuring the safety and efficacy
	of our products. Our future success depends on our ability to maintain and continuously improve our quality management program.
	A quality or safety issue may result in adverse inspection reports, warning letters, product recalls or seizures, monetary sanctions,
	injunctions to halt manufacture and distribution of products, civil or criminal sanctions, costly litigation, refusal of a government
	to grant approvals and licenses, restrictions on operations or withdrawal of existing approvals and licenses. An inability to address
	a quality or safety issue in an effective and timely manner may also cause negative publicity, a loss of customer confidence in
	us or our current or future products, which may result in the loss of sales and difficulty in successfully launching new
	products.
</P>
<P STYLE="MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
<I>
	If physicians and patients do not accept and use our product,
	our ability to generate revenue from sales will be materially impaired.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	Even if the FDA approves RI-002, physicians
	and patients may not accept and use it. Acceptance and use of our product will depend on a number of factors including:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	perceptions by members of the health care community, including physicians,
	about the safety and effectiveness of our product;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	cost-effectiveness of our product relative to competing products;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	availability of reimbursement for our product from government or other
	healthcare payers; and
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	effectiveness of marketing and distribution efforts by us and our
	licensees and distributors, if any.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	Because we expect sales of RI-002, if approved,
	to generate substantially all of our product revenues other than the revenue attainable from the sale of plasma collected by ADMA
	BioCenters, the failure of this product to find market acceptance would harm our business and could require us to seek additional
	financing or make such financing difficult to obtain on favorable terms, if at all.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
</P>
<!-- FIELD: PAGE; SEQUENCE: 29 -->
<DIV STYLE="MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	27
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage30"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<P STYLE="MARGIN: 0PT; TEXT-ALIGN: RIGHT; FONT-SIZE: 8PT">
<A HREF="#E615811_10K-ADMA_HTM_TOC" STYLE="FONT-STYLE: ITALIC">
	Table of Contents
</A>
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
<I>
	Industry and other market data used in this annual
	report and our other materials, including those undertaken by us or our engaged consultants, may not prove to be
	representative of current and future market conditions or future results.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	This annual report and our other materials
	include statistical and other industry and market data that we obtained from industry publications and research, surveys and studies
	conducted by third parties, and surveys and studies we commissioned, regarding the market potential for RI-002. Although we believe
	that such information has been obtained from sources believed to be reliable, neither the sources of such data, nor we, can guarantee
	the accuracy or completeness of such information. While we believe these industry publications and third party research, surveys
	and studies are reliable, we have not independently verified such data. With respect to the information from third party consultants,
	the results of that study represent the independent consultants&rsquo; own methodologies, assumptions, research, analysis, projections,
	estimations, composition of respondent pool, presentation of data, and adjustments, each of which may ultimately prove to be incorrect,
	and cause actual results and market viability to differ materially from those presented in such report. Readers should not place
	undue reliance on this information.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
<I>
	Our long-term success may depend on our ability to supplement
	our existing RI-002 product candidate through new product development or the in-license or acquisition of other new products, and
	if our business development efforts are not successful, our ability to achieve profitability may be negatively impacted.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	Our current product development portfolio
	consists primarily of RI-002. We intend to seek to expand our current portfolio through new product development efforts or to in-license
	or acquire additional products. If we are not successful in developing or acquiring additional products, we will have to depend
	on our ability to raise capital for, and the successful development and commercialization of, RI-002 and the revenue we may generate
	from the sale of plasma attributable to the operations of ADMA BioCenters.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
<I>
	Our loan and security agreement with Oxford Finance LLC,
	or Oxford, is subject to acceleration in specified circumstances, which may result in Oxford taking possession and disposing of
	any collateral. We became obligated to begin making payments of principal and interest on February 1, 2017, unless accelerated
	as a result of certain events of default or at our option.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	On June 19, 2015, we entered into a Loan
	and Security Agreement, or LSA, with Oxford for up to $21.0 million and refinanced our existing loan with Hercules Technology Growth
	Capital, Inc. or Hercules. The first tranche of $16.0 million from the Oxford loan was primarily used to repay our existing facility
	with Hercules. In May 2016, we amended the LSA with Oxford and we borrowed an additional $4.0 million, bringing the total principal
	amount borrowed to $20.0 million. The LSA bears interest at a rate per annum equal to the greater of (i) 7.80% and (ii) the sum
	of (a) the three month U.S. LIBOR rate (as reported in
<I>
	The Wall Street Journal
</I>
	) on the date occurring on the last business
	day of the month that immediately precedes the month in which the interest will accrue, plus (b) 7.54% on the outstanding principal
	balance. We became obligated to begin to repay the principal over 36 months beginning February 1, 2017, unless accelerated as a
	result of certain events of default.&nbsp; A final payment equal to 8.95% of the funded loan amount is due at the earlier of loan
	maturity or prepayment. In addition, a facility fee of $105,000 was paid at closing.&nbsp;&nbsp;In the event we elect to prepay
	the loan, we are obligated to pay a prepayment charge corresponding to a percentage of the principal amount of the loan, with such
	percentage being: (i) for a prepayment made on or after the funding date of the applicable term loan through and including the
	first anniversary of its funding date, an amount equal to 3.00% of the principal amount of the term loan prepaid; (ii) for a prepayment
	made after the first anniversary of the funding date of the applicable term loan through and including the second anniversary of
	such funding date, an amount equal to 2.00% of the principal amount of such term loan prepaid; and (iii) for a prepayment of a
	term loan made after the second anniversary of its funding date and prior to its maturity date, an amount equal to 1.00% of the
	principal amount of the term loan prepaid.&nbsp; The loan matures no later than January 1, 2020.&nbsp; The loan is secured by our
	assets, except for our intellectual property (which is subject to a negative pledge). Events of default under the agreement include,
	but are not limited to: (i) insolvency, liquidation, bankruptcy or similar events; (ii) failure to pay any debts due under the
	LSA or other loan documents on a timely basis; (iii) failure to observe any covenant or secured obligation under the LSA or other
	loan documents, which failure, in most cases, is not cured within 10 days of written notice by lender; (iv) occurrence of any default
	under any other agreement between us and the lender, which is not cured within 10 days; (v) occurrence of an event that could reasonably
	be expected to have a material adverse effect;&nbsp;&nbsp;(vi) material misrepresentations; (vii) occurrence of any default under
	any other agreement involving indebtedness or the occurrence of a default under any agreement that could reasonably be expected
	to have a material adverse effect; and (viii) certain money judgments are entered against us or a certain portion of its assets
	are attached or seized.&nbsp;Remedies for events of default include acceleration of amounts owing under the LSA and Oxford taking
	immediate possession of, and selling, any collateral securing the loan.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
</P>
<!-- FIELD: PAGE; SEQUENCE: 30 -->
<DIV STYLE="MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	28
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage31"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<P STYLE="MARGIN: 0PT; TEXT-ALIGN: RIGHT; FONT-SIZE: 8PT">
<A HREF="#E615811_10K-ADMA_HTM_TOC" STYLE="FONT-STYLE: ITALIC">
	Table of Contents
</A>
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
<I>
	Developments by competitors may render our products or
	technologies obsolete or non-competitive.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	The biotechnology and pharmaceutical industries
	are intensely competitive and subject to rapid and significant technological change. Should we obtain regulatory approval for RI-002
	or any future product we may develop, we will have to compete with existing therapies. In addition, other companies may pursue
	the development of pharmaceuticals that target the same diseases and conditions that we are targeting. We face competition from
	pharmaceutical and biotechnology companies in the U.S. and abroad. In addition, companies pursuing different but related
	fields represent substantial competition. Many of these organizations competing with us have substantially greater capital resources,
	larger research and development staffs and facilities, longer product development history in obtaining regulatory approvals and
	greater manufacturing and marketing capabilities than we do. These organizations also compete with us to attract qualified personnel
	and parties for acquisitions, joint ventures or other collaborations.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
<I>
	If we are unable to protect our patents, trade secrets
	or other proprietary rights, if our patent is challenged or if our provisional patent applications do not get approved, our competitiveness
	and business prospects may be materially damaged.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	As we move forward in clinical development
	we are also uncovering novel aspects of our product and are drafting patents to cover our inventions.&nbsp;&nbsp;We rely on a combination
	of patent rights, trade secrets and nondisclosure and non-competition agreements to protect our proprietary intellectual property,
	and we will continue to do so. There can be no assurance that our patent, trade secret policies and practices or other agreements
	will adequately protect our intellectual property. Our issued patent may be challenged, found to be over-broad or otherwise invalidated
	in subsequent proceedings before courts or the U.S. Patent and Trademark Office. Even if enforceable, we cannot provide
	any assurances that it will provide significant protection from competition. The processes, systems, and/or security measures we
	use to preserve the integrity and confidentiality of our data and trade secrets may be breached, and we may not have adequate remedies
	as a result of any such breaches. In addition, our trade secrets may otherwise become known or be independently discovered by competitors.
	There can be no assurance that the confidentiality, nondisclosure and non-competition agreements with employees, consultants and
	other parties with access to our proprietary information to protect our trade secrets, proprietary technology, processes and other
	proprietary rights, or any other security measures relating to such trade secrets, proprietary technology, processes and proprietary
	rights, will be adequate, will not be breached, that we will have adequate remedies for any breach, that others will not independently
	develop substantially equivalent proprietary information or that third parties will not otherwise gain access to our trade secrets
	or proprietary knowledge. To the extent that our consultants, contractors or collaborators use intellectual property owned by others
	in their work for us, disputes may arise as to the rights in related or resulting know-how and inventions.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
<I>
	We could lose market exclusivity of a product earlier
	than expected.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	In the pharmaceutical and biotechnology
	industries, the majority of an innovative product&rsquo;s commercial value is realized during its market exclusivity period. In
	the U.S. and in some other countries, when market exclusivity expires and generic versions are approved and marketed or when biosimilars
	are introduced (even if only for a competing product), there are usually very substantial and rapid declines in a product&rsquo;s
	revenues.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	Market exclusivity for our products is based
	upon patent rights and certain regulatory forms of exclusivity. The scope of our patent rights may vary from country to country
	and may also be dependent on the availability of meaningful legal remedies in a country. The failure to obtain patent and other
	intellectual property rights, or limitations on the use or loss of such rights, could be material to us. In some countries, basic
	patent protections for our products may not exist because certain countries did not historically offer the right to obtain specific
	types of patents and/or we (or our licensors) did not file in those markets. In addition, the patent environment can be unpredictable
	and the validity and enforceability of patents cannot be predicted with certainty. Absent relevant patent protection for a product,
	once the data exclusivity period expires, generic versions can be approved and marketed.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
</P>
<!-- FIELD: PAGE; SEQUENCE: 31 -->
<DIV STYLE="MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	29
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage32"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<P STYLE="MARGIN: 0PT; TEXT-ALIGN: RIGHT; FONT-SIZE: 8PT">
<A HREF="#E615811_10K-ADMA_HTM_TOC" STYLE="FONT-STYLE: ITALIC">
	Table of Contents
</A>
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	Patent rights covering our only product,
	RI-002, may become subject to patent litigation. In some cases, manufacturers may seek regulatory approval by submitting their
	own clinical trial data to obtain marketing approval or choose to launch a generic product &ldquo;at risk&rdquo; before the expiration
	of our patent rights/or before the final resolution of related patent litigation. Enforcement of claims in patent litigation can
	be very costly and&nbsp;no assurance can be given that we will prevail.&nbsp;There is no assurance that RI-002, or any other of
	our products for which we are issued a patent, will enjoy market exclusivity for the full time period of the respective patent.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
<I>
	Third parties could obtain patents that may require us
	to negotiate licenses to conduct our business, and there can be no assurance that the required licenses would be available on reasonable
	terms or at all.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	We may not be able to operate our business
	without infringing third-party patents. Numerous U.S. and foreign patents and pending patent applications owned by third
	parties exist in fields that relate to the development and commercialization of immune globulins. In addition, many companies have
	employed intellectual property litigation as a way to gain a competitive advantage. It is possible that infringement claims may
	occur as the number of products and competitors in our market increases. In addition, to the extent that we gain greater visibility
	and market exposure as a public company, we face a greater risk of being the subject of intellectual property infringement claims.
	We cannot be certain that the conduct of our business does not and will not infringe intellectual property or other proprietary
	rights of others in the U.S. and in foreign jurisdictions. If our products, methods, processes and other technologies
	are found to infringe third party patent rights, we could be prohibited from manufacturing and commercializing the infringing technology,
	process or product unless we obtain a license under the applicable third party patent and pay royalties or are able to design around
	such patent. We may be unable to obtain a license on terms acceptable to us, or at all, and we may not be able to redesign our
	products or processes to avoid infringement. Even if we are able to redesign our products or processes to avoid an infringement
	claim, our efforts to design around the patent could require significant time, effort and expense and ultimately may lead to an
	inferior or more costly product and/or process. Any claim of infringement by a third party, even those without merit, could cause
	us to incur substantial costs defending against the claim and could distract our management from our business. Furthermore, if
	any such claim is successful, a court could order us to pay substantial damages, including compensatory damages for any infringement,
	plus prejudgment interest and could, in certain circumstances, treble the compensatory damages and award attorney fees. These damages
	could be substantial and could harm our reputation, business, financial condition and operating results. A court also could enter
	orders that temporarily, preliminarily or permanently prohibit us, our licensees, if any, and our customers from making, using,
	selling, offering to sell or importing one or more of our products or practicing our proprietary technologies or processes, or
	could enter an order mandating that we undertake certain remedial activities. Any of these events could seriously harm our business,
	operating results and financial condition.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
<I>
	Continued instability in the credit and financial markets
	may negatively impact our business, results of operations and financial condition.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	Financial markets in the U.S.,
	Canada, Europe and Asia continue to experience disruption, including, among other things, significant volatility in security prices,
	declining valuations of certain investments, as well as severely diminished liquidity and credit availability. Business activity
	across a wide range of industries and regions continues to be greatly reduced and local governments and many businesses are still
	suffering from the lack of consumer spending and the lack of liquidity in the credit markets. As a clinical-stage biotechnology
	company, we rely on third parties for several important aspects of our business, including contract manufacturing of drug product,
	plasma collection supplies, transportation and storage of plasma, and conduct of our clinical trials. These third parties may be
	unable to satisfy their commitments to us due to tightening of global credit from time to time, which would adversely affect our
	business. The continued instability in the credit and financial market conditions may also negatively impact our ability to access
	capital and credit markets and our ability to manage our cash balance. While we are unable to predict the continued duration and
	severity of the adverse conditions in the U.S. and other countries, any of the circumstances mentioned above could adversely
	affect our business, financial condition, operating results and cash flow or cash position.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
<I>
	If we are unable to successfully manage our growth, our
	business may be harmed.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	Our success will depend on the expansion
	of our commercial, manufacturing, supply of plasma and overall operations and the effective management of our growth, which will
	place a significant strain on our management and on our administrative, operational and financial resources. To manage this growth,
	we must expand our facilities, augment our operational, financial and management systems and hire and train additional qualified
	personnel. If we are unable to manage our growth effectively, our business could be harmed.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
</P>
<!-- FIELD: PAGE; SEQUENCE: 32 -->
<DIV STYLE="MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	30
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage33"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<P STYLE="MARGIN: 0PT; TEXT-ALIGN: RIGHT; FONT-SIZE: 8PT">
<A HREF="#E615811_10K-ADMA_HTM_TOC" STYLE="FONT-STYLE: ITALIC">
	Table of Contents
</A>
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
<I>
	The loss of one or more key members of our management
	team could adversely affect our business.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	Our performance is substantially dependent
	on the continued service and performance of our management team, who have extensive experience and specialized expertise in our
	business. In particular, the loss of Adam S. Grossman, our President and Chief Executive Officer, could adversely affect our business
	and operating results. We do not have &quot;key person&quot; life insurance policies for any members of our management team. We
	have employment agreements with each of our executive officers; however, the existence of an employment agreement does not guarantee
	retention of members of our management team and we may not be able to retain those individuals for the duration of or beyond the
	end of their respective terms. The loss of services of key personnel, or the inability to attract and retain additional qualified
	personnel, could result in delays in development or approval of our product candidates and diversion of management resources.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
<I>
	If we are unable to hire additional qualified personnel,
	our ability to grow our business may be harmed.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	We will need to hire additional qualified
	personnel with expertise in commercialization, sales, marketing, medical affairs, reimbursement, government regulation, formulation
	and manufacturing and finance and accounting. In particular, over the next 12-24 months, we expect to hire several new employees
	devoted to commercialization, sales, marketing, medical and scientific affairs, regulatory affairs, quality control, financial,
	general and operational management, particularly if we close and consummate the Proposed Acquisition. We compete for qualified
	individuals with numerous biopharmaceutical companies, universities and other research institutions. Competition for such individuals
	is intense, and we cannot assure you that our search for such personnel will be successful. Attracting and retaining qualified
	personnel will be critical to our success and any failure to do so successfully may have a material adverse effect on us.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
<I>
	We currently collect human blood plasma at our ADMA BioCenters
	facilities located in&nbsp; Norcross and Marietta, Georgia, and if we cannot maintain FDA approval for these locations we may be
	adversely affected and potentially may not be able to sell and use this human blood plasma for future commercial purposes.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	We intend to maintain FDA and other governmental
	and regulatory approvals of our ADMA BioCenters collection facilities for the collection of human blood plasma. These facilities
	are subject to FDA and other governmental and regulatory inspections and extensive regulation, including compliance with cGMP,
	FDA and other government approvals. Failure to comply may result in enforcement action, which may significantly delay or suspend
	our operations for these locations.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
<I>
	We may incur substantial liabilities and may be required
	to limit commercialization of our products in response to product liability lawsuits.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	The testing and marketing of medical products
	entail an inherent risk of product liability. If we cannot successfully defend ourselves against product liability claims, we may
	incur substantial liabilities or be required to limit commercialization of our products. Our inability to obtain sufficient product
	liability insurance at an acceptable cost to protect against potential product liability claims could prevent or inhibit the commercialization
	of pharmaceutical products we develop, alone or with collaborators.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
<I>
	Many of our business practices are subject to scrutiny
	by regulatory authorities, as well as to lawsuits brought by private citizens under federal and state laws. Failure to comply with
	applicable law or an adverse decision in lawsuits may result in adverse consequences to us.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	The laws governing our conduct in the U.S. are enforceable by criminal, civil and administrative penalties. Violations of laws such as the Federal Food, Drug, and
	Cosmetic Act, the Social Security Act (including the Anti-Kickback Law), the Public Health Service Act and the Federal False Claims
	Act, and any regulations promulgated under the authority of the preceding, may result in jail sentences, fines or exclusion from
	federal and state programs, as may be determined by Medicare, Medicaid and the Department of Health and Human Services and other
	regulatory authorities as well as by the courts. There can be no assurance that our activities will not come under the scrutiny
	of regulators and other government authorities or that our practices will not be found to violate applicable laws, rules and regulations
	or prompt lawsuits by private citizen &quot;relators&quot; under federal or state false claims laws.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
</P>
<!-- FIELD: PAGE; SEQUENCE: 33 -->
<DIV STYLE="MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	31
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage34"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<P STYLE="MARGIN: 0PT; TEXT-ALIGN: RIGHT; FONT-SIZE: 8PT">
<A HREF="#E615811_10K-ADMA_HTM_TOC" STYLE="FONT-STYLE: ITALIC">
	Table of Contents
</A>
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	For example, under the Anti-Kickback Law
	and similar state laws and regulations, the offer or payment of anything of value for patient referrals, or in return for purchasing,
	leasing, ordering or arranging for or recommending the purchase, lease, or ordering of any time or service reimbursable in whole
	or in part by a federal health care program is prohibited.&nbsp;&nbsp;This places constraints on the marketing and promotion of
	products and on common business arrangements, such as discounted terms and volume incentives for customers in a position to recommend
	or choose products for patients, such as physicians and hospitals, and these practices can result in substantial legal penalties,
	including, among others, exclusion from the Medicare and Medicaid programs. Arrangements with referral sources such as purchasers,
	group purchasing organizations, physicians and pharmacists must be structured with care to comply with applicable requirements.
	Also, certain business practices, such as payments of consulting fees to healthcare providers, sponsorship of educational or research
	grants, charitable donations, interactions with healthcare providers that prescribe products for uses not&nbsp;approved by the
	FDA and financial support for continuing medical education programs, must be conducted within narrowly prescribed and controlled
	limits to avoid any possibility of wrongfully influencing healthcare providers to prescribe or purchase particular products or
	as a reward for past prescribing. Under the Patient Protection and Affordable Care Act and the companion Health Care and Education
	Reconciliation Act, which together are referred to as the healthcare reform law, such payments by pharmaceutical manufacturers
	to U.S. healthcare practitioners and academic medical centers must be publicly disclosed. A number of states have similar
	laws in place. Additional and stricter prohibitions could be implemented by federal and state authorities. Where such practices
	have been found to be improper incentives to use such products, government investigations and assessments of penalties against
	manufacturers have resulted in substantial damages and fines. Many manufacturers have been required to enter into consent decrees
	or orders that prescribe allowable corporate conduct.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	Failure to satisfy requirements under the
	Federal Food, Drug, and Cosmetic Act can also result in penalties, as well as requirements to enter into consent decrees or orders
	that prescribe allowable corporate conduct. In addition, while regulatory authorities generally do not regulate physicians' discretion
	in their choice of treatments for their patients, they do restrict communications by manufacturers on unapproved uses of approved
	products or on the potential safety and efficacy of unapproved products in development. Companies in the U.S., Canada
	and the European Union cannot promote approved products for other indications that are not specifically approved by the competent
	regulatory authorities (e.g., FDA in the U.S.), nor can companies promote unapproved products. In limited circumstances,
	companies may disseminate to physicians information regarding unapproved uses of approved products or results of studies involving
	investigational products. If such activities fail to comply with applicable regulations and guidelines of the various regulatory
	authorities, we may be subject to warnings from, or enforcement action by, these authorities. Furthermore, if such activities are
	prohibited, it may harm demand for our products. Promotion of unapproved drugs or devices or unapproved indications for a drug
	or device is a violation of the Federal Food, Drug, and Cosmetic Act and subjects us to civil and criminal sanctions. Furthermore,
	sanctions under the Federal False Claims Act have recently been brought against companies accused of promoting off-label uses of
	drugs, because such promotion induces the use and subsequent claims for reimbursement under Medicare and other federal programs.
	Similar actions for off-label promotion have been initiated by several states for Medicaid fraud. The healthcare reform law significantly
	strengthened provisions of the Federal False Claims Act, the Anti-Kickback Law that applies to Medicare and Medicaid, and other
	health care fraud provisions, leading to the possibility of greatly increased qui tam suits by relators for perceived violations.
	Violations or allegations of violations of the foregoing restrictions could materially and adversely affect our business.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	We may be required to report detailed pricing
	information, net of included discounts, rebates and other concessions, to the Centers for Medicare &amp; Medicaid Services, or
	CMS, for the purpose of calculating national reimbursement levels, certain federal prices and certain federal and state rebate
	obligations. Inaccurate or incomplete reporting of pricing information could result in liability under the False Claims Act, the
	federal Anti-Kickback Law and various other laws, rules and regulations.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	We will need to establish systems for collecting
	and reporting this data accurately to CMS and institute a compliance program to assure that the information collected is complete
	in all respects. If we report pricing information that is not accurate to the federal government, we could be subject to fines
	and other sanctions that could adversely affect our business. If we choose to pursue clinical development and commercialization
	in the European Union or otherwise market and sell our products outside of the U.S., we must obtain and maintain regulatory
	approvals and comply with regulatory requirements in such jurisdictions. The approval procedures vary among countries in complexity
	and timing. We may not obtain approvals from regulatory authorities outside the U.S. on a timely basis, if at all, which
	would preclude us from commercializing products in those markets.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
</P>
<!-- FIELD: PAGE; SEQUENCE: 34 -->
<DIV STYLE="MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	32
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage35"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<P STYLE="MARGIN: 0PT; TEXT-ALIGN: RIGHT; FONT-SIZE: 8PT">
<A HREF="#E615811_10K-ADMA_HTM_TOC" STYLE="FONT-STYLE: ITALIC">
	Table of Contents
</A>
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	In addition, some countries, particularly
	the countries of the European Union, regulate the pricing of prescription pharmaceuticals. In these countries, pricing discussions
	with governmental authorities can take considerable time after the receipt of marketing approval for a product. To obtain reimbursement
	or pricing approval in some countries, we may be required to conduct a clinical trial that compares the cost-effectiveness of their
	product candidate to other available therapies. Such trials may be time-consuming and expensive, and may not show an advantage
	in efficacy for our products. If reimbursement of our products is unavailable or limited in scope or amount, or if pricing is set
	at unsatisfactory levels, in either the U.S. or the European Union, we could be adversely affected.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	Also, under the U.S. Foreign Corrupt
	Practices Act, or FCPA, the U.S. has increasingly focused on regulating the conduct by U.S. businesses occurring
	outside of the U.S., generally prohibiting remuneration to foreign officials for the purpose of obtaining or retaining
	business. To enhance compliance with applicable health care laws, and mitigate potential liability in the event of noncompliance,
	regulatory authorities, such as the U.S. Health and Human Services Department Office of Inspector General, or OIG, have
	recommended the adoption and implementation of a comprehensive health care compliance program that generally contains the elements
	of an effective compliance and ethics program described in Section 8B2.1 of the U.S. Sentencing Commission Guidelines
	Manual. Increasing numbers of U.S.-based pharmaceutical companies have such programs. In the future, we may need to adopt
	healthcare compliance and ethics programs that would incorporate the OIG's recommendations, and train our applicable employees
	in such compliance. Such a program may be expensive and may not assure that we will avoid compliance issues.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
<I>
	The manufacturing processes for plasma based biologics
	are complex and involve biological intermediates that are susceptible to contamination.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	Plasma is a raw material that is susceptible
	to damage and contamination and may contain human pathogens, any of which would render the plasma unsuitable as raw material for
	further manufacturing. For instance, improper storage of plasma, by us or third-party suppliers, may require us to destroy some
	of our raw material. If unsuitable plasma is not identified and discarded prior to the release of the plasma to the manufacturing
	process, it may be necessary to discard intermediate or finished product made from that plasma or to recall any finished product
	released to the market, resulting in a charge to cost of goods sold. The manufacture of our plasma products is an extremely complex
	process of fractionation, purification, filling and finishing. Our products can become non-releasable or otherwise fail to meet
	our stringent specifications or regulatory agencies' specifications through a failure in one or more of these process steps. We
	may detect instances in which an unreleased product was produced without adherence to our manufacturing procedures or plasma used
	in our production process was not collected or stored in a compliant manner consistent with our cGMP or other regulations. Such
	an event of noncompliance would likely result in our determination that the implicated products should not be released or maybe
	replaced or withdrawn from the market and therefore should be destroyed. Once manufactured, our plasma-derived products must be
	handled carefully and kept at appropriate temperatures. Our failure, or the failure of third parties that supply, ship or distribute
	our products, to properly care for our products may require that those products be destroyed. Even if handled properly, biologics
	may form or contain particulates or have other issues or problems after storage which may require products to be destroyed or recalled.
	While we expect to write off small amounts of work-in-progress in the ordinary course of business due to the complex nature of
	plasma, our processes and our products, unanticipated events may lead to write-offs and other costs materially in excess of our
	expectations and the reserves we have established for these purposes. Such write-offs and other costs could cause material fluctuations
	in our profitability.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	Furthermore, contamination of our products
	could cause investors, consumers, or other third parties with whom we conduct business to lose confidence in the reliability of
	our manufacturing procedures, which could adversely affect our sales and profits. In addition, faulty or contaminated products
	that are unknowingly distributed could result in patient harm, threaten the reputation of our products and expose us to product
	liability damages and claims from companies for whom we do contract manufacturing.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
</P>
<!-- FIELD: PAGE; SEQUENCE: 35 -->
<DIV STYLE="MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	33
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage36"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<P STYLE="MARGIN: 0PT; TEXT-ALIGN: RIGHT; FONT-SIZE: 8PT">
<A HREF="#E615811_10K-ADMA_HTM_TOC" STYLE="FONT-STYLE: ITALIC">
	Table of Contents
</A>
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
<I>
	Our ability to continue to produce safe and effective
	products depends on the safety of our plasma supply and manufacturing processes against transmittable diseases.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	Despite overlapping safeguards, including
	the screening of donors and other steps to remove or inactivate viruses and other infectious disease causing agents, the risk of
	transmissible disease through blood plasma products cannot be entirely eliminated. For example, since plasma-derived therapeutics
	involves the use and purification of human plasma, there has been concern raised about the risk of transmitting human immunodeficiency
	virus, or HIV, prions, West Nile virus, H1N1 virus or &quot;swine flu&quot; and other blood-borne pathogens through plasma-derived
	products. There are also concerns about the future transmission of H5N1 virus, or &quot;bird flu.&quot; In the 1980s, thousands
	of hemophiliacs worldwide were infected with HIV through the use of contaminated Factor VIII. Other producers of Factor VIII, though
	not us, were defendants in numerous lawsuits resulting from these infections. New infectious diseases emerge in the human population
	from time to time. If a new infectious disease has a period during which time the causative agent is present in the bloodstream
	but symptoms are not present, it is possible that plasma donations could be contaminated by that infectious agent. Typically, early
	in an outbreak of a new disease, tests for the causative agent do not exist. During this early phase, we must rely on screening
	of donors (e.g., for behavioral risk factors or physical symptoms) to reduce the risk of plasma contamination. Screening methods
	are generally less sensitive and specific than a direct test as a means of identifying potentially contaminated plasma units. During
	the early phase of an outbreak of a new infectious disease, our ability to manufacture safe products would depend on the manufacturing
	process' capacity to inactivate or remove the infectious agent. To the extent that a product's manufacturing process is inadequate
	to inactivate or remove an infectious agent, our ability to manufacture and distribute that product would be impaired. If a new
	infectious disease were to emerge in the human population, the regulatory and public health authorities could impose precautions
	to limit the transmission of the disease that would impair our ability to procure plasma, manufacture our products or both. Such
	precautionary measures could be taken before there is conclusive medical or scientific evidence that a disease poses a risk for
	plasma-derived products. In recent years, new testing and viral inactivation methods have been developed that more effectively
	detect and inactivate infectious viruses in collected plasma. There can be no assurance, however, that such new testing and inactivation
	methods will adequately screen for, and inactivate, infectious agents in the plasma used in the production of our products.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
<I>
	We could become supply-constrained and our financial performance
	would suffer if we cannot obtain adequate quantities of FDA-approved source plasma with proper specifications.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	In order for plasma to be used in the manufacturing
	of our products, the individual centers at which the plasma is collected must be licensed by the FDA, and approved by the regulatory
	authorities of any country in which we may wish to commercialize our products. When we open a new plasma center, and on an ongoing
	basis after licensure, it must be inspected by the FDA for compliance with cGMP and other regulatory requirements. An unsatisfactory
	inspection could prevent a new center from being licensed or risk the suspension or revocation of an existing license. We do not
	and will not have adequate source plasma to manufacture RI-002. Therefore, we are reliant on purchasing normal source plasma to
	manufacture RI-002. We can give no assurances that normal source plasma will be available to us on commercially reasonable terms
	or at all. In order to maintain a plasma center's license, its operations must continue to conform to cGMP and other regulatory
	requirements. In the event that we determine that plasma was not collected in compliance with cGMP, we may be unable to use and
	may ultimately destroy plasma collected from that center, which would be recorded as a charge to cost of goods. Additionally, if
	non-compliance in the plasma collection process is identified after the impacted plasma has been pooled with compliant plasma from
	other sources, entire plasma pools, in-process intermediate materials and final products could be impacted. Consequently, we could
	experience significant inventory impairment provisions and write-offs which could adversely affect our business and financial results.
	We plan to increase our supplies of plasma for use in the manufacturing processes through increased purchases of plasma from third
	party suppliers as well as collections from our existing ADMA BioCenters plasma collection centers. This strategy is dependent
	upon our ability to maintain a cGMP compliant environment in both plasma centers and to expand production and attract donors to
	both centers. There is no assurance that the FDA will inspect and license our unlicensed plasma collection centers in a timely
	manner consistent with our production plans. If we misjudge the readiness of a center for an FDA inspection, we may lose credibility
	with the FDA and cause the FDA to more closely examine all of our operations. Such additional scrutiny could materially hamper
	our operations and our ability to increase plasma collections. Our ability to expand production and increase our plasma collection
	centers to more efficient production levels may be affected by changes in the economic environment and population in selected regions
	where ADMA BioCenters operates its current or future plasma centers, by the entry of competitive plasma centers into regions where
	ADMA BioCenters operates such centers, by misjudging the demographic potential of individual regions where ADMA BioCenters expects
	to expand production and attract new donors, by unexpected facility related challenges, or by unexpected management challenges
	at selected plasma centers.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
</P>
<!-- FIELD: PAGE; SEQUENCE: 36 -->
<DIV STYLE="MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	34
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage37"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<P STYLE="MARGIN: 0PT; TEXT-ALIGN: RIGHT; FONT-SIZE: 8PT">
<A HREF="#E615811_10K-ADMA_HTM_TOC" STYLE="FONT-STYLE: ITALIC">
	Table of Contents
</A>
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
<I>
	Our ability to commercialize our products, alone or with
	collaborators, will depend in part on the extent to which reimbursement will be available from governmental agencies, health administration
	authorities, private health maintenance organizations and health insurers and other healthcare payers, and also depend upon the
	approval, timing and representations by the FDA or other governmental authorities for our product candidates. As the FDA BLA review
	process is ongoing, we are subject to information requests and communications from the FDA on a routine basis and may not have
	clarity on any or all specific aspects of the approval timing, language, name, claims and any other future requirements that may
	be imposed by the FDA or other governmental agencies, for marketing authorization and ultimately financial reimbursement for patient
	utilization.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	Our ability to generate product revenues
	will be diminished if our products sell for inadequate prices or patients are unable to obtain adequate levels of reimbursement.
	Significant uncertainty exists as to the reimbursement status of newly approved healthcare products, as well as to the timing,
	language, specifications and other details pertaining to the approval of such products. Healthcare payers, including Medicare,
	are challenging the prices charged for medical products and services. Government and other healthcare payers increasingly attempt
	to contain healthcare costs by limiting both coverage and the level of reimbursement for products. Even if one of our product candidates
	is approved by the FDA, insurance coverage may not be available, and reimbursement levels may be inadequate, to cover such product.
	If government and other healthcare payers do not provide adequate coverage and reimbursement levels for one of our products, once
	approved, market acceptance of such product could be reduced. Prices in many countries, including many in Europe, are subject to
	local regulation and certain pharmaceutical products, such as plasma-derived products, are subject to price controls in several
	of the world's principal markets, including many countries within the European Union. In the U.S., where pricing levels
	for our products are substantially established by third-party payors, including Medicare, if payors reduce the amount of reimbursement
	for a product, it may cause groups or individuals dispensing the product to discontinue administration of the product, to administer
	lower doses, to substitute lower cost products or to seek additional price-related concessions. These actions could have a negative
	effect on financial results, particularly in cases where our products command a premium price in the marketplace, or where changes
	in reimbursement induce a shift in the site of treatment. The existence of direct and indirect price controls and pressures over
	our products could materially adversely affect our financial prospects and performance.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
<I>
	The new biosimilar pathway established as part of the
	healthcare reform may make it easier for competitors to market biosimilar products.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	The healthcare reform law
	introduced an abbreviated licensure pathway for biological products that are demonstrated to be biosimilar to an FDA-licensed
	biological product.&nbsp; A biological product may be demonstrated to be &ldquo;biosimilar&rdquo; if data show that, among
	other things, the product is &ldquo;highly similar&rdquo; to an already-approved biological product, known as a reference
	product, and has no clinically meaningful differences in terms of safety and effectiveness from the reference product. The
	law provides that a biosimilar application may be submitted as soon as four years after the reference product is first
	licensed, and that the FDA may not make approval of an application effective until 12 years after the reference product was
	first licensed.&nbsp; Since the enactment of the law, the FDA has issued several guidance documents to assist sponsors of
	biosimilar products prepare their approval applications.&nbsp; The FDA approved the first biosimilar product in 2015, and
	approved three biosimilar products in 2016.&nbsp; As a result of the biosimilar pathway in the U.S., we expect in
	the future to face greater competition from biosimilar products, including a possible increase in patent challenges.
</P>
<P STYLE="MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
<I>
	The implementation of the healthcare reform law in the
	U.S. may adversely affect our business.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	Through the March 2010 adoption of the healthcare
	reform law in the U.S., substantial changes are being made to the current system for paying for healthcare in the U.S., including programs to extend medical benefits to millions of individuals who currently lack insurance coverage. The changes
	contemplated by the healthcare reform law are subject to rule-making and implementation timelines that extend for several years,
	and this uncertainty limits our ability to forecast changes that may occur in the future. However, implementation has already begun
	with respect to certain significant cost-saving measures under the healthcare reform law, for example with respect to several government
	healthcare programs that may cover the cost of our future products, including Medicaid, Medicare Parts B and D, and these efforts
	could have a materially adverse impact on our future financial prospects and performance. For example, with respect to Medicaid,
	in order for a manufacturer's products to be reimbursed by federal funding under Medicaid, the manufacturer must enter into a Medicaid
	rebate agreement with the Secretary of the U.S. Department of Health and Human Services, and pay certain rebates to the
	states based on utilization data provided by each state to the manufacturer and to CMS, and pricing data provided by the manufacturer
	to the federal government. The states share this savings with the federal government, and sometimes implement their own additional
	supplemental rebate programs. Under the Medicaid drug rebate program, the rebate amount for most branded drug products was previously
	equal to a minimum of 15.1% of the Average Manufacturer Price, or AMP, or the AMP less Best Price, whichever is greater. Effective
	January 1, 2010, the healthcare reform law generally increases the size of the Medicaid rebates paid by manufacturers for single
	source and innovator multiple source (brand name) drug product from a minimum of 15.1% to a minimum of 23.1% of the AMP, subject
	to certain exceptions, for example, for certain clotting factors, the increase is limited to a minimum of 17.1% of the AMP. For
	non-innovator multiple source (generic) products, the rebate percentage is increased from a minimum of 11.0% to a minimum of 13.0%
	of AMP.&nbsp;&nbsp;In 2010, the healthcare reform law also newly extended this rebate obligation to prescription drugs covered
	by Medicaid managed care organizations. These increases in required rebates may adversely affect our future financial prospects
	and performance. In order for a pharmaceutical product to receive federal reimbursement under the Medicare Part B and Medicaid
	programs or to be sold directly to U.S. government agencies, the manufacturer must extend discounts to entities eligible to participate
	in the 340B drug pricing program.&nbsp;&nbsp;The required 340B discount on a given product is calculated based on the AMP and Medicaid
	rebate amounts reported by the manufacturer.&nbsp;&nbsp;As the 340B drug pricing is determined based on AMP and Medicaid rebate
	data, the revisions to the Medicaid rebate formula and AMP definition described above could cause the required 340B discount to
	increase.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
</P>
<!-- FIELD: PAGE; SEQUENCE: 37 -->
<DIV STYLE="MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	35
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage38"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<P STYLE="MARGIN: 0PT; TEXT-ALIGN: RIGHT; FONT-SIZE: 8PT">
<A HREF="#E615811_10K-ADMA_HTM_TOC" STYLE="FONT-STYLE: ITALIC">
	Table of Contents
</A>
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	Effective in 2011, the healthcare reform
	law imposed an annual, nondeductible fee on any entity that manufactures or imports certain branded prescription drugs and biologic
	agents, apportioned among these entities according to their market share in certain government healthcare programs. These fees
	may adversely affect our future financial prospects and performance.&nbsp;&nbsp;The healthcare reform law established the Center
	for Medicare and Medicaid Innovation within CMS to test innovative payment and service delivery models to lower Medicare and Medicaid
	spending, potentially including prescription drug spending. Funding has been allocated to support the mission of the Center for
	Medicare and Medicaid Innovation through 2019.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	The healthcare reform law also creates new
	rebate obligations for our products under Medicare Part D, a partial, voluntary prescription drug benefit created by the U.S. federal government primarily for persons 65 years old and over. The Part D drug program is administered through private
	insurers that contract with CMS. Beginning in 2011, the healthcare reform law generally requires that in order for a drug manufacturer's
	products to be reimbursed under Medicare Part D, the manufacturer must enter into a Medicare Coverage Gap Discount Program agreement
	with the Secretary of the U.S. Department of Health and Human Services, and reimburse each Medicare Part D plan sponsor
	an amount equal to 50% savings for the manufacturer's brand name drugs and biologics which the Part D plan sponsor has provided
	to its Medicare Part D beneficiaries who are in the &quot;donut hole&quot; (or a gap in Medicare Part D coverage for beneficiaries
	who have expended certain amounts for drugs). The Part D plan sponsor is responsible for calculating and providing the discount
	directly to its beneficiaries and for reporting these amounts paid to CMS's contractor, which notifies drug manufacturers of the
	rebate amounts it must pay to each Part D plan sponsor. The rebate requirement could adversely affect our future financial performance,
	particularly if contracts with Part D plans cannot be favorably renegotiated or the Part D plan sponsors fail to accurately calculate
	payments due in a manner that overstates our rebate obligation. Regarding access to our products, the healthcare reform law established
	and provided significant funding for a Patient-Centered Outcomes Research Institute to coordinate and fund Comparative Effectiveness
	Research, or CER. While the stated intent of CER is to develop information to guide providers to the most efficacious therapies,
	outcomes of CER could influence the reimbursement or coverage for therapies that are determined to be less cost-effective than
	others. Should any of our products be determined to be less cost effective than alternative therapies, the levels of reimbursement
	for these products, or the willingness to reimburse at all, could be impacted, which could materially impact our future financial
	prospects and results.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
</P>
<!-- FIELD: PAGE; SEQUENCE: 38 -->
<DIV STYLE="MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	36
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage39"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<P STYLE="MARGIN: 0PT; TEXT-ALIGN: RIGHT; FONT-SIZE: 8PT">
<A HREF="#E615811_10K-ADMA_HTM_TOC" STYLE="FONT-STYLE: ITALIC">
	Table of Contents
</A>
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
<I>
	Developments in the worldwide economy may adversely impact
	our business.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	The difficult economic environment may adversely
	affect demand for our products. RI-002, our current product candidate, is expected to be sold to hospitals, specialty pharmacies
	and clinicians in the U.S. As a result of loss of jobs, patients may lose medical insurance and be unable to purchase
	supply or may be unable to pay their share of deductibles or co-payments. Hospitals adversely affected by the economy may steer
	patients to less costly therapies, resulting in a reduction in demand, or demand may shift to public health hospitals, which may
	purchase at a lower government price. While to date we cannot directly trace any material reduction in demand to the recession,
	if economic conditions do not improve, the impact may become material.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	Risks Relating to our Finances, Capital Requirements and
	Other Financial Matters
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
<I>
	We are a late stage company with a history of operating
	losses that are expected to continue and we are unable to predict the extent of future losses, whether we will generate significant
	revenues or whether we will achieve or sustain profitability.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	We are a late stage company and our prospects
	must be considered in light of the uncertainties, risks, expenses and difficulties frequently encountered by similarly situated
	companies. We have generated net losses in all periods since our inception in June 2004, including losses of approximately $19.5
	million and $18.0 million for the years ended December 31, 2016 and 2015, respectively.&nbsp;&nbsp;We have an accumulated deficit
	of $106.9 million since inception. We expect to make substantial expenditures and incur increasing operating costs in the future
	and our accumulated deficit will increase significantly as we expand commercial development, infrastructure, manufacturing and
	inventory planned requirements and clinical trial activities for our product candidates. Our losses have had, and are expected
	to continue to have, an adverse impact on our working capital, total assets and stockholders' equity. Because of the risks and
	uncertainties associated with product development, we are unable to predict the extent of any future losses, whether we will ever
	generate significant revenues or if we will ever achieve or sustain profitability.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
<I>
	We require additional funding and may be unable to raise
	capital when needed, which would force us to delay, curtail or eliminate one or more of our research and development programs or
	commercialization efforts.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	Our operations have consumed
	substantial amounts of cash since inception. During the years ended December 31, 2016 and 2015, we incurred research and
	development expenses of approximately $7.7 million and $7.0 million, respectively. We expect to continue to spend substantial
	amounts on product development, including commercialization activities, procuring raw material plasma, manufacturing,
	conducting potential future clinical trials for our product candidates and purchasing clinical trial materials from our
	suppliers. We anticipate that, based upon our projected revenue and expenditures, our current cash and cash equivalents,
	short term investments and accounts receivable will be sufficient to fund our operations, as currently conducted, into
	the second half of 2017. This time frame may change based upon the timing of the closing of our Proposed Acquisition, and
	how aggressively we execute on our operational initiatives. If our assumptions underlying our estimated expenses prove to
	be wrong, we may have to raise additional capital sooner than the second half of 2017. These assumptions may also change
	based upon the timing of the completion of the Proposed Acquisition, anticipated during the first half of 2017, of which
	funds received from BPC at the closing of the Proposed Acquisition are expected to be sufficient to fund operations into
	the first quarter of 2018. We have based this estimate, however, on assumptions that may prove to be wrong, and we could
	spend our available financial resources much faster than we currently expect. Until such time, if ever, as we can generate
	a sufficient amount of product revenue and achieve profitability, we expect to seek to finance future cash needs through
	equity or debt financings or corporate collaboration and licensing arrangements. If we are unable to raise additional
	capital, we will have to delay, curtail or eliminate our product development, including conducting clinical trials for our
	product candidates and purchasing clinical trial materials from our suppliers, as well as future commercialization
	efforts.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
<I>
	Raising additional funds by issuing securities or through
	licensing or lending arrangements may cause dilution to our existing stockholders, restrict our operations or require us to relinquish
	proprietary rights.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	To the extent that we raise additional capital
	by issuing equity securities, the share ownership of existing stockholders will be diluted. Any future debt financing may involve
	covenants that restrict our operations, including limitations on our ability to incur liens or additional debt, pay dividends,
	redeem our stock, make certain investments and engage in certain merger, consolidation or asset sale transactions, among other
	restrictions. In addition, if we raise additional funds through licensing arrangements or the disposition of any of our assets,
	it may be necessary to relinquish potentially valuable rights to our product candidates, or grant licenses on terms that are not
	favorable to us.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
</P>
<!-- FIELD: PAGE; SEQUENCE: 39 -->
<DIV STYLE="MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	37
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage40"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<P STYLE="MARGIN: 0PT; TEXT-ALIGN: RIGHT; FONT-SIZE: 8PT">
<A HREF="#E615811_10K-ADMA_HTM_TOC" STYLE="FONT-STYLE: ITALIC">
	Table of Contents
</A>
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
<I>
	Our cash, cash equivalents and short-term investments
	could be adversely affected if the financial institutions in which we hold our cash, cash equivalents and short-term investments
	fail.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 27PT">
	We regularly maintain cash balances at third-party
	financial institutions in excess of the Federal Deposit Insurance Corporation, or FDIC, insurance limit. While we monitor daily
	the cash balances in the operating accounts and adjust the balances as appropriate, these balances could be impacted, and there
	could be a material adverse effect on our business, if one or more of the financial institutions with which we deposit fails or
	is subject to other adverse conditions in the financial or credit markets. To date, we have experienced no loss or lack of access
	to our invested cash or cash equivalents; however, we can provide no assurance that access to our invested cash and cash equivalents
	will not be impacted by adverse conditions in the financial and credit markets.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 27PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
<I>
	If we fail to maintain proper and effective internal control
	over financial reporting in the future, our ability to produce accurate and timely financial statements could be impaired, which
	could harm our operating results, investors' views of us and, as a result, the value of our common stock.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	Pursuant to Section 404 of the Sarbanes-Oxley
	Act of 2002 and related rules, or SOX, our management is required to report on the effectiveness of our internal control over financial
	reporting. The rules governing the standards that must be met for management to assess our internal control over financial reporting
	are complex and require significant documentation, testing and possible remediation. To comply with the requirements of being a
	reporting company under the Securities Exchange Act of 1934, or the Exchange Act, we have been required to upgrade, and may need
	to implement further upgrades to our systems, including information technology, implement additional financial and management controls,
	reporting systems and procedures and hire additional accounting and finance staff.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
<I>
	Our ability to use our Net Operating Loss carryforwards
	(NOLs) may be limited.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	We have incurred substantial losses during
	our history. As of December 31, 2016, we had Federal and state NOLs of $87.8 million and $75.2 million, respectively. The $87.8
	million and $75.2 million in Federal and state NOLs, respectively, will begin to expire at various dates beginning in 2027, if
	not limited by triggering events prior to such time. Under the provisions of the Internal Revenue Code, changes in our ownership,
	in certain circumstances, will limit the amount of Federal NOLs that can be utilized annually in the future to offset taxable income.
	In particular, Section 382 of the Internal Revenue Code imposes limitations on a company&rsquo;s ability to use NOLs upon certain
	changes in such ownership. If we are limited in our ability to use our NOLs in future years in which we have taxable income, we
	will pay more taxes than if we were able to utilize our NOLs fully. We may experience ownership changes in the future as a result
	of subsequent shifts in our stock ownership that we cannot predict or control that could result in further limitations being placed
	on our ability to utilize our federal NOLs.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	Risks Associated with our Common Stock
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
<I>
	The market price of our common stock may be volatile
	and may fluctuate in a way that is disproportionate to our operating performance.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	Our stock price may experience substantial
	volatility as a result of a number of factors, including:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	the closing and consummation, or failure thereof, of our Proposed Acquisition;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	sales or potential sales of substantial amounts of our common stock;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	delay or failure in initiating or completing preclinical or clinical
	trials or unsatisfactory results of these trials;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	delay in FDA approval for RI-002;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	the timing of acceptance, reimbursement and sales of RI-002;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	announcements about us or about our competitors, including clinical
	trial results, regulatory approvals or new product introductions;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
</P>
<!-- FIELD: PAGE; SEQUENCE: 40 -->
<DIV STYLE="MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	38
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage41"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<P STYLE="MARGIN: 0PT; TEXT-ALIGN: RIGHT; FONT-SIZE: 8PT">
<A HREF="#E615811_10K-ADMA_HTM_TOC" STYLE="FONT-STYLE: ITALIC">
	Table of Contents
</A>
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	developments concerning our licensors or product manufacturers;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	litigation and other developments relating to our patents or other
	proprietary rights or those of our competitors;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	conditions in the pharmaceutical or biotechnology industries;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	governmental regulation and legislation;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	variations in our anticipated or actual operating results; and
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	change in securities analysts&rsquo; estimates of our performance,
	or our failure to meet analysts&rsquo; expectations.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	Many of these factors are beyond our control.
	The stock markets in general, and the market for pharmaceutical and biotechnology companies in particular, have historically experienced
	extreme price and volume fluctuations. These fluctuations often have been unrelated or disproportionate to the operating performance
	of these companies. These broad market and industry factors could reduce the market price of our common stock, regardless of our
	actual operating performance.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
<I>
	Sales of a substantial number of shares of our common
	stock, or the perception that such sales may occur, may adversely impact the price of our common stock.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	As of December 31, 2016, almost all of our
	12,886,741 outstanding shares of common stock, as well as a substantial number of shares of our common stock underlying outstanding
	warrants, are available for sale in the public market, either pursuant to Rule 144 under the Securities Act of 1933, as amended,
	or the Securities Act, or may become available under registration statements we intend to file in the future. Sales of a substantial
	number of shares of our common stock, or the perception that such sales may occur, may adversely impact the price of our common
	stock.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
<I>
	We have never paid and do not intend to pay cash dividends
	in the foreseeable future. As a result, capital appreciation, if any, will be your sole source of gain.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	We have never paid cash dividends on any
	of our capital stock and we currently intend to retain future earnings, if any, to fund the development and growth of our business.
	In addition, the terms of existing and future debt agreements may preclude us from paying dividends. As a result, capital appreciation,
	if any, of our common stock will be your sole source of gain for the foreseeable future.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
<I>
	Our affiliates control the majority of our shares of common
	stock. Provisions in our certificate of incorporation, our by-laws and Delaware law might discourage, delay or prevent a change
	in control of our company or changes in our management and, therefore, depress the trading price of our common stock.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	Provisions of our certificate of incorporation,
	our by-laws and Delaware law may have the effect of deterring unsolicited takeovers or delaying or preventing a change in control
	of our company or changes in our management, including transactions in which our stockholders might otherwise receive a premium
	for their shares over then current market prices. Our directors and executive officers and their affiliates beneficially own approximately
	51% of the outstanding shares of common stock. In addition, these provisions may limit the ability of stockholders to approve transactions
	that they may deem to be in their best interests. These provisions include:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 48PX; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX; FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	the inability of stockholders to call special meetings; and the ability of our board of directors to designate the terms of and issue new series of preferred stock without stockholder approval, which could include the right to approve an acquisition or other change in our control or could be used to institute a rights plan, also known as a poison pill, that would work to dilute the stock ownership of a potential hostile acquirer, likely preventing acquisitions that have not been approved by our board of directors; and&nbsp;&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	classification of our board of directors and limitation on filling of vacancies could make it more difficult for a third party
	to acquire, or discourage a third party from seeking to acquire, control of our company.&nbsp;&nbsp;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 41 -->
<DIV STYLE="MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	39
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage42"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<P STYLE="MARGIN: 0PT; TEXT-ALIGN: RIGHT; FONT-SIZE: 8PT">
<A HREF="#E615811_10K-ADMA_HTM_TOC" STYLE="FONT-STYLE: ITALIC">
	Table of Contents
</A>
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	In addition, Section 203 of the Delaware
	General Corporation Law prohibits a publicly-held Delaware corporation from engaging in a business combination with an interested
	stockholder, generally a person which together with its affiliates owns, or within the last three years, has owned 15% of our voting
	stock, for a period of three years after the date of the transaction in which the person became an interested stockholder, unless
	the business combination is approved in a prescribed manner.&nbsp;&nbsp;The existence of the forgoing provisions and anti-takeover
	measures could limit the price that investors might be willing to pay in the future for shares of our common stock. They could
	also deter potential acquirers of our company, thereby reducing the likelihood that you could receive a premium for your common
	stock in an acquisition. In addition, as a result of the concentration of ownership of our shares of common stock, our stockholders
	may from time to time, observe instances where there may be less liquidity in the public markets for our securities.&nbsp;&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
<I>
	If we fail to adhere to the strict listing requirements
	of NASDAQ, we may be subject to delisting. As a result, our stock price may decline and our common stock may be delisted.&nbsp;&nbsp;If
	our stock were no longer listed on NASDAQ, the liquidity of our securities likely would be impaired.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	Our common stock currently trades on the
	NASDAQ Capital Market under the symbol &ldquo;ADMA&rdquo;. If we fail to adhere to NASDAQ's strict listing criteria, including
	with respect to stock price, our market capitalization&nbsp;and stockholders&rsquo; equity, our stock may be delisted. This could
	potentially impair the liquidity of our securities not only in the number of shares that could be bought and sold at a given price,
	which may be depressed by the relative illiquidity, but also through delays in the timing of transactions and the potential reduction
	in media coverage. As a result, an investor might find it more difficult to dispose of our common stock. We believe that current
	and prospective investors would view an investment in our common stock more favorably if it continues to be listed on NASDAQ. Any
	failure at any time to meet the continuing NASDAQ listing requirements could have an adverse impact on the value of and trading
	activity in our common stock. Although we currently satisfy the listing criteria for NASDAQ, if our stock price declines dramatically,
	we could be at risk of falling below NASDAQ continuing listing criteria.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
<I>
	We are an &ldquo;emerging growth company,&rdquo; and elect
	to comply with reduced public company reporting requirements applicable to emerging growth companies, which could make our common
	stock less attractive to investors.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	We are an &ldquo;emerging growth company,&rdquo;
	as defined by the JOBS Act. The JOBS Act contains provisions that, among other things, reduce certain reporting requirements for
	qualifying public companies.&nbsp;&nbsp;As an &ldquo;emerging growth company,&rdquo; we may, under Section 7(a)(2)(B) of the Securities
	Act, delay adoption of new or revised accounting standards applicable to public companies until such standards would otherwise
	apply to private companies.&nbsp;&nbsp;&nbsp;We may continue to take advantage of this extended transition period until the first
	to occur of the date that we (i) are no longer an &ldquo;emerging growth company&rdquo; or (ii) affirmatively and irrevocably opt
	out of this extended transition period.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	We could be an emerging growth company until
	December 31, 2018, which is the last day of the fiscal year following the fifth anniversary of the first sale of our common equity
	securities pursuant to an effective registration statement under the Securities Act. However, if certain events occur prior to
	the end of such five-year period, including if we become a &ldquo;large accelerated filer,&rdquo; our annual gross revenues exceed
	$1 billion or we issue more than $1 billion of non-convertible debt in any three-year period, we would cease to be an emerging
	growth company prior to the end of such five-year period.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	We have elected to take advantage of
	the benefits of this extended transition period.&nbsp;&nbsp;Our financial statements may therefore not be comparable to those
	of companies that comply with such new or revised accounting standards.&nbsp;&nbsp;Until the date that we are no longer an
	&ldquo;emerging growth company&rdquo; or affirmatively and irrevocably opt out of the exemption provided by Securities Act
	Section 7(a)(2)(B), upon issuance of a new or revised accounting standard that applies to our financial statements and that
	has a different effective date for public and private companies, we will disclose the date on which adoption is required for
	non-emerging growth companies and the date on which we will adopt the recently issued accounting standard. As an emerging
	growth company, we are also exempt from the requirement to have our independent registered public accounting firm provide an
	attestation report on our internal control over financial reporting.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
</P>
<!-- FIELD: PAGE; SEQUENCE: 42 -->
<DIV STYLE="MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	40
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage43"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<P STYLE="MARGIN: 0PT; TEXT-ALIGN: RIGHT; FONT-SIZE: 8PT">
<A HREF="#E615811_10K-ADMA_HTM_TOC" STYLE="FONT-STYLE: ITALIC">
	Table of Contents
</A>
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	We cannot predict if investors will find
	our common stock less attractive as a result of our reliance on these exemptions. If some investors find our common stock less
	attractive as a result of any choice we make to reduce disclosure, there may be a less active trading market for our common stock
	and our stock price may be more volatile.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	Risks Related to the Proposed Acquisition of Certain Assets
	from BPC
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
<I>
	Failure to complete the Proposed Acquisition could negatively
	impact our business, financial condition or results of operations or the trading price of our common stock.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	The completion of the Proposed Acquisition
	is subject to a number of conditions and there can be no assurance that the conditions to the completion of the Proposed Acquisition
	will be satisfied. If the Proposed Acquisition is not completed, we will be subject to several risks, including:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 48PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX; FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	the current trading price of our common stock may reflect a market assumption that the Proposed Acquisition will occur, meaning that a failure to complete the Proposed Acquisition could result in a decline in the trading price of our common stock;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
</TR>
</TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 48PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX; FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	certain of our executive officers and/or directors may seek other employment opportunities, and the departure of any of our executive officers and the possibility that we would be unable to recruit and hire an executive could impact negatively our business and operating result;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
</TR>
</TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 48PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX; FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	we may be required to pay a termination fee of $2.5 million to BPC if the Purchase Agreement
	is terminated by us under certain circumstances;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
</TR>
</TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 48PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX; FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	we have incurred and are expected to continue to incur substantial transaction costs in connection with the Proposed Acquisition whether or not the Proposed Acquisition is completed;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
</TR>
</TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 48PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX; FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	we would not realize any of the anticipated benefits of having completed the Proposed Acquisition; and
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
</TR>
</TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 48PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX; FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY">
	pursuant to the Purchase Agreement, we are subject to certain restrictions on the conduct of our business prior to completion of the Proposed Acquisition, which restrictions could adversely affect our ability to realize certain of our business strategies or take advantage of certain business opportunities.
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	If the Proposed Acquisition is not completed, these risks may
	materialize and affect materially and adversely our business, financial condition, results of operations, and/or the trading price
	of our common stock.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
<I>
	While the Proposed Acquisition is pending, we will be
	subject to business uncertainties that could adversely affect our businesses.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Uncertainty about the effect of the Proposed Acquisition on employees, customers, suppliers
	and other third parties with whom we interact may have an adverse effect on us. These uncertainties may impair our ability to attract,
	retain and motivate key personnel until the Proposed Acquisition is completed and for a period of time thereafter, and could cause
	customers, suppliers and others who deal with us to seek to change existing business relationships with us. Employee retention
	may be challenging during the pendency of the transaction, as certain employees may experience uncertainty about their future roles.
	If key employees depart because of issues related to the uncertainty and difficulty of integration or a desire not to remain with
	the business, our business, and the acquired business from BPC, as the case may be, could be materially
	adversely affected. In addition, the Proposed Acquisition includes restrictions on our ability to take specified actions until
	the consummation of the transaction, without the consent of the other party. These restrictions may prevent us from pursuing attractive
	business opportunities that may arise prior to the completion of the transaction.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
</P>
<!-- FIELD: PAGE; SEQUENCE: 43 -->
<DIV STYLE="MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	41
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage44"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<P STYLE="MARGIN: 0PT; TEXT-ALIGN: RIGHT; FONT-SIZE: 8PT">
<A HREF="#E615811_10K-ADMA_HTM_TOC" STYLE="FONT-STYLE: ITALIC">
	Table of Contents
</A>
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
<I>
	The issuance of shares of our common stock to BPC
	in connection with the Proposed Acquisition will dilute substantially the voting power of our current stockholders.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	Pursuant to the terms of the
	Purchase Agreement, it is anticipated that we will issue shares of our capital stock to BPC stockholders
	representing approximately 50% less one share of the outstanding shares of capital stock of the combined company as of
	immediately following completion of the Proposed Acquisition, consisting of 25% common stock and the balance
	non-voting common stock.&nbsp; Accordingly, the issuance of shares of our common stock to BPC in connection with the Proposed
	Acquisition will reduce significantly the relative voting power of each share of our common stock held by our current
	stockholders. Consequently, our stockholders as a group will have significantly less influence over the management and
	policies of the combined company after the completion of the Proposed Acquisition than prior to completion of the Proposed
	Acquisition.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
<I>
	The market price of our common stock following the Proposed
	Acquisition may decline as a result of the Proposed Acquisition.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	The market price of our common stock may
	decline as a result of the Proposed Acquisition for a number of reasons, including if:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 48PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX; FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	investors react negatively to the prospects of the combined organization&rsquo;s business and prospects from the Proposed Acquisition;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
</TR>
</TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 48PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX; FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	third parties may seek to terminate and/or renegotiate their relationships with us as a result of the Proposed Acquisition, whether pursuant to the terms of their existing agreements with us or otherwise;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
</TR>
</TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 48PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX; FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	the effect of the Proposed Acquisition on the combined organization&rsquo;s business and prospects is not consistent with the expectations of financial or industry analysts; or
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
</TR>
</TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 48PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX; FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	the combined organization does not achieve the perceived benefits of the Proposed Acquisition as rapidly or to the extent anticipated by financial or industry analysts.
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
<I>
	We have incurred and will continue to incur significant
	direct and indirect transaction costs in connection with the Proposed Acquisition, some of which will be required to be paid even
	if the Proposed Acquisition is not completed.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	We have incurred and will continue to incur
	significant transaction costs in connection with the Proposed Acquisition.&nbsp; These costs are primarily associated with the
	fees of our attorneys, accountants and financial advisors, but also include the diversion of our resources and the attention of
	our management team from the operation of our business. We will be required to pay most of these costs even if the Proposed Acquisition
	is not completed.&nbsp; In addition, if the Purchase Agreement is terminated due to certain triggering events specified in the Purchase
	Agreement, we may be required to pay Biotest a termination fee of $2.5 million.&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
<I>
	Third party lawsuits may be filed against us in connection
	with the Proposed Acquisition which may be frivolous but costly to defend.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	Third parties may assert claims against
	us alleging that the terms of the Proposed Acquisition are somehow unfair or inappropriate. Although our board of directors and
	management team may disagree, any claims against us, with or without merit, as well as claims initiated by us against third parties,
	can be time-consuming and expensive to defend or prosecute and resolve. We cannot assure you that litigation asserting claims against
	us will not be initiated or that we would prevail in any litigation. We cannot assure you that the Proposed Acquisition of certain
	assets of BPC would close if and to the extent a claim or claims were filed against us in this regard.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
</B>
</P>
<!-- FIELD: PAGE; SEQUENCE: 44 -->
<DIV STYLE="MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	42
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage45"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<P STYLE="MARGIN: 0PT; TEXT-ALIGN: RIGHT; FONT-SIZE: 8PT">
<A HREF="#E615811_10K-ADMA_HTM_TOC" STYLE="FONT-STYLE: ITALIC">
	Table of Contents
</A>
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	Risks Related to the Combined Company if the Proposed Acquisition
	is Completed
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
<I>
	The success of the Proposed Acquisition will depend, in
	large part, on the ability of the combined company following completion of the Proposed Acquisition to realize the anticipated
	benefits from acquiring certain assets of BPC.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	The Proposed Acquisition involves the integration
	of two businesses that previously have operated independently with principal offices in two distinct locations. Significant management
	attention and resources will be required to integrate the two companies after completion of the Proposed Acquisition. The failure
	to integrate successfully and to manage successfully the challenges presented by the integration process may result in the combined
	company&rsquo;s failure to achieve some or all of the anticipated benefits of the Proposed Acquisition.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	Potential difficulties that may be encountered
	in the integration process include the following:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 48PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX; FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	using our cash and other assets efficiently to develop the business on a post-transaction basis;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
</TR>
</TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 48PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX; FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	appropriately managing the liabilities of our Company on a post-transaction basis;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
</TR>
</TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 48PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX; FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	potential unknown or currently unquantifiable liabilities associated with the Proposed Acquisition and the operations of our Company on a post-transaction basis;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
</TR>
</TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 48PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX; FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	potential unknown and unforeseen expenses, delays or regulatory conditions associated with the Proposed Acquisition; and
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
</TR>
</TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 48PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX; FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	performance shortfalls in one or both of the businesses as a result of the diversion of the applicable management&rsquo;s attention caused by completing the Proposed Acquisition and integrating the businesses.
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	Delays in the integration process could
	adversely affect the combined company&rsquo;s business, financial results, financial condition and stock price following the Proposed
	Acquisition. Even if the combined company were able to integrate the business operations successfully, there can be no assurance
	that this integration will result in the realization of the full benefits of synergies, innovation and operational efficiencies
	that may be possible from this integration and that these benefits will be achieved within a reasonable period of time.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
<I>
	Ownership of our common stock on a post-transaction basis
	will be highly concentrated, and it may prevent our stockholders from influencing significant corporate decisions and may result
	in conflicts of interest that could cause the combined company&rsquo;s stock price to decline.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	Upon completion of the Proposed Acquisition,
	BPC, together with current members of our board of directors, are expected to beneficially own or control a majority of our
	Company. On a post-transaction basis, BPC will own 12,886,740 shares of our capital stock, consisting of 4,295,580 voting shares
	of our common stock and 8,591,160 nonvoting shares of our common stock, representing 50% less one share of our common stock outstanding,
	and the current members of our board of directors will own 5,991,740 voting shares of our common stock. Accordingly, these directors,
	executive officers and their affiliates and stockholders, acting individually or as a group, will have substantial influence over
	the outcome of a corporate action of the combined company requiring stockholder approval, including the election of directors,
	any merger, consolidation or sale of all or substantially all of the combined company&rsquo;s assets or any other significant corporate
	transaction.&nbsp; These stockholders also may exert influence in delaying or preventing a change in control of the combined company,
	even if such change in control would benefit the other stockholders of the combined company.&nbsp; In addition, the significant
	concentration of stock ownership may affect adversely the market value of the combined company&rsquo;s common stock due to investors&rsquo;
	perception that conflicts of interest may exist or arise.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
<I>
	Upon closing and consummation of the Proposed Acquisition,
	BPC will be a significant stockholder.&nbsp; Future sales, or the perception of future sales, of our common stock by this stockholder
	may negatively impact our stock price and impair our ability to raise capital in the future.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	Upon the closing and consummation of the
	Proposed Acquisition, we have agreed to deliver to BPC the Biotest Equity Interest, consisting of (x) common stock representing
	25% of our issued and outstanding common stock, equal to 4,295,580 voting shares of our common stock and (y) 8,591,160 nonvoting
	shares of our common stock, representing the balance of the Biotest Equity Interest which is convertible into common stock upon
	the occurrence of certain specified events. In addition, upon the closing of the Proposed Acquisition, we have agreed to issue
	to BPC warrants, if any, necessary to acquire additional shares of our capital stock equal to the excess, if any, of (x) the
	number of shares represented by rights, options and warrants issued by us between September 12, 2016 until the closing, over (y)
	184,000 shares.&nbsp; In connection with the execution of the Purchase Agreement, upon the closing, we and certain Biotest stockholders
	plan to enter into a Registration Rights Agreement (the &ldquo;Registration Rights Agreement&rdquo;), pursuant to which such Biotest
	stockholders, and certain other of our existing stockholders, will have, among other things, certain registration rights under
	the Securities Act with respect to their shares of our capital stock.&nbsp; In addition, upon the closing, we and Biotest
	will also enter into a Stockholders Agreement (the &ldquo;Stockholders Agreement&rdquo;), pursuant to which
	Biotest will be subject to lock-up, volume limitation and standstill provisions for a period of six months.&nbsp;
	Any sales of substantial amounts of our common stock in the public market, including sales or distributions of shares by Biotest
	stockholders, including Biotest, or the perception that such sales or distributions might occur, could harm the market price
	of our common stock and could impair our ability to raise capital through the sale of additional equity securities.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
</P>
<!-- FIELD: PAGE; SEQUENCE: 45 -->
<DIV STYLE="MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	43
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage46"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<P STYLE="MARGIN: 0PT; TEXT-ALIGN: RIGHT; FONT-SIZE: 8PT">
<A HREF="#E615811_10K-ADMA_HTM_TOC" STYLE="FONT-STYLE: ITALIC">
	Table of Contents
</A>
</P>
</DIV>
</EFX_RISK_FACTORS>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
</P>
<EFX_UNRESOLVED_STAFF_COMMENTS>
<A NAME="FIS_UNRESOLVED_STAFF_COMMENTS"></A>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<A NAME="E615811_10K-ADMA_HTM_ITEM1B">
</A>
	Item 1B. Unresolved Staff Comments
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Not Applicable.
</FONT>
</P>
</EFX_UNRESOLVED_STAFF_COMMENTS>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<EFX_PROPERTIES>
<A NAME="FIS_PROPERTIES"></A>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<A NAME="E615811_10K-ADMA_HTM_ITEM2">
</A>
	Item 2. Properties
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	Our executive offices are located in
	approximately 4,200 square feet of space at 465 State Route 17, Ramsey, New Jersey.&nbsp;&nbsp;Our telephone number is (201)
	478-5552.&nbsp;&nbsp;Currently we operate under a shared services agreement with Areth, LLC (&ldquo;Areth&rdquo;) for the
	office, warehouse space and certain related services and have the ability to cancel this agreement upon 30 days&rsquo;
	notice.&nbsp;&nbsp;Areth is a company controlled by Dr. Jerrold B. Grossman, our Vice Chairman, and Adam S. Grossman, our
	President and Chief Executive Officer, and we pay Areth monthly fees for the use of such office space and for other
	information technology, general warehousing and administrative services.&nbsp;&nbsp;Rent under the shared services agreement
	is $16,000 per month.&nbsp;&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	ADMA BioCenters&rsquo; facilities are located
	in Norcross and Marietta, Georgia. The combined facilities have a total of approximately 28,000 square feet of space for approximately
	$30,000 rent per month. The Norcross, Georgia lease, the term of which was extended by five years on January 1, 2014 pursuant to
	the first of two available five-year renewal options, expires on September 30, 2023, and the Marietta, Georgia lease expires on
	January 31, 2024.
</P>
</EFX_PROPERTIES>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<EFX_LEGAL_PROCEEDINGS>
<A NAME="FIS_LEGAL_PROCEEDINGS"></A>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<A NAME="E615811_10K-ADMA_HTM_ITEM3">
</A>
	Item 3. Legal Proceedings
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	We are and may become subject to certain
	legal proceedings and claims arising in connection with the normal course of our business. In the opinion of management, there
	are currently no claims that would have a material adverse effect on our consolidated financial position, results of operations
	or cash flows.
</P>
</EFX_LEGAL_PROCEEDINGS>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<EFX_MINE_SAFETY_DISCLOSURE>
<A NAME="FIS_MINE_SAFETY_DISCLOSURE"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
<A NAME="E615811_10K-ADMA_HTM_ITEM4">
</A>
	Item 4. Mine Safety Disclosures
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	Not applicable.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
</P>
<!-- FIELD: PAGE; SEQUENCE: 46 -->
<DIV STYLE="MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	44
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage47"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<P STYLE="MARGIN: 0PT; TEXT-ALIGN: RIGHT; FONT-SIZE: 8PT">
<A HREF="#E615811_10K-ADMA_HTM_TOC" STYLE="FONT-STYLE: ITALIC">
	Table of Contents
</A>
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	PART II
</B>
</P>
</EFX_MINE_SAFETY_DISCLOSURE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<EFX_MARKET>
<A NAME="FIS_MARKET"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
<A NAME="E615811_10K-ADMA_HTM_ITEM5">
</A>
	Item 5. Market for Registrant&rsquo;s Common Equity, Related
	Stockholder Matters and Issuer Purchases of Equity Securities
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	Market Information
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	Our common stock has been listed on the
	NASDAQ Capital Market under the symbol &quot;ADMA&quot; since November 10, 2014. Between October 17, 2013 and November 10, 2014,
	our common stock was quoted on the OTC Bulletin Board (OTCBB) and the OTC Markets (OTCQB) under the same symbol.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	The following table sets forth, for each
	of the calendar periods indicated, the high and low sales prices for our common stock, as reported by the NASDAQ Capital Market:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_2"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 90%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="7" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	Year&nbsp;Ended
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="7" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	Year&nbsp;Ended
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD>
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="7" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	December 31, 2016
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="7" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	December 31, 2015
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD>
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	High
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Low
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	High
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Low
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 40%; TEXT-ALIGN: LEFT">
	First Quarter
</TD>
<TD STYLE="WIDTH: 3%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
	8.28
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 3%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
	4.15
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 3%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
	11.95
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 3%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
	7.57
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Second Quarter
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	8.85
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	5.71
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	9.66
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	7.51
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Third Quarter
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	8.00
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	5.00
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	10.28
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	8.00
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Fourth Quarter
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	7.34
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	4.34
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	9.85
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	7.74
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	Holders
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	As of February 7, 2017, there were 6 record
	holders of our common stock, based upon information received from our transfer agent. However, this number does not include beneficial
	owners whose shares were held of record by nominees or broker dealers. We estimate that there are more than 1,400 beneficial owners
	of our common stock.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	Dividend Policy
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	We have never paid any cash dividends on
	our capital stock.&nbsp;&nbsp;We anticipate that we will retain earnings, if any, to support operations and to finance the growth
	and development of our business.&nbsp;&nbsp;In addition, the terms of&nbsp;our LSA with Oxford&nbsp;precludes us from paying cash&nbsp;dividends
	without the consent of Oxford.&nbsp;&nbsp;Therefore, we do not expect to pay cash dividends for the foreseeable future.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
</P>
<!-- FIELD: PAGE; SEQUENCE: 47 -->
<DIV STYLE="MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	45
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage48"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<P STYLE="MARGIN: 0PT; TEXT-ALIGN: RIGHT; FONT-SIZE: 8PT">
<A HREF="#E615811_10K-ADMA_HTM_TOC" STYLE="FONT-STYLE: ITALIC">
	Table of Contents
</A>
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_3"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	Securities Authorized for Issuance Under
	Equity Compensation Plans
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	The following table sets forth certain information
	regarding our equity compensation plans as of December 31, 2016:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-WEIGHT: BOLD; BORDER-BOTTOM: BLACK 1PT SOLID">
	Plan Category
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Number of securities
<BR>
	to be issued upon
<BR>
	exercise of
<BR>
	outstanding options,
<BR>
	warrants and rights
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Weighted-average
<BR>
	exercise price of
<BR>
	outstanding
<BR>
	options, warrants
<BR>
	and rights
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" NOWRAP STYLE="TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	&nbsp;
<B>
	Number
	of securities
</B>
<BR>
<B>
	remaining available for
</B>
<BR>
<B>
	future issuance under
</B>
<BR>
<B>
	equity compensation
</B>
<BR>
<B>
	plans
	(excluding securities
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	&nbsp;reflected
	in column (a))&nbsp;
</B>
</P>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 46%; TEXT-ALIGN: LEFT">
	Equity compensation plans approved by security holders
</TD>
<TD STYLE="WIDTH: 5%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 11%; TEXT-ALIGN: RIGHT">
	1,535,187
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 5%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 11%; TEXT-ALIGN: RIGHT">
	7.90
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 5%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 11%; TEXT-ALIGN: RIGHT">
	368,086
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Equity compensation plans not approved by security holders
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&mdash;&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&mdash;&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&mdash;&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD>
	Total
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1,535,187
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	7.90
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	368,086
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0IN">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0IN">
<B>
	Stock Performance Graph
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	Not applicable.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0IN">
<B>
	Sale of Unregistered Securities
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	During the fiscal year ended December 31,
	2016, we had no sales of unregistered securities that have not been previously disclosed in a Current Report on Form 8-K or Quarterly
	Reports on Form 10-Q.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0IN">
<B>
	Purchases of Equity Securities by the Issuer
	and Affiliated Purchasers
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	We did not repurchase any of our securities
	in the fourth quarter of 2016.
</P>
</EFX_MARKET>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<EFX_FINANCIAL_DATA>
<A NAME="FIS_FINANCIAL_DATA"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0IN">
<A NAME="E615811_10K-ADMA_HTM_ITEM6">
</A>
<B>
	Item 6. Selected Financial Data
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	Not applicable.
</P>
</EFX_FINANCIAL_DATA>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<EFX_MANAGEMENTS_DISCUSSION>
<A NAME="FIS_MANAGEMENTS_DISCUSSION"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<A NAME="E615811_10K-ADMA_HTM_ITEM7">
</A>
<B>
	Item 7. Management&rsquo;s Discussion and Analysis of Financial
	Condition and Results of Operations
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<I>
	This discussion, which refers to our historical results,
	should be read in conjunction with the other sections of this annual report, including &ldquo;Risk Factors,&rdquo; &ldquo;Business&rdquo;
	and the consolidated financial statements and other consolidated financial information included in this report.&nbsp;&nbsp;The
	various sections of this discussion contain a number of forward-looking statements, all of which are based on our current expectations
	and could be affected by the uncertainties and risk factors described throughout this report.&nbsp;&nbsp;See &ldquo;Special Note
	Regarding Forward-Looking Statements.&rdquo;&nbsp;&nbsp;Our actual results may differ materially.
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Financial Operations Overview
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	We are a late-stage biopharmaceutical company
	that develops, manufactures and intends to commercialize specialty plasma-based biologics for the proposed treatment of immune
	deficiencies and prevention of certain infectious diseases. Our targeted patient populations include immune-compromised individuals
	who suffer from an underlying immune deficiency disorder or who may be immune-suppressed for medical reasons. Our product candidates
	are intended to be used by physician specialists focused on caring for immune-compromised patients with or at risk for certain
	infectious diseases.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
<I>
	Revenues
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;Revenue for the year ended December
	31, 2016 of $10,661,037 is primarily comprised of $10,518,203 from the sale of normal source human plasma through our FDA-licensed,
	GHA and MFDA certified plasma collection centers segment and $142,834 of license and other revenue which are recorded as
	deferred revenue and amortized into income&nbsp;over the terms of the respective agreements.&nbsp;&nbsp;In exchange for the out-licensing
	of RI-002 to market and sell in Europe and selected countries in North Africa and the Middle East, BPC has provided us with
	certain services and a&nbsp;financial payment received&nbsp;in accordance with the related license agreement and is obligated to
	pay us certain amounts in the future if certain milestones are achieved.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
</P>
<!-- FIELD: PAGE; SEQUENCE: 48 -->
<DIV STYLE="MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	46
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage49"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<P STYLE="MARGIN: 0PT; TEXT-ALIGN: RIGHT; FONT-SIZE: 8PT">
<A HREF="#E615811_10K-ADMA_HTM_TOC" STYLE="FONT-STYLE: ITALIC">
	Table of Contents
</A>
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	A significant amount of our revenues are
	attributed to a single customer, BPC. For the fiscal year ended December 31, 2016, two of our customers, SK and BPC, represented
	greater than 95% of our total revenues, with BPC representing approximately 82% of our total revenues and SK representing approximately
	14% of our total revenues.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	Product revenues from the sale of human
	plasma collected at our FDA-licensed plasma collection centers are recognized at the time of transfer of title and risk of loss
	to the customer, which occurs, depending on the agreement with the customer, at the time of shipment or at the time of delivery
	if we retain the risk of loss during shipment.&nbsp;&nbsp;Revenue from license fees and research and development services rendered
	are recognized as revenue when the performance obligations under the terms of the license agreement have been completed.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	During the third quarter of 2015, we recorded
	deferred revenue of $1,500,000 for a milestone payment provided to us from BPC upon filing the BLA for RI-002 with the FDA,
	in accordance with the terms of the license agreement. Deferred revenue is recognized over the term of the license. Deferred revenue
	is amortized into income for a period of approximately 20 years, which is the term of the license agreement.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
<I>
	Research and Development Expense
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	Research and development, or R&amp;D, expenses,
	attributable to our R&amp;D segment, consists of clinical research organization costs, clinical trial costs related to our clinical
	trial, consulting expenses relating to regulatory and medical affairs, quality assurance and control, manufacturing, assay development,
	ongoing testing costs, drug product manufacturing costs, including the cost of plasma, plasma storage and transportation costs,
	as well as wages and benefits for employees, including stock-based compensation directly related to the R&amp;D of RI-002. All
	R&amp;D costs are expensed as incurred.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	The process of conducting preclinical studies,
	clinical trials and regulatory activities necessary to obtain FDA approval is costly and time consuming.&nbsp;&nbsp;The probability
	of success for each product candidate and clinical trial may be affected by a variety of factors, including, among others, the
	quality of the product candidate&rsquo;s early clinical data, investment in the program, competition, regulatory, manufacturing
	capabilities and commercial viability.&nbsp;&nbsp;As a result of the uncertainties discussed above, the uncertainties associated
	with clinical trial enrollments and the risks inherent in the development process, we are unable to determine the duration and
	completion costs of current or future clinical stages of our product candidates or when, or to what extent, we will generate revenues
	from the commercialization and sale of any of our product candidates.&nbsp;&nbsp;Development timelines, probability of success
	and development costs vary widely. For the year ended December 31, 2016, R&amp;D expenses increased as compared to R&amp;D expenses
	for the year ended December 31, 2015 due to higher validation, testing and production costs related to RI-002 along with increased
	regulatory consulting services related to our BLA. We anticipate that 2017 R&amp;D expenses will decrease, as compared to 2016,
	as a result of reduced testing and validation services related to RI-002 offset by increased costs related to regulatory activities
	in connection with the CRL. Once we have clarity for the timing of our expected BLA resubmission and anticipated RI-002 approval,
	we would then expect our R&amp;D costs to increase.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
<I>
	General and Administrative Expense
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	General and administrative, or G&amp;A,
	expenses, consist of wages, stock-based compensation, benefits for senior management and staff unrelated to R&amp;D, legal fees,
	accounting and auditing fees, commercialization and marketing activities, information technology, investor relations fees, rent,
	maintenance and utilities, insurance, travel and other expenses related to the general operations of our business. For the year
	ended December 31, 2016, G&amp;A expenses increased as a result of higher marketing, commercial planning, increased headcount,
	wages and benefits for employees, including stock-based compensation and consulting expenses associated with commercialization
	activities as well as additional expenses incurred related to the Proposed Acquisition of certain assets of BPC. We expect that our G&amp;A expenses will decrease as we continue to manage our costs through deferring certain pre-launch
	and commercial planning activities, while we focus on addressing the CRL. Once we have clarity for the timing of our expected BLA
	resubmission and anticipated RI-002 approval, we would then expect our G&amp;A costs to increase.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
<I>
	Other Income and Expense
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	Interest income consists of interest earned
	on our cash and cash equivalents and short-term investments. Interest expense consists of interest incurred on our notes payable,
	as well as the amortization of end of term fees, back end fees, value of warrants issued, facility and financing fees. We anticipate
	other income and expense to remain consistent throughout 2017 as a result of our current outstanding debt and interest earned on
	investments.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
</P>
<!-- FIELD: PAGE; SEQUENCE: 49 -->
<DIV STYLE="MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	47
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage50"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<P STYLE="MARGIN: 0PT; TEXT-ALIGN: RIGHT; FONT-SIZE: 8PT">
<A HREF="#E615811_10K-ADMA_HTM_TOC" STYLE="FONT-STYLE: ITALIC">
	Table of Contents
</A>
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
<I>
	Segment Reporting
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	We are engaged in the development and commercialization
	of human plasma and plasma-derived therapeutics. We also operate two FDA-licensed source plasma collection facilities located in
	Norcross, Georgia and Marietta, Georgia. We define our segments as those business units whose operating results are regularly reviewed
	by the chief operating decision maker (&ldquo;CODM&rdquo;) to analyze performance and allocate resources. Our CODM is our President
	and Chief Executive Officer.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	The plasma collection center segment includes
	our operations in Georgia. The research and development segment includes our plasma development operations in New Jersey.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	Summarized financial information concerning
	reportable segments is included in Note 11 of the consolidated financial statements.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<EFX_RESULTS_OF_OPERATIONS>
<A NAME="FIS_RESULTS_OF_OPERATIONS"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	Results of Operations
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_4"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	Year Ended December 31, 2016 Compared to Year Ended December
	31, 2015
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
<I>
	Summary Table
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	The following table presents a summary of
	our results of operations for the year ended December 31, 2016 compared to the year ended December 31, 2015.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD COLSPAN="7" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Years Ended December 31,
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: CENTER">
<B>
	2016
</B>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: CENTER">
<B>
	2015
</B>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD COLSPAN="9">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 56%; TEXT-ALIGN: LEFT">
	Product revenue
</TD>
<TD STYLE="WIDTH: 2%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 14%; TEXT-ALIGN: RIGHT">
	10,518,203
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 2%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 14%; TEXT-ALIGN: RIGHT">
	7,050,283
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.5PT">
	License and other revenue
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	142,834
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	127,350
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.5PT">
	Total revenues
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	10,661,037
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	7,177,633
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Cost of product revenue
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	6,360,761
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	4,311,461
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Research and development
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	7,688,238
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	7,015,946
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Plasma centers
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	5,447,691
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	4,618,065
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.5PT">
	General and administrative
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	8,494,742
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	6,745,968
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.5PT">
	Total operating expenses
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	27,991,432
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	22,691,440
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Loss from operations
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(17,330,395
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(15,513,807
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Interest income
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	50,317
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	37,830
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Interest expense
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(2,239,569
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(1,842,716
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Other income
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	4,496
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&mdash;&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Change in fair value of stock warrants
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&mdash;&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	67,860
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.5PT">
	Loss on extinguishment of debt
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	&mdash;&nbsp;&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(719,097
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.5PT">
	Net loss
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE; TEXT-ALIGN: RIGHT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE; TEXT-ALIGN: RIGHT">
	(19,515,151
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE; TEXT-ALIGN: RIGHT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE; TEXT-ALIGN: RIGHT">
	(17,969,930
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-RIGHT: 0; MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; COLOR: RED">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; COLOR: RED">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
<I>
	Revenue
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	We recorded total revenue of $10,661,037
	during the year ended December 31, 2016 compared to $7,177,633 during the year ended December 31, 2015. Product revenue was $10,518,203
	for the year ended December 31, 2016,&nbsp;which is attributable to our ADMA BioCenters plasma collection centers segment and derived
	from the sale of human source plasma collected in our FDA-licensed, GHA and MFDS-certified Georgia-based blood plasma collection
	centers, compared to product revenue of $7,050,283 for the year ended December 31, 2015.&nbsp;&nbsp;The increase in product revenue
	of $3,467,920 was primarily attributable to increased plasma collections and sales from our Marietta, Georgia plasma center which
	received FDA approval to sell human source plasma within the U.S. during the third quarter of 2015. Product revenue for the year
	ended December 31, 2016 was primarily attributable to sales made pursuant to our plasma supply agreement with BPC under which
	BPC purchases normal source plasma from ADMA BioCenters for their manufacturing, in addition to selling increased quantities
	of normal source plasma to a second customer. We sold a majority of the normal source plasma collected from our plasma centers
	throughout 2016.&nbsp;&nbsp;The normal source plasma and high-titer RSV plasma we did not sell was allocated to inventory in anticipation
	of commercial manufacturing.&nbsp;&nbsp;For the years ended December 31, 2016 and 2015, license and other revenue was $142,834
	and $127,350, respectively, which relates to services&nbsp;and financial payments provided&nbsp;by BPC and Biotest in accordance
	with our license agreement.&nbsp;&nbsp;We have not generated any revenue from our therapeutics research and development business.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
</P>
<!-- FIELD: PAGE; SEQUENCE: 50 -->
<DIV STYLE="MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	48
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage51"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<P STYLE="MARGIN: 0PT; TEXT-ALIGN: RIGHT; FONT-SIZE: 8PT">
<A HREF="#E615811_10K-ADMA_HTM_TOC" STYLE="FONT-STYLE: ITALIC">
	Table of Contents
</A>
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
<I>
	Cost of Product Revenue
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	Cost of product revenue was $6,360,761 for
	the year ended December 31, 2016 and $4,311,461 for the year ended December 31, 2015. The increased cost of product revenues of
	$2,049,300 for the year ended December 31, 2016 was directly related to the increase in 2016 product revenues primarily related
	to our second plasma center.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
<I>
	Research and Development Expenses
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	R&amp;D expenses, which are attributable
	to our R&amp;D segment, were $7,688,238 for the year ended December 31, 2016, an increase of $672,292 as compared to $7,015,946
	for the year ended December 31, 2015.&nbsp;&nbsp;R&amp;D expenses consist of clinical research organization costs, consulting expenses
	relating to regulatory affairs, quality control and manufacturing, assay development and ongoing testing costs, clinical trial
	costs and fees, drug product manufacturing including the cost of plasma, plasma storage and transportation costs, as well as wages
	and benefits for staff directly related to the research and development of RI-002. R&amp;D expenses increased for the year ended
	December 31, 2016, as compared to the year ended December 31, 2015, primarily as a result of an increase in validation, testing
	and production costs related to RI-002 and an increase in regulatory consulting fees.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
<I>
	Plasma Center Operating Expenses
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	Plasma center operating expenses were $5,447,691
	for the year ended December 31, 2016, an increase of $829,626 as compared to $4,618,065 for the year ended December 31, 2015.&nbsp;&nbsp;Plasma
	center operating expenses consist of: general and administrative plasma center costs; overhead comprised of rent, maintenance,
	utilities, wages, stock-based compensation and benefits for center staff, plasma collection supplies, plasma transportation and
	storage (off-site); advertising and promotion expenses; and computer software fees related to donor collections. The increase in
	expenses was primarily the result of increased plasma collections at our ADMA BioCenters Marietta collection facility, which received
	FDA approval during the third quarter of 2015. The increased expenses include higher costs in wages, rent, maintenance and plasma
	collection supplies for the year ended December 31, 2016 as compared to the year ended December 31, 2015.&nbsp; We expect that
	as plasma collection increases, our operating expenses will also increase accordingly.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
<I>
	General and Administrative Expenses
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	G&amp;A expenses were $8,494,742 for the
	year ended December 31, 2016, an increase of $1,748,774 from $6,745,968 for the year ended December 31, 2015.&nbsp;&nbsp;General
	and administrative expenses consist of Proposed Acquisition fees, wages and stock-based compensation for our senior management
	and staff unrelated to research and development, professional fees for commercialization and marketing consulting, attorneys, accountants
	and auditors, investor relations, maintenance and utilities, insurance, information technology, travel and other expenses related
	to the general operations of the business. G&amp;A expenses primarily increased as a result of fees incurred for the Proposed Acquisition
	fees paid for legal, accounting and financial advisors. The increase was also attributed to consulting services provided to us
	related to pre-launch, commercial planning, and market research, along with increased rent expense, higher wages and benefits for
	employees and consulting fees.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: ITALIC 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	Other Income (Expense)
</B>
</P>
<P STYLE="FONT: ITALIC 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	Other expense, net, was $2,184,756 for the
	year ended December 31, 2016, as compared to $2,456,123 for the year ended December 31, 2015. The decrease of $271,367 is primarily
	related to a loss on extinguishment of debt of $719,097, which was recorded in the second quarter of 2015 for the refinancing of
	an existing loan with our new lender, Oxford Finance LLC, or Oxford. Such expenses are comprised of a write-off of deferred financing
	costs, end of term fees and prepayment penalties for the repayment of debt to our prior lender, offset by increased interest expense
	due to an increase of $4,000,000 to our current debt in the second quarter of 2016, which includes debt discounts amortization
	for our new lender&rsquo;s end of term fees, back end fees, value of warrants issued, facility and financing fees.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
</P>
<!-- FIELD: PAGE; SEQUENCE: 51 -->
<DIV STYLE="MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	49
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage52"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<P STYLE="MARGIN: 0PT; TEXT-ALIGN: RIGHT; FONT-SIZE: 8PT">
<A HREF="#E615811_10K-ADMA_HTM_TOC" STYLE="FONT-STYLE: ITALIC">
	Table of Contents
</A>
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
<I>
	Net Loss
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	Net loss increased to $19,515,151 for the
	year ended December 31, 2016 as compared to $17,969,930 for the year ended December 31, 2015, for the reasons previously stated.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
<I>
	Net Cash Used in Operating Activities
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	Net cash used in operating activities was
	$18,268,973 for the year ended December 31, 2016. The net loss for this period was higher than net cash used in operating activities
	by $1,246,178, which was primarily attributable to stock-based compensation of $1,250,074, depreciation and amortization of $469,576
	and amortization of debt discount of $676,943, offset by an increase of inventories of $1,574,373 related to collection and purchases
	of RSV plasma and normal source plasma, an increase in accounts payable of $476,826 and accrued expenses of $416,972 primarily
	related to fees associated to the Proposed Acquisition.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	Net cash used in operating activities was
	$15,418,404 for the year ended December 31, 2015. The net loss for this period was higher than net cash used in operating activities
	by $2,551,526, which was primarily attributable to increases in inventories of $1,737,010 related to allocating additional plasma
	to inventory in preparation for commercial manufacturing activities anticipated in 2016, increased deferred revenue of $1,525,000
	from a milestone payment received from BPC resulting from the BLA filing of RI-002, increases in accounts receivable of $540,507
	related to sales of our normal source plasma, offset by stock-based compensation of $1,711,047, a loss on extinguishment of debt
	of $719,097 attributable to the refinancing of previous debt with a new venture debt lender and depreciation and amortization of
	$469,821.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
<I>
	Net Cash Provided by (Used in) Investing Activities
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	Net cash provided by investing activities
	was $904,583 for the year ended December 31, 2016, which was related to the purchases and redemptions of short-term investments
	of $977,993 and purchases of computers and equipment of $73,410, primarily related to our second plasma centers which received
	FDA approval in September 2015.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	Net cash used in investing
	activities was $1,741,575 for the year ended December 31, 2015, which was related to the purchases and redemptions of short-term
	investments of $1,715,502 and $26,073 in purchases of computers and equipment.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
<I>
	Net Cash Provided by Financing Activities
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	Net cash provided by financing activities
	totaled $16,838,298 for the year ended December 31, 2016, which primarily consisted of $14,145,000 received from the issuance of
	common stock during the second quarter of 2016 offset by equity issuance costs of $1,244,459, proceeds of $4,000,000 received from
	Oxford during the second quarter of 2016, offset by payment of debt issue costs to Oxford of $47,104 in addition to amortization
	of our leasehold improvement loan for our ADMA BioCenters subsidiary.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	Net cash provided by financing activities
	totaled $10,401,908 for the year ended December 31, 2015, which primarily consisted of $16,000,000 received from the loan from
	Oxford during the second quarter of 2015, and $10,257,380 received from the issuance of common stock during the first quarter of
	2015, offset by the $15,300,781 related to the repayment of a pre-existing loan with Hercules, prepayment premium to Hercules of
	$229,512, debt issue costs to Oxford of $228,065 and an end of term fee payment of $132,500 to Hercules in addition to amortization
	of our leasehold improvement loan for our ADMA BioCenters wholly-owned subsidiary.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
</P>
<!-- FIELD: PAGE; SEQUENCE: 52 -->
<DIV STYLE="MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	50
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage53"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<P STYLE="MARGIN: 0PT; TEXT-ALIGN: RIGHT; FONT-SIZE: 8PT">
<A HREF="#E615811_10K-ADMA_HTM_TOC" STYLE="FONT-STYLE: ITALIC">
	Table of Contents
</A>
</P>
</DIV>
</EFX_RESULTS_OF_OPERATIONS>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
</P>
<EFX_LIQUIDITY_CAPITAL>
<A NAME="FIS_LIQUIDITY_CAPITAL"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	Liquidity and Capital Resources
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
<I>
	Overview
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	As of December 31, 2016, we had working
	capital of $10.4 million, consisting primarily of $9.9 million of cash and cash equivalents, $5.4 million of short term investments,
	$5.0 million of inventories, $1.0 million of accounts receivable and $0.3 million of prepaid expenses, offset by $11.2 million
	of current liabilities, which are mainly comprised of the current portion of our note payable due to Oxford and accounts payable
	and accrued expenses.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	We have had limited revenue from operations
	and we have incurred cumulative losses of $106.9 million since inception.&nbsp;&nbsp; We have funded our operations to date primarily
	from equity investments, loans from venture debt lenders and loans from our primary stockholders. In May 2016, we completed an
	underwritten public offering of our common stock and we received net proceeds of approximately $12.9 million. In May 2016, we amended
	our Loan and Security Agreement, or LSA, with Oxford and borrowed an additional $4.0 million. In March 2015, we received net cash
	proceeds of approximately $10.2 million from an underwritten public offering from the sale of our common stock. In October 2013,
	we received net cash proceeds of approximately $26.6 million from our initial public offering, or IPO. In various financings since
	2012, we received a total of $20.0 million from venture debt lenders. In February 2012, we received net cash proceeds of approximately
	$15.3 million from a private placement of our common stock. Our funds are being used and have been used: to conduct clinical trials;
	to manufacture drug products; to collect and procure plasma; to test plasma donors for RSV titers; to file our BLA for RI-002;
	to conduct pre-launch activities; for commercialization and marketing activities; for the buildout and expansion of our first plasma
	center and the buildout of our second plasma center; for our Proposed Acquisition of certain assets of BPC and the remainder for
	payment of existing accounts payable; for general and administrative, research and development expenses; and for other business
	activities and general corporate purposes.&nbsp;&nbsp;&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	We expect to continue to spend substantial
	amounts of capital on product development, including commercialization activities, procuring raw material plasma, manufacturing
	activities, regulatory activities, consulting fees in connection with our BLA and the potential approval of RI-002, conducting
	potential future studies and/or clinical trials for our product candidates and purchasing clinical trial materials from our suppliers.
	Based upon our projected revenue and expenditures for 2017, including the ongoing regulatory activities associated with pursuing
	the BLA for RI-002, implementation of our planned potential commercialization and expansion activities, we currently believe that
	our cash, cash equivalents, short-term investments and accounts receivable as of February 24, 2017 are sufficient to fund
	our operations, as currently conducted, into the second half of 2017. In order to have sufficient cash to fund our operations thereafter
	and to continue as a going concern, we will need to raise additional equity or debt capital by the end of the second half of 2017,
	and we cannot provide any assurance that we will be successful in fundraising.&nbsp; This time frame may change based upon the
	timing of the closing of our Proposed Acquisition of certain assets of BPC, our interactions with
	FDA, potential timing of our commercial manufacturing scale up activities, our generation of future revenue, how aggressively we
	execute on our regulatory strategy and/or commercial initiatives and when the FDA approves our BLA for RI-002, if at all. This
	timing may also change based upon the timing of the completion of the Proposed Acquisition, anticipated during the first half of
	2017. Upon the closing of the Proposed Acquisition, BPC will be providing us funds consisting of: $12.5 million in funding,
	$15.0 million in debt financing and an additional $12.5 million commitment towards a future equity financing is expected to be
	sufficient to fund operations into this first quarter of 2018.&nbsp;&nbsp;Other than the funding to be provided by BPC we currently
	do not have arrangements to obtain additional financing. There is no assurance that we will be able to successfully close on the
	Proposed Acquisition. Any such financing could be difficult to obtain or only available on unattractive terms and could result
	in significant dilution of stockholders' interests. Failure to secure any necessary financing in a timely manner and on favorable
	terms could have a material adverse effect on our business plan and financial performance and, as a result, we&nbsp;could be forced
	to delay, discontinue or prevent product development, clinical trial or commercialization activities,&nbsp;delay or discontinue&nbsp;the
	approval of any of our potential products, curtail our activities and potentially significantly reduce,&nbsp;or potentially cease
	operations. In addition, we could be forced to reduce or forego sales and marketing efforts and forego attractive business opportunities.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
</P>
<!-- FIELD: PAGE; SEQUENCE: 53 -->
<DIV STYLE="MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	51
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage54"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<P STYLE="MARGIN: 0PT; TEXT-ALIGN: RIGHT; FONT-SIZE: 8PT">
<A HREF="#E615811_10K-ADMA_HTM_TOC" STYLE="FONT-STYLE: ITALIC">
	Table of Contents
</A>
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	We believe that we will incur net losses
	and negative net cash flows from operating activities for the foreseeable future, which raises substantial doubt about our ability
	to continue as a going concern. As there are numerous risks and uncertainties associated with the research, development and future
	commercialization of our product candidate RI-002, we are unable to estimate with certainty the amounts of increased capital outlays
	and operating expenditures associated with our anticipated development and commercialization activities.&nbsp;&nbsp;Our current
	estimates may be subject to change as circumstances and requirements further develop.&nbsp;&nbsp;We may decide to raise capital
	through public or private equity offerings, debt financings, grants or corporate collaboration and licensing arrangements.&nbsp;&nbsp;The
	sale of additional equity or debt securities, if convertible, could result in dilution to our stockholders.&nbsp;&nbsp;The incurrence
	of indebtedness would result in increased fixed obligations and could also result in covenants that would restrict our operations
	or other financing alternatives.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
<I>
	Loan and Security Agreement
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	In June 2015, we entered into the LSA with
	Oxford , as collateral agent and lender, pursuant to which we were provided an initial term loan in the aggregate principal amount
	of $16.0 million, of which $15.7 million was used to repay an existing loan balance of $15.0 million, along with $0.4 million of
	interest and $0.3 million of prepayment premium&nbsp;and other fees, under our prior loan and security agreement, dated December
	21, 2012, with Hercules (the &ldquo;Prior Loan Agreement&rdquo;), as amended on February 24, 2014 (the &ldquo;Prior Loan Amendment&rdquo;).
	In May 2016, we amended the LSA with Oxford (the &ldquo;Amended LSA&rdquo;) which provided us with an additional $4.0 million term
	loan, bringing the total principal amount borrowed to $20.0 million. The LSA bears interest at a rate per annum equal to the greater
	of (i) 7.80% and (ii) the sum of (a) the three month U.S. LIBOR rate (as reported in
<I>
	The Wall Street Journal
</I>
	) on the date
	occurring on the last business day of the month that immediately precedes the month in which the interest will accrue, plus (b)
	7.54% on the outstanding principal balance. We are obligated to begin to repay the principal over 36 months beginning February
	1, 2017, unless accelerated as a result of certain events of default.&nbsp; At our option, if we receive BLA approval for RI-002
	within the initial 18-month interest only period, the interest only period may be extended for an additional six months. A final
	payment equal to 8.95% of the funded loan amount is due at the earlier of loan maturity or prepayment. In the event of the six-month
	interest only extension, the final payment will be 9.95% of the funded loan, which shall also be due at the earlier of loan maturity
	or prepayment. In addition, a facility fee of $105,000 was paid at closing.&nbsp;&nbsp;In the event we elect to prepay the loan,
	we are obligated to pay a prepayment charge corresponding to a percentage of the principal amount of the loan, with such percentage
	being: (i) for a prepayment made on or after the funding date of the applicable term loan through and including the first anniversary
	of its funding date, an amount equal to 3.00% of the principal amount of the term loan prepaid; (ii) for a prepayment made after
	the first anniversary of the funding date of the applicable term loan through and including the second anniversary of such funding
	date, an amount equal to 2.00% of the principal amount of such term loan prepaid; and (iii) for a prepayment of a term loan made
	after the second anniversary of its funding date and prior to its maturity date, an amount equal to 1.00% of the principal amount
	of the term loan prepaid. The loan matures no later than January 1, 2020.&nbsp; The loan is secured by our assets, except for our
	intellectual property (which is subject to a negative pledge). The LSA contains customary representations, warranties and covenants,
	including limitations on incurring indebtedness, engaging in mergers or acquisitions and making investments, distributions or transfers.&nbsp;&nbsp;The
	representations, warranties and covenants contained in the LSA were made only for purposes of such agreement and as of a specific
	date or specific dates, were solely for the benefit of the parties to such agreement, and may be subject to limitations agreed
	upon by the contracting parties, including being qualified by confidential disclosures exchanged between the parties in connection
	with the execution of the LSA. Events of default under the agreement include, but are not limited to: (i) insolvency, liquidation,
	bankruptcy or similar events; (ii) failure to pay any debts due under the LSA or other loan documents on a timely basis; (iii)
	failure to observe any covenant or secured obligation under the LSA or other loan documents, which failure, in most cases, is not
	cured within 10 days of written notice by lender; (iv) occurrence of any default under any other agreement between us and the lender,
	which is not cured within 10 days; (v) occurrence of an event that could reasonably be expected to have a material adverse effect;&nbsp;&nbsp;(vi)
	material misrepresentations; (vii) occurrence of any default under any other agreement involving indebtedness or the occurrence
	of a default under any agreement that could reasonably be expected to have a material adverse effect; and (viii) certain money
	judgments are entered against us or a certain portion of our assets are attached or seized.&nbsp;Remedies for events of default
	include acceleration of amounts owing under the LSA and taking immediate possession of, and selling, any collateral securing the
	loan.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
</P>
<!-- FIELD: PAGE; SEQUENCE: 54 -->
<DIV STYLE="MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	52
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage55"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<P STYLE="MARGIN: 0PT; TEXT-ALIGN: RIGHT; FONT-SIZE: 8PT">
<A HREF="#E615811_10K-ADMA_HTM_TOC" STYLE="FONT-STYLE: ITALIC">
	Table of Contents
</A>
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	In connection with the LSA, on June 19,
	2015, we issued Oxford a seven-year warrant, expiring on June 19, 2022, to purchase 74,309 shares of common stock at an exercise
	price of $8.51 per share. We recorded $367,700 as the fair value of the warrant to additional paid-in capital and as a debt discount
	to the carrying value of the loan. The key assumptions used to value the warrants included: (i) volatility of 57% on our common
	stock based upon a pro rata percentage of our common stock&rsquo;s volatility and similar public companies&rsquo; volatilities
	for comparison; (ii) an expected dividend yield of 0.0%; (iii) a risk-free interest rate of 1.99%; and (iv) a term of seven years.
	As a result of prepaying the Hercules loan prior to maturity, we incurred a loss on extinguishment of debt of $0.7 million comprised
	of unamortized debt issuance costs, unamortized debt discount related to the warrants issued to Hercules, along with a prepayment
	penalty.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	Pursuant to the Amended LSA, (i) we paid
	a total facility fee of $125,000, consisting of $105,000 previously paid and an additional $20,000 paid on the date the Term B
	Loan was funded; (ii) certain adjustments were made to the time periods for any applicable prepayment fees; and (iii) certain defined
	terms were adjusted, including a new Amortization Date that is defined as&nbsp;(a) February 17, 2017, if the Term C Loan is not
	made and (b) August 1, 2017 if the Term C Loan is made.&nbsp;&nbsp;The Amended LSA further provides for customary representations,
	warranties and covenants for us.&nbsp;&nbsp;Except as otherwise amended, the Amended LSA does not alter the terms of the LSA. In
	addition, on May 13, 2016, pursuant to the terms and conditions of the LSA as modified by the Amended LSA, we agreed to issue to
	the lenders warrants to purchase shares of our common stock, upon our draw of each term loan tranche. The aggregate number of shares
	of common stock issuable upon exercise of the warrants is equal to 3.95% of the amount drawn of such tranche, divided by the average
	reported closing price per share of common stock for the consecutive 10 trading days prior to the applicable draw.&nbsp;&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 40.5PT">
	In connection with the Amended
	LSA, on May 13, 2016, we issued to Oxford a seven-year warrant, expiring on May 23, 2023, to purchase 24,800 shares of
	common stock at an exercise price of $6.37 per share, equal to 3.95% of the amount drawn of such tranche, divided by the average
	reported closing price per share of common stock for the consecutive 10 trading days prior to the applicable draw, in accordance with our
	drawdown of the Term B Loan. We recorded $86,300 as the fair value of the warrant to additional paid-in capital and as a debt
	discount to the carrying value of the loan.&nbsp;&nbsp;The key assumptions used to value the warrants included: volatility of
	53.5% on our common stock based upon a pro rata percentage of our common stock&rsquo;s volatility and similar
	public companies&rsquo; volatilities for comparison, an expected dividend yield of 0.0%, a risk-free interest rate of 1.51%
	and a term of seven years.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 40.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	In connection with our Prior Loan Agreement
	with Hercules, we borrowed a total of $15.0 million, which was repaid and terminated in June 2015 through a new loan with Oxford.
	We recorded a loss on extinguishment of $0.7 million comprised of an early prepayment penalty and the remaining unamortized debt
	issuance costs and end of term fee. The loan&rsquo;s interest at a rate per annum was equal to the greater of (i) 8.75% and (ii)
	the sum of (a) 8.75% plus (b) the Prime Rate (as reported in
<I>
	The Wall Street Journal
</I>
	) minus (c) 5.75%. Payment-in-kind interest
	accrues on the outstanding principal balance of the loan compounded monthly at 1.95% per annum. Such accrued and unpaid interest
	is added to the principal balance of the loan on the first day of each month beginning on the month after the closing. In connection
	with the Prior Loan Agreement and Prior Loan Amendment with Hercules, we issued to Hercules a warrant to purchase 31,750 shares
	of common stock in December 2012, with an exercise price of $7.56 and in connection with the Prior Loan Agreement and Prior Loan
	Amendment, we issued to Hercules a warrant to purchase an additional 58,000 shares of our common stock, comprised of a warrant
	to purchase 23,200 shares of common stock issued in February 2014 and a warrant to purchase 34,800 shares of common stock issued
	in December 2014, each warrant issued under the Prior Loan Amendment and Prior Loan Agreement having an exercise price of $7.50.&nbsp;&nbsp;The
	warrants expire after 10 years and have piggyback registration rights with respect to the shares of common stock underlying the
	warrant.&nbsp;&nbsp;The fair value of the Prior Loan Agreement and Prior Loan Amendment warrants were calculated using a lattice-based
	option model in order to account for features in the warrant that could cause the exercise price to reset (&ldquo;down round protection&rdquo;)
	as a result of the next issuance of our common stock (&ldquo;the next round of equity financing&rdquo;). We initially recorded
	the fair value of the warrant of $219,588 as warrant liability and as a debt discount to the carrying value of the loan. The key
	assumptions used to value the warrants included the expected date of the next round of equity financing, volatility of 59% for
	our common stock based upon similar public companies&rsquo; volatilities for comparison, an expected dividend yield of 0.0%, a
	risk-free interest rate of 2.53% and a term of 10 years. As of December 31, 2014, we recorded $476,760 as the fair value of the
	warrant for the purchase of 58,000 shares of common stock. As a result of the increase in warrant liability, we recorded an expense
	of $74,356 from the change in the fair value of warrant liability. During the first quarter ended March 31, 2015, we recorded $408,900
	as the fair value of the warrant for the purchase of 58,000 shares of common stock. As a result of the decrease in warrant liability,
	we recorded a change in the fair value of stock warrants of $67,860 from the December 31, 2014 balance. The key assumptions used
	to value the warrants included the expected date of the next round of equity financing, volatility of 58% based upon a pro rata
	percentage of our common stock and similar public companies&rsquo; volatilities, an expected dividend yield of 0.0%, a risk-free
	rate of 1.99% and a term of 10 years. This warrant liability was adjusted from the date of the Prior Loan Agreement on February
	24, 2014 to fair value each reporting period using a lattice-based option model and the debt discount will be amortized to interest
	expense over the term of the loan. The down round warrant protection feature resulting in the warrant liability&rsquo;s quarterly
	&ldquo;mark-to-market&rdquo; valuation has terminated as of February 24, 2015, which was the end of the one-year period following
	the amended loan closing on February 24, 2014 and as a result the warrant liability of $408,900 was reclassified to additional
	paid-in capital.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
</P>
<!-- FIELD: PAGE; SEQUENCE: 55 -->
<DIV STYLE="MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	53
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage56"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<P STYLE="MARGIN: 0PT; TEXT-ALIGN: RIGHT; FONT-SIZE: 8PT">
<A HREF="#E615811_10K-ADMA_HTM_TOC" STYLE="FONT-STYLE: ITALIC">
	Table of Contents
</A>
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
<I>
	Future Financing Needs
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	We expect to continue to spend
	substantial amounts on product development, including commercialization activities, procuring raw material plasma,
	manufacturing, conducting potential future clinical trials for our product candidates and purchasing clinical trial materials
	from our suppliers. We anticipate that, based upon our projected revenue and expenditures, our current cash and cash
	equivalents, short-term investments and accounts receivable will be sufficient to fund our operations into the second half of
	2017. In order to have sufficient cash to fund our operations thereafter, we will need to raise additional equity or debt
	capital by the end of the second half of 2017 in order to continue as a going concern, and we cannot provide any assurance
	that we will be successful in doing so.&nbsp;Upon the closing of the Proposed Acquisition, BPC will be providing us
	funds consisting of: $12.5 million in funding, $15.0 million in debt financing and an additional $12.5 million commitment
	towards a future equity financing is expected to be sufficient to fund operations into this first quarter of
	2018.&nbsp;&nbsp;Other than the funding to be provided by BPC we currently do not have arrangements to obtain additional
	financing. There is no assurance that we will be able to successfully close on the Proposed Acquisition. This time frame may
	change based upon the timing of our commercial manufacturing scale up activities, how aggressively we execute on our
	commercial initiatives and when the FDA approves our BLA, if at all.&nbsp;We currently do not have arrangements to obtain
	additional financing. Any such financing could be difficult to obtain or only available on unattractive terms and could
	result in significant dilution of stockholders' interests. Failure to secure any necessary financing in a timely manner and
	on favorable terms could have a material adverse effect on our business plan and financial performance and we could be forced
	to delay, discontinue or prevent product development, clinical trial or commercialization activities,&nbsp;delay or
	discontinue&nbsp;the approval of any of our potential products, or potentially cease operations.&nbsp;In addition, we could
	be forced to reduce or forego sales and marketing efforts and forego attractive business opportunities.&nbsp;&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;We cannot predict with certainty that
	we will not need to raise additional funds in the future or when we will reach profitability, if at all. Furthermore, if our assumptions
	underlying our estimated expenses, the timing of FDA resubmission or approval for RI-002 and generation of revenues from RI-002
	are incorrect, we may have to raise additional capital sooner than anticipated.&nbsp;&nbsp;Because of numerous risks and uncertainties
	associated with the research and development and potential future commercialization of our product candidate, we are unable to
	estimate with certainty the amounts of increased capital outlays and operating expenditures associated with our anticipated clinical
	trials and development activities.&nbsp;&nbsp;Our current estimates may be subject to change as circumstances regarding our business
	requirements evolve. We may decide to raise capital through public or private equity offerings, such financings may only be available
	on unattractive terms, resulting in significant dilution of stockholders&rsquo; interests and, in such event, the value and potential
	future market price of our common stock may decline, or we may decide to obtain debt financings or a bank credit facility or to
	enter into corporate collaboration and licensing arrangements.&nbsp;&nbsp; The sale of additional equity or debt securities, if
	convertible, could result in dilution to our current stockholders.&nbsp;&nbsp;The incurrence of indebtedness would result in increased
	fixed obligations and could also result in covenants that would restrict our operations or other future financing alternatives.
	Additional equity or debt financing, grants, or corporate collaboration and potential licensing arrangements may not be available
	on acceptable terms, if at all.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	If adequate funds are not available, we
	may be required to delay, reduce the scope of or eliminate our research and development programs, reduce our planned clinical trials
	and delay or abandon potential commercialization efforts of our lead product candidate or other product candidates.&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	Our long-term liquidity depends on our ability
	to raise additional capital, to fund our research and development and commercial programs and meet our obligations on a timely
	basis.&nbsp;&nbsp;We have reported losses since inception in June 2004 through December 31, 2016, and we have as of December 31,
	2016, an accumulated deficit of $106.9 million. We believe that we will continue to incur losses and negative cash flows from operating
	activities to fund our research and development, commercial programs and meet our obligations on a timely basis through the foreseeable
	future.&nbsp;&nbsp;As such, these conditions raise substantial doubt about our ability to continue as a going concern.&nbsp;&nbsp;If
	we are unable to successfully raise sufficient additional capital, we will likely not have sufficient cash flow and liquidity to
	fund our business operations as we currently operate, which may force us to delay, discontinue or prevent product development and
	clinical trial activities or the approval of any of our potential products, curtail our activities and potentially significantly
	reduce,&nbsp;or potentially cease operations.&nbsp;&nbsp;Even if we are able to raise additional capital, such financings may only
	be available on unattractive terms, or could result in significant dilution to stockholders&nbsp;and, in such event, the value
	and potential future market price of our common stock may decline.&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
</P>
<!-- FIELD: PAGE; SEQUENCE: 56 -->
<DIV STYLE="MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	54
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage57"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<P STYLE="MARGIN: 0PT; TEXT-ALIGN: RIGHT; FONT-SIZE: 8PT">
<A HREF="#E615811_10K-ADMA_HTM_TOC" STYLE="FONT-STYLE: ITALIC">
	Table of Contents
</A>
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;&nbsp;&nbsp;&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	Financial markets in the U.S.,
	Canada, Europe and Asia continue to experience disruption, including, among other things, significant volatility in security prices,
	declining valuations of certain investments, as well as severely diminished liquidity and credit availability.&nbsp;&nbsp;Business
	activity across a wide range of industries and regions continues to be greatly reduced and local governments and many businesses
	are still suffering from the lack of consumer spending and the lack of liquidity in the credit markets.&nbsp;&nbsp;Instability
	in the credit and financial market conditions may negatively impact our ability to access capital and credit markets and our ability
	to manage our cash balance.&nbsp;&nbsp;While we are unable to predict the continued duration and severity of the adverse conditions
	in the U.S. and other countries, any of the circumstances mentioned above could adversely affect our business, financial
	condition, operating results and cash flows or cash position.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	Effect of Inflation
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	Inflation did not have a significant impact
	on ADMA&rsquo;s net sales, revenues or income from continuing operations in 2014, 2015 or 2016.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	Summary of Proposed Acquisition of Certain Assets of BPC
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	On January 21, 2017, we and Buyer
	entered into the Purchase Agreement with Seller, and for certain limited purposes set forth in the Purchase Agreement, the
	Biotest Guarantors, pursuant to which Buyer has agreed to acquire certain assets and assume certain liabilities constituting
	the Business. The Business includes (a) a FDA-licensed immune globulin manufacturing and plasma products production facility
	of two commercial buildings of approximately 126,000 square feet located on approximately 15 acres of land in Boca Raton,
	Florida, and the associated real property, (b) all exclusive rights to FDA licensed biologics products Nabi-HB&reg;,
	BIVIGAM&reg; and the investigational product CIVACIR&reg;, (c) in-process inventory with an agreed-upon value of at least
	$5.0 million, (d) certain other properties and assets used exclusively in the Business, and (e) certain additional assets
	which relate to both the Business and Seller&rsquo;s plasma business, the arrangement with respect to which will be
	documented in a transition services agreement to be mutually agreed by the parties between the signing of the Purchase
	Agreement and the closing of the Proposed Acquisition.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	Subject to the terms and conditions of
	the Purchase Agreement, (i) upon the closing, Buyer has agreed to assume the Assumed Liabilities; (ii) upon the closing, we
	have agreed to deliver to Seller the Biotest Equity Interest, consisting of (x) common stock representing 25% of our issued
	and outstanding common stock, equal to 4,295,580 common shares and (y) non-voting common stock equal to 8,591,160 shares of
	our non-voting common stock representing the balance of the Biotest Equity Interest which is convertible into our common
	stock upon the occurrence of certain specified events; (iii) upon the closing, we agreed to issue to Seller warrants, if
	any, necessary to acquire additional shares of our capital stock equal to the excess, if any, of (x) the
	number of shares represented by rights, options and warrants issued by us between September 12, 2016 until the closing, over
	(y) 184,000 shares; and (iv) on January 1, 2019, pursuant to the terms of a separate purchase agreement to be entered into by
	the parties at the closing, we will agree to sell, transfer and convey to Seller for no additional consideration, all of
	our right, title and interest in and to our certain biocenter located in Norcross, Georgia and our certain biocenter
	located in Marietta, Georgia, which are subject to a repurchase right in favor of us if within five years after January
	1, 2019, the Biotest stockholders and its related entities own less than 20% of our issued and outstanding capital stock.
	As part of the consideration, upon the closing, Seller will also be granted the right to designate one director and one
	observer to our board of directors, and under certain circumstances, Seller will be granted the right to designate an
	additional director.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
</P>
<!-- FIELD: PAGE; SEQUENCE: 57 -->
<DIV STYLE="MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	55
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage58"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<P STYLE="MARGIN: 0PT; TEXT-ALIGN: RIGHT; FONT-SIZE: 8PT">
<A HREF="#E615811_10K-ADMA_HTM_TOC" STYLE="FONT-STYLE: ITALIC">
	Table of Contents
</A>
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	Additionally, on the closing
	date, Seller has agreed to (i) deliver to us a capital contribution of $12.5 million in respect of the Biotest
	Equity Interest, which capital contribution will be contributed by Seller to Buyer; and (ii) fund a $15.0 million unsecured
	subordinated loan to us, which (a) will bear interest at a rate of 6% per annum, payable semiannually in arrears, (b) has a
	term of five years and (c) will not be subject to any prepayment penalty or other breakage costs. Such loan will be
	subordinated to our existing indebtedness as of the signing of the Purchase Agreement and any additional indebtedness
	approved by our board of directors which is secured only by a mortgage on the owned real property acquired in connection with
	the transaction. Such loan will rank pari passu with all additional indebtedness approved by our board of directors that is
	not secured only by a mortgage on such owned real property and if such additional indebtedness is secured, the loan from
	Seller will be secured on a pari passu basis with such additional indebtedness. At any time after the closing, if we
	undertake an underwritten equity financing or a Private Investment in Public Equity, or PIPE, offering involving at least
	one unrelated third party, Biotest and/or Seller have agreed to participate pro rata in accordance with the Biotest Equity
	Interest up to an aggregate amount equal to $12.5 million.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	Upon the closing, the parties will
	also enter into a ten-year plasma supply agreement, pursuant to which (x) Seller will sell to us high titer Hepatitis B
	plasma at a specified price (indexed by inflation), and (y) we will purchase from Seller all Hepatitis B plasma necessary to
	produce Nabi-HB&reg; unless we require more than a specified amount, in which case we may use alternative sources for the
	excess quantity. Additionally, the parties have agreed to a mutual release with respect to any claims relating to or arising
	from any breach or default under the Manufacturing Supply and License Agreement and Master Services Agreement between Buyer
	and Seller. The mutual release is effective as of the signing of the Purchase Agreement conditioned on the closing of the
	Proposed Acquisition at which time the Manufacturing Supply and License Agreement and Master Services Agreement will
	terminate and the mutual release will no longer be conditional.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	The Purchase Agreement contains customary
	representations and warranties of the parties, including, without limitation, with respect to: organization; power and authority;
	due authorization; enforceability; capitalization; no conflict; no consents required; no actions; no orders; financial statements;
	indebtedness; no undisclosed liabilities; absence of certain changes; taxes; contracts; customers and suppliers; intellectual property;
	title to properties; real property; employee benefit plans; employees; insurance; compliance with laws; environmental; material
	permits; inventory; affiliate transactions; and no brokers.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	The Purchase Agreement also
	contains customary covenants and agreements, including covenants and agreements of: Seller to conduct the Business in the
	ordinary course until the Proposed Acquisition is completed or terminated and to not take certain actions relating to the
	Business during the interim period between signing and closing, without our prior consent not to be unreasonably withheld,
	conditioned or delayed; our ability to conduct our business in the ordinary course until the Proposed Acquisition is
	completed or terminated and to not take certain actions relating to our business during the interim period between signing
	and closing, without Seller&rsquo;s prior consent not to be unreasonably withheld, conditioned or delayed; Seller not to
	compete with us in certain lines of business for a period of five years following the closing date; Seller and the Biotest
	Guarantors not to solicit our employees for one year following the closing date; we and Buyer not to solicit
	Seller&rsquo;s employees for one year following the closing date; and Seller not to interfere with our
	customers for five years following the closing date.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	Subject to certain limitations, Buyer
	or Seller may terminate the Purchase Agreement if the Proposed Acquisition has not been consummated by September 30, 2017. A
	termination of the Purchase Agreement under certain customary circumstances relating to (i) our board of directors
	exercising their fiduciary out will entitle Seller to receive from us a termination fee in an amount equal to $2.5 million;
	or (ii) our failure to obtain the requisite stockholder approval will entitle Seller to receive expense reimbursement in an
	amount up to $2.5 million. In no event will Seller be entitled to both a termination fee and expense reimbursement.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	We and Seller will each indemnify
	the other party after the closing for any losses arising from breaches of its representations, warranties, covenants and agreements
	in the Purchase Agreement. In addition, Buyer will indemnify Seller after the closing for any assumed liability, and Seller
	will indemnify us after the closing for any excluded asset or excluded liability. The representations, warranties and
	pre-closing covenants generally survive for 15 months following the closing of the transaction and each party&rsquo;s indemnification
	obligations with respect to (a) its representations and warranties (other than its fundamental representations, which include representations
	related to taxes, organization, due authorization, organizational documents, no conflicts; enforceability, title; sufficiency,
	the Kedrion Contract, brokers, etc. and ownership of our securities) are subject to a $25,000 mini-basket and $750,000
	true deductible; and (b) its representations and warranties (other than fundamental) and pre-closing covenants are subject to a
	$25.0 million cap.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
</P>
<!-- FIELD: PAGE; SEQUENCE: 58 -->
<DIV STYLE="MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	56
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage59"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<P STYLE="MARGIN: 0PT; TEXT-ALIGN: RIGHT; FONT-SIZE: 8PT">
<A HREF="#E615811_10K-ADMA_HTM_TOC" STYLE="FONT-STYLE: ITALIC">
	Table of Contents
</A>
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	Seller will be entering into a standstill
	with ADMA, which will limit Seller&rsquo;s ability to control us. Seller will also agree to a six (6) month lock-up
	of the sale of ADMA securities.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	The consummation of the Proposed
	Acquisition is subject to the satisfaction of certain conditions, including approval of the Proposed Acquisition by the
	stockholders of ADMA and approval of the amended and restated certificate of incorporation of the Company by the stockholders
	of ADMA. The Proposed Acquisition is not subject to any financing conditions. There can be no assurance as to when the closing
	conditions will be satisfied, if at all.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	Upon consummation and closing of the Proposed
	Acquisition, we believe we will be uniquely positioned to offer a fully vertically integrated plasma products and immune
	globulin platform in the U.S.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	Recent Accounting Pronouncements
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 27PT; BACKGROUND-COLOR: WHITE">
	In January 2017,
	the Financial Accounting Standards Board, or FASB, issued Accounting Standards Update, or ASU, No. 2017-01,
<I>
	Business Combinations
	&ndash; Clarifying the Definition of a Business,
</I>
	which clarifies the definition of a business to assist entities with evaluating
	whether transactions should be accounted for as acquisitions or disposals of assets or businesses. The standard introduces a screen
	for determining when assets acquired are not a business and clarifies that a business must include, at a minimum, an input and
	a substantive process that contribute to an output to be considered a business. This standard is effective for fiscal years beginning
	after December 15, 2017, including interim periods within that reporting period. We do not expect this new guidance to have a material
	impact on our consolidated financial statements.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 27PT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	In March 2016, the FASB issued ASU No. 2016-09,
<I>
	Improvements to Employee Share-Based Payment Accounting (Topic 718),
</I>
	which provides for simplification of certain aspects
	of employee share-based payment accounting including income taxes, classification of awards as either equity or liabilities, accounting
	for forfeitures and classification on the statement of cash flows. ASU 2016-09 will be effective for us in the first quarter of
	2017 and will be applied either prospectively, retrospectively or using a modified retrospective transition approach depending
	on the area covered in this update. The adoption of this ASU is not expected to have a material impact on our consolidated financial
	statements and related disclosures.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;In February 2016, the FASB issued
	ASU No. 2016-02,
<I>
	Leases (Topic 842),
</I>
	which requires lessees to recognize assets and liabilities for the rights and obligations
	created by most leases on their balance sheet. The guidance is effective for fiscal years beginning after December 15, 2018, including
	interim periods within those fiscal years. Early application is permitted. ASU 2016-02 requires modified retrospective adoption
	for all leases existing at, or entered into after, the date of initial application, with an option to use certain transition relief.
	We are currently evaluating the impact the standard may have on our consolidated financial statements and related disclosures.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 27PT; BACKGROUND-COLOR: WHITE">
	In November 2015,
	the FASB issued ASU No. 2015-17
<I>
	, Income Taxes (Topic 740), Balance Sheet Classification of Deferred Taxes
</I>
	, which includes
	amendments that require deferred tax liabilities and assets be classified as non-current in a classified statement of financial
	position.&nbsp; The amendments in this ASU are effective for financial statements issued for annual periods beginning after December
	15, 2017, and interim periods within annual periods beginning after December 15, 2018.&nbsp; Earlier application is permitted as
	of the beginning of an interim or annual reporting period.&nbsp; The amendments may be applied either prospectively to all deferred
	tax liabilities and assets or retrospectively to all periods presented.&nbsp;We do not expect this new guidance to have a material
	impact on our consolidated financial statements.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 27PT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 27PT; BACKGROUND-COLOR: WHITE">
</P>
<!-- FIELD: PAGE; SEQUENCE: 59 -->
<DIV STYLE="MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	57
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage60"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<P STYLE="MARGIN: 0PT; TEXT-ALIGN: RIGHT; FONT-SIZE: 8PT">
<A HREF="#E615811_10K-ADMA_HTM_TOC" STYLE="FONT-STYLE: ITALIC">
	Table of Contents
</A>
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 27PT; BACKGROUND-COLOR: WHITE">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 27PT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN; BACKGROUND-COLOR: WHITE">
	In September 2015,
	the FASB issued ASU No. 2015-16,
<I>
	Business Combinations (Topic 805), Simplifying the Accounting for Measurement-Period Adjustments
</I>
	,
	which includes amendments that require an acquirer to recognize adjustments to provisional amounts that are identified during the
	measurement period in the reporting period in which the adjustment amounts are determined.&nbsp; The amendments in this ASU require
	that the acquirer record, in the same period&rsquo;s financial statements, the effect on earnings of changes in depreciation, amortization,
	or other income effects, if any, as a result of the changes to the provisional amounts, calculated as if the accounting had been
	completed at the acquisition date. The amendments in this ASU require an entity to present separately on the face of the income
	statement or disclose in the notes the portion of the amount recorded in current period earnings by line item that would have been
	recorded in previous reporting periods if the adjustment to the provisional amounts had been recognized as of the acquisition date.&nbsp;
	The amendments in this ASU are effective for fiscal years beginning after December 15, 2016, and interim periods within fiscal
	years beginning after December 15, 2017.&nbsp; The amendments should be applied prospectively to adjustments to provisional amounts
	that occur after the effective date of the ASU with earlier application permitted for financial statements that have not yet been
	made available for issuance. We do not expect this new guidance to have a material impact on our consolidated financial statements.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN; BACKGROUND-COLOR: WHITE">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	In July 2015, the FASB issued ASU No. 2015-11,
<I>
	Inventory (Topic 330): Simplifying the Measurement of Inventory
</I>
	. The standard requires entities to measure most inventory
	&ldquo;at the lower of cost and net realizable value,&rdquo; thereby simplifying the current guidance under which an entity must
	measure inventory at the lower of cost or market (market in this context is defined as one of three different measures, one of
	which is net realizable value). The standard is effective for us prospectively beginning January 1, 2017. The adoption of ASU 2015-11
	is not expected to have a material impact on our consolidated financial statements.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	In April 2015, the FASB issued ASU No. 2015-03,
<I>
	Interest
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&mdash;
</FONT>
	Imputation of Interest
</I>
	, which requires that
	debt issuance costs related to a recognized debt liability be presented in the balance sheet as a direct deduction from the carrying
	amount of the related debt liability instead of being presented as an asset. Debt disclosures will include the face amount of the
	debt liability and the effective interest rate. The update requires retrospective application and represents a change in accounting
	principle. The update is effective for fiscal years beginning after December 15, 2015. Early adoption is permitted for financial
	statements that have not been previously issued. We have early adopted ASU 2015-03 in the second quarter 2015 consolidated financial
	statements and recast the prior period balances to conform to the current period presentation.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	In August&nbsp;2014, the FASB issued
	ASU No. 2014-15,
<I>
	Presentation of Financial Statements-Going Concern (Subtopic 205-40): Disclosure of Uncertainties about
	an Entity&rsquo;s Ability to Continue as a Going Concern,
</I>
	which provides guidance on determining when and how reporting
	entities must disclose going-concern uncertainties in their financial statements. The new standard requires management to
	perform interim and annual assessments of an entity&rsquo;s ability to continue as a going concern within one year of the
	date of issuance of the entity&rsquo;s financial statements (or within one year after the date on which the financial
	statements are available to be issued, when applicable). Further, an entity must provide certain disclosures if there is
	&ldquo;substantial doubt about the entity&rsquo;s ability to continue as a going concern.&rdquo; The FASB believes that
	requiring management to perform the assessment will enhance the timeliness, clarity, and consistency of related disclosures
	and improve convergence with International Financial Reporting Standards (&ldquo;IFRS&rdquo;) (which emphasize
	management&rsquo;s responsibility for performing the going-concern assessment). However, the time horizon for the assessment
	(look-forward period) and the disclosure thresholds under GAAP and IFRSs will continue to differ. This guidance is effective
	for annual reporting periods ending after December&nbsp;15, 2016, and for annual periods and interim periods thereafter, with
	early adoption permitted. We have adopted this standard which has not had a material impact on its consolidated
	financial statements.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	In May 2014, FASB issued ASU No. 2014-09,&nbsp;
<I>
	Revenue
	from Contracts with Customers
</I>
	, which requires that an entity recognize the amount of revenue to which it expects to be entitled
	for the transfer of promised goods or services to its customers. In order to achieve this core principle, an entity should apply
	the following steps: (1) identify the contract(s) with a customer; (2) identify the performance obligations in the contract; (3)
	determine the transaction price; (4) allocate the transaction price to the performance obligations in the contract; and (5) recognize
	revenue when (or as) the entity satisfies a performance obligation. This update will replace existing revenue recognition guidance
	under Accounting Principles Generally Accepted in the U.S., or GAAP, when it becomes effective for us beginning
	January 1, 2018, with early adoption permitted in the first quarter of 2017. The updated standard will permit the use of either
	the retrospective or cumulative effect transition method.
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	We are currently
	assessing the impact of the new guidance on our results of operations. Based on our procedures performed to date, nothing has
	come to our attention that would indicate that the adoption of ASU 2014-09 will have a material impact on our financial statements,
	however, we will continue to evaluate this assessment. We have not yet selected a transition method.
</FONT>
	We are still evaluating
	disclosure requirements under the new standard. We will continue to evaluate the standard as well as additional changes, modifications
	or interpretations which may impact our current conclusions.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
</P>
<!-- FIELD: PAGE; SEQUENCE: 60 -->
<DIV STYLE="MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	58
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage61"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<P STYLE="MARGIN: 0PT; TEXT-ALIGN: RIGHT; FONT-SIZE: 8PT">
<A HREF="#E615811_10K-ADMA_HTM_TOC" STYLE="FONT-STYLE: ITALIC">
	Table of Contents
</A>
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	Critical Accounting Policies and Estimates
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	On April 5, 2012, the Jumpstart Our Business
	Startups Act, or the JOBS Act, was signed into law.&nbsp;&nbsp;The JOBS Act contains provisions that, among other things, reduce
	certain reporting requirements for qualifying public companies.&nbsp;&nbsp;We could be an emerging growth company until December
	31, 2018, which is the last day of the fiscal year following the fifth anniversary of the first sale of our common equity securities
	pursuant to an effective registration statement under the Securities Act. However, if certain events occur prior to the end of
	such five-year period, including if we become a &ldquo;large accelerated filer,&rdquo; our annual gross revenues exceed $1 billion
	or we issue more than $1 billion of non-convertible debt in any three-year period, we would cease to be an emerging growth company
	prior to the end of such five-year period. As an &ldquo;emerging growth company,&rdquo; we may, under Section 7(a)(2)(B) of the
	Securities Act, delay adoption of new or revised accounting standards applicable to public companies until such standards would
	otherwise apply to private companies.&nbsp;&nbsp;We may take advantage of this extended transition period until the first to occur
	of the date that we (i) are no longer an &ldquo;emerging growth company&rdquo; or (ii) affirmatively and irrevocably opt out of
	this extended transition period.&nbsp;&nbsp;We have elected to take advantage of the benefits of this extended transition period.&nbsp;&nbsp;Our
	financial statements may therefore not be comparable to those of companies that comply with such new or revised accounting standards.&nbsp;&nbsp;Until
	the date that we are no longer an &ldquo;emerging growth company&rdquo; or affirmatively and irrevocably opt out of the exemption
	provided by Securities Act Section 7(a)(2)(B), upon issuance of a new or revised accounting standard that applies to our financial
	statements and that has a different effective date for public and private companies, we will disclose the date on which adoption
	is required for non-emerging growth companies and the date on which we will adopt the recently issued accounting standard. As an
	emerging growth company, we are also exempt from the requirement to have our independent auditors provide an attestation report
	on our internal control over financial reporting.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	This Management&rsquo;s Discussion and Analysis
	of Financial Condition and Results of Operations is based on our financial statements, which have been prepared in accordance with
	accounting principles generally accepted in the U.S., or GAAP.&nbsp;&nbsp;The preparation of these financial
	statements requires us to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and
	expenses.&nbsp;&nbsp;On an ongoing basis, we evaluate these estimates and assumptions, including those described below.&nbsp;&nbsp;We
	base our estimates on our historical experience and on various other assumptions that we believe to be reasonable under the circumstances.&nbsp;&nbsp;These
	estimates and assumptions form the basis for making judgments about the carrying values of assets and liabilities that are not
	readily apparent from other sources.&nbsp;&nbsp;Actual results and experiences may differ materially from these estimates.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	Some of the estimates and assumptions we
	have to make under GAAP require difficult, subjective and/or complex judgments about matters that are inherently uncertain and,
	as a result, actual results could differ from those estimates.&nbsp;&nbsp;Due to the estimation processes involved, the following
	summarized accounting policies and their application are considered to be critical to understanding our business operations, financial
	condition and results of operations.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
<I>
	Stock-Based Compensation
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	Stock-based compensation cost is measured
	at grant date, based on the estimated fair value of the award, and is recognized as expense over the employee&rsquo;s requisite
	service period on a straight-line basis.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	We account for stock options granted to
	non-employees on a fair value basis using the Black-Scholes option pricing method. The noncash charge to operations for non-employee
	options with vesting are revalued at the end of each reporting period based upon the change in the fair value of the options and
	amortized to consulting expense over the related contract service period.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	For purposes of valuing stock options granted
	to our employees, non-employees and directors and officers during the year ended December 31, 2016, we used the Black-Scholes option
	pricing model. We granted options to purchase an aggregate of 100,984 shares of common stock during the year ended December 31,
	2016. To determine the risk-free interest rate, we utilized the U.S. Treasury yield curve in effect at the time of the grant with
	a term consistent with the expected term of our awards. The expected term of the options granted is in accordance with Staff Accounting
	Bulletins 107 and 110, which is based on the average between vesting terms and contractual terms. The expected dividend yield reflects
	our current and expected future policy for dividends on our common stock. The expected stock price volatility for our stock options
	was calculated by examining the pro rata historical volatilities for similar publicly traded industry peers and the trading history
	for our common stock. We will continue to analyze the expected stock price volatility and expected term assumptions. We have not
	experienced any material forfeitures of stock options and, as such, have not established a forfeiture rate since the stock options
	currently outstanding are primarily held by our senior management and directors. We will continue to evaluate the effects of such
	future potential forfeitures, as they may arise, to evaluate our estimated forfeiture rate.&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
</P>
<!-- FIELD: PAGE; SEQUENCE: 61 -->
<DIV STYLE="MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	59
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage62"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<P STYLE="MARGIN: 0PT; TEXT-ALIGN: RIGHT; FONT-SIZE: 8PT">
<A HREF="#E615811_10K-ADMA_HTM_TOC" STYLE="FONT-STYLE: ITALIC">
	Table of Contents
</A>
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
<I>
	Research and Development Costs
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	Our R&amp;D costs are expensed as incurred,
	including costs associated with (i) planning and conducting clinical trials, (ii) drug product manufacturing, including the cost
	of plasma, plasma storage and transportation costs; (iii) quality testing, validation, regulatory consulting and filing fees; and
	(iv) employees&rsquo; compensation expenses directly related to R&amp;D activities.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
<I>
	Revenue Recognition
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	Depending on the agreement with the customer,
	revenue from the sale of human plasma collected by ADMA BioCenters is recognized at the time of transfer of title and risk of loss
	to the customer, which usually occurs at the time of shipment. Product revenue is recognized at the time of delivery if we retain
	the risk of loss during shipment. Our product revenues are substantially attributable to two customers. One customer accounts for
	greater than 80% and another customer accounts for greater than 10% of our product revenues for the year ended December 31, 2016.
	Revenue from license fees and research and development services rendered are recognized as revenue when the performance obligations
	under the terms of the license agreement with Biotest have been completed. During the third quarter 2015, we recorded deferred
	revenue of $1.5 million in accordance with a license agreement payment we received related to the filing of our BLA with the FDA.
	Deferred revenue of $1.7 million was recorded in 2013 as a result of certain research and development services provided in accordance
	with a license agreement. Deferred revenue is recognized over the term of the license. Deferred revenue is amortized into income
	for a period of approximately 20 years, the term of the license agreement.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	Accounting for Loan and Security Agreement
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	On June 19, 2015, we entered into a LSA
	with Oxford for up to $21.0 million and refinanced our then existing debt.&nbsp;&nbsp;The first tranche of $16.0 million from the
	Oxford loan was primarily used to repay our existing debt and the remaining $5.0 million was available at our option upon RI-002&rsquo;s
	BLA being approved from the FDA no later than January 31, 2017, which funding would have also extended our interest only period
	for an additional six months pursuant to the May 2016 amendment to the LSA.&nbsp;&nbsp;The LSA bears interest at a rate per annum
	equal to the greater of (i) 7.80% and (ii) the sum of (a) the three month U.S. LIBOR rate (as reported in
<I>
	The Wall Street Journal
</I>
	)
	on the date occurring on the last business day of the month that immediately precedes the month in which the interest will accrue,
	plus (b) 7.54% on the outstanding principal balance.&nbsp;&nbsp;We are obligated to begin to repay the principal over 36 months
	beginning February 1, 2017, unless accelerated as a result of certain events of default.&nbsp; A final payment equal to 8.95% of
	the funded loan amount is due at the earlier of loan maturity or prepayment.&nbsp;&nbsp;In the event of the six-month interest
	only extension, the final payment will be 9.95% of the funded loan, which shall also be due at the earlier of loan maturity or
	prepayment. In the event we elect to prepay the loan, we are obligated to pay a prepayment charge corresponding to a percentage
	of the principal amount of the loan, with such percentage being: (i) for a prepayment made on or after the funding date of the
	applicable term loan through and including the first anniversary of its funding date, an amount equal to 3.00% of the principal
	amount of the term loan prepaid; (ii) for a prepayment made after the first anniversary of the funding date of the applicable term
	loan through and including the second anniversary of such funding date, an amount equal to 2.00% of the principal amount of such
	term loan prepaid; and (iii) for a prepayment of a term loan made after the second anniversary of its funding date and prior to
	its maturity date, an amount equal to 1.00% of the principal amount of the term loan prepaid.&nbsp; All term loans mature no later
	than January 1, 2020.&nbsp; The loans are secured by our assets, except for our intellectual property (which is subject to a negative
	pledge). The LSA contains customary representations, warranties and covenants, including limitations on incurring indebtedness,
	engaging in mergers or acquisitions and making investments, distributions or transfers.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
</P>
<!-- FIELD: PAGE; SEQUENCE: 62 -->
<DIV STYLE="MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	60
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage63"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<P STYLE="MARGIN: 0PT; TEXT-ALIGN: RIGHT; FONT-SIZE: 8PT">
<A HREF="#E615811_10K-ADMA_HTM_TOC" STYLE="FONT-STYLE: ITALIC">
	Table of Contents
</A>
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	In connection with the LSA, on June 19,
	2015, we issued to Oxford a seven-year warrant, expiring on June 19, 2022, to purchase 74,309 shares of common stock at an exercise
	price of $8.51 per share.&nbsp;&nbsp;We recorded $367,700 as the fair value of the warrant to additional paid-in capital and as
	a debt discount to the carrying value of the loan.&nbsp;&nbsp;The key assumptions used to value the warrants included: (i) volatility
	of 57% on our common stock based upon a pro rata percentage of our common stock&rsquo;s volatility and similar public companies&rsquo;
	volatilities for comparison; (ii) an expected dividend yield of 0.0%; (iii) a risk-free interest rate of 1.99%; and (iv) a term
	of seven years.&nbsp;&nbsp;As a result of prepaying our prior loan before maturity, we incurred a loss on extinguishment of debt
	of $0.7 million comprised of debt issuance costs, debt discount related to the warrants issued to our prior lender, and a prepayment
	penalty.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	In May 2016, we entered into an amendment
	to our LSA with Oxford,&nbsp;pursuant to which&nbsp;we borrowed an additional $4.0 million, as an extension to the&nbsp;original
	LSA entered into on June 19, 2015, which brings the total principal borrowed to $20.0 million.&nbsp; In connection therewith, we&nbsp;issued
	warrants to purchase an aggregate of up to&nbsp;24,800&nbsp;shares of our common stock at an exercise price equal to $6.37, which
	will expire seven years after their issuance on May 13, 2023. We paid a total facility fee of $125,000, consisting of $105,000
	previously paid and an additional $20,000 paid on the date the $4.0 million loan was funded.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	Off-Balance Sheet Arrangements
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	We have entered into leases for our ADMA
	BioCenters&rsquo; facilities in Norcross, Georgia and Marietta, Georgia. The Norcross, Georgia lease, the term of which was extended
	by five years on January 1, 2014 pursuant to the first of two available five-year renewal options, expires on September 30, 2023,
	and the Marietta, Georgia lease expires on January 31, 2024. There is a total minimum aggregate rent due under these leases of
	$2.6 million through the end of the respective lease terms.
</P>
</EFX_LIQUIDITY_CAPITAL>
</EFX_MANAGEMENTS_DISCUSSION>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<EFX_MARKET_RISK>
<A NAME="FIS_MARKET_RISK"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<A NAME="E615811_10K-ADMA_HTM_ITEM7A">
</A>
<B>
	Item 7A. Quantitative and Qualitative Disclosures About Market
	Risk
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Not
	applicable.
</FONT>
</P>
</EFX_MARKET_RISK>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<EFX_FINANCIAL_STATEMENTS>
<A NAME="FIS_FINANCIAL_STATEMENTS"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
<A NAME="E615811_10K-ADMA_HTM_ITEM8">
</A>
	Item 8. Financial Statements and Supplementary Data
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Our
	financial statements required to be filed pursuant to this Item 8 appear in a separate section of this annual report on Form 10-K,
	beginning on page F-1.
</FONT>
</P>
</EFX_FINANCIAL_STATEMENTS>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<EFX_ACCOUNTING_CHANGES>
<A NAME="FIS_ACCOUNTING_CHANGES"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<A NAME="E615811_10K-ADMA_HTM_ITEM9">
</A>
<B>
	Item 9. Changes in and Disagreements With Accountants on
	Accounting and Financial Disclosure
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	None.
</FONT>
</P>
</EFX_ACCOUNTING_CHANGES>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<EFX_CONTROL_AND_PROCEDURES>
<A NAME="FIS_CONTROL_AND_PROCEDURES"></A>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
<A NAME="E615811_10K-ADMA_HTM_ITEM9A">
</A>
	Item 9A. Controls and Procedures
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	Disclosure Controls and Procedures
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	We
	designed our disclosure controls and procedures, as such term is defined in Rule 13a-15(e) under the Exchange Act, to provide reasonable
	assurance that information required to be disclosed by us in reports we file or submit under the Exchange Act is (i) recorded,
	processed, summarized and reported within the time periods specified in the SEC&rsquo;s rules and forms, and (ii) is accumulated
	and communicated to our management, including our principal executive officer and principal financial officer, as appropriate to
	allow timely decisions regarding required disclosures.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Under
	the supervision and with the participation of our management, including our principal executive officer and principal financial
	officer, we conducted an evaluation of our disclosure controls and procedures as of December 31, 2016. Based on this evaluation,
	our principal executive officer and our principal financial officer concluded that our disclosure controls and procedures as of
	December 31, 2016 are functioning effectively to provide reasonable assurance that the information required to be disclosed by
	us in reports filed under the Exchange Act is (i) recorded, processed, summarized and reported within the time periods specified
	in the SEC&rsquo;s rules and forms, and (ii) accumulated and communicated to our management, including our chief executive officer
	and chief financial officer, as appropriate to allow timely decisions regarding disclosures.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-WEIGHT: NORMAL">
</FONT>
</P>
<!-- FIELD: PAGE; SEQUENCE: 63 -->
<DIV STYLE="MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	61
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage64"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<P STYLE="MARGIN: 0PT; TEXT-ALIGN: RIGHT; FONT-SIZE: 8PT">
<A HREF="#E615811_10K-ADMA_HTM_TOC" STYLE="FONT-STYLE: ITALIC">
	Table of Contents
</A>
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: LEFT">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	A
	control system, no matter how well designed and operated, cannot provide absolute assurance that the objectives of the control
	system are met, and no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if
	any, within a company have been detected.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	Management&rsquo;s Annual Report on Internal
	Control Over Financial Reporting
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	The
	management of the Company is responsible for establishing and maintaining adequate internal control over financial reporting for
	the Company. Internal control over financial reporting is defined in Rules 13a-15(f) and 15d-15(f) promulgated under the Exchange
	Act.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	The
	Company&rsquo;s management assessed the effectiveness of the Company&rsquo;s internal control over financial reporting as of December
	31, 2016. In making this assessment, the Company&rsquo;s management used the criteria set forth by the Committee of Sponsoring
	Organization of the Treadway Commission in its 2013 &ldquo;Internal Control-Integrated Framework.&rdquo; Based on this assessment,
	management concluded that as of December 31, 2016, the Company&rsquo;s internal control over financial reporting is effective.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	As
	a smaller reporting company, the Company is not required to include in this annual report a report on the effectiveness of internal
	control over financial reporting by the Company&rsquo;s independent registered public accounting firm.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	Changes in Internal Control Over Financial
	Reporting
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	There
	has been no change in our internal control over financial reporting during the quarter ended December 31, 2016 that has materially
	affected, or is reasonably likely to materially affect, our internal control over financial reporting. A control system, no matter
	how well designed and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system
	are met, and therefore, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud,
	if any, within a company have been detected. We do not expect that our disclosure controls and procedures or our internal control
	over financial reporting are able to prevent with certainty all errors and all fraud.
</FONT>
</P>
</EFX_CONTROL_AND_PROCEDURES>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<EFX_OTHER_INFORMATION>
<A NAME="FIS_OTHER_INFORMATION"></A>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
<A NAME="E615811_10K-ADMA_HTM_ITEM9B">
</A>
	Item 9B. Other Information
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	On February 17, 2017, ADMA BioCenters, entered into a lease
	(the &ldquo;Lease&rdquo;) with Home Center Properties, LLC, a Georgia limited liability company (&ldquo;Landlord&rdquo;), for approximately
	12,167 square feet located at 166 Earnest W. Barrett Parkway, Marietta, Georgia 30066 (the &ldquo;Premises&rdquo;). Pursuant to
	the Lease, ADMA BioCenters will utilize the Premises as a facility specializing in the collection of human plasma and blood, general
	office administration and any other related use.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	The Lease has an initial term of approximately
	eight years and nine months (the &ldquo;Initial Term&rdquo;), commencing upon substantial completion of &ldquo;Landlord&rsquo;s
	Work&rdquo; (as defined in the Lease) (the &ldquo;Lease Commencement Date&rdquo;), with rent payments commencing 150 days after
	the Lease Commencement Date. ADMA BioCenters&rsquo; total monthly cost of the Premises (inclusive of Landlord&rsquo;s &ldquo;Operating
	Costs&rdquo;, &ldquo;Taxes&rdquo; and &ldquo;Insurance Charges&rdquo; (as such terms are defined in the Lease)) will range from
	approximately $20,000 to $27,000 during the Initial Term;
<I>
	provided
</I>
	,
<I>
	however
</I>
	,
<I>
	that
</I>
	, provided ADMA BioCenters
	is not in default of the Lease beyond the expiration of any applicable notice and cure period, ADMA BioCenters shall not be obligated
	to make any rent payments for the first five calendar months of the Initial Term beginning on the Lease Commencement Date and the
	last four months of the Initial Term beginning on the 102
<SUP>
	nd
</SUP>
	month after the Lease Commencement Date. Provided that the
	Lease is in full force and effect and provided there has been no &ldquo;Event of Default&rdquo; (as defined in the Lease) beyond
	the expiration of any applicable notice and cure period, ADMA BioCenters shall have the option to extend the term of the Lease
	for two additional periods of five years each (each, an &ldquo;Extension Term&rdquo;), each Extension Term on the same terms, covenants
	and conditions as the Lease, with the rent for each Extension Term to equal the mutually agreed fair market value of the Premises
	on the commencement of such Extension Term. The Lease also contains customary default provisions, representations, warranties and
	covenants.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	The foregoing summary of the material terms
	of the Lease is qualified in its entirety by reference to the full text of the Lease, which is attached hereto as Exhibit 10.22
	and incorporated herein by reference.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-WEIGHT: NORMAL">
</FONT>
</P>
<!-- FIELD: PAGE; SEQUENCE: 64 -->
<DIV STYLE="MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	62
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage65"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<P STYLE="MARGIN: 0PT; TEXT-ALIGN: RIGHT; FONT-SIZE: 8PT">
<A HREF="#E615811_10K-ADMA_HTM_TOC" STYLE="FONT-STYLE: ITALIC">
	Table of Contents
</A>
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: LEFT">
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	Part III
</P>
</EFX_OTHER_INFORMATION>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<EFX_DIRECTORS_AND_OFFICERS>
<A NAME="FIS_DIRECTORS_AND_OFFICERS"></A>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
<A NAME="E615811_10K-ADMA_HTM_ITEM10">
</A>
	Item 10. Directors, Executive Officers
	and Corporate Governance
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Information
	required to be disclosed by this Item with respect to our executive officers is incorporated in this annual report on Form 10-K
	by reference from the section entitled &ldquo;Executive Officers and Director and Officer Compensation: Executive Officers&rdquo;
	contained in our definitive proxy statement for our 2017 annual meeting of stockholders, which we intend to file within 120 days
	of the end of our fiscal year.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Information
	required to be disclosed by this Item about our board of directors is incorporated in this annual report on Form 10-K by reference
	from the section entitled &ldquo;Proposal No. 1: Election of Directors&rdquo; contained in our definitive proxy statement for our
	2017 annual meeting of stockholders, which we intend to file within 120 days of the end of our fiscal year.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Information
	required to be disclosed by this Item about the Section 16(a) compliance of our directors and executive officers is incorporated
	in this annual report on Form 10-K by reference from the section entitled &ldquo;Section 16(a) Beneficial Ownership Reporting Compliance&rdquo;
	contained in our definitive proxy statement for our 2017 annual meeting of stockholders, which we intend to file within 120 days
	of the end of our fiscal year.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	Information required to be disclosed by
	this Item about our board of directors, the audit committee of our board of directors, our audit committee financial expert, our
	Code of Ethics and Business Conduct Standards, and other corporate governance matters is incorporated in this annual report on
	Form 10-K by reference from the section entitled &ldquo;Corporate Governance&rdquo; contained in our definitive proxy statement
	for our 2017 annual meeting of stockholders, which we intend to file within 120 days of the end of our fiscal year.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	The text of our Code of Ethics and Business
	Conduct Standards, which applies to our directors and employees (including our principal executive officer, principal financial
	officer, and principal accounting officer or controller, and persons performing similar functions), is posted in the &ldquo;Corporate
	Governance&rdquo; section of our website, http://www.admabiologics.com/. A copy of the Code of Ethics and Business Conduct Standards
	can be obtained free of charge on our website. We intend to disclose on our website any amendments to, or waivers from, our Code
	of Ethics and Business Conduct Standards that are required to be disclosed pursuant to the rules of the SEC and The NASDAQ Stock
	Market.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	The
	information presented on our website is not a part of this annual report on Form 10-K and the reference to our website is intended
	to be an inactive textual reference only.
</FONT>
</P>
</EFX_DIRECTORS_AND_OFFICERS>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<EFX_COMPENSATION>
<A NAME="FIS_COMPENSATION"></A>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
<A NAME="E615811_10K-ADMA_HTM_ITEM11">
</A>
	Item 11. Executive Compensation
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Information
	required to be disclosed by this Item is incorporated in this annual report on Form 10-K by reference from the section entitled
	&ldquo;Executive Officers and Director and Officer Compensation&rdquo; contained in our definitive proxy statement for our 2017
	annual meeting of stockholders, which we intend to file within 120 days of the end of our fiscal year.
</FONT>
</P>
</EFX_COMPENSATION>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<EFX_SECURITY_OWNERS>
<A NAME="FIS_SECURITY_OWNERS"></A>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
<A NAME="E615811_10K-ADMA_HTM_ITEM12">
</A>
	Item 12. Security Ownership of Certain
	Beneficial Owners and Management and Related Stockholder Matters
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Information
	required to be disclosed by this Item is incorporated in this annual report on Form 10-K by reference from the sections entitled
	&ldquo;Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters&rdquo; contained in our definitive
	proxy statement for our 2017 annual meeting of stockholders, which we intend to file within 120 days of the end of our fiscal year.
</FONT>
</P>
</EFX_SECURITY_OWNERS>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<EFX_OFFICER_TRANSACTIONS>
<A NAME="FIS_OFFICER_TRANSACTIONS"></A>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
<A NAME="E615811_10K-ADMA_HTM_ITEM13">
</A>
	Item 13. Certain Relationships and Related
	Transactions, and Director Independence
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	The
	information required to be disclosed by this Item is incorporated in this annual report on Form 10-K by reference from the section
	entitled &ldquo;Certain Relationships and Related Transactions, and Director Independence&rdquo; contained in our definitive proxy
	statement for our 2017 annual meeting of stockholders, which we intend to file within 120 days of the end of our fiscal year.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-WEIGHT: NORMAL">
</FONT>
</P>
<!-- FIELD: PAGE; SEQUENCE: 65 -->
<DIV STYLE="MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	63
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage66"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<P STYLE="MARGIN: 0PT; TEXT-ALIGN: RIGHT; FONT-SIZE: 8PT">
<A HREF="#E615811_10K-ADMA_HTM_TOC" STYLE="FONT-STYLE: ITALIC">
	Table of Contents
</A>
</P>
</DIV>
</EFX_OFFICER_TRANSACTIONS>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
	&nbsp;
</P>
<EFX_ACCOUNTANT_FEES>
<A NAME="FIS_ACCOUNTANT_FEES"></A>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
<A NAME="E615811_10K-ADMA_HTM_ITEM14">
</A>
	Item 14. Principal Accountant Fees and
	Services
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	The
	information required to be disclosed by this Item is incorporated in this annual report on Form 10-K by reference from the section
	entitled &ldquo;Audit and Other Fees&rdquo; contained in our definitive proxy statement for our 2017 annual meeting of stockholders,
	which we intend to file within 120 days of the end of our fiscal year.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-WEIGHT: NORMAL">
</FONT>
</P>
<!-- FIELD: PAGE; SEQUENCE: 66 -->
<DIV STYLE="MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	64
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage67"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<P STYLE="MARGIN: 0PT; TEXT-ALIGN: RIGHT; FONT-SIZE: 8PT">
<A HREF="#E615811_10K-ADMA_HTM_TOC" STYLE="FONT-STYLE: ITALIC">
	Table of Contents
</A>
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.5IN">
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	Part IV
</P>
</EFX_ACCOUNTANT_FEES>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<EFX_EXHIBITS>
<A NAME="FIS_EXHIBITS"></A>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
<A NAME="E615811_10K-ADMA_HTM_ITEM15">
</A>
	Item 15. Exhibits and Financial Statement
	Schedules
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	Financial Statement Schedules
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	(a) The following documents are filed as part of this annual
	report on Form 10-K:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	(1)&nbsp;&nbsp;Consolidated Financial Statements.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 92%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 8%; BORDER-BOTTOM: BLACK 1.5PT SOLID; TEXT-ALIGN: CENTER">
	Page
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
<TD>
	Report of Independent Registered Public Accounting Firm
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	F-2
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD>
	Consolidated Balance Sheets as of December 31, 2016 and 2015
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	F-3
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
<TD>
	Consolidated Statements of Operations for the years ended December 31, 2016 and 2015
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	F-4
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD STYLE="VERTICAL-ALIGN: TOP">
	Consolidated Statements of Changes in Stockholders&rsquo; (Deficiency) Equity for the years ended December 31, 2016 and 2015
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER">
	F-5
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
<TD>
	Consolidated Statements of Cash Flows for the years ended December 31, 2016 and 2015
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	F-6
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD>
	Notes to Consolidated Financial Statements
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	F-7
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	(2)&nbsp;&nbsp;Financial Statement Schedules.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Required
	information is included in the footnotes to the financial statements.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	(3)&nbsp;&nbsp;Exhibits.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	See the Exhibit Index immediately following the financial statements
	to this annual report on Form 10-K.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
<A NAME="E615811_10K-ADMA_HTM_ITEM16">
</A>
	Exhibit 16. Form 10-K Summary
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	None.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-WEIGHT: NORMAL">
</FONT>
</P>
<!-- FIELD: PAGE; SEQUENCE: 67 -->
<DIV STYLE="MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	65
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage68"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<P STYLE="MARGIN: 0PT; TEXT-ALIGN: RIGHT; FONT-SIZE: 8PT">
<A HREF="#E615811_10K-ADMA_HTM_TOC" STYLE="FONT-STYLE: ITALIC">
	Table of Contents
</A>
</P>
</DIV>
</EFX_EXHIBITS>
</EFX_PART_IV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
</P>
<EFX_SIGNATURES>
<A NAME="FIS_SIGNATURES"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	SIGNATURES
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	Pursuant to the requirements of Section
	13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the
	undersigned, thereunto duly authorized.&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-RIGHT: 0; MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT">
</P>
<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD COLSPAN="2">
<B>
	ADMA Biologics, Inc.
</B>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD COLSPAN="2">
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 50%">
	Date: February 24, 2017
</TD>
<TD STYLE="WIDTH: 5%">
	By:
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 46%">
	/s/ Adam S. Grossman
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
	Name:&nbsp;
</P>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
	Title:
</P>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; BORDER-TOP: #000000 1PX SOLID">
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
	Adam S. Grossman
</P>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
	President and Chief Executive Officer
</P>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
	&nbsp;&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	Pursuant to the requirements of the Securities
	Exchange Act of 1934, report has been signed below by the following persons on behalf of the registrant and in the capacities and
	on the dates indicated:&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; WIDTH: 34%">
<B>
	Signature
</B>
</TD>
<TD STYLE="WIDTH: 2%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; WIDTH: 31%">
<B>
	Title
</B>
</TD>
<TD STYLE="WIDTH: 2%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; WIDTH: 31%">
<B>
	Date
</B>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID">
	/s/ Adam S. Grossman
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	President and Chief Executive
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	Adam S. Grossman
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	Officer (Principal Executive Officer)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	February 24, 2017
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID">
	/s/ Brian Lenz
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	Brian Lenz
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	Chief Financial Officer (Principal Financial Officer and Principal Accounting Officer)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	February 24, 2017
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID">
	/s/ Steven A. Elms&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	Steven A. Elms
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	Chairman of the Board of Directors and Director
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	February 24, 2017
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
</TR>
</TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 34%; BORDER-BOTTOM: BLACK 1PT SOLID">
	/s/ Dr. Jerrold B. Grossman
</TD>
<TD STYLE="WIDTH: 2%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 31%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 2%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 31%">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	Dr. Jerrold B. Grossman
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	Vice Chairman of the Board of Directors and Director
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	February 24, 2017
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID">
	/s/ Bryant E. Fong&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	Bryant E. Fong
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	Director
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	February 24, 2017
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID">
	/s/ Dov A. Goldstein, M.D.&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	Dov A. Goldstein, M.D.
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	Director
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	February 24, 2017
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
</TR>
</TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 34%; BORDER-BOTTOM: BLACK 1PT SOLID">
	/s/ Lawrence P. Guiheen&nbsp;
</TD>
<TD STYLE="WIDTH: 2%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 31%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 2%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 31%">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	Lawrence P. Guiheen
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	Director
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	February 24, 2017
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID">
	/s/ Eric I. Richman&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	Eric I. Richman
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	Director
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	February 24, 2017
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
</P>
<!-- FIELD: PAGE; SEQUENCE: 68 -->
<DIV STYLE="MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	66
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</P>
</DIV>
<A NAME="eolPage69"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	ADMA BIOLOGICS, INC. AND SUBSIDIARIES
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	CONSOLIDATED FINANCIAL STATEMENTS
<BR>
<BR>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	TABLE OF CONTENTS
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 92%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 8%">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
	Page
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; BORDER-BOTTOM: BLACK 0.5PT SOLID">
</P>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: RGB(204,238,255)">
<TD>
	Report of Independent Registered Public Accounting Firm
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	F-2
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD>
	Consolidated Balance Sheets as of December 31, 2016 and 2015
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	F-3
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: RGB(204,238,255)">
<TD>
	Consolidated Statements of Operations for the years ended December 31, 2016 and 2015
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	F-4
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD STYLE="VERTICAL-ALIGN: TOP">
	Consolidated Statements of Changes in Stockholders&rsquo; (Deficiency) Equity for the years ended December 31, 2016 and 2015
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER">
	F-5
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: RGB(204,238,255)">
<TD>
	Consolidated Statements of Cash Flows for the years ended December 31, 2016 and 2015
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	F-6
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD>
	Notes to Consolidated Financial Statements
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	F-7
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
</B>
</P>
<!-- FIELD: PAGE; SEQUENCE: 69; OPTIONS: NEWSECTION -->
<DIV STYLE="MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	1
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
</EFX_SIGNATURES>
<A NAME="eolPage70"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	&nbsp;
</B>
	&nbsp;
</P>
<EFX_AUDITORS_OPINION>
<A NAME="FIS_AUDITORS_OPINION"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	Report of Independent Registered Public
	Accounting Firm
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	To the Board of Directors and Stockholders
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	ADMA Biologics, Inc.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	We have audited the accompanying consolidated
	balance sheets of ADMA Biologics, Inc. and Subsidiaries as of December 31, 2016 and 2015, and the related consolidated statements
	of operations, changes in stockholders&rsquo; (deficiency) equity, and cash flows for the years then ended. The Company&rsquo;s
	management is responsible for these consolidated financial statements. Our responsibility is to express an opinion on these consolidated
	financial statements based on our audits.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	We conducted our audits in accordance with
	the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform
	the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement.
	The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting.
	Our audit included consideration of internal control over financial reporting as a basis for designing audit procedures that are
	appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company&rsquo;s
	internal control over financial reporting. Accordingly, we express no such opinion. An audit also includes examining, on a test
	basis, evidence supporting the amounts and disclosures in the consolidated financial statements, assessing the accounting principles
	used and significant estimates made by management, as well as evaluating the overall consolidated financial statement presentation.
	We believe that our audits provide a reasonable basis for our opinion.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	In our opinion, the consolidated financial
	statements referred to above present fairly, in all material respects, the financial position of ADMA Biologics, Inc. and Subsidiaries
	as of December 31, 2016 and 2015, and the results of their operations and their cash flows for the years then ended, in conformity
	with accounting principles generally accepted in the United States of America.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	The accompanying consolidated financial
	statements have been prepared assuming that the Company will continue as a going concern. As further discussed in Note 1 to the
	accompanying consolidated financial statements, management believes that the Company will continue to incur net losses and negative
	net cash flows from operating activities through the drug development, approval and commercialization preparation process. These
	conditions raise substantial doubt about the Company&rsquo;s ability to continue as a going concern. The consolidated financial
	statements do not include any adjustments that might result from the outcome of this uncertainty.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD COLSPAN="2">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	/s/ CohnReznick LLP
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
</P>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 80%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 20%">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD COLSPAN="2">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Roseland, New Jersey
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	February 24, 2017
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
</P>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-RIGHT: 0; MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-RIGHT: 0; MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT">
</P>
<!-- FIELD: PAGE; SEQUENCE: 70 -->
<DIV STYLE="MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	2
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
</EFX_AUDITORS_OPINION>
<A NAME="eolPage71"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-RIGHT: 0; MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
</P>
<EFX_BALANCE_SHEET>
<A NAME="FIS_BALANCE_SHEET"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	ADMA BIOLOGICS, INC. AND SUBSIDIARIES
</B>
<BR>
<B>
	CONSOLIDATED BALANCE SHEETS
</B>
<BR>
<B>
	December 31, 2016 and 2015
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER; COLOR: RED">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER; COLOR: RED">
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD>
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	December 31,
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	December 31,
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD>
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2016
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2015
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD COLSPAN="9">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-WEIGHT: BOLD">
	ASSETS
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Current Assets:
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 56%; TEXT-ALIGN: LEFT; TEXT-INDENT: 9.35PT">
	Cash and Cash Equivalents
</TD>
<TD STYLE="WIDTH: 2%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 14%; TEXT-ALIGN: RIGHT">
	9,914,867
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 2%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 14%; TEXT-ALIGN: RIGHT">
	10,440,959
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 9.35PT">
	Short-Term Investments
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	5,390,184
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	6,368,177
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 9.35PT">
	Accounts Receivable
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1,018,027
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	924,468
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-INDENT: 9.35PT">
	Inventories
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	5,020,146
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	3,445,773
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.5PT; TEXT-INDENT: 9.35PT">
	Prepaid Expenses
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	313,914
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	111,027
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.5PT; TEXT-INDENT: 28.3PT">
	Total Current Assets
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	21,657,138
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	21,290,404
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.5PT">
	Property and Equipment at Cost, Net
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	2,000,784
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	2,396,950
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Other Assets:
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-INDENT: 9.35PT">
	Deposits
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	27,163
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	27,163
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.5PT; TEXT-INDENT: 28.3PT">
	Total Other Assets
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	27,163
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	27,163
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.5PT">
	TOTAL ASSETS
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	23,685,085
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	23,714,517
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</EFX_BALANCE_SHEET>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<EFX_UNIDENTIFIED_TABLE>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<A NAME="FIS_UNIDENTIFIED_TABLE_5"></A>
	LIABILITIES AND STOCKHOLDERS' (DEFICIENCY) EQUITY
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Current Liabilities:
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 9.35PT">
	Accounts Payable
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	2,564,681
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	2,087,855
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 9.35PT">
	Accrued Expenses
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	2,385,356
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1,968,384
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 9.35PT">
	Current Portion of Note Payable
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	6,111,111
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&mdash;&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 9.35PT">
	Current Portion of Deferred Revenue
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	145,154
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	145,154
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.5PT; TEXT-INDENT: 9.35PT">
	Current Portion of Leasehold Improvement Loan
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	16,559
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	15,139
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 18.85PT">
	Total Current Liabilities
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	11,222,861
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	4,216,532
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Notes Payable, Net of Debt Discount
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	12,321,640
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	14,247,212
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	End of Term Liability, Notes Payable
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1,790,000
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1,432,000
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Deferred Revenue, Net of Current Portion
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	2,690,033
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	2,832,867
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Deferred Rent Liability
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	98,116
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	128,676
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.5PT">
	Leasehold Improvement Loan, Net of Current Portion
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	19,697
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	36,256
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.5PT">
	TOTAL LIABILITIES
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	28,142,347
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	22,893,543
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</EFX_UNIDENTIFIED_TABLE>
<EFX_BALANCE_SHEET>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<A NAME="FIS_BALANCE_SHEET_2"></A>
	COMMITMENTS AND CONTINGENCIES
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	STOCKHOLDERS' (DEFICIENCY) EQUITY
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-INDENT: 9.35PT">
	Common Stock $0.0001 par value 75,000,000 shares
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 18.85PT">
	authorized, and 12,886,741 and 10,713,087 shares issued
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-INDENT: 18.85PT">
	and outstanding as of December 31, 2016 and December 31, 2015,
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-INDENT: 18.85PT">
	respectively
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1,289
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1,072
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 9.35PT">
	Additional Paid-In Capital
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	102,476,267
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	88,239,569
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.5PT; TEXT-INDENT: 9.35PT">
	Accumulated Deficit
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(106,934,818
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(87,419,667
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.5PT">
	TOTAL STOCKHOLDERS' (DEFICIENCY) EQUITY
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(4,457,262
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	820,974
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.5PT">
	TOTAL LIABILITIES AND STOCKHOLDERS' (DEFICIENCY) EQUITY
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	23,685,085
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	23,714,517
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</EFX_BALANCE_SHEET>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER; COLOR: RED">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER; COLOR: RED">
	&nbsp;&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	See notes to consolidated financial statements
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
</P>
<!-- FIELD: PAGE; SEQUENCE: 71 -->
<DIV STYLE="MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	3
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage72"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	&nbsp;&nbsp;
</P>
<EFX_INCOME_STATEMENT>
<A NAME="FIS_INCOME_STATEMENT"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	ADMA BIOLOGICS, INC. AND SUBSIDIARIES
</B>
<BR>
<B>
	CONSOLIDATED STATEMENTS OF OPERATIONS
</B>
<BR>
<B>
	Years Ended December 31, 2016 and 2015
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD>
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2016
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2015
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD COLSPAN="9">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-WEIGHT: BOLD">
	REVENUES:
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="WIDTH: 56%; TEXT-ALIGN: LEFT; TEXT-INDENT: 7.3PT">
	Product revenue
</TD>
<TD STYLE="WIDTH: 2%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 14%; TEXT-ALIGN: RIGHT">
	10,518,203
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 2%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 14%; TEXT-ALIGN: RIGHT">
	7,050,283
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.5PT; TEXT-INDENT: 7.3PT">
	License and other revenue
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	142,834
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	127,350
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.5PT; TEXT-INDENT: 20PT">
	Total Revenues
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	10,661,037
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	7,177,633
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	OPERATING EXPENSES:
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 7.3PT">
	Cost of product revenue
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	6,360,761
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	4,311,461
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 7.3PT">
	Research and development
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	7,688,238
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	7,015,946
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 7.3PT">
	Plasma centers
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	5,447,691
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	4,618,065
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.5PT; TEXT-INDENT: 7.3PT">
	General and administrative
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	8,494,742
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	6,745,968
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.5PT">
	TOTAL OPERATING EXPENSES
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	27,991,432
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	22,691,440
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.5PT">
	LOSS FROM OPERATIONS
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(17,330,395
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(15,513,807
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	OTHER INCOME (EXPENSE):
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 7.3PT">
	Interest income
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	50,317
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	37,830
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 7.3PT">
	Interest expense
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(2,239,569
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(1,842,716
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 7.3PT">
	Other income
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	4,496
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&mdash;&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 7.3PT">
	Change in fair value of stock warrants
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&mdash;&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	67,860
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.5PT; TEXT-INDENT: 7.3PT">
	Loss on extinguishment of debt
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	&mdash;&nbsp;&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(719,097
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.5PT">
	OTHER EXPENSE, NET
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(2,184,756
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(2,456,123
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.5PT">
	NET LOSS
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	(19,515,151
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	(17,969,930
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: BOLD">
	NET LOSS PER COMMON SHARE,
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.5PT; TEXT-INDENT: 7.3PT">
	Basic and Diluted
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	(1.61
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	(1.73
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-WEIGHT: BOLD">
	WEIGHTED AVERAGE SHARES
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.5PT; TEXT-INDENT: 7.3PT">
	OUTSTANDING, Basic and Diluted
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	12,153,407
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	10,412,305
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_INCOME_STATEMENT>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER; COLOR: RED">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER; COLOR: RED">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	See notes to consolidated financial statements
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
</P>
<!-- FIELD: PAGE; SEQUENCE: 72 -->
<DIV STYLE="MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	4
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage73"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	&nbsp;&nbsp;
</P>
<EFX_STOCKHOLDERS_EQUITY>
<A NAME="FIS_STOCKHOLDERS_EQUITY"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	ADMA BIOLOGICS, INC. AND SUBSIDIARIES
</B>
<BR>
<B>
	CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS&rsquo; (DEFICIENCY) EQUITY
</B>
<BR>
<B>
	Years Ended December 31, 2016 and 2015
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD>
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD COLSPAN="7" STYLE="FONT-WEIGHT: BOLD; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: CENTER">
	Common Stock
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-WEIGHT: BOLD; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: CENTER">
	Additional
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-WEIGHT: BOLD; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: CENTER">
	Accumulated
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD COLSPAN="3">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD>
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-WEIGHT: BOLD; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: CENTER">
	Shares
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-WEIGHT: BOLD; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: CENTER">
	Amount
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-WEIGHT: BOLD; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: CENTER">
	Paid-in Capital
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-WEIGHT: BOLD; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: CENTER">
	Deficit
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-WEIGHT: BOLD; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: CENTER">
	Total
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD COLSPAN="21">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 35%">
	Balance - December 31, 2014
</TD>
<TD STYLE="WIDTH: 2%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 9%; TEXT-ALIGN: RIGHT">
	9,291,823
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 2%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 9%; TEXT-ALIGN: RIGHT">
	929
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 2%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 9%; TEXT-ALIGN: RIGHT">
	75,457,458
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 2%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 9%; TEXT-ALIGN: RIGHT">
	(69,449,737
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="WIDTH: 2%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 9%; TEXT-ALIGN: RIGHT">
	6,008,650
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Stock-based compensation
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&mdash;&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&mdash;&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1,711,047
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&mdash;&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1,711,047
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Issuance of common stock, net
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1,408,750
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	141
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	10,245,239
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&mdash;&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	10,245,380
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Stock issued in connection with stock options exercised
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	7,514
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	49,226
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&mdash;&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	49,227
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Restricted stock
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	5,000
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(1
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&mdash;&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&mdash;&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Elimination of warrant liability
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&mdash;&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&mdash;&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	408,900
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&mdash;&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	408,900
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Warrants issued in connection with note payable
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&mdash;&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&mdash;&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	367,700
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&mdash;&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	367,700
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.5PT">
	Net loss
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	&mdash;&nbsp;&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	&mdash;&nbsp;&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	&mdash;&nbsp;&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(17,969,930
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(17,969,930
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD>
	Balance - December 31, 2015
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	10,713,087
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1,072
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	88,239,569
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(87,419,667
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	820,974
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Stock-based compensation
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&mdash;&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&mdash;&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1,250,074
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&mdash;&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1,250,074
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Issuance of common stock, net
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	2,176,154
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	217
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	12,900,324
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&mdash;&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	12,900,541
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Restricted stock
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(2,500
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&mdash;&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&mdash;&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&mdash;&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&mdash;&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Warrants issued in connection with note payable
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&mdash;&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&mdash;&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	86,300
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&mdash;&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	86,300
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.5PT">
	Net loss
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	&mdash;&nbsp;&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	&mdash;&nbsp;&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	&mdash;&nbsp;&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(19,515,151
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(19,515,151
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	Balance - December 31, 2016
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	12,886,741
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	1,289
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	102,476,267
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	(106,934,818
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	(4,457,262
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
</TABLE>
</EFX_STOCKHOLDERS_EQUITY>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER; COLOR: RED">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER; COLOR: RED">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	See notes to consolidated financial statements
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
</P>
<!-- FIELD: PAGE; SEQUENCE: 73 -->
<DIV STYLE="MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	5
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage74"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	&nbsp;&nbsp;
</P>
<EFX_CASH_FLOW>
<A NAME="FIS_CASH_FLOW"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	ADMA BIOLOGICS, INC. AND SUBSIDIARIES
</B>
<BR>
<B>
	CONSOLIDATED STATEMENTS OF CASH FLOWS
</B>
<BR>
<B>
	Years Ended December 31, 2016 and 2015
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD>
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2016
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2015
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	CASH FLOWS FROM OPERATING ACTIVITIES:
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="WIDTH: 56%; TEXT-ALIGN: LEFT; TEXT-INDENT: 6.6PT">
	Net loss
</TD>
<TD STYLE="WIDTH: 2%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 14%; TEXT-ALIGN: RIGHT">
	(19,515,151
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="WIDTH: 2%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 14%; TEXT-ALIGN: RIGHT">
	(17,969,930
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 6.6PT">
	Adjustments to reconcile net loss to net
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 10PT">
	cash used in operating activities:
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 14.75PT">
	Depreciation and amortization
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	469,576
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	469,821
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 14.75PT">
	Stock-based compensation
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1,250,074
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1,711,047
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 14.75PT">
	Warrant liability
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&mdash;&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(67,860
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 14.75PT">
	Amortization of debt discount
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	676,943
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	353,635
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 14.75PT">
	Amortization of deferred financing costs
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&mdash;&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	39,717
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 14.75PT">
	Payment-in-kind interest
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&mdash;&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	124,536
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 14.75PT">
	Amortization of license and other revenue
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(142,834
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(127,350
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 14.75PT">
	Loss on extinguishment of debt
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&mdash;&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	719,097
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 6.6PT">
	Changes in operating assets and liabilities:
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 14.75PT">
	Accounts receivable
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(93,559
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(540,507
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-INDENT: 14.75PT">
	Inventories
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(1,574,373
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(1,737,010
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 14.75PT">
	Prepaid expenses
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(202,887
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	32,559
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 14.75PT">
	Accounts payable
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	476,826
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	202,994
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 14.75PT">
	Accrued expenses
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	416,972
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(199,615
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 14.75PT">
	Deferred revenue
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&mdash;&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1,525,000
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.5PT; TEXT-INDENT: 14.75PT">
	Deferred rent liability
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(30,560
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	45,462
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.5PT; TEXT-INDENT: 14.75PT">
	Net cash used in operating activities
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(18,268,973
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(15,418,404
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	CASH FLOWS FROM INVESTING ACTIVITIES:
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 14.75PT">
	Purchases of short-term investments
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(15,680,000
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(18,130,000
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 14.75PT">
	Redemptions of short-term investments
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	16,657,993
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	16,414,498
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.5PT; TEXT-INDENT: 14.75PT">
	Purchase of property and equipment
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(73,410
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(26,073
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.5PT; TEXT-INDENT: 14.75PT">
	Net cash provided by (used in) investing activities
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	904,583
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(1,741,575
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	CASH FLOWS FROM FINANCING ACTIVITIES:
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 14.75PT">
	Proceeds from Oxford note payable
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	4,000,000
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	16,000,000
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 14.75PT">
	Proceeds from issuance of common stock
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	14,145,000
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	10,257,380
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 14.75PT">
	Proceeds from stock options exercised
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&mdash;&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	49,227
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 14.75PT">
	Repayment of Hercules note payable
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&mdash;&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(15,300,781
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 14.75PT">
	Prepayment penalty of early extinguishment of note payable
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&mdash;&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(229,512
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 14.75PT">
	Payment of debt issuance costs
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(47,104
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(228,065
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 14.75PT">
	Payment of Hercules end of term fee
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&mdash;&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(132,500
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 14.75PT">
	Equity issuance costs
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(1,244,459
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&mdash;&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.5PT; TEXT-INDENT: 14.75PT">
	Payments of leasehold improvement loan
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(15,139
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(13,841
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.5PT; TEXT-INDENT: 14.75PT">
	Net cash provided by financing activities
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	16,838,298
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	10,401,908
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	NET DECREASE IN CASH AND CASH EQUIVALENTS
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(526,092
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(6,758,071
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.5PT">
	CASH AND CASH EQUIVALENTS - BEGINNING OF YEAR
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	10,440,959
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	17,199,030
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.5PT">
	CASH AND CASH EQUIVALENTS - END OF YEAR
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	9,914,867
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	10,440,959
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	SUPPLEMENTAL INFORMATION:
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.5PT; TEXT-INDENT: 14.75PT">
	Cash paid for interest
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	1,530,235
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	1,326,788
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	Supplemental Disclosure of Noncash Financing Activities:
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.5PT; TEXT-INDENT: 14.75PT">
	Reclassification of equity issuance costs to additional paid-in capital
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	&mdash;&nbsp;&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	12,000
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.5PT; TEXT-INDENT: 14.75PT">
	Warrants issued in connection with note payable
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	86,300
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	367,700
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.5PT; TEXT-INDENT: 14.75PT">
	End of term liability in connection with note payable
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	358,000
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	1,432,000
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.5PT; TEXT-INDENT: 14.75PT">
	Elimination of warrant liability
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	&mdash;&nbsp;&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	408,900
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_CASH_FLOW>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	See notes to consolidated financial statements
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
</P>
<!-- FIELD: PAGE; SEQUENCE: 74 -->
<DIV STYLE="MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	6
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage75"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	ADMA BIOLOGICS, INC. AND SUBSIDIARIES
</B>
<BR>
<EFX_NOTES_TO_FINANCIAL_STATEMENT>
<A NAME="FIS_NOTES_TO_FINANCIAL_STATEMENT"></A>
<B>
	NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
</B>
<BR>
<B>
	DECEMBER 31, 2016 AND 2015
</B>
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	&nbsp;&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>
	ORGANIZATION
	AND BUSINESS
</U>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	ADMA Biologics,
	Inc. (&ldquo;ADMA&rdquo; or the &ldquo;Company&rdquo;) is a late stage biopharmaceutical company that develops, manufactures,
	and intends to commercialize specialty plasma-based biologics for the proposed treatment of immune deficiencies and
	prevention of certain infectious diseases. The Company&rsquo;s targeted patient populations include immune-compromised
	individuals who suffer from an underlying immune deficiency disease or who may be immune-suppressed for medical reasons. ADMA
	also operates through its wholly-owned subsidiary, ADMA Bio Centers Georgia Inc., (&ldquo;ADMA BioCenters&rdquo;), a source
	plasma collection business with U.S. Food and Drug Administration (&ldquo;FDA&rdquo;) approved facilities in Norcross,
	Georgia and Marietta, Georgia. Each facility holds certifications from the German Health Authority (&ldquo;GHA&rdquo;) and
	the Korean Ministry of Food and Drug Safety (&ldquo;MFDS&rdquo;). ADMA BioCenters supplies ADMA with a portion of its raw
	material plasma for the manufacture of RI-002, ADMA&rsquo;s lead product candidate, which the Company is currently developing
	for the treatment of Primary Immune Deficiency Disease (&ldquo;PIDD&rdquo;). A Biologics License Application
	(&ldquo;BLA&rdquo;) for RI-002 was submitted to the FDA and accepted for review during the third quarter of 2015 for the
	treatment of PIDD. In July 2016, the FDA issued a Complete Response Letter (&ldquo;CRL&rdquo;) to the Company for its BLA for
	RI-002. The CRL did not cite any concerns with the clinical safety or efficacy data for RI-002 submitted in the BLA, nor did
	the FDA request any additional clinical studies be completed prior to FDA approval of RI-002. The FDA identified in the CRL,
	among other things, certain outstanding inspection issues and deficiencies at the Company&rsquo;s third-party contract
	manufacturers and vendors and requested documentation of corrections for a number of those issues. The FDA indicated in the
	CRL that it cannot grant final approval of the BLA until, among other things,&nbsp;these deficiencies are resolved. Since
	receiving the CRL, the Company has worked diligently with its contract fill and finisher as well as the contract testing
	laboratory. The Company has also continued to work with its third-party contract manufacturer, Biotest Pharmaceuticals
	Corporation (&ldquo;BPC&rdquo; or &ldquo;Seller&rdquo;), and on January 21, 2017, the Company signed a definitive acquisition agreement to
	acquire certain manufacturing and therapy-related assets from Biotest in Boca Raton, Florida, a wholly-owned subsidiary of
	Biotest Aktiengesellschaft (&ldquo;Biotest&rdquo;) in efforts to address the CRL and remediate the outstanding warning
	letter at the manufacturing facility. The acquisition of certain manufacturing and therapy-related assets of Biotest (the &ldquo;Proposed Acquisition&rdquo;) is anticipated to close during the first half of 2017. The Company
	and its vendors are awaiting certain feedback from the agency on submissions already made and the Company intends to provide
	a timeline for resubmission of the BLA for RI-002 as soon as practicable.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	The Company has experienced net losses and
	negative cash flows from operations since inception in 2004 and expects these conditions to continue for the foreseeable future.
	Since inception, the Company has needed to raise capital from the sales of its equity securities and debt financings to sustain
	operations. In May 2016, the Company completed an underwritten public offering of its common stock, raising gross proceeds of approximately
	$14.1 million, and subsequently borrowed an additional $4.0 million under its Loan and Security Agreement (&ldquo;LSA&rdquo;) with
	Oxford Finance LLC (&ldquo;Oxford&rdquo;), which brought the total principal borrowed to $20.0 million (see Note 5). In February
	and December 2014, the Company borrowed a total of $15 million from Hercules Technology Growth Capital, Inc. (&ldquo;Hercules&rdquo;)
	and subsequently refinanced its borrowings of $16 million with Oxford (see Note 5). In March 2015, ADMA completed an underwritten
	public offering of its common stock, raising gross proceeds of $11.3 million.&nbsp;In June 2015, ADMA entered into the LSA with Oxford, as collateral agent and lender, pursuant to which ADMA accessed an initial term
	loan in the aggregate principal amount of $16.0 million, of which $15.7 million was used to repay the Hercules loan balance of
	$15.0 million, along with $0.4 million of interest, and $0.3 million of prepayment premium&nbsp;and other fees, (the &ldquo;Prior
	Loan Agreement&rdquo;).&nbsp;&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
</P>
<!-- FIELD: PAGE; SEQUENCE: 75 -->
<DIV STYLE="MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	7
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage76"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	ADMA BIOLOGICS, INC. AND SUBSIDIARIES
</B>
<BR>
<B>
	NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
</B>
<BR>
<B>
	DECEMBER 31, 2016 AND 2015
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	As of December 31, 2016, the Company had
	working capital of $10.4 million, consisting primarily of $9.9 million of cash and cash equivalents, $5.4 million of short-term
	investments, $1.0 million of accounts receivable, $5.0 million of inventories, and $0.3 million of prepaid expenses, offset primarily
	by the current portion of note payable due to Oxford of $6.1 million, $2.6 million of accounts payable, $2.4 million of accrued
	expenses and $0.2 million of deferred revenue. Based upon the Company&rsquo;s projected revenue and expenditures for 2017, including
	the fees associated to the Proposed Acquisition of certain BPC assets, regulatory and consulting fees for RI-002 associated
	with third-party manufacturers and ongoing discussions with the FDA, continuing implementation of the Company&rsquo;s commercialization
	and expansion activities and certain other assumptions, management currently believes that its cash, cash equivalents, short-term
	investments, projected revenue and accounts receivable are sufficient to fund ADMA&rsquo;s operations, as currently conducted,
	into the second half of 2017. These estimates may change based upon the timing of the closing of the Proposed Acquisition of certain
	BPC assets, whether or when the FDA approves RI-002, the timing of any required commercial manufacturing scale up activities
	or if any other assumptions of the Company change.
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
	&nbsp;
	This timing may also change based upon the timing of the completion of the Proposed Acquisition, anticipated during the first half
	of 2017. Upon the closing of the Proposed Acquisition, BPC will be providing funds to ADMA consisting of: $12.5 million in
	funding, $15.0 million in debt financing and an additional $12.5 million commitment towards a future equity financing is expected
	to be sufficient to fund operations into the first quarter of 2018.&nbsp;&nbsp;There is no assurance that we will be able to successfully
	close on the Proposed Acquisition. Other than the funding to be provided by BPC, the Company does not currently have arrangements
	to obtain additional financing. Furthermore, if the Company&rsquo;s assumptions underlying its estimated expenses and revenues
	are incorrect, it may have to raise additional capital sooner than anticipated.&nbsp;&nbsp;Due to numerous risks and uncertainties
	associated with the research and development and potential future commercialization of its product candidate, the Company is unable
	to estimate with certainty the amounts of increased capital outlays and operating expenditures associated with its development
	activities.&nbsp;&nbsp;The Company&rsquo;s current estimates may be subject to change as circumstances regarding its business requirements
	evolve. The Company may decide to raise capital through public or private equity offerings or debt financings, or obtain a bank
	credit facility or corporate collaboration and licensing arrangements.&nbsp;&nbsp;The Company does not have any existing commitments
	for future external funding.&nbsp;&nbsp;The sale of additional equity or debt securities, if convertible, could result in dilution
	to the Company&rsquo;s stockholders.&nbsp;&nbsp;The incurrence of indebtedness would result in increased fixed obligations and
	could also result in covenants that would restrict the Company&rsquo;s operations or other financing alternatives.&nbsp;&nbsp;Additional
	equity or debt financing, grants, or corporate collaboration and potential licensing arrangements may not be available on acceptable
	terms, if at all.&nbsp;&nbsp;If adequate funds are not available, the Company may be required to delay, reduce the scope of or
	eliminate the Company&rsquo;s research and development programs, reduce the Company&rsquo;s planned clinical trials and delay or
	abandon potential commercialization efforts of the Company&rsquo;s lead or other product candidates.&nbsp;The Company has reported
	losses since inception in June 2004 through December 31, 2016 of $106.9 million. Management believes that the Company will continue
	to incur net losses and negative net cash flows from operating activities to fund its research and development, commercial programs
	and meet its obligations on a timely basis through the foreseeable future. As such, these factors raise substantial doubt about
	the Company&rsquo;s ability to continue as a going concern. The accompanying consolidated financial statements do not include any
	adjustments relating to the recoverability and classification of asset carrying amounts and the classification of liabilities that
	might be necessary from the outcome of this uncertainty.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	ADMA&rsquo;s long-term liquidity will be
	dependent upon on its ability to raise additional capital, to fund its research and development and commercial programs and meet
	its obligations on a timely basis. If ADMA is unable to successfully raise sufficient additional capital, it will likely not have
	sufficient cash flow and liquidity to fund its business operations, forcing ADMA to curtail activities and, potentially significantly
	reduce, or potentially cease operations. Even if ADMA is able to raise additional capital, such financings may only be available
	on unattractive terms, resulting in significant dilution of stockholders&rsquo; interests and, in such event, the value and potential
	future market price of its common stock may decline.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	There can be no assurance that the Company&rsquo;s
	research and development will be successfully completed or that any product will be approved or commercially viable. The Company
	is subject to risks common to companies in the biotechnology industry including, but not limited to, dependence on collaborative
	arrangements, development by the Company or its competitors of new technological innovations, dependence on key personnel, protection
	of proprietary technology, and compliance with FDA and other governmental regulations and approval requirements.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
</P>
<!-- FIELD: PAGE; SEQUENCE: 76 -->
<DIV STYLE="MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	8
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage77"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	ADMA BIOLOGICS, INC. AND SUBSIDIARIES
</B>
<BR>
<B>
	NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
</B>
<BR>
<B>
	DECEMBER 31, 2016 AND 2015
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>
	SUMMARY OF
	SIGNIFICANT ACCOUNTING POLICIES
</U>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	The following comprises the Company&rsquo;s
	significant accounting policies:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<U>
	Basis of presentation
</U>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	The accompanying consolidated financial
	statements include the accounts of ADMA Biologics, Inc. and its wholly-owned subsidiaries. All significant intercompany transactions
	and balances have been eliminated in consolidation.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<U>
	Cash and cash equivalents
</U>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	The Company considers all highly-liquid
	instruments purchased with a maturity of three months or less to be cash equivalents. The Company purchases certificates of deposit
	with maturity schedules of three, six, nine and twelve months. Instruments with original maturities greater than three months but
	less than twelve months are included in short-term investments.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	The Company regularly maintains cash and
	short-term investments at third-party financial institutions in excess of the Federal Deposit Insurance Corporation, or FDIC, insurance
	limit. While the Company monitors the daily cash balances in the operating accounts and adjusts the balances as appropriate, these
	balances could be impacted, and there could be a material adverse effect on the Company&rsquo;s business, if one or more of the
	financial institutions with which the Company has deposits fails or is subject to other adverse conditions in the financial or
	credit markets. To date, the Company has not experienced a loss or lack of access to its invested cash or cash equivalents; however,
	the Company cannot provide assurance that access to its invested cash and cash equivalents will not be impacted by adverse conditions
	in the financial and credit markets.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<U>
	Inventories
</U>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	Plasma inventories (both plasma intended
	for resale and plasma intended for internal use in&nbsp;the&nbsp;Company's&nbsp;research and development and future anticipated
	commercialization activities of which certain quantities are labeled as normal source and Respiratory Syncytial Virus, (&ldquo;RSV&rdquo;)
	high titer) are carried at the lower of cost or market value determined by the first-in, first-out method.&nbsp;&nbsp;Research
	and development plasma used in clinical trials was processed to a finished product and subsequently expensed to research and development.&nbsp;&nbsp;Inventory
	at December 31, 2016 and 2015 consists of high titer RSV plasma and normal source plasma.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<U>
	Revenue recognition
</U>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	Depending on the agreement with the customer,
	product revenues from the sale of human plasma collected at the Company&rsquo;s FDA-licensed plasma collection centers are recognized
	at the time of transfer of title and risk of loss to the customer, which occurs at the time of shipment.&nbsp;&nbsp;Product revenues
	are recognized at the time of delivery if the Company retains the risk of loss during shipment.&nbsp;&nbsp;For the fiscal year
	ended December 31, 2016, two of the Company&rsquo;s customers, SK Plasma Co., Ltd., &ldquo;SK&rdquo;, and BPC, represented
	greater than 95% of our total revenues, with BPC representing approximately 82% of our total revenues and SK representing approximately
	14% of our total revenues.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;&nbsp;Revenue from license fees and
	research and development services rendered are recognized as revenue when the performance obligations under the terms of the license
	agreement have been completed.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	Revenues for the year ended December 31,
	2016 are comprised of product revenues from the sale of normal source human plasma collected from the Company&rsquo;s plasma collection
	centers segment and license and other revenues are primarily attributable to the out-licensing of RI-002 to Biotest AG to market
	and sell in Europe and selected countries in North Africa and the Middle East.&nbsp;&nbsp;Biotest and BPC, a subsidiary
	of Biotest, have provided the Company with certain services and financial payments in accordance with the related Biotest
	license agreement and is obligated to pay the Company certain amounts in the future if certain milestones are achieved.&nbsp;&nbsp;During
	the third quarter of 2015, the Company recorded deferred revenue of $1.5 million for a milestone payment provided to the Company
	after the BLA for RI-002 was filed with the FDA, in accordance with the terms of the Biotest license agreement. Deferred revenue
	is recognized over the term of the Biotest AG license.&nbsp;&nbsp;Deferred revenue is amortized into income for a period of approximately
	20 years, the term of the Biotest license agreement.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
</P>
<!-- FIELD: PAGE; SEQUENCE: 77 -->
<DIV STYLE="MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	9
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage78"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	ADMA BIOLOGICS, INC. AND SUBSIDIARIES
</B>
<BR>
<B>
	NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
</B>
<BR>
<B>
	DECEMBER 31, 2016 AND 2015
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<U>
	Concentration of significant customers and accounts receivable
</U>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	As of and for the years ended December 31,
	2016 and 2015, the Company&rsquo;s trade receivable balance and revenues were substantially attributable to two customers.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<U>
	Research and development costs
</U>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	The Company expenses all research and development
	costs as incurred, of which such expenses include costs associated with planning and conducting clinical trials, manufacturing,
	quality, testing, validation, regulatory consulting and filing fees and employees&rsquo; compensation expenses directly related
	to R&amp;D activities.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<U>
	Use of estimates
</U>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	The preparation of financial statements
	requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure
	of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses
	during the reporting period. Actual results could differ from those estimates. Significant estimates include valuation of inventory,
	assumptions used in the fair value determination of stock-based compensation, warrants and the allowance for the valuation of future
	tax benefits.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<U>
	Concentration of credit risk
</U>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	Financial instruments which potentially
	subject the Company to concentrations of credit risk consist of cash and cash equivalents and short-term investments.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<U>
	Property and equipment
</U>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	Fixed assets are stated at cost less accumulated
	depreciation. Depreciation is calculated using the straight-line method over the asset&rsquo;s estimated useful life, which is
	five to ten years. Leasehold improvements are amortized over the lesser of the lease term or their estimated useful lives.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<U>
	Income taxes
</U>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	The Company recognizes deferred tax liabilities
	and assets for the expected future tax consequences of events that have been included in the consolidated financial statements
	or tax returns. Under this method, deferred tax liabilities and assets are determined on the basis of the difference between the
	tax basis of assets and liabilities and their respective financial reporting amounts (&ldquo;temporary differences&rdquo;) at enacted
	tax rates in effect for the years in which the temporary differences are expected to reverse. The Company records a valuation allowance
	on its deferred income tax assets if it is more likely than not that these deferred income tax assets will not be realized.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	The Company has no unrecognized tax benefits
	at December 31, 2016 and 2015. The Company&rsquo;s U.S. Federal and state income tax returns prior to fiscal year 2013 are closed
	and management continually evaluates expiring statutes of limitations, audits, proposed settlements, changes in tax law and new
	authoritative rulings.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	The Company will recognize interest and
	penalties associated with tax matters as income tax expense.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<U>
	Earnings Loss Per Share
</U>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	Basic net loss per share is computed by
	dividing net loss attributable to common stockholders by the weighted average number of shares of common stock outstanding during
	the period.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
</P>
<!-- FIELD: PAGE; SEQUENCE: 78 -->
<DIV STYLE="MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	10
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage79"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	ADMA BIOLOGICS, INC. AND SUBSIDIARIES
</B>
<BR>
<B>
	NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
</B>
<BR>
<B>
	DECEMBER 31, 2016 AND 2015
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 6PT; TEXT-ALIGN: LEFT; TEXT-INDENT: 20PT">
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Diluted
	net loss per share is calculated by dividing net loss attributable to common stockholders as adjusted for the effect of dilutive
	securities, if any, by the weighted average number of common stock and dilutive common stock outstanding during the period. Potential
	common stock includes the shares of common stock issuable upon the exercise of outstanding stock options and warrants (using the
	treasury stock method). Potential common stock in the diluted net loss per share computation is excluded to the extent that it
	would be anti-dilutive. No potentially dilutive securities are included in the computation of any diluted per share amounts as
	the Company reported a net loss for all periods presented. The aggregate number of potentially dilutive securities upon the exercise
	of outstanding warrants and stock options was 1.8 million and 1.7 million as of December 31, 2016 and 2015, respectively.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<U>
	Stock-based compensation
</U>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	The Company follows recognized accounting
	guidance which requires all stock-based payments, including grants of stock options, to be recognized in the statement of operations
	as compensation expense, based on their fair values on the grant date. The estimated fair value of stock options granted under
	the Company&rsquo;s 2007 Employee Stock Option Plan (the &ldquo;Plan&rdquo;) and the 2014 Omnibus Incentive Compensation Plan (the
	&ldquo;2014 Plan&rdquo;) is recognized as compensation expense over the option-vesting period.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	During the years ended December 31, 2016
	and 2015, stock options to purchase 100,984 and 432,500 shares of common stock, respectively, were issued to employees and non-employee
	directors. During the year ended December 31, 2016, options to purchase 21,334 shares of common stock were forfeited and options
	to purchase 8,666 shares of common stock expired. During the year ended December 31, 2015, options to purchase 7,514 shares of
	common stock were exercised by an employee and options to purchase 9,710 shares of common stock were forfeited.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	On June 19, 2014, at the Annual Meeting
	of Stockholders (the &ldquo;Annual Meeting&rdquo;), the stockholders approved the 2014 Plan, which was approved by the Board of
	Directors of ADMA (the &ldquo;Board&rdquo;) on February 21, 2014. The maximum number of shares reserved for grant under the 2014
	Plan is: (a) 800,000 shares; plus (b) an annual increase as of the first day of the Company&rsquo;s fiscal year, beginning in 2015
	and occurring each year thereafter through 2020, equal to the least of (i) 200,000 shares, (ii) 1% of the outstanding shares of
	common stock as of the end of the Company&rsquo;s immediately preceding fiscal year, and (iii) any lesser number of shares determined
	by the Board; provided, however, that the aggregate number of shares available for issuance pursuant to such increases shall not
	exceed a total of 800,000 shares.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	During the years ended December 31, 2016
	and 2015, the Company recorded stock-based compensation expense to employees of $1,250,074 and $1,711,047, respectively. The fair
	value of employee options granted was determined on the date of grant using the Black-Scholes model. The Black-Scholes option valuation
	model was developed for use in estimating the fair value of publicly traded options, which have no vesting restrictions and are
	fully transferable. In addition, option valuation models require the input of highly subjective assumptions including the expected
	stock price volatility. The Company&rsquo;s employee stock options have characteristics significantly different from those of traded
	options, and changes in the subjective input assumptions can materially affect the fair value estimate. To determine the risk-free
	interest rate, the Company utilized the U.S. Treasury yield curve in effect at the time of the grant with a term consistent with
	the expected term of the Company&rsquo;s awards. The expected term of the options granted is in accordance with Staff Accounting
	Bulletins 107 and 110, which is based on the average between vesting terms and contractual terms. The expected dividend yield reflects
	the Company&rsquo;s current and expected future policy for dividends on the Company&rsquo;s common stock. The expected stock price
	volatility for the Company&rsquo;s stock options was calculated by examining the pro rata historical volatilities for similar publicly
	traded industry peers and the trading history for the Company&rsquo;s common stock. The Company will continue to analyze the expected
	stock price volatility and expected term assumptions. The Company has not experienced any material forfeitures of stock options
	and, as such, has not established a forfeiture rate since the stock options currently outstanding are primarily held by the Company&rsquo;s
	senior management and directors. The Company will continue to evaluate the effects of such future potential forfeitures, as they
	may arise, to evaluate the Company&rsquo;s estimated forfeiture rate.&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
</P>
<!-- FIELD: PAGE; SEQUENCE: 79 -->
<DIV STYLE="MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	11
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage80"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_6"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	ADMA BIOLOGICS, INC. AND SUBSIDIARIES
</B>
<BR>
<B>
	NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
</B>
<BR>
<B>
	DECEMBER 31, 2016 AND 2015
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	The Company records compensation expense
	associated with stock options and other forms of equity compensation using the Black-Scholes option-pricing model and the following
	assumptions:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER; COLOR: RED">
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 90%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD>
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	Year Ended
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	Year Ended
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD>
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	December 31, 2016
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	December 31, 2015
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Expected term
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	5.8-6.3 years
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	5.8-6.3 years
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Volatility
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	51-52
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	%
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	51-58
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	%
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 55%; TEXT-ALIGN: LEFT">
	Dividend yield
</TD>
<TD STYLE="WIDTH: 2%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 16%; TEXT-ALIGN: RIGHT">
	0.0
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 2%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 16%; TEXT-ALIGN: RIGHT">
	0.0
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Risk-free interest rate
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	1.54-1.79%
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	1.49-2.14%
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD COLSPAN="10">
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER; COLOR: RED">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER; COLOR: RED">
	&nbsp;&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<U>
	Fair value of financial instruments
</U>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	The carrying amounts of certain of the Company&rsquo;s
	financial instruments, including cash and cash equivalents, short-term investments, accounts payable, and notes payable are shown
	at cost which approximates fair value due to the short-term nature of these instruments.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<U>
	Recent Accounting Pronouncements
</U>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	In January 2017, the Financial Accounting
	Standards Board, or FASB, issued Accounting Standards Update, or ASU No. 2017-01,
<I>
	Business
</I>
<I>
	Combinations &ndash; Clarifying
	the Definition of a Business,
</I>
	which clarifies the definition of a business to assist entities with evaluating whether transactions
	should be accounted for as acquisitions or disposals of assets or businesses. The standard introduces a screen for determining
	when assets acquired are not a business and clarifies that a business must include, at a minimum, an input and a substantive process
	that contribute to an output to be considered a business. This standard is effective for fiscal years beginning after December
	15, 2017, including interim periods within that reporting period. The Company does not expect this new guidance to have a material
	impact on its consolidated financial statements.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	In March 2016, the FASB, issued ASU No.
	2016-09,
<I>
	Improvements to Employee Share-Based Payment Accounting (Topic 718),
</I>
	which provides for simplification of certain
	aspects of employee share-based payment accounting including income taxes, classification of awards as either equity or liabilities,
	accounting for forfeitures and classification on the statement of cash flows. ASU 2016-09 will be effective for the Company in
	the first quarter of 2017 and will be applied either prospectively, retrospectively or using a modified retrospective transition
	approach depending on the area covered in this update. The adoption of this ASU is not expected to have a material impact on the
	Company&rsquo;s consolidated financial statements and related disclosures.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	In February 2016, the FASB issued ASU No.
	2016-02,
<I>
	Leases (Topic 842),
</I>
	which requires lessees to recognize assets and liabilities for the rights and obligations created
	by most leases on their balance sheet. The guidance is effective for fiscal years beginning after December 15, 2018, including
	interim periods within those fiscal years. Early application is permitted. ASU 2016-02 requires modified retrospective adoption
	for all leases existing at, or entered into after, the date of initial application, with an option to use certain transition relief.
	The Company is currently evaluating the impact the standard may have on its consolidated financial statements and related disclosures.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	In November 2015, the FASB issued ASU No.
	2015-17
<I>
	, Income Taxes (Topic 740), Balance Sheet Classification of Deferred Taxes
</I>
	, which includes amendments that require
	deferred tax liabilities and assets be classified as non-current in a classified statement of financial position.&nbsp; The amendments
	in this ASU are effective for financial statements issued for annual periods beginning after December 15, 2017, and interim periods
	within annual periods beginning after December 15, 2018.&nbsp; Earlier application is permitted as of the beginning of an interim
	or annual reporting period.&nbsp; The amendments may be applied either prospectively to all deferred tax liabilities and assets
	or retrospectively to all periods presented.&nbsp;&nbsp;The adoption of this ASU is not expected to have a material impact on the
	Company&rsquo;s consolidated financial statements and related disclosures.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
</P>
<!-- FIELD: PAGE; SEQUENCE: 80 -->
<DIV STYLE="MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	12
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage81"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	ADMA BIOLOGICS, INC. AND SUBSIDIARIES
</B>
<BR>
<B>
	NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
</B>
<BR>
<B>
	DECEMBER 31, 2016 AND 2015
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	In September 2015, the FASB issued ASU No.
	2015-16,
<I>
	Business Combinations (Topic 805), Simplifying the Accounting for Measurement-Period Adjustments
</I>
	, which includes
	amendments that require an acquirer to recognize adjustments to provisional amounts that are identified during the measurement
	period in the reporting period in which the adjustment amounts are determined.&nbsp; The amendments in this ASU require that the
	acquirer record, in the same period&rsquo;s financial statements, the effect on earnings of changes in depreciation, amortization,
	or other income effects, if any, as a result of the changes
<I>
	&nbsp;
</I>
	to the provisional amounts, calculated as if the accounting
	had been completed at the acquisition date. The amendments in this ASU require an entity to present separately on the face of the
	income statement or disclose in the notes the portion of the amount recorded in current period earnings by line item that would
	have been recorded in previous reporting periods if the adjustment to the provisional amounts had been recognized as of the acquisition
	date.&nbsp; The amendments in this ASU are effective for fiscal years beginning after December 15, 2016, and interim periods within
	fiscal years beginning after December 15, 2017.&nbsp; The amendments should be applied prospectively to adjustments to provisional
	amounts that occur after the effective date of the ASU with earlier application permitted for financial statements that have not
	yet been made available for issuance. The adoption of this ASU is not expected to have a material impact on the Company&rsquo;s
	consolidated financial statements and related disclosures.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	In July 2015, the FASB issued ASU 2015-11,
<I>
	Inventory (Topic 330): Simplifying the Measurement of Inventory
</I>
	. The standard requires entities to measure most inventory
	&ldquo;at the lower of cost and net realizable value,&rdquo; thereby simplifying the current guidance under which an entity must
	measure inventory at the lower of cost or market (market in this context is defined as one of three different measures, one of
	which is net realizable value). The standard is effective for the Company prospectively beginning January 1, 2017. The adoption
	of ASU 2015-11 is not expected to have a material impact on the Company&rsquo;s consolidated financial statements.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	In April 2015, the FASB issued ASU 2015-03,
<I>
	Interest
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&mdash;
</FONT>
	Imputation of Interest
</I>
	, which requires that
	debt issuance costs related to a recognized debt liability be presented in the balance sheet as a direct deduction from the carrying
	amount of the related debt liability instead of being presented as an asset. Debt disclosures will include the face amount of the
	debt liability and the effective interest rate. The update requires retrospective application and represents a change in accounting
	principle. The update is effective for fiscal years beginning after December 15, 2015. The Company adopted ASU 2015-03 in its second
	quarter 2015 consolidated financial statements and recast the prior period balances to conform to the current period presentation.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	In August&nbsp;2014, the FASB issued ASU
	No. 2014-15,
<I>
	Presentation of Financial Statements-Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity&rsquo;s
	Ability to Continue as a Going Concern,
</I>
	which provides guidance on determining when and how reporting entities must disclose
	going-concern uncertainties in their financial statements. The new standard requires management to perform interim and annual assessments
	of an entity&rsquo;s ability to continue as a going concern within one year of the date of issuance of the entity&rsquo;s financial
	statements (or within one year after the date on which the financial statements are available to be issued, when applicable). Further,
	an entity must provide certain disclosures if there is &ldquo;substantial doubt about the entity&rsquo;s ability to continue as
	a going concern.&rdquo; The FASB believes that requiring management to perform the assessment will enhance the timeliness, clarity,
	and consistency of related disclosures and improve convergence with International Financial Reporting Standards (&ldquo;IFRS&rdquo;)
	(which emphasize management&rsquo;s responsibility for performing the going-concern assessment). However, the time horizon for
	the assessment (look-forward period) and the disclosure thresholds under GAAP and IFRSs will continue to differ. This guidance
	is effective for annual reporting periods ending after December&nbsp;15, 2016, and for annual periods and interim periods thereafter,
	with early adoption permitted. The Company has adopted this standard which has not had a material impact on its consolidated financial
	statements.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	In May 2014, the FASB issued ASU 2014-09,&nbsp;
<I>
	Revenue
	from Contracts with Customers
</I>
	, which requires that an entity recognize the amount of revenue to which it expects to be entitled
	for the transfer of promised goods or services to its customers. In order to achieve this core principle, an entity should apply
	the following steps: (1) identify the contract(s) with a customer; (2) identify the performance obligations in the contract; (3)
	determine the transaction price; (4) allocate the transaction price to the performance obligations in the contract; and (5) recognize
	revenue when (or as) the entity satisfies a performance obligation. This update will replace existing revenue recognition guidance
	under GAAP, when it becomes effective for us beginning January 1, 2018, with early adoption permitted in the first quarter of
	2017. The updated standard will permit the use of either the retrospective or cumulative effect transition method. The Company
	is
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	currently assessing the impact of the new guidance on its results
	of operations. Based on its procedures performed to date, nothing has come to the Company&rsquo;s attention that would indicate
	that the adoption of ASU 2014-09 will have a material impact on its consolidated financial statements, however, the Company will
	continue to evaluate this assessment. The Company has not yet selected a transition method.
</FONT>
	The Company is still evaluating
	disclosure requirements under the new standard. The Company will continue to evaluate the standard as well as additional changes,
	modifications or interpretations which may impact its current conclusions.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
</P>
<!-- FIELD: PAGE; SEQUENCE: 81 -->
<DIV STYLE="MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	13
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage82"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_7"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	ADMA BIOLOGICS, INC. AND SUBSIDIARIES
</B>
<BR>
<B>
	NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
</B>
<BR>
<B>
	DECEMBER 31, 2016 AND 2015
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>
	PROPERTY
	AND EQUIPMENT
</U>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD>
	Property and equipment consist of the following at December 31,
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2016
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2015
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 56%; TEXT-ALIGN: LEFT; TEXT-INDENT: 9.95PT">
	Lab and office equipment
</TD>
<TD STYLE="WIDTH: 2%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 14%; TEXT-ALIGN: RIGHT">
	1,336,668
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 2%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 14%; TEXT-ALIGN: RIGHT">
	1,272,042
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 9.95PT">
	Computer software
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	188,277
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	188,277
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.5PT; TEXT-INDENT: 9.95PT">
	Leasehold improvements
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	2,699,104
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	2,690,320
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	4,224,049
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	4,150,639
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.5PT; TEXT-INDENT: 9.95PT">
	Less: Accumulated depreciation and amortization
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(2,223,265
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(1,753,689
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	2,000,784
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	2,396,950
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	The Company recorded depreciation and amortization expense of
	$469,576 and $469,821 for the years ended December 31, 2016 and 2015, respectively.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>
	LEASEHOLD
	IMPROVEMENT LOAN
</U>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	In connection with the lease of commercial
	real estate by the Company&rsquo;s wholly-owned subsidiary for the operation of the plasma collection center, the Company borrowed
	$125,980 from the lessor to pay for leasehold improvement costs in excess of the allowance provided for in the lease agreement.
	The loan bears interest at 9% and is payable in 120 monthly installments of $1,596 maturing January 2019. Principal maturities
	under the loan are as follows:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_8"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 50%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 43%; TEXT-ALIGN: LEFT">
	2017
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 10%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 43%; TEXT-ALIGN: RIGHT">
	16,559
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	2018
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	18,113
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	2019
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	1,584
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	36,256
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	5.
<U>
	DEBT
</U>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<U>
	Loan and Security Agreement
</U>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	On June 19, 2015, the Company entered into
	an LSA with Oxford for up to $21.0 million of debt financing in two term loan tranches.&nbsp;The first term loan tranche of $16.0
	million from the LSA (the &ldquo;Term A Loan&rdquo;) was primarily used to repay the Company&rsquo;s&nbsp;previous debt facility
	with Hercules dated December 2012. As a result of prepaying the Hercules loan prior to maturity, the Company incurred a loss on
	extinguishment of debt of $0.7 million comprised of unamortized debt issuance costs, unamortized debt discount related to the warrants
	issued to Hercules, along with a prepayment penalty.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	The outstanding term loans bear interest
	at a rate per annum equal to the greater of (i) 7.80% and (ii) the sum of (a) the three month U.S. LIBOR rate (as reported in
<I>
	The
	Wall Street Journal
</I>
	) on the date occurring on the last business day of the month that immediately precedes the month in which
	the interest will accrue, plus (b) 7.54% on the outstanding principal balance.&nbsp;&nbsp;The Company became obligated to begin
	to repay the principal over 36 months beginning on February 1, 2017, unless accelerated as a result of certain events of default.&nbsp;
	A final payment equal to 8.95% of the funded loan amount is due at the earlier of loan maturity or prepayment. All term loans mature
	no later than January 1, 2020.&nbsp; The loans are secured by the Company&rsquo;s assets, except for its intellectual property
	(which is subject to a negative pledge). The LSA contains customary representations, warranties and covenants, including limitations
	on incurring indebtedness, engaging in mergers or acquisitions and making investments, distributions or transfers.&nbsp;&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
</P>
<!-- FIELD: PAGE; SEQUENCE: 82 -->
<DIV STYLE="MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	14
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage83"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	ADMA BIOLOGICS, INC. AND SUBSIDIARIES
</B>
<BR>
<B>
	NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
</B>
<BR>
<B>
	DECEMBER 31, 2016 AND 2015
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	In connection with the entry into the LSA,
	on June 19, 2015, the Company issued to Oxford a seven-year warrant, expiring on June 19, 2022, to purchase 74,309 shares of common
	stock at an exercise price of $8.51 per share. The Company recorded $367,700 as the fair value of the warrant to additional paid-in
	capital and as a debt discount to the carrying value of the loan.&nbsp;&nbsp;The key assumptions used to value the warrants included:
	(i) volatility of 57% on our common stock based upon a pro rata percentage of our common stock&rsquo;s volatility and similar public
	companies&rsquo; volatilities for comparison; (ii) an expected dividend yield of 0.0%; (iii) a risk-free interest rate of 1.99%;
	and (iv) a term of seven years.&nbsp;&nbsp;As a result of prepaying the Company&rsquo;s prior loan before maturity, the Company
	incurred a loss on extinguishment of debt of $0.7 million comprised of unamortized debt issuance costs and unamortized debt discount
	related to the warrants issued to the Company&rsquo;s prior lender, along with a prepayment penalty.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	In May 2016, the Company amended the LSA
	with Oxford (the &ldquo;Amended LSA&rdquo;) which provided ADMA with an additional $4.0 million term loan (the &ldquo;Term B Loan&rdquo;),
	the availability of which was conditioned on completing an equity financing of its common stock of at least $10.0 million in gross
	proceeds no later than May 31, 2016. On May 3, 2016, the Company completed an underwritten public offering of its common stock,
	raising gross proceeds of approximately $14.1 million and subsequently borrowed the additional $4.0 million from Oxford under the
	Amended LSA, which brings the total principal amount borrowed to $20.0 million.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	In the event the Company prepays&nbsp;a
	term loan for any reason, the Company is obligated to pay a prepayment charge corresponding to a percentage of the principal amount
	of the applicable&nbsp;term loan prepaid. The Amended LSA further modified the fees payable by the Company on mandatory or voluntary
	prepayment of a term loan prior to its maturity date as follows:&nbsp;&nbsp;(i) for a prepayment made on or after the funding date
	of the applicable term loan through and including the first anniversary of its funding date, an amount equal to 3.00% of the principal
	amount of the term loan prepaid; (ii) for a prepayment made after the first anniversary of the funding date of the applicable term
	loan through and including the second anniversary of such funding date, an amount equal to 2.00% of the principal amount of such
	term loan prepaid; and (iii) for a prepayment of a term loan made after the second anniversary of its funding date and prior to
	its maturity date, an amount equal to 1.00% of the principal amount of the term loan prepaid.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	Pursuant to the Amended LSA, (i) the Company
	paid a total facility fee of $125,000, consisting of $105,000 previously paid and an additional $20,000 paid on the date the Term
	B Loan was funded; (ii) certain adjustments were made to the time periods for any applicable prepayment fees; and (iii) certain
	defined terms were adjusted, including a new Amortization Date that is defined as&nbsp;(a) February 17, 2017, if the Term C Loan
	is not made and (b) August 1, 2017 if the Term C Loan is made.&nbsp;&nbsp;The Amended LSA further provides for customary representations,
	warranties and covenants for the Company.&nbsp;&nbsp;Except as otherwise amended, the Amended LSA does not alter the terms of the
	LSA.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	In connection with the Amended LSA, on May
	13, 2016, the Company issued to Oxford a seven-year warrant, expiring on May 23, 2023, to purchase 24,800 shares of common stock
	at an exercise price of $6.37 per share, equal to 3.95% of the amount drawn of such tranche, divided by the average reported closing
	price per share of common stock for the consecutive 10 trading days prior to the applicable draw in accordance with the Company&rsquo;s
	drawdown of the Term B Loan. The Company recorded $86,300 as the fair value of the warrant to additional paid-in capital and as
	a debt discount to the carrying value of the loan.&nbsp;&nbsp;The key assumptions used to value the warrants included: volatility
	of 53.5% on the Company&rsquo;s common stock based upon a pro rata percentage of the Company&rsquo;s common stock&rsquo;s volatility
	and similar public companies&rsquo; volatilities for comparison, an expected dividend yield of 0.0%, a risk-free interest rate
	of 1.51% and a term of seven years.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
</P>
<!-- FIELD: PAGE; SEQUENCE: 83 -->
<DIV STYLE="MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	15
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage84"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_9"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	ADMA BIOLOGICS, INC. AND SUBSIDIARIES
</B>
<BR>
<B>
	NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
</B>
<BR>
<B>
	DECEMBER 31, 2016 AND 2015
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	A summary of the Oxford loan balance is
	as follows:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; COLOR: RED">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; COLOR: RED">
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 90%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD>
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	December 31, 2016
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	December 31, 2015
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD>
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 56%; TEXT-ALIGN: LEFT">
	Gross proceeds
</TD>
<TD STYLE="WIDTH: 2%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 16%; TEXT-ALIGN: RIGHT">
	20,000,000
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 2%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 16%; TEXT-ALIGN: RIGHT">
	16,000,000
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
<U>
	Less: debt discount, net
</U>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 7.3PT">
	End of term fee
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(1,155,157
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(1,250,194
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-INDENT: 7.3PT">
	Warrants
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(257,201
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(310,196
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.5PT; TEXT-INDENT: 7.3PT">
	Financing fees
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(154,891
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(192,398
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.5PT">
	Note payable
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	18,432,751
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	14,247,212
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; COLOR: RED">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; COLOR: RED">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; COLOR: RED">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Future amortization of financing fees for each of the
	years subsequent to December 31, 2016 are as follows:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_10"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 50%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD COLSPAN="3">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="3">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 43%; TEXT-ALIGN: LEFT">
	2017
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 10%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 43%; TEXT-ALIGN: RIGHT">
	708,720
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	2018
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	529,888
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	2019
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	328,641
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	1,567,249
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; COLOR: RED; TEXT-INDENT: 0.5IN">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; COLOR: RED; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; COLOR: RED; TEXT-INDENT: 0.5IN">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>
	STOCKHOLDERS&rsquo;
	EQUITY
</U>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	On May 3, 2016, the Company completed an
	underwritten public offering of 2,176,154 shares of its common stock, for gross proceeds of approximately $14.1 million. Net proceeds
	from this offering were approximately $13.0 million, after payment of underwriting discounts and offering expenses of approximately
	$1.1 million. The shares were sold under a shelf registration statement on Form S-3 (File No. 333-200638) that was declared effective
	by the SEC on December 23, 2014.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="BACKGROUND-COLOR: WHITE">
	On
	March 18, 2015, the Company closed an underwritten sale of 1,225,000 shares of its common stock, as well as 183,750 additional
	shares of its common stock pursuant to the full exercise of the over-allotment option granted to the underwriters, for gross proceeds
	of approximately $11.3 million. Net proceeds from this offering were approximately $10.2 million, net of underwriting discounts
	and offering expenses of approximately $1.1 million. The shares were sold under a shelf registration statement on Form S-3 (File
	No. 333-200638) that was declared effective by the SEC on December 23, 2014.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<U>
	Oxford and Hercules Debt Financing Warrant Issuance
</U>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	In May 2016, the Company issued to Oxford
	warrants to purchase an aggregate of up to 24,800 shares of the Company&rsquo;s common stock at an exercise price equal to $6.37
	per share. The warrants became exercisable on May 13, 2016 for cash or by net exercise and will expire seven years after their
	issuance on May 13, 2023. In connection with the LSA with Oxford, on June 19, 2015, the Company issued to Oxford a seven year warrant,
	expiring on June 19, 2022, to purchase 74,309 shares of common stock at an exercise price of $8.51 per share. In connection with
	the Prior Loan Agreement with Hercules, on December 21, 2012, the Company issued to Hercules a warrant to purchase 31,750 shares
	of common stock with an exercise price of $7.56, subject to customary anti-dilution adjustments. In connection with the Loan Amendment,
	the Company issued to Hercules a warrant to purchase 23,200 and 34,800 shares of common stock of the Company in February and December
	2014, respectively, with an exercise price set at the lower of (i) $7.50 per share or (ii) the price per share of the next round
	of financing from the expiration of the exercise price adjustment, subject to customary anti-dilution adjustments. The warrant
	expires after 10 years and has piggyback registration rights with respect to the shares of common stock underlying the warrant.
	The down round warrant protection feature resulting in the warrant liability&rsquo;s quarterly &ldquo;mark-to-market&rdquo; valuation
	has terminated as of the end of the one-year period following the amended Loan Closing on February 24, 2014 (see Note 5).
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
</P>
<!-- FIELD: PAGE; SEQUENCE: 84 -->
<DIV STYLE="MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	16
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage85"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	ADMA BIOLOGICS, INC. AND SUBSIDIARIES
</B>
<BR>
<B>
	NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
</B>
<BR>
<B>
	DECEMBER 31, 2016 AND 2015
</B>
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>
	RELATED PARTY
	TRANSACTIONS
</U>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	The Company leases an office building and
	equipment from an entity owned by related parties on a month-to-month basis of which terms were amended by the Company&rsquo;s
	Board of Directors in June 2016. Rent expense amounted to $192,000 and $96,448 for the years ended December 31, 2016 and 2015,
	respectively. The Company also reimburses its landlord and affiliates for office and building related (common area) expenses, equipment
	and certain other operational expenses, which have been insignificant to the consolidated financial statements for the years ended
	December 31, 2016 and 2015.&nbsp;&nbsp;The Company maintains deposits and other accounts at a bank which&nbsp;was less than 5%-owned
	by related parties through January 2016,&nbsp;and where a stockholder and Company director was previously a member of the bank&rsquo;s&nbsp;board
	of directors through January 2016, and is now a member of its Corporate Advisory Council.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>
	COMMITMENTS
	AND CONTINGENCIES
</U>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<U>
	Lease commitments
</U>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	The Company has entered into leases for
	its ADMA BioCenters&rsquo; facilities located in Norcross, Georgia and in Marietta, Georgia. The Norcross, Georgia lease, the term
	of which was extended by five years on January 1, 2014 pursuant to the first of two available five-year renewal options, expires
	on September 30, 2023, and the Marietta, Georgia lease expires on January 31, 2024. Total rent expense for its New Jersey and Georgia
	facilities during the years ended 2016 and 2015 was approximately $535,000 and $420,000, respectively.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Future minimum lease payments for both leases, for each of the
	five years ending December 31 and thereafter are as follows:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_11"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 50%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 43%; TEXT-ALIGN: LEFT">
	2017
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 10%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 43%; TEXT-ALIGN: RIGHT">
	359,059
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	2018
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	362,774
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	2019
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	375,198
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	2020
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	376,812
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	2021
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	381,329
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Thereafter
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	732,079
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	2,587,251
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; COLOR: RED">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; COLOR: RED">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<U>
	Vendor and Licensor Commitments
</U>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	On December 31, 2012, the Company entered
	into a Manufacturing, Supply and License Agreement with BPC, which replaces a prior agreement that expired on December 31,
	2012.&nbsp;&nbsp;Under the agreement, the Company agreed to purchase exclusively from BPC its worldwide requirements of RSV
	immune globulin manufactured from human plasma containing RSV antibodies.&nbsp;&nbsp;The term of the agreement is for a period
	of ten years from January 1, 2013, renewable for two additional five-year periods at the agreement of both parties. The Company
	is obligated under this agreement to purchase a minimum of at least one lot of product during each calendar year after the finished
	product is approved by the FDA.&nbsp;&nbsp;This number is subject to increase at the Company&rsquo;s option.&nbsp;&nbsp;As consideration
	for BPC&rsquo;s obligations under the agreement, the Company is obligated to pay a dollar amount per lot of RSV immune globulin
	manufactured from human plasma containing RSV antibodies, as well as a percentage royalty on the sales thereof and of RI-002, up
	to a specified cumulative maximum.&nbsp;&nbsp;The agreement may be terminated by either party (a) by reason of a material breach
	if the breaching party fails to remedy the breach within 120 days after receiving notice of the breach from the other party, (b)
	upon bankruptcy, insolvency, dissolution, or winding up of the other party, or (c) if the other party is unable to fulfill its
	obligations under the agreement for 120 consecutive days or more as a result of (a) or (b) above. The parties have agreed to a
	mutual release with respect to any claims relating to or arising from any breach or default under the existing Manufacturing Supply
	and License Agreement and Master Services Agreement between the Company and BPC.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
</P>
<!-- FIELD: PAGE; SEQUENCE: 85 -->
<DIV STYLE="MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	17
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage86"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	ADMA BIOLOGICS, INC. AND SUBSIDIARIES
</B>
<BR>
<B>
	NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
</B>
<BR>
<B>
	DECEMBER 31, 2016 AND 2015
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	In a separate license agreement effective
	December 31, 2012, the Company granted BPC an exclusive license to market and sell RSV antibody-enriched Immune Globulin Intravenous
	(&ldquo;IVIG&rdquo;) in Europe and in selected countries in North Africa and the Middle East, collectively referred to as the Territory,
	to have access to the Company&rsquo;s testing services for testing of BPC&rsquo;s plasma samples using the Company&rsquo;s
	proprietary RSV assay, and to reference (but not access) the Company&rsquo;s proprietary information for the purpose of BPC
	seeking regulatory approval for the RSV antibody-enriched IVIG in the Territory.&nbsp;&nbsp;As consideration for the license, BPC
	agreed to provide the Company with certain services at no charge and also compensate us with cash payments upon the completion
	of certain milestones.&nbsp;&nbsp;Such services have been accounted for as deferred revenue which were recorded in 2013 as a result
	of certain research and development services as provided for in accordance with a license agreement. Deferred revenue is recognized
	over the term of the license and is amortized into income for a period of approximately 20 years, the term of the license agreement.
	BPC is also obligated to pay the Company an adjustable royalty based on a percentage of revenues from the sale of RSV antibody-enriched
	IVIG in the Territory for 20 years from the date of first commercial sale. Additionally, BPC has agreed to grant the Company
	an exclusive license for marketing and sales in the U.S. and Canada for BPC&rsquo;s Varicella Zoster Immune Globulin
	(&ldquo;VZIG&rdquo;); however, as a result of the Proposed Acquisition the terms associated to VZIG will be terminated upon the
	closing of the Proposed Acquisition during the first half of 2017.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	Pursuant to the terms of a Plasma Purchase
	Agreement with BPC, the Company has agreed to purchase from BPC an annual minimum volume of source plasma containing antibodies
	to RSV to be used in the manufacture of RI-002.&nbsp;&nbsp;This volume will increase at the earlier of the Company&rsquo;s receipt
	of a BLA from the FDA, or March 31, 2016.&nbsp;&nbsp;The Company must purchase a to-be-determined and agreed upon annual minimum
	volume from BPC but may also collect high-titer RSV plasma from up to five wholly-owned ADMA BioCenters.&nbsp;&nbsp;During
	2015, BPC and ADMA amended their Plasma Purchase Agreement to allow ADMA the ability to collect its raw material
	RSV high-titer plasma from other third party collection organizations, thus allowing ADMA to expand its reach for raw material
	supply as the Company approaches commercialization for RI-002. Unless terminated earlier, the agreement expires in November 2021,
	after which it may be renewed for two additional five-year periods if agreed to by the parties.&nbsp;&nbsp;Either party may terminate
	the agreement if the other party fails to remedy any material default in the performance of any material condition or obligation
	under the agreement following notice.&nbsp;&nbsp;Either party may also terminate the agreement, after providing written notice,
	if a proceeding under any bankruptcy, reorganization, arrangement of debts, insolvency or receivership law is filed by or against
	the other party, and is not dismissed or stayed, or a receiver or trustee is appointed for all or a substantial portion of the
	assets of the other party, or the other party makes an assignment for the benefit of its creditors or becomes insolvent.&nbsp;&nbsp;The
	Company may also terminate the agreement upon written notice if the clinical development of its product candidate is halted or
	terminated, whether by the FDA, a Data Safety Monitoring Board, or any other regulatory authority.&nbsp;&nbsp;Upon termination
	of the agreement, the Company must pay for any source plasma already delivered to the Company and for any source plasma collected
	under the terms of the agreement. As part of the acquisition of certain assets of BPC, BPC and ADMA amended the Plasma
	Purchase Agreement, to extend the purchase from BPC an annual minimum of plasma containing antibodies to RSV for ten years
	through the closing date of the transaction which is anticipated during the first half of 2017.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<U>
	Employment contracts
</U>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	The Company has entered into employment
	agreements with its executive management team consisting of its President and Chief Executive Officer, Chief Medical and Scientific
	Officer and Chief Financial Officer.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<U>
	General legal matters
</U>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	The Company is and may become subject to
	certain legal proceedings and claims arising in connection with the normal course of its business. In the opinion of management,
	there are currently no claims that would have a material adverse effect on its consolidated financial position, results of operations
	or cash flows.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<U>
	Other commitments
</U>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	In the normal course of business, the Company
	enters into contracts that contain a variety of indemnifications with its employees, licensors, suppliers and service providers.
	Further, the Company indemnifies its directors and officers who are, or were, serving at the Company&rsquo;s request in such capacities.
	The Company&rsquo;s maximum exposure under these arrangements is unknown as of December 31, 2016. The Company does not anticipate
	recognizing any significant losses relating to these arrangements.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
</P>
<!-- FIELD: PAGE; SEQUENCE: 86 -->
<DIV STYLE="MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	18
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage87"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	ADMA BIOLOGICS, INC. AND SUBSIDIARIES
</B>
<BR>
<B>
	NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
</B>
<BR>
<B>
	DECEMBER 31, 2016 AND 2015
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	9.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>
	STOCK OPTIONS
</U>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	The Company has adopted two stock
	option plans. On July 16, 2007 (the &ldquo;Effective Date&rdquo;), the Company&rsquo;s Board and stockholders adopted the
	2007 Plan. On July 17, 2012, the Company&rsquo;s Board and stockholders amended the 2007 Plan to increase the aggregate
	number of options available for grant to 903,224. On February 21, 2014 the Board approved the 2014 Plan, which was approved
	by stockholders at the Annual Meeting of Stockholders (the &ldquo;Annual Meeting&rdquo;) on June 19, 2014. Additionally, the
	Board also, approved subject to stockholder approval at the Annual Meeting under the Prospective Plan, 800,000 shares of
	common stock plus an annual increase to be added as of the first day of the Company&rsquo;s fiscal year, beginning in 2015
	and occurring each year thereafter through 2020, equal to the lower of 200,000, or 1% of the outstanding shares of common
	stock as of the end of the Company&rsquo;s immediately preceding fiscal year and any lesser number of shares determined by
	the Board, provided that the aggregate number of shares available for issuance pursuant to such increases shall not exceed a
	total of 800,000 shares reserved for issuance under the terms of the 2014 Plan. As of December 31, 2016, the aggregate
	options approved in the 2007 Plan and 2014 Plan are 1,903,273 with 1,535,187 outstanding and expected to vest and 368,086
	available for future issuance. During the year ended December 31, 2016, there were 21,334 options forfeited and 8,666 options
	expired; such options were included in the stock option plans.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	The 2007 and 2014 Plans provides for the
	Board or a Committee of the Board (the &ldquo;Committee&rdquo;) to grant awards to optionees and to determine the exercise price,
	vesting term, expiration date and all other terms and conditions of the awards, including acceleration of the vesting of an award
	at any time. All options granted under the 2007 and 2014 Plans are intended to be incentive stock options (&ldquo;ISOs&rdquo;),
	unless specified by the Committee to be non-qualified options (&ldquo;NQOs&rdquo;) as defined by the Internal Revenue Code. ISOs
	and NQOs may be granted to employees, consultants or Board members at an option price not less than the fair market value of the
	common stock subject to the stock option agreement. The following table summarizes information about stock options outstanding
	as of December 31, 2016 and 2015:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_12"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD>
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="7" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	Year Ended
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="7" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	Year Ended
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD>
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD COLSPAN="7" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	December 31, 2016
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD COLSPAN="7" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	December 31, 2015
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="3">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	Weighted
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="3">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	Weighted
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="3">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	Average
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="3">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	Average
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="3">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	Exercise
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="3">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	Exercise
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD>
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Shares
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Price
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Shares
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Price
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD COLSPAN="17">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 40%">
	Outstanding at beginning of period
</TD>
<TD STYLE="WIDTH: 3%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
	1,464,203
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 3%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
	8.02
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 3%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
	1,048,927
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 3%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
	7.24
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD>
	Forfeited
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(21,334
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	8.02
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(9,710
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	9.16
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD>
	Expired
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(8,666
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	7.88
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(7,514
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	6.55
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	Granted
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	100,984
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	6.20
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	432,500
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	9.92
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.5PT">
	Outstanding at end of period and expected to vest
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	1,535,187
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	7.90
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	1,464,203
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	8.02
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.5PT">
	Options exercisable
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	1,179,143
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	7.64
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	880,457
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	7.19
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD>
	Weighted average fair value of options
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.5PT; TEXT-INDENT: 9.1PT">
	granted during the year
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	&mdash;&nbsp;&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	5.25
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-RIGHT: 0; MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; COLOR: RED">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	The weighted average remaining contractual
	term of stock options outstanding and expected to vest at December 31, 2016 is 6.4 years. The weighted average remaining contractual
	term of stock options exercisable at December 31, 2016 is 5.8 years.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
</P>
<!-- FIELD: PAGE; SEQUENCE: 87 -->
<DIV STYLE="MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	19
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage88"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_13"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	ADMA BIOLOGICS, INC. AND SUBSIDIARIES
</B>
<BR>
<B>
	NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
</B>
<BR>
<B>
	DECEMBER 31, 2016 AND 2015
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	&nbsp;&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Stock-based compensation expense for the years ended December
	31, 2016 and 2015 was:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 90%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD>
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2016
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2015
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD COLSPAN="9">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 56%; TEXT-ALIGN: LEFT">
	Research and development
</TD>
<TD STYLE="WIDTH: 2%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 14%; TEXT-ALIGN: RIGHT">
	439,982
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 2%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 14%; TEXT-ALIGN: RIGHT">
	724,776
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Plasma centers
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	52,973
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	48,386
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.5PT">
	General and administrative
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	757,119
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	937,885
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.5PT; TEXT-INDENT: 9.5PT">
	Total stock-based compensation expense
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	1,250,074
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	1,711,047
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER; COLOR: RED">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER; COLOR: RED">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	As of December 31, 2016, the total unrecognized
	compensation expense related to unvested options totaled $1,616,337. The weighted-average vesting period over which the total compensation
	expense will be recorded related to unvested options at December 31, 2016 was approximately 2.2 years.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	The aggregate intrinsic value is calculated
	as the difference between (i) the closing price of the common stock at December 31, 2016 and (ii) the exercise price of the underlying
	awards, multiplied by the number of options that had an exercise price less than the closing price on the last trading day. The
	Company&rsquo;s outstanding and&nbsp;exercisable options had an intrinsic value of $260,974 as of December 31, 2016.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_14"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	10.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>
	INCOME TAXES
</U>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	A reconciliation of income taxes at the U.S. Federal statutory
	rate to the benefit for income taxes is as follows:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 95%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD>
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="7" STYLE="TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Year Ended December 31,
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD>
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2016
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2015
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 56%; TEXT-ALIGN: LEFT">
	Benefit at U.S. Federal statutory rate
</TD>
<TD STYLE="WIDTH: 2%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 14%; TEXT-ALIGN: RIGHT">
	(6,635,151
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="WIDTH: 2%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 14%; TEXT-ALIGN: RIGHT">
	(6,109,776
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	State taxes - deferred
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(266,312
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(124,874
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Increase in valuation allowance, inclusive of true-ups
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	5,755,413
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	6,021,614
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Research and development credits
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(322,499
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(389,355
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="PADDING-BOTTOM: 1PT">
	Other
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	1,468,549
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	602,391
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.5PT">
	Benefit for income taxes
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	&mdash;&nbsp;&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	&mdash;&nbsp;&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	A summary of the Company&rsquo;s deferred tax assets is as follows:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_15"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 95%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD>
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="7" STYLE="TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	December 31,
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD>
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2016
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2015
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 56%; TEXT-ALIGN: LEFT">
	Federal and state net operating loss carryforwards
</TD>
<TD STYLE="WIDTH: 2%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 14%; TEXT-ALIGN: RIGHT">
	30,843,479
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 2%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 14%; TEXT-ALIGN: RIGHT">
	25,834,860
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Federal and state research credits
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	4,099,249
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	4,353,534
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Transaction costs
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	652,695
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&mdash;&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Deferred revenue
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	972,345
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1,020,872
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	Accrued expenses and other
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	747,586
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	350,675
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 10PT">
	Total gross deferred tax assets
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	37,315,354
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	31,559,941
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	Less: valuation allowance for deferred tax assets
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(37,315,354
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(31,559,941
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.5PT; TEXT-INDENT: 10PT">
	Net deferred tax assets
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	&mdash;&nbsp;&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	&mdash;&nbsp;&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
</P>
<!-- FIELD: PAGE; SEQUENCE: 88 -->
<DIV STYLE="MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	20
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage89"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	ADMA BIOLOGICS, INC. AND SUBSIDIARIES
</B>
<BR>
<B>
	NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
</B>
<BR>
<B>
	DECEMBER 31, 2016 AND 2015
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	We have incurred substantial losses during
	our history. As of December 31, 2016, we had Federal and state Net Operating Losses, (&ldquo;NOLs&rdquo;) of $87.8 million and
	$75.2 million, respectively, as well as Federal research and development tax credit carryforwards of approximately $4.1 million.
	The $87.8 million and $75.2 million in Federal and state NOLs, respectively, will begin to expire at various dates beginning in
	2027, if not limited by triggering events prior to such time. Under the provisions of the Internal Revenue Code, changes in our
	ownership, in certain circumstances, will limit the amount of Federal NOLs that can be utilized annually in the future to offset
	taxable income. In particular, Section 382 of the Internal Revenue Code imposes limitations on a company&rsquo;s ability to use
	NOLs upon certain changes in such ownership. If we are limited in our ability to use our NOLs in future years in which we have
	taxable income, we will pay more taxes than if we were able to utilize our NOLs fully. We may experience ownership changes in the
	future as a result of subsequent shifts in our stock ownership that we cannot predict or control that could result in further limitations
	being placed on our ability to utilize our Federal NOLs.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	A valuation allowance, if needed, reduces
	deferred tax assets to the amount expected to be realized. When determining the amount of net deferred tax assets that are more
	likely than not to be realized, the Company assesses all available positive and negative evidence. This evidence includes, but
	is not limited to, prior earnings history, expected future earnings, carry-back and carry-forward periods and the feasibility of
	ongoing tax strategies that could potentially enhance the likelihood of the realization of a deferred tax asset. The weight given
	to the positive and negative evidence is commensurate with the extent the evidence may be objectively verified. As such, it is
	generally difficult for positive evidence regarding projected future taxable income exclusive of reversing taxable temporary differences
	to outweigh objective negative evidence of recent financial reporting losses. Based on these criteria and the relative weighting
	of both the positive and negative evidence available, management continues to maintain a full valuation allowance against its net
	deferred tax assets.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	11.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>
	SEGMENTS
</U>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	The Company is engaged in the development
	and commercialization of human plasma and plasma-derived therapeutics. The Company also operates two FDA-licensed source plasma
	collection facilities located in Norcross, Georgia and Marietta, Georgia. The Company defines its segments as those business units
	whose operating results are regularly reviewed by the chief operating decision maker (&ldquo;CODM&rdquo;) to analyze performance
	and allocate resources. The Company&rsquo;s CODM is its President and Chief Executive Officer.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	The plasma collection center segment includes
	the Company&rsquo;s operations in Georgia. The research and development segment includes the Company&rsquo;s plasma development
	operations in New Jersey.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
</P>
<!-- FIELD: PAGE; SEQUENCE: 89 -->
<DIV STYLE="MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	21
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage90"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<EFX_INCOME_STATEMENT>
<A NAME="FIS_INCOME_STATEMENT_2"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	ADMA BIOLOGICS, INC. AND SUBSIDIARIES
</B>
<BR>
<B>
	NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
</B>
<BR>
<B>
	DECEMBER 31, 2016 AND 2015
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	Summarized financial
	information concerning reportable segments is shown in the following tables:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	Year Ended December 31,
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	Plasma Collection
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	Research and
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="3">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="3">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2016
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Centers
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Development
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Corporate
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Consolidated
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 35%">
	Revenues
</TD>
<TD STYLE="WIDTH: 2%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	10,518,203
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 2%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	&mdash;&nbsp;&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 2%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	142,834
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 2%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	10,661,037
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Cost of product revenue
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	6,360,761
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&mdash;&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&mdash;&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	6,360,761
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Gross profit
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	4,157,442
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&mdash;&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	142,834
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	4,300,276
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Loss from operations
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(1,290,249
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(7,688,238
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(8,351,908
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(17,330,395
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Other expense
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&mdash;&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&mdash;&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(2,184,756
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(2,184,756
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Loss before income taxes
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(1,290,249
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(7,688,238
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(10,536,664
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(19,515,151
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Total assets
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	2,421,535
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&mdash;&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	21,263,550
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	23,685,085
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Depreciation and
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	amortization expense
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	414,464
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	&mdash;&nbsp;&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	55,112
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	469,576
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	Year Ended December 31,
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Plasma Collection
</B>
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Research and
</B>
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	2015
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Centers
</B>
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Development
</B>
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Corporate
</B>
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Consolidated
</B>
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD>
	Revenues
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	7,050,283
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&mdash;&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	127,350
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	7,177,633
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Cost of product revenue
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	4,311,461
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&mdash;&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&mdash;&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	4,311,461
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Gross profit
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	2,738,822
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&mdash;&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	127,350
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	2,866,172
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Loss from operations
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(1,879,243
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(7,015,946
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(6,618,618
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(15,513,807
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Other expense
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&mdash;&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&mdash;&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(2,456,123
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(2,456,123
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Loss before income taxes
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(1,879,243
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(7,015,946
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(9,074,741
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(17,969,930
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Total assets
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	2,719,641
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&mdash;&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	20,994,876
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	23,714,517
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Depreciation and
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	amortization expense
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	419,301
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	&mdash;&nbsp;&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	50,520
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	469,821
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_INCOME_STATEMENT>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-RIGHT: 0; MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	The &ldquo;Corporate&rdquo; column includes
	general and administrative overhead expenses. Total assets included in the &ldquo;Corporate&rdquo; column above includes assets
	related to corporate and support functions.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	12.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>
	OTHER EMPLOYEE
	BENEFITS
</U>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	The Company sponsors a 401(k) savings
	plan. Under the plan, employees may make contributions which are eligible for a Company discretionary percentage contribution
	as defined in the plan and determined by the Board of Directors. The Company recognized approximately $0.2 million and $0.1
	million of related compensation expense for the years ended December 31, 2016 and 2015, respectively.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
</P>
<!-- FIELD: PAGE; SEQUENCE: 90 -->
<DIV STYLE="MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	22
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage91"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	ADMA BIOLOGICS, INC. AND SUBSIDIARIES
</B>
<BR>
<B>
	NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
</B>
<BR>
<B>
	DECEMBER 31, 2016 AND 2015
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	13.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>
	SUBSEQUENT
	EVENTS
</U>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	Summary of Proposed Acquisition of Certain Assets of BPC
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	On January 21, 2017, the Company and
	its wholly-owned subsidiary, ADMA BioManufacturing, LLC, a Delaware limited liability company (&ldquo;Buyer&rdquo;), entered
	into a definitive Master Purchase and Sale Agreement (as amended, restated, supplemented, or otherwise modified from time to
	time (the &ldquo;Purchase Agreement&rdquo;) with Seller, and for certain limited purposes set forth in the
	Purchase Agreement, Biotest, and Biotest US Corporation, a Delaware corporation and subsidiary of Biotest (together with
	Biotest, the &ldquo;Biotest Guarantors&rdquo;), pursuant to which Buyer has agreed to acquire certain assets and assume
	certain liabilities constituting the therapy business of Seller (the &ldquo;Business&rdquo;). The foregoing transactions and
	the other transactions contemplated by the Purchase Agreement are collectively referred to as the &ldquo;Proposed
	Acquisition.&rdquo; The Business includes (a) a FDA-licensed immune globulin manufacturing and plasma products production
	facility of two buildings in Boca Raton, Florida, and the associated real property, (b) all exclusive rights to FDA licensed
	biologics products Nabi-HB&reg;, BIVIGAM&reg; and the investigational product CIVACIR&reg;, (c) in-process inventory with an
	agreed-upon value of at least $5.0 million, (d) certain other properties and assets used exclusively in the Business, and (e)
	certain additional assets which relate to both the Business and Seller&rsquo;s plasma business the arrangement with respect
	to which will be documented in a transition services agreement to be mutually agreed by the parties between the signing of
	the Purchase Agreement and the closing of the Proposed Acquisition.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	Subject to the terms and conditions of
	the Purchase Agreement, (i) upon the closing, the Company has agreed to assume certain liabilities of Seller related to the
	Business, including, without limitation, related to (x) product liabilities, breach of warranty, product complaints, product
	returns, post-market commitments, recalls, adverse event reporting, product deviation reporting, lookbacks, market
	withdrawals and field corrections or similar claims for injury to person or property with respect to the Business or any
	product of the Business to the extent such liabilities relate to products manufactured and sold by Buyer after the
	closing (other than inventory transferred to the Company at the closing, which will be allocated 50% to Buyer and 50%
	to Seller if not traceable to acts or omissions of a particular party); and (y) other regulatory matters, whether related to
	the pre-closing or post-closing period and including any liabilities related to the products of the Business, the FDA warning
	letter (the warning letter issued by the FDA to Seller in connection with outstanding issues requiring remediation at the
	manufacturing facility in Boca Raton, Florida), noncompliance with applicable laws and legal proceedings related to the
	foregoing, but excluding such liabilities that arise out of any fraud, willful misconduct or intentional misrepresentation by
	Seller prior to the closing (the &ldquo;Assumed Liabilities&rdquo;); (ii) upon the closing, the Company has agreed to
	deliver to Seller an aggregate equity interest in the Company equal to 50%, less one share, of its issued and outstanding
	capital stock (calculated as of immediately following the closing and on a post-closing issuance basis) (the &ldquo;Biotest
	Equity Interest&rdquo;), consisting of (x) common stock representing 25% of the Company&rsquo;s issued and outstanding common stock,
	equal to 4,295,580 common shares and (y) non-voting common stock equal to 8,591,160 shares of the Company&rsquo;s non-voting
	common stock representing the balance of the Biotest Equity Interest which is convertible into common stock of the Company
	upon the occurrence of certain specified events; (iii) upon the closing, the Company agreed to issue to Seller warrants, if
	any, necessary to acquire additional shares of the Company&rsquo;s capital stock equal to the excess, if any, of (x) the
	number of shares represented by rights, options and warrants issued by the Company between September 12, 2016 until the
	closing, over (y) 184,000 shares; and (iv) on January 1, 2019, pursuant to the terms of a separate purchase agreement to be
	entered into by the parties at the closing, the Company has agreed to sell, transfer and convey to Seller for no additional
	consideration, all of its right, title and interest in and to the Company&rsquo;s certain biocenter located in Norcross,
	Georgia and the Company&rsquo;s certain biocenter located in Marietta, Georgia, which are subject to a repurchase right in
	favor of the Company if within five years after January 1, 2019, the Biotest stockholders and its related entities own
	less than 20% of the Company&rsquo;s issued and outstanding capital stock. As part of the consideration, upon the closing,
	Seller will also be granted the right to designate one director and one observer to the Company&rsquo;s board of directors,
	and under certain circumstances, Seller will be granted the right to designate an additional director.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	Additionally, on the closing
	date, Seller has agreed to (i) deliver to the Company a capital contribution of $12.5 million in respect of the Biotest
	Equity Interest, which capital contribution will be contributed by Seller to Buyer; and (ii) fund a $15.0 million unsecured
	subordinated loan to the Company, which (a) will bear interest at a rate of 6% per annum, payable semiannually in arrears,
	(b) has a term of five years and (c) will not be subject to any prepayment penalty or other breakage costs. Such loan will be
	subordinated to the Company&rsquo;s existing indebtedness as of the signing of the Purchase Agreement and any additional
	indebtedness approved by the Company&rsquo;s board of directors which is secured only by a mortgage on the owned real
	property acquired in connection with the transaction. Such loan will rank pari passu with all additional indebtedness
	approved by the Company&rsquo;s board of directors that is not secured only by a mortgage on such owned real property and if
	such additional indebtedness is secured, the loan from Seller will be secured on a pari passu basis with such additional
	indebtedness. At any time after the closing, if the Company undertakes an underwritten equity financing or a Private
	Investment in Public Equity, or PIPE, offering involving at least one unrelated third party, Biotest and/or Seller have
	agreed to participate pro rata in accordance with the Biotest Equity Interest up to an aggregate amount equal to $12.5
	million.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
</P>
<!-- FIELD: PAGE; SEQUENCE: 91 -->
<DIV STYLE="MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	23
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage92"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	ADMA BIOLOGICS, INC. AND SUBSIDIARIES
</B>
<BR>
<B>
	NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
</B>
<BR>
<B>
	DECEMBER 31, 2016 AND 2015
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	Upon the closing, the parties will also
	enter into a ten-year plasma supply agreement, pursuant to which (x) Seller will sell to the Company high titer Hepatitis B plasma
	at a specified price (indexed by inflation), and (y) the Company will purchase from Seller all Hepatitis B plasma necessary to
	produce Nabi-HB&reg; unless the Company requires more than a specified amount, in which case the Company may use alternative sources
	for the excess quantity. Additionally, the parties have agreed to a mutual release with respect to any claims relating to or arising
	from any breach or default under the Manufacturing Supply and License Agreement and Master Services Agreement between
	the Company and Seller. The mutual release is effective as of the signing of the Purchase Agreement conditioned on the closing
	of the Proposed Acquisition at which time the Manufacturing Supply and License Agreement and Master Services Agreement will terminate
	and the mutual release will no longer be conditional.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	The Purchase Agreement contains customary
	representations and warranties of the parties, including, without limitation, with respect to: organization; power and authority;
	due authorization; enforceability; capitalization; no conflict; no consents required; no actions; no orders; financial statements;
	indebtedness; no undisclosed liabilities; absence of certain changes; taxes; contracts; customers and suppliers; intellectual property;
	title to properties; real property; employee benefit plans; employees; insurance; compliance with laws; environmental; material
	permits; inventory; affiliate transactions; and no brokers.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	The Purchase Agreement also
	contains customary covenants and agreements, including covenants and agreements of: Seller to conduct the Business in the
	ordinary course until the Proposed Acquisition is completed or terminated and to not take certain actions relating to the
	Business during the interim period between signing and closing, without the Company&rsquo;s prior consent not to be
	unreasonably withheld, conditioned or delayed; the Company to conduct its business in the ordinary course until the Proposed
	Acquisition is completed or terminated and to not take certain actions relating to its business during the interim period
	between signing and closing, without Seller&rsquo;s prior consent not to be unreasonably withheld, conditioned or delayed;
	Seller not to compete with the Company in certain lines of business for a period of five years following the closing date;
	Seller and the Biotest Guarantors not to solicit the Company&rsquo;s employees for one year following the closing date; the
	Company not to solicit Seller&rsquo;s employees for one year following the closing date; and Seller not to interfere with
	the Company&rsquo;s customers for five years following the closing date.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	Subject to certain limitations, the Company
	or Seller may terminate the Purchase Agreement if the Proposed Acquisition has not been consummated by September 30, 2017. A termination
	of the Purchase Agreement under certain customary circumstances relating to (i) the Company&rsquo;s board of directors exercising
	their fiduciary out will entitle Seller to receive from the Company a termination fee in an amount equal to $2.5 million; or (ii)
	the Company&rsquo;s failure to obtain the requisite stockholder approval will entitle Seller to receive expense reimbursement
	in an amount up to $2.5 million. In no event will Seller be entitled to both a termination fee and expense reimbursement.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	Seller and the Company will each indemnify
	the other party after the closing for any losses arising from breaches of its representations, warranties, covenants and agreements
	in the Purchase Agreement. In addition, the Company will indemnify Seller after the closing for any assumed liability, and Seller
	will indemnify the Company after the closing for any excluded asset or excluded liability. The representations, warranties and
	pre-closing covenants generally survive for 15 months following the closing of the transaction and each party&rsquo;s indemnification
	obligations with respect to (a) its representations and warranties (other than its fundamental representations, which include representations
	related to taxes, organization, due authorization, organizational documents, no conflicts; enforceability, title; sufficiency,
	the Amended and Restated Product Distribution Agreement, effective as of January 19, 2016, by and between Seller and
<FONT STYLE="BACKGROUND-COLOR: WHITE">
	Kedrion
	Biopharma Inc., or the Kedrion Contract
</FONT>
	, brokers, etc. and ownership of the Company&rsquo;s securities) are subject to a
	$25,000 mini-basket and $750,000 true deductible; and (b) its representations and warranties (other than fundamental) and pre-closing
	covenants are subject to a $25.0 million cap.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
</P>
<!-- FIELD: PAGE; SEQUENCE: 92 -->
<DIV STYLE="MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	24
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage93"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	ADMA BIOLOGICS, INC. AND SUBSIDIARIES
</B>
<BR>
<B>
	NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
</B>
<BR>
<B>
	DECEMBER 31, 2016 AND 2015
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	Seller will be entering into a
	standstill with the Company, which will limit Seller&rsquo;s ability to control the Company. Seller will also agree to a six (6)
	month lock-up of the sale of the Company&rsquo;s securities.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	The consummation of the Proposed
	Acquisition is subject to the satisfaction of certain conditions, including approval of the Proposed Acquisition by the
	stockholders of ADMA and approval of the amended and restated certificate of incorporation of the Company by the stockholders
	of ADMA. The Proposed Acquisition is not subject to any financing conditions. There can be no assurance as to when the closing
	conditions will be satisfied, if at all.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	Upon consummation and closing of the Proposed
	Acquisition, the Company believes it will be uniquely positioned to offer a fully vertically integrated plasma products and immune
	globulin platform in the U.S.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	Summary of Lease with Home Center Properties, LLC
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	On February 17, 2017, ADMA Bio Centers Georgia
	Inc. (&ldquo;ADMA BioCenters&rdquo;), a Delaware corporation and a wholly owned subsidiary of the Company, entered into a lease
	(the &ldquo;Lease&rdquo;) with Home Center Properties, LLC, a Georgia limited liability company (&ldquo;Landlord&rdquo;), for approximately
	12,167 square feet located at 166 Earnest W. Barrett Parkway, Marietta, Georgia 30066 (the &ldquo;Premises&rdquo;). Pursuant to
	the Lease, ADMA BioCenters will utilize the Premises as a facility specializing in the collection of human plasma and blood, general
	office administration and any other related use.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	The Lease has an initial term of approximately
	eight years and nine months (the &ldquo;Initial Term&rdquo;), commencing upon substantial completion of &ldquo;Landlord&rsquo;s
	Work&rdquo; (as defined in the Lease) (the &ldquo;Lease Commencement Date&rdquo;), with rent payments commencing 150 days after
	the Lease Commencement Date. ADMA BioCenters&rsquo; total monthly cost of the Premises (inclusive of Landlord&rsquo;s &ldquo;Operating
	Costs&rdquo;, &ldquo;Taxes&rdquo; and &ldquo;Insurance Charges&rdquo; (as such terms are defined in the Lease)) will range from
	approximately $20,000 to $27,000 during the Initial Term;
<I>
	provided
</I>
	,
<I>
	however
</I>
	,
<I>
	that
</I>
	, provided ADMA BioCenters
	is not in default of the Lease beyond the expiration of any applicable notice and cure period, ADMA BioCenters shall not be obligated
	to make any rent payments for the first five calendar months of the Initial Term beginning on the Lease Commencement Date and the
	last four months of the Initial Term beginning on the 102
<SUP>
	nd
</SUP>
	month after the Lease Commencement Date. Provided that the
	Lease is in full force and effect and provided there has been no &ldquo;Event of Default&rdquo; (as defined in the Lease) beyond
	the expiration of any applicable notice and cure period, ADMA BioCenters shall have the option to extend the term of the Lease
	for two additional periods of five years each (each, an &ldquo;Extension Term&rdquo;), each Extension Term on the same terms, covenants
	and conditions as the Lease, with the rent for each Extension Term to equal the mutually agreed fair market value of the Premises
	on the commencement of such Extension Term. The Lease also contains customary default provisions, representations, warranties and
	covenants.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	The foregoing summary of the material terms
	of the Lease is qualified in its entirety by reference to the full text of the Lease, which is attached hereto as Exhibit 10.22
	and incorporated herein by reference.&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
</P>
<!-- FIELD: PAGE; SEQUENCE: 93 -->
<DIV STYLE="MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	25
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
</EFX_NOTES_TO_FINANCIAL_STATEMENT>
<A NAME="eolPage94"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
</P>
<EFX_EXHIBIT_INDEX>
<A NAME="FIS_EXHIBIT_INDEX"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	EXHIBIT INDEX
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_16"></A>
<TABLE CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 11%; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<B>
	Exhibit No.
</B>
</TD>
<TD STYLE="WIDTH: 2%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 87%; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<B>
	Description
</B>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	2.1 (16)
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	Master Purchase and Sale Agreement, dated as of January 21, 2017, by and among Biotest Pharmaceuticals Corporation, ADMA BioManufacturing, LLC, ADMA Biologics, Inc., Biotest AG and Biotest US Corporation.
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	3.1
<FONT STYLE="FONT-SIZE: 10PT">
	(1)
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	Certificate of Incorporation, as amended.
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	3.2
<FONT STYLE="FONT-SIZE: 10PT">
	(2)
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	Certificate of Amendment of Certificate of Incorporation.
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	3.3
<FONT STYLE="FONT-SIZE: 10PT">
	(3)
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	Amended and Restated Bylaws.
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	4.1
<FONT STYLE="FONT-SIZE: 10PT">
	(4)
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	Specimen Common Stock Certificate.
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	4.2
<FONT STYLE="FONT-SIZE: 10PT">
	(1)
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	Form of Placement Agent Warrant.
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	4.3
<FONT STYLE="FONT-SIZE: 10PT">
	(5)
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	Form of Warrant Agreement with Hercules Technology Growth Capital, Inc.
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	4.4
<FONT STYLE="FONT-SIZE: 10PT">
	(13)
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	Form of Warrant Agreement with Oxford Finance LLC.
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	4.5
<FONT STYLE="FONT-SIZE: 10PT">
	(5)
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	Form of Secured Term Loan Promissory Note issued to Hercules Technology Growth Capital, Inc.
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	4.6
<FONT STYLE="FONT-SIZE: 10PT">
	(13)
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	Form of Secured Term B Loan Promissory Note issued to Oxford Finance LLC.
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	10.1&dagger;
<FONT STYLE="FONT-SIZE: 10PT">
	(6)
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	2007 Employee Stock Option Plan, as amended by Amendment No. 3.
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	10.2
<FONT STYLE="FONT-SIZE: 10PT">
	(1)
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	Amended and Restated Placement Agency Agreement, dated February 12, 2012, between ADMA Biologics, Inc. and
<FONT STYLE="BACKGROUND-COLOR: WHITE">
	Rodman &amp; Renshaw, LLC.
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	10.3&dagger;
<FONT STYLE="FONT-SIZE: 10PT">
	(12)
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	Amended and Restated Employment Agreement, dated January 28, 2016, by and between ADMA Biologics, Inc. and Adam Grossman.
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	10.4+
<FONT STYLE="FONT-SIZE: 10PT">
	(7)
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	Manufacturing Agreement, dated as of October 23, 2006, by and between Biotest Pharmaceuticals Corporation and ADMA Biologics, Inc., as amended as of October 23, 2011 and as of December 2, 2011.
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	10.5+
<FONT STYLE="FONT-SIZE: 10PT">
	(7)
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	Plasma Purchase Agreement, dated as of November 17, 2011, by and between Biotest Pharmaceuticals Corporation and ADMA Biologics, Inc., as amended as of December 1, 2011.
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	10.5.1+
<FONT STYLE="FONT-SIZE: 10PT">
	(12)
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	Second Amendment to Plasma Purchase Agreement, dated as of December 18, 2015, by and between Biotest Pharmaceuticals Corporation and ADMA Biologics, Inc.
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	10.5.2
<FONT STYLE="FONT-SIZE: 10PT">
	(13)
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	Third Amendment to Plasma Purchase Agreement, dated as of April 8, 2016, by and between Biotest Pharmaceuticals Corporation and ADMA Biologics, Inc.
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	10.6
<FONT STYLE="FONT-SIZE: 10PT">
	(15)
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	Amended and Restated Agreement for Services, effective as of January 1, 2016, by and between ADMA Biologics, LLC and Areth LLC.
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	10.7
<FONT STYLE="FONT-SIZE: 10PT">
	(1)
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	Agreement of Lease, effective June 1, 2008 and confirmed on November 13, 2008, by and among ADMA Bio Centers Georgia Inc., ADMA Biologics, Inc. and C1VF I-GA1W15-W23, LLC (DCT Holdings), as amended on January 20, 2011, May 24, 2012 and January 1, 2014.
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	10.8+ (11)
<SUP>
</SUP>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	Lease, dated as of January 20, 2014, by and between ADMA Bio Centers Georgia Inc. and U.S. Bank National Association, effective February 1, 2014, as amended on December 18, 2014 and July 9, 2015.
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	10.9
<FONT STYLE="FONT-SIZE: 10PT">
	(1)
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	Form of Indemnification Agreement.
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	10.10 &dagger;
<FONT STYLE="FONT-SIZE: 10PT">
	(12)
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	Amended and Restated Employment Agreement, dated January 28, 2016, by and between ADMA Biologics, Inc. and Brian Lenz.
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	10.11
<FONT STYLE="FONT-SIZE: 10PT">
	(8)
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	Placement Agency Modification and Release Agreement, dated as of June 15, 2012, by and between ADMA Biologics, Inc. and Rodman &amp; Renshaw, LLC.
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	10.12+
<FONT STYLE="FONT-SIZE: 10PT">
	(9)
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	Testing Services Agreement, dated as of June 8, 2012, by and between ADMA Biologics, Inc. and Quest Diagnostics Clinical Laboratories, Inc.
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	10.13+
<FONT STYLE="FONT-SIZE: 10PT">
	(12)
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	Amended and Restated Plasma Supply Agreement, dated as of March 23, 2016, by and between ADMA Biologics, Inc. and Biotest Pharmaceuticals Corporation.
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	10.14&dagger;
<FONT STYLE="FONT-SIZE: 10PT">
	(12)
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	Amended and Restated Employment Agreement, dated January 28, 2016, by and between ADMA Biologics, Inc. and James Mond,
<FONT STYLE="BACKGROUND-COLOR: WHITE">
	M.D., Ph.D.&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	10.15
<FONT STYLE="FONT-SIZE: 10PT">
	(5)
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	Loan and Security Agreement, dated as of December 21, 2012, by and among ADMA Biologics, Inc., ADMA Plasma Biologics, Inc., ADMA Bio Centers Georgia Inc. and Hercules Technology Growth Capital, Inc.
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	10.15.1 (11)
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	First Amendment to Loan and Security Agreement, dated as of February 24, 2014, by and among ADMA Biologics, Inc., ADMA Plasma Biologics, Inc., ADMA Bio Centers Georgia Inc. and Hercules Technology Growth Capital, Inc.
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 94 -->
<DIV STYLE="MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	26
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage95"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
</P>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_17"></A>
<TABLE CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 11%">
	10.16 (14)
</TD>
<TD STYLE="WIDTH: 2%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 87%">
	Loan and Security Agreement, dated as of June 19, 2015, by and among Oxford Finance LLC, the lenders party thereto, ADMA Biologics, Inc., ADMA Plasma Biologics, Inc. and ADMA Bio Centers Georgia Inc.
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	10.16.1 (14)
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	First Amendment to Loan and Security Agreement, dated as of May 13, 2016, by and among Oxford Finance LLC, the lenders party thereto, ADMA Biologics, Inc., ADMA Plasma Biologics, Inc. and ADMA Bio Centers Georgia Inc.
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	10.17
<FONT STYLE="FONT-SIZE: 10PT">
	(5)
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	Equity Rights Letter, dated December 21, 2012, from ADMA Biologics, Inc. to Hercules Technology Growth Capital, Inc.
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	10.18+
<FONT STYLE="FONT-SIZE: 10PT">
	(5)
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	Manufacturing, Supply and License Agreement, dated as of December 31, 2012, by and between Biotest Pharmaceuticals Corporation and ADMA Biologics, Inc.
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	10.19+
<FONT STYLE="FONT-SIZE: 10PT">
	(5)
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	License Agreement, effective as of December 31, 2012, by and between ADMA Biologics, Inc. and Biotest Aktiengesellschaft.
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	10.20 (16)
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	Master Purchase and Sale Agreement, dated as of January 21, 2017, by and among Biotest Pharmaceuticals Corporation, ADMA BioManufacturing, LLC, ADMA Biologics, Inc., Biotest AG and Biotest US Corporation.
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	10.21&dagger;
<SUP>
</SUP>
	(10)
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	ADMA Biologics, Inc. 2014 Omnibus Incentive Compensation Plan.
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	10.22*
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	Lease, effective as of February 17, 2017, by and between Home Center Properties, LLC and ADMA Bio Centers Georgia Inc.
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	21.1
<FONT STYLE="FONT-SIZE: 10PT">
	(4)
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	Subsidiaries of Registrant.
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	23.1*
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	CohnReznick LLP Consent.
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	24.1*
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	Power of Attorney (included on signature page).
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	31.1*
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	Certification of Principal Executive Officer pursuant to Rules 13a-14(a) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	31.2*
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	Certification of Principal Financial Officer pursuant to Rules 13a-14(a) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	32.1**
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	Certification of Principal Executive Officer pursuant to 18 U.S.C Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	32.2**
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	Certification of Principal Financial Officer pursuant to 18 U.S.C Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	101*
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	The following materials from ADMA Biologics, Inc. Form 10-K for the year ended December 31, 2016, formatted in Extensible Business Reporting Language (XBRL): (i) Consolidated Balance Sheets at December 31, 2016 and December 31, 2015, (ii) Consolidated Statements of Operations for the years ended December 31, 2016 and 2015 (iii) Consolidated Statements of Changes in Stockholders&rsquo; Equity for the years ended December 31, 2016 and 2015, (iv) Consolidated Statements of Cash Flows for the years ended December 31, 2016 and 2015 and (v) Notes to Consolidated Financial Statements.
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	+ Confidential treatment has been granted with respect as to
	certain portions of this exhibit.&nbsp;&nbsp;Such portions have been redacted and submitted separately to the SEC.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	# Portions of this exhibit (indicated by asterisks) have been
	omitted pursuant to a request for confidential treatment pursuant to Rule 24b-2 under the Securities Exchange Act of 1934.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	* Filed herewith.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	** Furnished herewith.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&dagger; Management compensatory plan, contract or arrangement.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 48PX">
	(1)
</TD>
<TD>
	Incorporated herein by reference to the Company&rsquo;s Current Report on Form 8-K, filed with the SEC on February 13, 2012.
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
</TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 48PX">
	(2)
</TD>
<TD>
	Incorporated herein by reference to Exhibit 3.1 to the Company&rsquo;s Current Report on Form 8-K , filed with the SEC on August 26, 2013.
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
</TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 48PX">
	(3)
</TD>
<TD>
	Incorporated herein by reference to Exhibit 3.1 to the Company&rsquo;s Current Report on Form 8-K, filed with the SEC on October 7, 2016.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 95 -->
<DIV STYLE="MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	27
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage96"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<P STYLE="MARGIN: 0PT; TEXT-ALIGN: RIGHT; FONT-SIZE: 8PT">
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
</P>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 48PX">
	(4)
</TD>
<TD>
	Incorporated herein by reference to Amendment No. 1 to the Company&rsquo;s Current Report on Form 8-K/A, filed with the SEC on March 29, 2012.
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
</TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 48PX">
	(5)
</TD>
<TD>
	Incorporated herein by reference to the Company&rsquo;s Registration Statement on Form S-1, filed with the SEC on February 11, 2013.
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
</TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 48PX">
	(6)
</TD>
<TD>
	Incorporated herein by reference to Exhibit A to the Information Statement on Schedule 14C, filed with the SEC on October 29, 2012.
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
</TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 48PX">
	(7)
</TD>
<TD>
	Incorporated herein by reference to Amendment No. 3 to the Company&rsquo;s Current Report on Form 8-K/A, filed with the SEC on June 22, 2012.
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
</TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 48PX">
	(8)
</TD>
<TD>
	Incorporated herein by reference to Exhibit 10.1 to the Company&rsquo;s Current Report on Form 8-K, filed with the SEC on June 21, 2012.
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
</TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 48PX">
	(9)
</TD>
<TD>
	Incorporated herein by reference to Amendment No. 4 to the Company&rsquo;s Registration Statement on Form S-1, filed with the SEC on August 10, 2012.
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
</TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 48PX">
	(10)
</TD>
<TD>
	Incorporated herein by reference to Appendix A to the Company&rsquo;s Definitive Proxy Statement filed with the SEC on April 29, 2014.
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
</TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 48PX">
	(11)
</TD>
<TD>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Incorporated by reference to the Company&rsquo;s annual report
	on Form 10-K, filed with the SEC on March 28, 2014.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
</P>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	(12)
</TD>
<TD>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Incorporated by reference to the Company&rsquo;s annual report
	on Form 10-K, filed with the SEC on March 23, 2016.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
</P>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	(13)
</TD>
<TD>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Incorporated by reference to the Company&rsquo;s Quarterly Report
	on Form 10-Q, filed with the SEC on May 13, 2016.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
</P>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	(14)
</TD>
<TD>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Incorporated by reference to Exhibit 10.23 to the Company&rsquo;s
	Quarterly Report on Form 10-Q, filed with the SEC on August 11, 2015.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
</P>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	(15)
</TD>
<TD>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Incorporated by reference to Exhibit 10.18 to the Company&rsquo;s
	Quarterly Report on Form 10-Q, filed with the SEC on August 12, 2016.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
</P>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	(16)
</TD>
<TD>
	Incorporated by reference to Exhibit 2.1 to the Company&rsquo;s Current Report on Form 8-K, filed with the SEC on January 23, 2017.
</TD>
</TR>
</TABLE>
</EFX_EXHIBIT_INDEX>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: RIGHT">
</P>
</EFX_FORM>

<DIV CLASS="eolNewPage"></DIV>
<A NAME="eolPage97"></A>
<A NAME="E615811_EX10-22_HTM"></A>
<EFX_EXHIBIT_10>
<A NAME="FIS_EXHIBIT_10"></A>
<P STYLE="MARGIN: 0">
	&nbsp;
</P>
<P STYLE="MARGIN: 0">
</P>
<!-- FIELD: RULE-PAGE -->
<DIV ALIGN="LEFT" STYLE="MARGIN-TOP: 1PT; MARGIN-BOTTOM: 1PT">
<DIV STYLE="FONT-SIZE: 0.75PT; BORDER-TOP: BLACK 0.75PT SOLID; BORDER-BOTTOM: BLACK 0.75PT SOLID; WIDTH: 100%">
	&nbsp;
</DIV>
</DIV>
<!-- FIELD: /RULE-PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	LEASE
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	166 EARNEST W. BARRETT PARKWAY
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	MARIETTA, GA 30066
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	KENNESAW MARKET
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	By and Between
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	HOME CENTER PROPERTIES, LLC,
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	a Georgia limited liability company
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	(&ldquo;Landlord&rdquo;)
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	and
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	ADMA BIO CENTERS GEORGIA INC.,
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	a Delaware corporation
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	(&ldquo;Tenant&rdquo;)
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	This 17th day of February 2017
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<!-- FIELD: RULE-PAGE -->
<DIV ALIGN="LEFT" STYLE="MARGIN-TOP: 1PT; MARGIN-BOTTOM: 1PT">
<DIV STYLE="FONT-SIZE: 0.75PT; BORDER-TOP: BLACK 0.75PT SOLID; BORDER-BOTTOM: BLACK 0.75PT SOLID; WIDTH: 100%">
	&nbsp;
</DIV>
</DIV>
<!-- FIELD: /RULE-PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
</P>
<!-- FIELD: PAGE; SEQUENCE: 1 -->
<DIV STYLE="MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
</P>
</DIV>
<A NAME="eolPage98"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<P STYLE="MARGIN: 0PT; TEXT-ALIGN: RIGHT; FONT-SIZE: 18PT">
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	&nbsp;
</B>
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	TABLE OF CONTENTS
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
<U>
	LEASE
</U>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD COLSPAN="3" STYLE="TEXT-ALIGN: CENTER">
<B>
	ARTICLE
	I
</B>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD COLSPAN="3" STYLE="TEXT-ALIGN: CENTER">
<B>
<U>
	EXHIBITS,
	PREMISES, USE OF PREMISES AND TERM
</U>
</B>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 10%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 60%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 5%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: RGB(204,238,255)">
<TD>
	Section 1.1
</TD>
<TD STYLE="TEXT-DECORATION: UNDERLINE">
<U>
	Definitions
</U>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD>
	Section 1.2
</TD>
<TD STYLE="TEXT-DECORATION: UNDERLINE">
<U>
	Exhibits
</U>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	3
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: RGB(204,238,255)">
<TD>
	Section 1.3
</TD>
<TD STYLE="TEXT-DECORATION: UNDERLINE">
<U>
	Covenants of Landlord&rsquo;s Authority
</U>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	3
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD>
	Section 1.4
</TD>
<TD STYLE="TEXT-DECORATION: UNDERLINE">
<U>
	Premises Leased by Tenant
</U>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	3
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: RGB(204,238,255)">
<TD>
	Section 1.5
</TD>
<TD STYLE="TEXT-DECORATION: UNDERLINE">
<U>
	Use of Premises
</U>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	3
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD>
	Section 1.6
</TD>
<TD STYLE="TEXT-DECORATION: UNDERLINE">
<U>
	Lease Term
</U>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	3
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: RGB(204,238,255)">
<TD>
	Section 1.7
</TD>
<TD STYLE="TEXT-DECORATION: UNDERLINE">
<U>
	Rent Commencement Date
</U>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	3
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD>
	Section 1.8
</TD>
<TD STYLE="TEXT-DECORATION: UNDERLINE">
<U>
	Lease Year
</U>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	4
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: RGB(204,238,255)">
<TD>
	Section 1.9
</TD>
<TD STYLE="TEXT-DECORATION: UNDERLINE">
<U>
	Acceptance of Possession of Premises
</U>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	4
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD COLSPAN="3" STYLE="TEXT-ALIGN: CENTER">
<B>
	ARTICLE
	II
</B>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD COLSPAN="3" STYLE="TEXT-ALIGN: CENTER">
<B>
<U>
	RENT
</U>
</B>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: RGB(204,238,255)">
<TD>
	Section 2.1
</TD>
<TD STYLE="TEXT-DECORATION: UNDERLINE">
<U>
	Fixed Minimum Rent
</U>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	4
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD>
	Section 2.2
</TD>
<TD STYLE="TEXT-DECORATION: UNDERLINE">
<U>
	Late Payment Fee
</U>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	4
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: RGB(204,238,255)">
<TD>
	Section 2.3
</TD>
<TD STYLE="TEXT-DECORATION: UNDERLINE">
<U>
	Additional Rent - Definition
</U>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	4
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD>
	Section 2.4
</TD>
<TD STYLE="TEXT-DECORATION: UNDERLINE">
<U>
	Percentage Rent
</U>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	5
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: RGB(204,238,255)">
<TD>
	Section 2.5
</TD>
<TD STYLE="TEXT-DECORATION: UNDERLINE">
<U>
	&ldquo;Gross Sales&rdquo; Defined
</U>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	5
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD>
	Section 2.6
</TD>
<TD STYLE="TEXT-DECORATION: UNDERLINE">
<U>
	Statements of Gross Sales
</U>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	5
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: RGB(204,238,255)">
<TD>
	Section 2.7
</TD>
<TD STYLE="TEXT-DECORATION: UNDERLINE">
<U>
	Tenant&rsquo;s Gross Sales Records
</U>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	5
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD COLSPAN="3" STYLE="TEXT-ALIGN: CENTER">
<B>
	ARTICLE
	III
</B>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD COLSPAN="3" STYLE="TEXT-ALIGN: CENTER">
<B>
<U>
	COMMON
	AREAS AND FACILITIES
</U>
</B>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: RGB(204,238,255)">
<TD>
	Section 3.1
</TD>
<TD STYLE="TEXT-DECORATION: UNDERLINE">
<U>
	Common Area
</U>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	5
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD>
	Section 3.2
</TD>
<TD STYLE="TEXT-DECORATION: UNDERLINE">
<U>
	Use of Common Area
</U>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	5
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: RGB(204,238,255)">
<TD>
	Section 3.3
</TD>
<TD STYLE="TEXT-DECORATION: UNDERLINE">
<U>
	Tenant to Share Expense of Common Areas
</U>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	5
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD>
	Section 3.4
</TD>
<TD STYLE="TEXT-DECORATION: UNDERLINE">
<U>
	Landlord&rsquo;s Operating Costs
</U>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	6
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD COLSPAN="3" STYLE="TEXT-ALIGN: CENTER">
<B>
	ARTICLE
	IV
</B>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD COLSPAN="3" STYLE="TEXT-ALIGN: CENTER">
<B>
<U>
	UTILITY
	SERVICES
</U>
</B>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: RGB(204,238,255)">
<TD>
	Section 4.1
</TD>
<TD STYLE="TEXT-DECORATION: UNDERLINE">
<U>
	Utilities
</U>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	6
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD COLSPAN="3" STYLE="TEXT-ALIGN: CENTER">
<B>
	ARTICLE
	V
</B>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD COLSPAN="3" STYLE="TEXT-ALIGN: CENTER">
<B>
<U>
	TAXES
</U>
</B>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: RGB(204,238,255)">
<TD>
	Section 5.1
</TD>
<TD STYLE="TEXT-DECORATION: UNDERLINE">
<U>
	Tenant&rsquo;s Taxes
</U>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	7
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD>
	Section 5.2
</TD>
<TD STYLE="TEXT-DECORATION: UNDERLINE">
<U>
	Tenant&rsquo;s Participation in Real Estate Taxes
</U>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	7
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 2 -->
<DIV STYLE="MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
	-
<!-- FIELD: SEQUENCE; TYPE: LOWERROMAN; NAME: PAGENO -->
	i
<!-- FIELD: /SEQUENCE -->
	-
</P>
</DIV>
<A NAME="eolPage99"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<P STYLE="MARGIN: 0PT; TEXT-ALIGN: RIGHT; FONT-SIZE: 18PT">
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD COLSPAN="3" STYLE="TEXT-ALIGN: CENTER">
<B>
	ARTICLE
	VI
</B>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD COLSPAN="3" STYLE="TEXT-ALIGN: CENTER">
<B>
<U>
	REPAIRS
	AND MAINTENANCE
</U>
</B>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 10%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 60%">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; WIDTH: 5%">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: RGB(204,238,255)">
<TD>
	Section 6.1
</TD>
<TD STYLE="TEXT-DECORATION: UNDERLINE">
<U>
	Repairs by Landlord
</U>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	8
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD>
	Section 6.2
</TD>
<TD STYLE="TEXT-DECORATION: UNDERLINE">
<U>
	Repairs and Maintenance by Tenant
</U>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	8
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: RGB(204,238,255)">
<TD>
	Section 6.3
</TD>
<TD STYLE="TEXT-DECORATION: UNDERLINE">
<U>
	Right of Entry
</U>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	9
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD>
	Section 6.4
</TD>
<TD STYLE="TEXT-DECORATION: UNDERLINE">
<U>
	Sidewalks and Outside Areas
</U>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	9
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: RGB(204,238,255)">
<TD>
	Section 6.5
</TD>
<TD STYLE="TEXT-DECORATION: UNDERLINE">
<U>
	Replacement of Glass
</U>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	9
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD COLSPAN="3" STYLE="TEXT-ALIGN: CENTER">
<B>
	ARTICLE
	VII
</B>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD COLSPAN="3" STYLE="TEXT-ALIGN: CENTER">
<B>
<U>
	RESTRICTIONS
	ON USE OF PREMISES
</U>
</B>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD>
	Section 7.1
</TD>
<TD STYLE="TEXT-DECORATION: UNDERLINE">
<U>
	Restrictions on Use of Premises
</U>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	9
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: RGB(204,238,255)">
<TD>
	Section 7.2
</TD>
<TD STYLE="TEXT-DECORATION: UNDERLINE">
<U>
	Tenant&rsquo;s Normal Business Operation
</U>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	9
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD>
	Section 7.3
</TD>
<TD STYLE="TEXT-DECORATION: UNDERLINE">
<U>
	Retail Restriction Limit
</U>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	10
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: RGB(204,238,255)">
<TD>
	Section 7.4
</TD>
<TD STYLE="TEXT-DECORATION: UNDERLINE">
<U>
	Rules and Regulations
</U>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	10
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD COLSPAN="3" STYLE="TEXT-ALIGN: CENTER">
<B>
	ARTICLE
	VIII
</B>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD COLSPAN="3" STYLE="TEXT-ALIGN: CENTER">
<B>
<U>
	ADDITIONS,
	ALTERATIONS, REPLACEMENTS AND TRADE FIXTURES
</U>
</B>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: RGB(204,238,255)">
<TD>
	Section 8.1
</TD>
<TD STYLE="TEXT-DECORATION: UNDERLINE">
<U>
	By Landlord
</U>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	10
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD>
	Section 8.2
</TD>
<TD STYLE="TEXT-DECORATION: UNDERLINE">
<U>
	By Tenant
</U>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	10
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: RGB(204,238,255)">
<TD>
	Section 8.3
</TD>
<TD STYLE="TEXT-DECORATION: UNDERLINE">
<U>
	Construction Insurance and Indemnity
</U>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	11
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD>
	Section 8.4
</TD>
<TD STYLE="TEXT-DECORATION: UNDERLINE">
<U>
	Mechanic&rsquo;s Liens and Additional Construction
</U>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	11
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: RGB(204,238,255)">
<TD>
	Section 8.5
</TD>
<TD STYLE="TEXT-DECORATION: UNDERLINE">
<U>
	Trade Fixtures
</U>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	11
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD COLSPAN="3" STYLE="TEXT-ALIGN: CENTER">
<B>
	ARTICLE
	IX
</B>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD COLSPAN="3" STYLE="TEXT-ALIGN: CENTER">
<B>
<U>
	INSURANCE
	AND INDEMNITY
</U>
</B>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: RGB(204,238,255)">
<TD>
	Section 9.1
</TD>
<TD STYLE="TEXT-DECORATION: UNDERLINE">
<U>
	Tenant&rsquo;s Insurance
</U>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	12
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD>
	Section 9.2
</TD>
<TD STYLE="TEXT-DECORATION: UNDERLINE">
<U>
	Extra Hazard Insurance Premiums
</U>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	12
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: RGB(204,238,255)">
<TD>
	Section 9.3
</TD>
<TD STYLE="TEXT-DECORATION: UNDERLINE">
<U>
	Indemnity
</U>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	12
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD>
	Section 9.4
</TD>
<TD STYLE="TEXT-DECORATION: UNDERLINE">
<U>
	Tenant&rsquo;s Participation in Insurance
</U>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	13
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: RGB(204,238,255)">
<TD>
	Section 9.5
</TD>
<TD STYLE="TEXT-DECORATION: UNDERLINE">
<U>
	Mutual Waiver of Claims and Subrogation
</U>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	13
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD COLSPAN="3" STYLE="TEXT-ALIGN: CENTER">
<B>
	ARTICLE
	X
</B>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD COLSPAN="3" STYLE="TEXT-ALIGN: CENTER">
<B>
<U>
	DAMAGE
	OR DESTRUCTION BY FIRE OR OTHER CASUALTY AND CONDEMNATION
</U>
</B>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: RGB(204,238,255)">
<TD>
	Section 10.1
</TD>
<TD STYLE="TEXT-DECORATION: UNDERLINE">
<U>
	Damage or Destruction by Fire or Other Casualty
</U>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	14
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD>
	Section 10.2
</TD>
<TD STYLE="TEXT-DECORATION: UNDERLINE">
<U>
	Condemnation
</U>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	14
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD COLSPAN="3" STYLE="TEXT-ALIGN: CENTER">
<B>
	ARTICLE XI
</B>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD COLSPAN="3" STYLE="TEXT-ALIGN: CENTER">
<B>
<U>
	DEFAULT AND REMEDIES
</U>
</B>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: RGB(204,238,255)">
<TD>
	Section 11.1
</TD>
<TD STYLE="TEXT-DECORATION: UNDERLINE">
<U>
	Default
</U>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	15
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD>
	Section 11.2
</TD>
<TD STYLE="TEXT-DECORATION: UNDERLINE">
<U>
	Remedies
</U>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	15
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD COLSPAN="3" STYLE="TEXT-ALIGN: CENTER">
<B>
	ARTICLE
	XII
</B>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD COLSPAN="3" STYLE="TEXT-ALIGN: CENTER">
<B>
<U>
	SECURITY
	DEPOSIT
</U>
</B>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: RGB(204,238,255)">
<TD>
	Section 12.1
</TD>
<TD STYLE="TEXT-DECORATION: UNDERLINE">
<U>
	Security Deposit
</U>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	17
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 3 -->
<DIV STYLE="MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
	-
<!-- FIELD: SEQUENCE; TYPE: LOWERROMAN; NAME: PAGENO -->
	ii
<!-- FIELD: /SEQUENCE -->
	-
</P>
</DIV>
<A NAME="eolPage100"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<P STYLE="MARGIN: 0PT; TEXT-ALIGN: RIGHT; FONT-SIZE: 18PT">
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD COLSPAN="2" STYLE="TEXT-ALIGN: CENTER">
<B>
	ARTICLE
	XIII
</B>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD COLSPAN="2" STYLE="TEXT-ALIGN: CENTER">
<B>
<U>
	ADDITIONAL
	TENANT AGREEMENTS
</U>
</B>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 10%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 60%">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; WIDTH: 5%">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: RGB(204,238,255)">
<TD>
	Section 13.1
</TD>
<TD STYLE="TEXT-DECORATION: UNDERLINE">
<U>
	Mortgage Financing, Subordination and Attornment
</U>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	17
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD>
	Section 13.2
</TD>
<TD STYLE="TEXT-DECORATION: UNDERLINE">
<U>
	Assignment or Subletting
</U>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	18
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: RGB(204,238,255)">
<TD>
	Section 13.3
</TD>
<TD STYLE="TEXT-DECORATION: UNDERLINE">
<U>
	Tenant&rsquo;s Notice to Landlord of Default
</U>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	18
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD>
	Section 13.4
</TD>
<TD STYLE="TEXT-DECORATION: UNDERLINE">
<U>
	No Recording of Lease
</U>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	18
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: RGB(204,238,255)">
<TD>
	Section 13.5
</TD>
<TD STYLE="TEXT-DECORATION: UNDERLINE">
<U>
	Surrender of Premises and Holding Over
</U>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	18
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD>
	Section 13.6
</TD>
<TD STYLE="TEXT-DECORATION: UNDERLINE">
<U>
	Estoppel Certificate
</U>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	19
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: RGB(204,238,255)">
<TD>
	Section 13.7
</TD>
<TD STYLE="TEXT-DECORATION: UNDERLINE">
<U>
	Compliance with Law, Waste and Quiet Enjoyment
</U>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	19
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD>
	Section 13.8
</TD>
<TD STYLE="TEXT-DECORATION: UNDERLINE">
<U>
	Abandonment
</U>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	19
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: RGB(204,238,255)">
<TD>
	Section 13.9
</TD>
<TD STYLE="TEXT-DECORATION: UNDERLINE">
<U>
	Relocation
</U>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	19
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD COLSPAN="3" STYLE="TEXT-ALIGN: CENTER">
<B>
	ARTICLE
	XIV
</B>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD COLSPAN="3" STYLE="TEXT-ALIGN: CENTER">
<B>
<U>
	MISCELLANEOUS
	PROVISIONS
</U>
</B>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: RGB(204,238,255)">
<TD>
	Section 14.1
</TD>
<TD STYLE="TEXT-DECORATION: UNDERLINE">
<U>
	Notices
</U>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	19
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD>
	Section 14.2
</TD>
<TD STYLE="TEXT-DECORATION: UNDERLINE">
<U>
	Entire and Binding Agreement
</U>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	19
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: RGB(204,238,255)">
<TD>
	Section 14.3
</TD>
<TD STYLE="TEXT-DECORATION: UNDERLINE">
<U>
	Provisions Severable
</U>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	20
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD>
	Section 14.4
</TD>
<TD STYLE="TEXT-DECORATION: UNDERLINE">
<U>
	Captions
</U>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	20
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: RGB(204,238,255)">
<TD>
	Section 14.5
</TD>
<TD STYLE="TEXT-DECORATION: UNDERLINE">
<U>
	Relationship of the Parties
</U>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	20
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD>
	Section 14.6
</TD>
<TD STYLE="TEXT-DECORATION: UNDERLINE">
<U>
	Accord and Satisfaction
</U>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	20
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: RGB(204,238,255)">
<TD>
	Section 14.7
</TD>
<TD STYLE="TEXT-DECORATION: UNDERLINE">
<U>
	Broker&rsquo;s Commission
</U>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	20
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD>
	Section 14.8
</TD>
<TD STYLE="TEXT-DECORATION: UNDERLINE">
<U>
	Corporate Status
</U>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	20
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: RGB(204,238,255)">
<TD>
	Section 14.9
</TD>
<TD STYLE="TEXT-DECORATION: UNDERLINE">
<U>
	Hazardous Substances
</U>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	20
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD>
	Section 14.10
</TD>
<TD STYLE="TEXT-DECORATION: UNDERLINE">
<U>
	Inability to Perform
</U>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	22
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: RGB(204,238,255)">
<TD>
	Section 14.11
</TD>
<TD STYLE="TEXT-DECORATION: UNDERLINE">
<U>
	Joint and Several Liability
</U>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	22
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD>
	Section 14.12
</TD>
<TD STYLE="TEXT-DECORATION: UNDERLINE">
<U>
	Time of the Essence
</U>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	22
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: RGB(204,238,255)">
<TD>
	Section 14.13
</TD>
<TD STYLE="TEXT-DECORATION: UNDERLINE">
<U>
	Governing Law
</U>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	22
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD>
	Section 14.14
</TD>
<TD STYLE="TEXT-DECORATION: UNDERLINE">
<U>
	Attorney&rsquo;s Fees
</U>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	22
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: RGB(204,238,255)">
<TD>
	Section 14.15
</TD>
<TD STYLE="TEXT-DECORATION: UNDERLINE">
<U>
	Signage
</U>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	23
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD>
	Section 14.16
</TD>
<TD STYLE="TEXT-DECORATION: UNDERLINE">
<U>
	No Offer
</U>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	23
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: RGB(204,238,255)">
<TD>
	Section 14.17
</TD>
<TD STYLE="TEXT-DECORATION: UNDERLINE">
<U>
	Tenant&rsquo;s Representation
</U>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	23
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD>
	Section 14.18
</TD>
<TD STYLE="TEXT-DECORATION: UNDERLINE">
<U>
	Landlord&rsquo;s Representation
</U>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	24
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: RGB(204,238,255)">
<TD>
	Section 14.19
</TD>
<TD STYLE="TEXT-DECORATION: UNDERLINE">
<U>
	Pro Rata Share
</U>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	24
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD>
	Section 14.20
</TD>
<TD STYLE="TEXT-DECORATION: UNDERLINE">
<U>
	Tenant&rsquo;s Financial Records
</U>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	24
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: RGB(204,238,255)">
<TD>
	Section 14.21
</TD>
<TD STYLE="TEXT-DECORATION: UNDERLINE">
<U>
	Pest Control
</U>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	24
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD>
	Section 14.22
</TD>
<TD STYLE="TEXT-DECORATION: UNDERLINE">
<U>
	Confidentiality
</U>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	24
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: RGB(204,238,255)">
<TD>
	Section 14.23
</TD>
<TD STYLE="TEXT-DECORATION: UNDERLINE">
<U>
	Mold
</U>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	24
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD>
	Section 14.24
</TD>
<TD STYLE="TEXT-DECORATION: UNDERLINE">
<U>
	Anti-Terrorism Representation and Warranty
</U>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	24
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: RGB(204,238,255)">
<TD>
	Section 14.25
</TD>
<TD STYLE="TEXT-DECORATION: UNDERLINE">
<U>
	Limitation on Right of Recovery Against Landlord
</U>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	25
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-RIGHT: 0; MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-RIGHT: 0; MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT">
</P>
<!-- FIELD: PAGE; SEQUENCE: 4 -->
<DIV STYLE="MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
	-
<!-- FIELD: SEQUENCE; TYPE: LOWERROMAN; NAME: PAGENO -->
	iii
<!-- FIELD: /SEQUENCE -->
	-
</P>
</DIV>
<A NAME="eolPage101"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<P STYLE="MARGIN: 0PT; TEXT-ALIGN: RIGHT; FONT-SIZE: 18PT">
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-RIGHT: 0; MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT">
	&nbsp;&nbsp;&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-RIGHT: 0; MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT">
<B>
<IMG SRC="http://content.edgar-online.com/edgar_conv_img/2017/02/24/0001193805-17-000330_PIC1.JPG" ALT="">
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	&nbsp;&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	LEASE
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	THIS LEASE, made and
	entered into as of this 17
<SUP>
	th
</SUP>
	day of February 2017 (the &ldquo;Effective Date&rdquo;), by and between Landlord and Tenant
	as specified in Items 1 and 2 of the Definitions appearing in Section 1.1 hereof.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Landlord hereby demises and rents unto
	Tenant, and Tenant hereby leases from Landlord, certain Premises, as described in Item 3 of the Definitions appearing in Section
	1.1 hereof, and upon the terms, covenants and conditions contained herein. It is the express intent of the parties that a landlord/tenant
	relationship is established by this Lease, that Tenant has a usufruct pursuant to this Lease, and that no estate for years or other
	estate shall pass out of Landlord as a result of this Lease.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_18"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	ARTICLE I
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
<U>
	EXHIBITS, PREMISES, USE OF PREMISES
	AND TERM
</U>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	Section 1.1 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>
	Definitions
</U>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	The following Items shall be defined or be referred to as indicated
	below for the purposes of this Lease and the Exhibits attached hereto:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" ALIGN="CENTER" STYLE="WIDTH: 95%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 10%">
<FONT STYLE="FONT-SIZE: 10PT">
	Item 1 -
</FONT>
</TD>
<TD STYLE="WIDTH: 40%">
<FONT STYLE="FONT-SIZE: 10PT">
	Landlord:
</FONT>
</TD>
<TD STYLE="WIDTH: 50%">
<FONT STYLE="FONT-SIZE: 10PT">
	HOME CENTER PROPERTIES, LLC, a Georgia limited liability company
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Item 2 -
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Tenant:
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	ADMA BIO CENTERS GEORGIA INC., a Delaware corporation
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Item 3 -
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Premises (Section 1.4):
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	166 EARNEST W. BARRETT PARKWAY MARIETTA, GA&nbsp;&nbsp;30066
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	:
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	166 EARNEST W. BARRETT PARKWAY MARIETTA, GA&nbsp;&nbsp;30066
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	comprising the entirety of that certain building containing approximately 12,167 square feet, together with the use of the driveways, parking spaces, entranceways and exits included within the red boundary line shown on the Site Plan attached hereto as Exhibit &quot;B-1&quot; (collectively, &quot;Tenant's Parking&quot;).
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Item 4 -
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Use of Premises (Section 1.5):
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	The Premises shall be utilized as a facility specializing in the collection of human plasma or blood used to make special medications for the treatment and prevention of diseases, general office administration and any other related use.
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Item 5 -
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Tenant&rsquo;s Trade Name:
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	ADMA BIO CENTERS GEORGIA INC.
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Item 6 -
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Lease Term (Section 1.6):
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	EIGHT (8) YEARS, NINE (9) MONTHS
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Item 7 -
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Lease Commencement Date (Section 1.6):
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	The Lease shall commence upon substantial completion of Landlord&rsquo;s Work (as described on Exhibit &quot;B-4&quot; attached hereto).
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Lease Expiration Date (Section 1.6):
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Upon the expiration of one hundred five (105) months after the Lease Commencement Date.
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Item 8 -
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Rent Commencement Date (Section 1.7):
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Upon the expiration of one hundred fifty (150) days after the Lease Commencement Date.
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Item 9 -
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Fixed Minimum Rent (Section 2.1):
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	SEE EXHIBIT &ldquo;A&rdquo; ATTACHED HERETO
</FONT>
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 5; OPTIONS: NEWSECTION -->
<DIV STYLE="MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
	-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	1
<!-- FIELD: /SEQUENCE -->
	-
</P>
</DIV>
<A NAME="eolPage102"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<P STYLE="MARGIN: 0PT; TEXT-ALIGN: RIGHT; FONT-SIZE: 18PT">
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" ALIGN="CENTER" STYLE="WIDTH: 95%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<EFX_UNIDENTIFIED_TABLE>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<A NAME="FIS_UNIDENTIFIED_TABLE_19"></A>
<FONT STYLE="FONT-SIZE: 10PT">
	Item 10 -
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Percentage Rent:
</FONT>
</TD>
<TD COLSPAN="3">
<FONT STYLE="FONT-SIZE: 10PT">
	N/A
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="3">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 10%">
<FONT STYLE="FONT-SIZE: 10PT">
	Item 11 -
</FONT>
</TD>
<TD STYLE="WIDTH: 40%">
<FONT STYLE="FONT-SIZE: 10PT">
	Tenant&rsquo;s Participation in
</FONT>
</TD>
<TD STYLE="WIDTH: 2%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 2%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 46%">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Operating Costs (Section 3.4):
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Estimated Landlord&rsquo;s Operating
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Costs for Year 2017:
</FONT>
</TD>
<TD COLSPAN="3">
<FONT STYLE="FONT-SIZE: 10PT">
	$1,238.09 per month
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="3">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Item 12 -
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Tenant&rsquo;s Participation in Insurance
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	(Section 9.4):
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Estimated Insurance Charge for Year 2017:
</FONT>
</TD>
<TD COLSPAN="3">
<FONT STYLE="FONT-SIZE: 10PT">
	$112.00 per month
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="3">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Item 13 -
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Participation in Promotional Programs:
</FONT>
</TD>
<TD COLSPAN="3">
<FONT STYLE="FONT-SIZE: 10PT">
	N/A
</FONT>
</TD>
</TR>
</EFX_UNIDENTIFIED_TABLE>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="3">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Item 14 -
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Tenant&rsquo;s Participation in Real Estate
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Taxes (Section 5.2):
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Estimated Tax Charge for Year 2017:
</FONT>
</TD>
<TD COLSPAN="3">
<FONT STYLE="FONT-SIZE: 10PT">
	$1,632.00 per month
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="3">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Item 15 -
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Amounts Due from Tenant at Lease Execution:
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	$20,282.09&nbsp;&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	-&nbsp;&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Initial Monthly Charges (to be applied to the Fixed Minimum Rent, Landlord&rsquo;s Operating Costs, Taxes, and Insurance charges for the first month rent is due hereunder).
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Item 16 -
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Notices (Section 14.1):
</FONT>
</TD>
<TD COLSPAN="3" STYLE="TEXT-DECORATION: UNDERLINE">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
<U>
	TENANT:
</U>
</B>
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="3">
<FONT STYLE="FONT-SIZE: 10PT">
	ADMA BIO CENTERS GEORGIA INC.
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="3">
<FONT STYLE="FONT-SIZE: 10PT">
	166 EARNEST W. BARRETT PARKWAY
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="3">
<FONT STYLE="FONT-SIZE: 10PT">
	MARIETTA, GA&nbsp;&nbsp;30066
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="3">
<FONT STYLE="FONT-SIZE: 10PT">
	ATTENTION:&nbsp;&nbsp;Center Director
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="3">
<FONT STYLE="FONT-SIZE: 10PT; TEXT-TRANSFORM: UPPERCASE">
	Telephone
</FONT>
<FONT STYLE="FONT-SIZE: 10PT">
	: (678) 495-5803
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="3">
<FONT STYLE="FONT-SIZE: 10PT">
	EMAIL:&nbsp;&nbsp;ctolman@admabio.com
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="3">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="TEXT-DECORATION: UNDERLINE">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
<U>
	WITH A COPY TO
</U>
	:
</B>
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="3">
<FONT STYLE="FONT-SIZE: 10PT">
	ADMA Biologics Inc.
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="3">
<FONT STYLE="FONT-SIZE: 10PT">
	465 Route 17 South
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="3">
<FONT STYLE="FONT-SIZE: 10PT">
	Ramsey, NJ 07446
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="3">
<FONT STYLE="FONT-SIZE: 10PT">
	ATTENTION:&nbsp;&nbsp;Brian Lenz
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="3">
<FONT STYLE="FONT-SIZE: 10PT; TEXT-TRANSFORM: UPPERCASE">
	Telephone
</FONT>
<FONT STYLE="FONT-SIZE: 10PT">
	: 201-478-5552
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="3">
<FONT STYLE="FONT-SIZE: 10PT">
	EMAIL:&nbsp;&nbsp;blenz@admabio.com
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="3">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="TEXT-DECORATION: UNDERLINE">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
<U>
	LANDLORD:
</U>
</B>
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="3">
<FONT STYLE="FONT-SIZE: 10PT">
	HOME CENTER PROPERTIES, LLC
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="3">
<FONT STYLE="FONT-SIZE: 10PT">
	780 OLD ROSWELL PLACE
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="3">
<FONT STYLE="FONT-SIZE: 10PT">
	SUITE 100
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="3">
<FONT STYLE="FONT-SIZE: 10PT">
	ROSWELL, GA&nbsp;&nbsp;30076
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="3">
<FONT STYLE="FONT-SIZE: 10PT">
	TELEPHONE: (770) 518-2200
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="3">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-INDENT: 0IN">
	Item 17
</TD>
<TD STYLE="TEXT-INDENT: 0IN">
	Special Provisions:
</TD>
<TD COLSPAN="3" STYLE="TEXT-INDENT: 0IN">
	SEE SPECIAL STIPULATIONS ATTACHED HERETO AS EXHIBIT &ldquo;A&rdquo;.
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 279PT; TEXT-INDENT: -279PT">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-RIGHT: 0; MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 279PT; TEXT-INDENT: -279PT">
<B>
	&nbsp;
</B>
</P>
<!-- FIELD: PAGE; SEQUENCE: 6 -->
<DIV STYLE="MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
	-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	2
<!-- FIELD: /SEQUENCE -->
	-
</P>
</DIV>
<A NAME="eolPage103"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<P STYLE="MARGIN: 0PT; TEXT-ALIGN: RIGHT; FONT-SIZE: 18PT">
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 279PT">
<B>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 279PT; TEXT-INDENT: -279PT">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 279PT; TEXT-INDENT: -279PT">
<B>
	Section 1.2 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>
	Exhibits
</U>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 279PT; TEXT-INDENT: -279PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	The exhibits listed hereunder and attached to this Lease are
	incorporated and made a part hereof by reference:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<B>
	EXHIBIT &ldquo;A&rdquo; &#9;&ndash; &#9;SPECIAL STIPULATIONS
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<B>
	EXHIBIT &ldquo;B-1&rdquo; &#9;&ndash; &#9;SITE PLAN
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<B>
	EXHIBIT &ldquo;B-2&rdquo; &#9;&ndash; &#9;EXISTING FLOOR
	PLAN
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<B>
	EXHIBIT &ldquo;B-3&rdquo; &#9;&ndash; &#9;PROPOSED FLOOR
	PLAN
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<B>
	EXHIBIT &ldquo;B-4&rdquo; &#9;&ndash; &#9;LANDLORD&rsquo;S
	WORK
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<B>
	EXHIBIT &ldquo;B-5&rdquo; &#9;&ndash; &#9;PYLON SIGNAGE
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<B>
	EXHIBIT &ldquo;C&rdquo; &#9;&ndash; &#9;RULES AND REGULATIONS
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<B>
	EXHIBIT &quot;D&quot; -- LEASE COMMENCEMENT
	DATE LETTER
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<B>
	EXHIBIT &quot;E&quot; --&#9;TENANT'S SIGN PACKAGE
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<B>
	EXHIBIT &quot;F&quot; --&#9;BUILDING ENVELOPE ASSESSMENT
	REPORT
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	Section 1.3 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>
	Covenants of Landlord&rsquo;s Authority
</U>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Landlord represents and covenants that:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 27.35PT">
	a)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	prior to commencement of the Lease Term, it will have good title to or a valid leasehold interest
	in the land and building of which the Premises form a part; and
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 27PT">
	b)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	upon performing all of its obligations hereunder, Tenant shall peacefully and quietly have, hold
	and enjoy the Premises for the Term of this Lease, subject, however, to matters of record.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	Section 1.4 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>
	Premises Leased by Tenant
</U>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	The Premises leased by Tenant are located
	at the address set forth in Item 3 of the Definitions, which Premises are particularly described in Item 3 of the Definitions.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	The boundaries and location of the Premises
	are highlighted on the Site Plan diagram attached hereto as Exhibit &ldquo;B-1&rdquo; and the Existing Floor Plan of the Premises,
	attached hereto as Exhibit &ldquo;B-2&rdquo;, which set forth the general layout of the Premises, respectively, as of the Effective
	Date of this Lease, but neither Exhibit &ldquo;B-1&rdquo; or Exhibit &ldquo;B-2&rdquo; shall be deemed to be a warranty, representation,
	or agreement upon the part of the Landlord that said Premises will be exactly as indicated on said diagram.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	The Premises shall extend to the exterior
	faces of all walls, and shall include the appurtenances specifically granted in this Lease, but reserving and excepting to Landlord
	the use of the exterior walls and the roof and the right to install, maintain, use, repair, and replace pipes, ducts, conduits,
	and wires leading through the Premises in locations which will not materially interfere with Tenant&rsquo;s use thereof.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Consistent with Section 3.2 hereof, Tenant
	shall have the non-exclusive use of the driveways, parking spaces, entranceways, exits, and all Common Areas of the Premises for
	its employees, agents, customers, suppliers, or invitees, so long as such use shall not unreasonably interfere with the use of
	such areas by Landlord.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	Section 1.5 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>
	Use of Premises
</U>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 27PT">
	a)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Tenant shall use the Premises solely for the purpose specified in Item 4 of the Definitions.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 27PT">
	b)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Tenant shall operate its business in the Premises pursuant to Section 7.1 hereof under the trade
	name as specified in Item 5 of the Definitions.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	Section 1.6 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>
	Lease Term
</U>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	The term of this Lease shall be for the
	period specified in Item 6 of the Definitions commencing and expiring as provided in Item 7 of the Definitions, unless sooner terminated
	or extended as hereinafter provided (hereinafter referred to as the &ldquo;Term&rdquo;). If the Lease commences on any day other
	than the first day of a calendar month, the Term shall be extended by that part of one month necessary to cause the Lease Expiration
	Date to be on the last day of a calendar month.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	Section 1.7 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>
	Rent Commencement
	Date
</U>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Tenant shall commence payment of rent at
	the date specified in Item 8 of the Definitions. If the Rent Commencement Date falls on a day other than the first day of a calendar
	month, the Fixed Minimum Rent for such month shall be prorated on a per diem basis, calculated on the basis of a thirty (30) day
	month. The Rent Commencement Date shall automatically be extended if the Lease Commencement Date is extended pursuant to the provisions
	of Exhibit &quot;B-4&quot; attached hereto. Within ten (10) business days of the Lease Commencement Date, Landlord and Tenant shall
	execute a Lease Commencement Date Letter substantially in the same form as attached hereto and incorporated herein as Exhibit &quot;D&quot;,
	acknowledging the Lease Commencement Date and the Rent Commencement Date of this Lease.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
</P>
<!-- FIELD: PAGE; SEQUENCE: 7 -->
<DIV STYLE="MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
	-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	3
<!-- FIELD: /SEQUENCE -->
	-
</P>
</DIV>
<A NAME="eolPage104"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<P STYLE="MARGIN: 0PT; TEXT-ALIGN: RIGHT; FONT-SIZE: 18PT">
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	Section 1.8 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>
	Lease Year
</U>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	For purpose of this Lease, the term Lease
	Year is defined to mean a calendar year (beginning January 1 and extending through December 31 of any given year). Any portion
	of a year which is less than a Lease Year, that is, from the Lease Commencement Date through the next December 31, and from the
	last January 1 falling within the Term of the Lease through the last day of the Term, shall be defined as a Partial Lease Year.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	Section 1.9 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>
	Acceptance
	of Possession of Premises
</U>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	On the Lease Commencement Date, Landlord
	shall grant and Tenant shall accept possession of the Premises described in the Lease in its present &ldquo;as is&rdquo; condition,
	with the exception of the work as described on Exhibit &ldquo;B-4&rdquo; (the &ldquo;Landlord&rsquo;s Work&rdquo;). With the Exception
	of the Landlord&rsquo;s Work, Landlord has made no agreements for any labor, materials or work to be performed by Landlord in or
	to the Premises. In the event Landlord is required to perform any improvements in the Premises prior to granting possession of
	same to Tenant, Landlord, at Landlord's expense, shall be responsible for obtaining all permits necessary to complete such improvements.
	Tenant acknowledges that except for work, which is to be performed by Landlord according to the terms and conditions of the Lease,
	the Tenant shall accept the balance and remainder of any portion of the Premises that Landlord is not required by this Lease to
	make improvements in or on its &ldquo;as is&rdquo; condition.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Subject to compliance with the term of
	this Lease, Tenant shall make all improvements to the Premises which Tenant is required to make for the preparation of Tenant&rsquo;s
	use of the Premises, as permitted hereunder. Tenant agrees and understands that it is Tenant&rsquo;s obligation to obtain or cause
	to be obtained: (i) any and all permits and approvals for any Tenant improvements from the applicable governmental agency with
	jurisdiction over the Premises; and (ii) Tenant&rsquo;s certificate of occupancy for the Premises.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	ARTICLE II&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
<U>
	RENT
</U>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	Section 2.1 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>
	Fixed Minimum Rent
</U>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	The total Fixed Minimum Rent for the Lease
	Term shall be payable by Tenant as specified in Item 9 of the Definitions and in the Special Stipulations attached hereto as Exhibit
	&ldquo;A&rdquo;.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	The Fixed Minimum Rent shall be payable
	monthly in advance on the first day of each month, without prior demand therefore and without any deduction or setoff whatsoever.
	In addition, Tenant covenants and agrees to pay Landlord all applicable sales or other taxes which may be imposed on the above
	specified rents or payments hereinafter provided for to be received by Landlord when each such payment is made. If Tenant pays
	any installment of Fixed Minimum Rent or any other sum by check and such check is returned for insufficient funds or other reasons
	not the fault of Landlord, then Tenant shall pay to Landlord on demand a service fee of $30.00 per returned check plus the amount
	of any fees charged to Landlord by a bank as a result of the check not being honored.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	Section 2.2 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>
	Late Payment Fee
</U>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Should Tenant fail to pay when due any
	installment of Fixed Minimum Rent or any other sum payable to Landlord under the terms of this Lease, then Landlord shall assess
	a servicing fee of Five Percent (5%) of any sum due to Landlord (the &quot;Late Payment Fee&quot;) from and after the tenth (10th)
	day following the date on which any sum shall be due and payable; provided, however, Landlord agrees to waive the Late Payment
	Fee once during any 12-month period provided that Tenant pays the amount due under this Lease within ten (10) days after receipt
	of written notice from Landlord. Tenant acknowledges and agrees that such late fee is intended as liquidated damages, and not as
	a penalty, to compensate Landlord for its costs of handling the late payment. Failure of Landlord to enforce the late payment fee
	shall not constitute a waiver of Landlord&rsquo;s right to assess said fee in the future and shall not constitute a waiver of any
	other rights Landlord may have at law or in equity.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	Section 2.3 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>
	Additional Rent -
	Definition
</U>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	In addition to the foregoing Fixed Minimum
	Rent, all payments to be made under this Lease by Tenant to Landlord shall be deemed to be and shall become Additional Rent hereunder
	and, together with Fixed Minimum Rent, shall be included in the term &ldquo;Rent&rdquo; whenever such term is used herein. Unless
	another time shall be herein expressly provided for the payment thereof, any Additional Rent shall be due and payable together
	with each installment of Fixed Minimum Rent, and Landlord shall have the same remedies for failure to pay Additional Rent as for
	non-payment of Fixed Minimum Rent. Subject to any notice and cure periods set forth in this Lease, Landlord, at its election, shall
	have the right to pay or do any act which requires the expenditure of any sums of money by reason of the failure or neglect of
	Tenant to perform any of the provisions of this Lease, and in the event Landlord elects to pay such sums or do such acts requiring
	the expenditure of monies, all such sums so paid by Landlord, together with interest thereon, shall be deemed to be Additional
	Rent and payable as such by Tenant to Landlord upon demand.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
</P>
<!-- FIELD: PAGE; SEQUENCE: 8 -->
<DIV STYLE="MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
	-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	4
<!-- FIELD: /SEQUENCE -->
	-
</P>
</DIV>
<A NAME="eolPage105"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<P STYLE="MARGIN: 0PT; TEXT-ALIGN: RIGHT; FONT-SIZE: 18PT">
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	&nbsp;Section
	2.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#9;
<U>
	Percentage
	Rent
</U>
	&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
	[INTENTIONALLY OMITTED]
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	Section
	2.5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#9;
<U>
	&ldquo;Gross
	Sales&rdquo; Defined
</U>
	&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
	[INTENTIONALLY OMITTED]
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	Section 2.6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#9;
<U>
	Statements of Gross
	Sales
</U>
	&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[INTENTIONALLY OMITTED]
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	Section 2.7&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#9;
<U>
	Tenant&rsquo;s Gross
	Sales Records
</U>
	&#9;&nbsp;&nbsp;&nbsp;[INTENTIONALLY OMITTED]
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; TEXT-ALIGN: CENTER">
<B>
	ARTICLE III
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; TEXT-ALIGN: CENTER">
<B>
<U>
	COMMON AREAS AND FACILITIES
</U>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	Section 3.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#9;
<U>
	Common Areas
</U>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Landlord shall make available for Tenant&rsquo;s
	non-exclusive use, exterior areas of the Premises designated for common use, including but not limited to, parking areas, driveways,
	pedestrian sidewalks, access and egress roads, landscaped and planted areas, and common exterior other facilities, serving the
	Premises (the &ldquo;Common Areas&rdquo;).
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Landlord shall operate, manage, light,
	repair and maintain said Common Areas for its intended purposes in such manner as Landlord, in its sole discretion, shall determine.
	Additionally, so long as Landlord does not materially and adversely affect Tenant&rsquo;s business operation on the Premises, or
	Tenant&rsquo;s ability to access and park on the Premises, Landlord reserves the right to change from time to time the size, location,
	nature and use of any Common Areas, to make additional installations therein and to move and remove the same, and Landlord shall
	not be subject to liability therefore nor shall Tenant be entitled to any compensation, or diminution or abatement of Rent, nor
	shall any such action be deemed an actual or constructive eviction of Tenant.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	Section 3.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#9;
<U>
	Use of Common Areas
</U>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	During the Term of this Lease, Tenant and
	its permitted concessionaires, officers, employees, agents, customers and invitees shall have the non-exclusive right, in common
	with Landlord and all others to whom Landlord has or may hereafter grant rights, to use the Common Areas as (defined in Section
	3.1 above), subject to such reasonable rules and regulations as Landlord may from time to time impose. Tenant agrees after notice
	thereof to abide by such rules and regulations and to use its best efforts to cause its permitted concessionaires, officers, employees,
	agents, customers and invitees to conform thereto. Landlord may at any time close temporarily any Common Areas to make repairs
	or changes to same and grant to third persons the non-exclusive right to cross over and use the Common Areas along with Landlord,
	and Landlord shall not be subject to liability therefore nor shall any such action be deemed an actual or constructive eviction
	of Tenant. Further, Landlord may do such other acts in and to the Common Areas as in its reasonable judgment may be desirable to
	improve the convenience thereof. Neither Tenant nor Tenant&rsquo;s employees, concessionaires, officers or agents may solicit business
	in the Common Areas, including but not limited to the distribution of handbills or other advertising matter and placing any such
	handbills or advertising matter in or on any vehicles parked at the Premises without Landlord&rsquo;s prior written consent. Tenant
	shall at no time unreasonably interfere with the rights of Landlord and others to use and enjoy any part of the Common Areas.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	Section 3.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#9;
<U>
	Tenant to Share Expense
	of Common Areas
</U>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Tenant shall pay to Landlord, in the manner
	provided in Section 3.4, Tenant&rsquo;s pro rata share of Operating Costs. &ldquo;Operating Costs&rdquo; shall be defined as and
	consist of all costs and expenses of every kind and nature, paid or incurred by Landlord, its agents or any contractor employed
	by Landlord with respect to the operation and maintenance of the Common Areas and the buildings on the Premises including but not
	be limited to: maintaining lighting fixtures, including cost of light bulbs and electric current (provided, however, that if a
	Tenant requires that the Premise remain illuminated after 11 p.m., Tenant shall be responsible for the cost allocable to said requirement);
	salaries and related costs of all on-site personnel (full-time and part-time); repairs, maintenance and replacements necessary
	for operation of the Common Areas, including all repairs, maintenance to the fire sprinkler system and all components thereof (but
	excluding replacements of the fire sprinkler system); costs and expenses of planting, maintaining, replanting and replacing flowers
	and other landscaping; mowing of grass; utilities; all costs of roof repairs and replacements including gutters and downspouts
	for up to fifty percent (50%) of the roof areas of the building on the Premises, all costs of paving repairs including resealing
	and restriping, patching holes and repaving for up to fifty percent (50%) of the parking lot and access drives on serving the Premises;
	removal of trash, rubbish, garbage and other refuse; cleaning; supplies; cost of operating, maintaining and repairing retaining
	walls, stairs, ramps, sidewalks, and other elements exterior to the building on the Premises; costs incurred by Landlord for the
	illumination and maintenance of the pylon sign at Home Center Village on which Tenant&rsquo;s sign panels will be located; equipment
	depreciation; parcel pick-up stations; service contracts with independent contractors; advertising and promotion; and management,
	administrative and overhead costs equal to three percent (3%) of the total annual Fixed Minimum Rent. Notwithstanding the foregoing,
	with the exception of any expenses set forth above, which are by their nature capital expenditures, Operating Costs shall not include
	any other capital expenditures. During the Lease term in no event shall Tenant&rsquo;s pro rata share of actual Landlord&rsquo;s
	Operating Costs increase more than five percent (5%) on a cumulative going forward basis after the first Lease Year adjustment,
	excluding controllable expenses such as utilities, insurance, taxes, snow/ice and debris/trash removal.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
</P>
<!-- FIELD: PAGE; SEQUENCE: 9 -->
<DIV STYLE="MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
	-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	5
<!-- FIELD: /SEQUENCE -->
	-
</P>
</DIV>
<A NAME="eolPage106"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<P STYLE="MARGIN: 0PT; TEXT-ALIGN: RIGHT; FONT-SIZE: 18PT">
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	Section 3.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#9;
<U>
	Landlord&rsquo;s Operating
	Costs
</U>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Tenant shall pay to Landlord the Estimated
	Landlord&rsquo;s Operating Costs specified in Item 11 of the Definitions, payable in advance in equal monthly installments, together
	with the payment of the monthly Fixed Minimum Rent, during the first Lease Year or Partial Lease Year of the Lease Term. At the
	end of each Lease Year, Landlord shall determine Tenant&rsquo;s actual pro rata share of the Operating Costs paid or incurred by
	Landlord during the prior Lease Year. In the event Tenant&rsquo;s actual pro rata share of Operating Costs, as determined by Landlord,
	exceeds the sums paid by Tenant during the Lease Year in which such costs are incurred, Tenant shall pay to Landlord the excess
	on or before the first day of the month following receipt of Landlord&rsquo;s statement invoicing the amount due by Tenant. The
	monthly Estimated Landlord&rsquo;s Operating Costs for each succeeding year may be adjusted, at Landlord&rsquo;s option, based
	on Landlord&rsquo;s estimate of such costs for each succeeding period.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	If the Lease expires during a Partial Lease
	Year, and Tenant&rsquo;s pro rata share of Landlord&rsquo;s Operating Costs, as determined by Landlord, exceeds the sums paid by
	Tenant during the Partial Lease Year, Landlord shall bill Tenant within a reasonable time after the expiration or sooner termination
	of the Lease, for such excess costs for the Partial Lease Year. Tenant shall remit full payment to Landlord within fifteen (15)
	days of such bill. If Tenant fails to remit such full payment to Landlord, Landlord in its sole discretion may deduct the amount
	due from the Security Deposit and shall be entitled to all other rights and remedies hereunder for Tenant&rsquo;s default.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Tenant shall have the right, upon ten (10)
	business days' prior notice (which may be telephonic) to Landlord, to audit the books and accounts of Landlord to confirm the calculation
	and accuracy of Operating Costs for any Lease Year or Partial Lease Year, as applicable, during the Lease Term. Such audit shall
	be conducted at a place reasonably designated by Landlord. In the event of an inaccuracy in Operating Costs actually paid by Tenant
	as compared to Operating Costs actually incurred and owed by Tenant, such shall be reconciled within thirty (30) days of discovering
	same. In the event that amounts Tenant actually paid for Operating Costs exceed the amount for Operating Costs actually owed by
	Tenant hereunder, when correctly accounted for and calculated, by three percent (3%) or greater of such amount actually owed, then
	Landlord shall pay or reimburse Tenant for the reasonable cost of the audit.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	ARTICLE IV
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
<U>
	UTILITY SERVICES
</U>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	Section 4.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#9;
<U>
	Utilities
</U>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Tenant agrees that it shall not install
	any equipment which will exceed or overload the capacity of any utility facilities existing in the Premises on the Lease Commencement
	Date and that if any equipment installed by Tenant shall require additional utility facilities, the same shall be installed at
	Tenant&rsquo;s expense in accordance with plans and specifications to be approved in writing by Landlord, such approval not to
	be unreasonably withheld, conditioned or delayed. Tenant shall contract for all utilities in its own name and shall promptly pay
	for all utilities rendered or furnished to the Premises from and after the date Tenant assumes possession of the Premises (irrespective
	of whether Tenant shall have opened for business in the Premises) including, but not limited to, water/sewer, gas, and electricity
	charges and all taxes thereon.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Landlord shall not be liable to Tenant
	for damages due to any interruption or impairment of any such utility or related service, except if the cause of such interruption
	or impairment is due to the intentional misconduct of Landlord or Landlord&rsquo;s agents, representatives, contractors and employees.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
</P>
<!-- FIELD: PAGE; SEQUENCE: 10 -->
<DIV STYLE="MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
	-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	6
<!-- FIELD: /SEQUENCE -->
	-
</P>
</DIV>
<A NAME="eolPage107"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<P STYLE="MARGIN: 0PT; TEXT-ALIGN: RIGHT; FONT-SIZE: 18PT">
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	ARTICLE V
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
<U>
	TAXES
</U>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	Section 5.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#9;
<U>
	Tenant&rsquo;s Taxes
</U>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Tenant covenants and agrees to pay timely
	when due all taxes imposed upon its business operations and its personal property situated in the Premises.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	Section 5.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#9;
<U>
	Tenant&rsquo;s Participation
	in Real Estate Taxes
</U>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Landlord will pay all &ldquo;Real Estate
	Taxes&rdquo; which shall include:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 27.35PT">
</TD>
<TD STYLE="WIDTH: 27.35PT">
	(i)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	all real property taxes, including extraordinary, general, and/or special assessments imposed by
	federal, state, or local governmental authority or any other taxing authority having jurisdiction over the Premises;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 27.35PT">
</TD>
<TD STYLE="WIDTH: 27.35PT">
	(ii)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	all real estate taxes levied and/or assessed against the Premises being located within the jurisdiction
	of a community development district, tax allocation district, community improvement district, special tax district, municipal tax
	district, a business park, municipal improvement district, and/or other similar tax program (collectively referred to as the &ldquo;Special
	Tax Assessments&rdquo;) and which are included in the tax bill (or in the alternative are charged by the applicable governmental
	and/or quasi-governmental agency(ies) to Landlord);
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 27.35PT">
</TD>
<TD STYLE="WIDTH: 27.35PT">
	(iii)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	any resource recovery taxes or fees, retrofit taxes or fees, or any other special tax which may
	be assessed and imposed on the Premises by any federal, state, or local government, including, without limitation, the Special
	Tax Assessments, or any other special assessment against the Premises; and
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 27PT">
</TD>
<TD STYLE="WIDTH: 27PT">
	(iv)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	any other assessments which may be levied or imposed on the Premises which are included on the
	Landlord&rsquo;s realty tax or assessment bill, including but not limited to, any and all costs, fees, and expenses incurred by
	Landlord in negotiating, appealing or contesting such taxes and assessments.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Notwithstanding anything herein to the
	contrary, Real Estate Taxes shall not include: (i) any franchise, capital, stock, transfer, inheritance, succession, special assessment,
	estate, gift or income tax; and (ii) late payment charges, interest and penalties imposed on Landlord.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Tenant, for each Lease Year or Partial
	Lease Year, as defined in Section 1.8, during the Term of this Lease or any renewal thereof, shall pay to Landlord its prorata
	share, as hereinafter defined, of all Real Estate Taxes assessed or levied against the Premises. Tenant shall pay to Landlord the
	Estimated Tax Charge specified in Item 14 of the Definitions, payable in advance in equal monthly installments, together with the
	payment of the monthly Fixed Minimum Rent, during the first Lease Year or Partial Lease Year of the Lease Term. At the end of such
	year and each Lease Year thereafter, Landlord shall furnish Tenant a statement of the actual Real Estate Taxes together with an
	invoice for any additional Tax Charge, which shall be paid within thirty (30) days after receipt of Landlord&rsquo;s statement.
	If the aggregate amount of Real Estate Taxes actually paid by Tenant during a given Lease Year or Partial Lease Year, as applicable,
	exceeds Tenant's actual liability for such Lease Year or Partial Lease Year, the excess shall be credited against the Real Estate
	Taxes next due from Tenant during the immediately subsequent Lease Year or Partial Lease Year, as applicable, except that in the
	event that such excess is paid by Tenant during the final Lease Year or Partial Lease Year, as applicable, of the Lease Term, then
	upon the expiration of the Lease Term, Landlord shall pay Tenant the then-applicable excess within fifteen (15) days after determination
	thereof. The monthly Estimated Tax Charge for each succeeding year may be adjusted based on Landlord&rsquo;s estimate of the Real
	Estate Taxes for each period. Tenant&rsquo;s share shall be prorated in the event Tenant is required to make such payment for a
	Partial Lease Year. In addition, should the taxing authorities include in such Real Estate Taxes the value of any improvements
	made by Tenant, or include machinery, equipment, fixtures, inventory or other personal property or assets of the Tenant then Tenant
	shall also pay 100% of the Personal Property Taxes and Real Estate Taxes for such items. If the Lease expires during a Partial
	Lease Year, Landlord shall bill Tenant, not more than sixty (60) days prior to the expiration date to the Lease, for its estimated
	pro rata share of Real Estate Taxes for the Partial Lease Year. Tenant shall remit full payment to Landlord within fifteen (15)
	days of such bill. Should any governmental taxing authority, acting under any present or future law, ordinance, or regulation,
	levy, assess or impose a tax, excise and/or assessment (other than income or franchise tax) upon or against or in any way related
	to the land and buildings comprising the Premises, either by way of substitution or in addition to any existing tax on land and
	buildings or otherwise, Tenant shall be responsible for and shall pay to Landlord its pro rata share as set forth above of such
	tax, excise and/or assessment. Notwithstanding anything to the contrary contained in this Lease, in no event shall Tenant be responsible
	or be required to pay or contribute to the payment of any Real Estate Taxes applicable to the period prior to the Lease Commencement
	Date or after the Lease Expiration Date.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
</P>
<!-- FIELD: PAGE; SEQUENCE: 11 -->
<DIV STYLE="MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
	-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	7
<!-- FIELD: /SEQUENCE -->
	-
</P>
</DIV>
<A NAME="eolPage108"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<P STYLE="MARGIN: 0PT; TEXT-ALIGN: RIGHT; FONT-SIZE: 18PT">
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	ARTICLE VI
</B>
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
<U>
	REPAIRS AND MAINTENANCE
</U>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	Section 6.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#9;
<U>
	Repairs by Landlord
</U>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Landlord shall keep the foundations, exterior
	structural/load bearing walls, gutters, downspouts and the roof over the Premises in good order and repair (subject to reimbursement
	by Tenant in accordance with Section 3.3), and shall make the exterior and structural repairs and replacements necessary to keep
	the Premises in good order and repair, including maintenance and repair of the pipes, lines, wires, and ducts exterior to the Premises
	up to, but not including, Tenant&rsquo;s service connections therewith, but subject to Landlord&rsquo;s recovery of such expenses
	as may be provided in this Lease. Landlord shall not be liable for any injury or damage to persons or property resulting from fire,
	explosion, falling plaster, steam, gas, electricity, water, rain or leaks from any part of the Premises or from the pipes, appliances
	or plumbing works or from the roof, street or subsurface or from any other place or by dampness or by any other cause of whatsoever
	nature. All property of Tenant, including merchandise and furnishings, kept or stored on the Premises shall be so kept or stored
	at the risk of Tenant only and Tenant shall hold Landlord harmless from any and all claims arising out of damage to same. If Landlord
	is required to make repairs by reason of the negligence or willful misconduct of Tenant, any permitted subtenants, concessionaires
	or their respective employees, agents, invitees, licensees or contractors, the cost of such repairs shall be borne by Tenant and
	shall be due and payable immediately upon receipt of Landlord&rsquo;s notification of the amount due.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	In addition to the foregoing, Landlord
	shall maintain, repair, and replace as necessary the fire sprinkler system in the building on the Premises, subject to reimbursement
	of such costs by Tenant pursuant to Section 3.3 above.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Landlord agrees both to commence the maintenance,
	repairs, replacements or restoration described in this Section with reasonable promptness and to diligently pursue same and in
	such manner as not to unreasonably interfere with Tenant's use and occupancy of the Premises. If Landlord fails to perform such
	maintenance or repair within thirty (30) days after receiving from Tenant written notice of the need for same or if such maintenance
	or repair cannot be performed within thirty (30) days, commence the maintenance and repair within thirty (30) days, and diligently
	prosecute it to completion, Tenant may make such repairs after giving Landlord ten (10) days prior written notice and using the
	lowest of three (3) competitive bids, and deduct the costs thereof from sums due Landlord hereunder.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	Section 6.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#9;
<U>
	Repairs and Maintenance
	by Tenant
</U>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Tenant shall, at Tenant&rsquo;s sole cost
	and expense, make all repairs to the Premises for which Landlord is not specifically responsible under Section 6.1, and shall replace
	all things necessary to keep the same in good order and repair, including, but not limited to, all fixtures, furnishings, lighting,
	windows, doors, and store signs of Tenant. Further, Tenant shall maintain, replace and keep in good order and repair all plumbing
	(including grease traps), electrical, and heating, venting and air conditioning (&ldquo;HVAC&rdquo;) systems for the Premises.
	Any HVAC system supplied by Tenant shall remain as a part of the Premises for the duration of the Lease Term and any renewals thereof,
	and shall become the property of Landlord upon installation of such system. Tenant shall at all times keep the Premises and the
	immediate areas in front of, behind and adjacent to it, exterior entrances, all glass and show windows, moldings and bulkheads,
	and all partitions, doors, floor surfaces, fixtures, equipment and appurtenances thereof in good order, condition and repair, and
	shall maintain the Premises in a satisfactory condition of cleanliness and appearance, including reasonable periodic painting of
	the interior and, if applicable, the exterior of the Premises. Tenant shall be fully responsible and liable for the maintenance,
	repair, and lighting of all its exterior signs and the maintenance and repair of its sign panels installed on the pylon sign (such
	sign panels to be maintained in conformity with Tenant&rsquo;s Sign Package affixed hereto as Exhibit E) that is shared by all
	the tenants in the Home Center Village Shopping Center, and shall periodically repaint metal surfaces that rust or begin to deteriorate
	from any causes. Any damage to the exterior walls to which a sign may be attached, including but not limited to rust stains and
	structural cracking of the fascia, caused by Tenant&rsquo;s signage shall be repaired by Tenant at its sole cost.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Tenant shall obtain and deliver to Landlord,
	at Tenant&rsquo;s sole cost, a maintenance agreement with a reputable licensed HVAC
<I>
	contractor reasonably approved by Landlord
	for the servicing of the HVAC system throughout the Term of this Lease and all &#9;extensions thereof. At a minimum, the HVAC
	system shall be serviced at least once per quarter by the service provider, &#9;including, but not limited to: (i) changing the
	filters, (ii) inspecting and, if necessary, cleaning condensing coils and &#9;evaporator coils, (iii) inspecting and, if necessary,
	tightening or replacing the belt on any HVAC unit having a belt &#9;driven &#9;fan, and (iv) inspecting and, if necessary, tightening
	any electrical terminations.
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	If Tenant refuses or neglects to properly
	repair and/or maintain the Premises as required herein to the reasonable satisfaction of Landlord, Landlord may, but shall not
	be obligated to, complete such repairs and/or maintenance, without liability for any loss or damage that may accrue to Tenant&rsquo;s
	merchandise, fixtures, or other property or to Tenant&rsquo;s business by reason thereof, and upon completion thereof, Tenant shall
	pay Landlord&rsquo;s costs for making such repairs within thirty (30) days of receipt of an invoice from Landlord, which invoice
	shall include documentation supporting such costs.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
</P>
<!-- FIELD: PAGE; SEQUENCE: 12 -->
<DIV STYLE="MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
	-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	8
<!-- FIELD: /SEQUENCE -->
	-
</P>
</DIV>
<A NAME="eolPage109"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<P STYLE="MARGIN: 0PT; TEXT-ALIGN: RIGHT; FONT-SIZE: 18PT">
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	Section 6.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#9;
<U>
	Right of Entry
</U>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Landlord or its representatives shall have
	the right to enter the Premises at reasonable hours of any day during the Lease Term upon not less than forty-eight (48) hours
	prior telephone notice to Tenant (except in the case of an emergency) in order to:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 27.35PT">
	a)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	ascertain if the Premises are in proper repair and condition, and further, Landlord or its representatives
	shall have the right, without liability, to enter the Premises for the purposes of making repairs, additions or alterations thereto
	or to the building in which the same are located, including the right to take the required materials therefore into and upon the
	Premises without the same constituting an eviction of Tenant in whole or in part, and the Rent shall not abate while such repairs,
	alterations, replacements or improvements are being made by reason of loss or interruption of Tenant&rsquo;s business due to the
	performance of any such work; provided, however, that Landlord shall use reasonable efforts to minimize interference with Tenant's
	business operations and Tenant's occupancy and use of the Premises; and
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 27PT">
	b)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	show the Premises to prospective purchasers and lenders. During the ninety (90) days prior to the
	expiration or earlier termination of the Lease Term, Landlord may place a &ldquo;For Lease&rdquo; sign on the Premises and show
	the Premises to prospective tenants.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 27PT">
	c)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Tenant may require such individuals to register with Tenant and be accompanied by a Tenant representative
	at all times while on the Premises. Notwithstanding the foregoing, in the event that Landlord requires entry to the Premises during
	a circumstance that Landlord reasonably deems to be an emergency, and representatives of Tenant shall not be present to open and
	permit such entry into the Premises, Landlord and its employees and agents may enter the Premises by means of a master key or otherwise.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	Section 6.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#9;
<U>
	Sidewalks and Outside
	Areas
</U>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Nothing shall be thrown or swept out of
	doors or windows of the Premises onto sidewalks, entrances, passages, courts, plazas or any of the Common Area. Tenant shall diligently
	keep the sidewalks and outside areas immediately in front and behind the Premises broom-clean and otherwise keep said areas free
	of trash, litter, ice, snow, or obstruction of any kind.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	Section 6.5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#9;
<U>
	Replacement of Glass
</U>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	At the commencement of the Term of this
	Lease, all glass in the Premises shall be in good condition, scraped clean of any paint and undamaged. Tenant shall, at its own
	expense, replace all glass thereafter broken or damaged with glass of the same quality and physical properties.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	ARTICLE VII
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
<U>
	RESTRICTIONS ON USE OF PREMISES
</U>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	Section 7.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#9;
<U>
	Restrictions on Use
	of Premises
</U>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Tenant covenants and agrees to use the
	Premises only for the permitted uses set forth in Item 4 of the Definitions and for no other purpose, and Tenant shall not maintain
	or permit to be maintained any vending machines of any nature in exterior areas adjacent to the Premises or in the Premises which
	block the flow of pedestrian traffic therein.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	The Premises shall, during the Term of
	this Lease, be used only and exclusively for lawful purposes and no part of the Premises shall be used in any manner whatsoever
	that will injure the commercial reputation of the Premises nor for any purposes in violation of the laws, ordinances, regulations
	or orders of the United States, or the State, County and/or City where the Premises are located or the Fire Insurance Rating organization
	and/or the Board of Fire Insurance Underwriters, or any duly constituted subdivision, department or board thereof. Tenant shall
	comply with all such laws, ordinances, regulations or orders now in effect or hereafter enacted or passed during the Term of this
	Lease insofar as the Premises and any signs of Tenant are concerned, and shall make at Tenant&rsquo;s own cost and expense all
	repairs, additions and alterations to the Premises and signs ordered or required by such authorities, whether to meet the special
	needs of Tenant, or by reason of the occupancy of Tenant, or otherwise.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	Section 7.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#9;
<U>
	Tenant&rsquo;s Right
	to Go Dark; Landlord&rsquo;s Recapture Right
</U>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	At any time during the Term, including
	any Extension Term (as defined in Exhibit &quot;A&quot;), Tenant shall have the right, but not the obligation, to cease its business
	operations within the Premises (which may be referred to herein as &ldquo;Go Dark&rdquo; or any verb-tense variation thereof);
	provided, however, that nothing herein shall be deemed to affect Tenant&rsquo;s obligation to pay full Rent during the period Tenant
	has Gone Dark. If Tenant Goes Dark from the Premises for a period of one hundred eighty (180) or more consecutive days or for a
	period of three hundred sixty five (365) or more days in the aggregate at any time during the Term (&ldquo;Dark Period&rdquo;),
	except for a Permitted Closure (as defined below), Landlord shall have the right, but not the obligation, as its sole and exclusive
	remedy for early termination of the Lease, to terminate this Lease and recapture the Premises at any time after such Dark Period
	by delivering written notice to Tenant indicating its election to so terminate this Lease (&ldquo;Termination Notice&rdquo;). This
	Lease shall terminate thirty (30) days after Tenant&rsquo;s receipt of the Termination Notice; provided, however, that Tenant may
	nullify such termination by Landlord if, within thirty (30) days after Tenant&rsquo;s receipt of the Termination Notice, Tenant
	re-opens for business in the Premises. Notwithstanding the foregoing, from the date of the Termination Notice through the effective
	date of termination as set forth in such Termination Notice, Tenant shall continue to pay full Rent and remain liable for all liabilities
	accrued through the Termination Date. Notwithstanding anything contained herein to the contrary, Tenant shall not be required to
	open for business in the Premises (i) on nationally recognized holidays (e.g., Christmas Day, Thanksgiving Day, New Year&rsquo;s
	Day, etc.), (ii) for periods of closure for permitted remodeling, renovation or alterations, (iii) for periods of closure due to
	force majeure events, or (iv) for periods of closure due to casualty or condemnation (any of the foregoing being a &ldquo;Permitted
	Closure&rdquo;). Notwithstanding anything to the contrary contained herein, the Dark Period shall not be interrupted by, and Tenant
	shall be deemed to be not operating, during any single day or other temporary resumption of operations by Tenant in bad faith and
	not in the normal course of business for the sole purpose of avoiding the exercise of Landlord's recapture right. If Tenant Goes
	Dark, Tenant shall maintain a security alarm for the Premises with a reputable company approved by Landlord, sufficient to notify
	the police or fire officials in the event of an emergency; maintain the temperature within the Premises at 45&ordm; degrees Fahrenheit
	or higher in order to prevent any damage to the Premises due to freezing temperatures; and comply with all other terms and conditions
	of the Lease.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
</P>
<!-- FIELD: PAGE; SEQUENCE: 13 -->
<DIV STYLE="MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
	-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	9
<!-- FIELD: /SEQUENCE -->
	-
</P>
</DIV>
<A NAME="eolPage110"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<P STYLE="MARGIN: 0PT; TEXT-ALIGN: RIGHT; FONT-SIZE: 18PT">
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	Section 7.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#9;
<U>
	Retail Restriction
	Limit
</U>
	[Intentionally Omitted]
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	Section 7.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#9;
<U>
	Rules and Regulations
</U>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Tenant&rsquo;s use of the Premises shall
	be subject to Landlord&rsquo;s right to adopt, modify and/or rescind reasonable rules and regulations not in conflict with any
	of the express provisions hereof governing the use of the Common Areas and/or Premises and other matters affecting the general
	management and appearance of the Premises but no such rule or regulation shall discriminate against Tenant. The current rules and
	regulations are attached hereto as Exhibit &ldquo;C&rdquo; and made a part hereof. Landlord will provide any newly promulgated
	rules and regulations to Tenant prior to same being effective and enforceable.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	ARTICLE VIII
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
<U>
	ADDITIONS, ALTERATIONS, REPLACEMENTS
	AND TRADE FIXTURES
</U>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	Section 8.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#9;
<U>
	By Landlord
</U>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Landlord also reserves the right to construct
	other buildings or improvements in the Common Areas from time to time and to make alterations thereof or additions thereof and
	to build additional stories on any such building or buildings so constructed provided that such construction does not interfere
	or interrupt Tenant's business and access to the Areas and to Tenant's Parking.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	Section 8.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#9;
<U>
	By Tenant
</U>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Tenant may, from time to time, at its expense,
	make alterations or improvements in and to the Premises (hereinafter collectively referred to as &quot;Alterations&quot;) without
	acquiring the prior written consent of Landlord in each instance, provided that: (a) the Alterations are non-structural and the
	structural integrity of the building in which the Premises is located shall not be affected; (b) the Alterations are to the interior
	of the Premises; (c) the proper functioning of the electrical, mechanical, plumbing, HVAC or other systems servicing the Premises
	is not impaired; or (d) the cost in each case does not exceed Ten Thousand and No/100 Dollars ($10,000.00) (the &quot;Permitted
	Alterations&quot;). For any other Alterations, Tenant shall be required to obtain the prior written consent of Landlord, which
	consent Landlord shall not unreasonably withhold, condition, or delay. If Tenant makes written request for any Alterations requiring
	Landlord's prior written consent, such request must be accompanied by a description of the proposed Alterations. If Landlord fails
	to deny consent to the proposed Alterations in writing accompanied by reasons for such denial within thirty (30) days of Tenant's
	request, then Landlord shall be deemed to have granted consent to the Alterations described. After obtaining Landlord's consent
	for any Alterations (either expressly or by inference), Tenant shall give Landlord at least five (5) days' prior written notice
	of the commencement of any Alterations at the Premises, and Landlord may elect to record and post notices of non-responsibility
	at the Premises. This provision shall apply to improvements made by Tenant at any time, including Tenant&rsquo;s initial leasehold
	improvements and fixturing. No changes, alterations, or improvements affecting the exterior of the Premises shall be made by Tenant
	without the prior written approval of Landlord. Tenant also agrees to pay one hundred percent (100%) of any increase in the Real
	Estate Taxes or Landlord&rsquo;s Personal Property Taxes resulting from such improvements.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
</P>
<!-- FIELD: PAGE; SEQUENCE: 14 -->
<DIV STYLE="MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
	-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	10
<!-- FIELD: /SEQUENCE -->
	-
</P>
</DIV>
<A NAME="eolPage111"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<P STYLE="MARGIN: 0PT; TEXT-ALIGN: RIGHT; FONT-SIZE: 18PT">
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	All alterations, decorations, additions
	and improvements made by Tenant, or made by Landlord on Tenant&rsquo;s behalf as provided in this Lease, shall be the property
	of Landlord. Upon obtaining the prior written consent of Landlord, Tenant shall remove such alterations, decorations, additions
	and improvements made by Tenant and restore the Premises as provided in Section 8.5, and if Tenant fails to do so and moves from
	the Premises, all such alterations, decorations, and additions and improvements shall remain the property of Landlord.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	Section 8.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#9;
<U>
	Construction Insurance
	and Indemnity
</U>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Tenant shall indemnify and hold Landlord
	harmless from any and all claims for loss or damages or otherwise based upon or in any manner growing out of any alterations or
	construction undertaken by Tenant under the terms of this Lease, including all costs, damages, expenses, court costs and attorneys&rsquo;
	fees incurred in or resulting from claims made by any person or persons.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Before undertaking any alterations or construction
	(excluding any Permitted Alterations), Tenant shall obtain and pay for a public liability policy insuring Landlord and Tenant against
	any liability which may arise on account of such proposed alterations or construction work in limits of not less than $1,000,000.00
	for any one person, $1,000,000.00 for more than one person in any one accident and $1,000,000.00 for property damage; and a copy
	of such policy shall be delivered to Landlord prior to the commencement of such proposed work. Tenant shall also maintain at all
	times fire insurance with extended coverage in the name of Landlord and Tenant as their interests may appear in the amount adequate
	to cover the cost of replacement of all alterations, decoration, additions or improvements in and to the Premises and all trade
	fixtures therein, in the event of fire or extended coverage loss. Tenant shall deliver to Landlord copies of such fire insurance
	policies which shall contain a clause requiring the insurer to give Landlord thirty (30) days&rsquo; notice of cancellation of
	such policies.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	Section 8.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#9;
<U>
	Mechanic&rsquo;s Liens
	and Additional Construction
</U>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	If by reason of any alteration, repair,
	or labor performed or materials furnished to the Premises for or on behalf of Tenant any mechanic&rsquo;s or other lien shall be
	filed, claimed, perfected or otherwise established as provided by law against the Premises, Tenant shall discharge or remove the
	lien by bonding or otherwise, within thirty (30) days after notice from Landlord to Tenant of the filing of same, and Tenant shall
	indemnify and hold the Landlord harmless from and against any such lien and any costs, damages, charges and expenses, including,
	but not limited to, attorney&rsquo;s fees, incurred in connection with or with respect to such lien.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Landlord and Tenant expressly acknowledge
	and agree that neither the Tenant nor any one claiming by, through or under the Tenant, including without limitation contractors,
	sub-contractors, materialmen, mechanics and laborers, shall have any right to file or place any mechanics&rsquo; or materialmen&rsquo;s
	liens of any kind whatsoever upon the Premises nor upon any building or improvement thereon; such liens being specifically prohibited.
	Tenant shall notify all parties with whom it deals that Tenant (and such party acting by and through Tenant) has no power to subject
	the Landlord&rsquo;s interest in the Premises to any claim or lien of any kind or character and any parties dealing with the Tenant
	must look solely to the credit of the Tenant for payment and not to the Landlord&rsquo;s interest in the Premises or otherwise.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	Section 8.5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#9;
<U>
	Trade Fixtures
</U>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	All trade fixtures and equipment installed
	by Tenant in the Premises shall remain the property of Tenant. Provided Tenant is not in default hereunder beyond any applicable
	notice and cure periods, Tenant shall have the right, upon the expiration or termination of this Lease, to remove any and all such
	trade fixtures and equipment not constituting a part of the freehold which it may have stored or installed in the Premises, including,
	but not limited to, counters, shelving, showcases, chairs, and moveable machinery purchased or provided by Tenant, provided this
	right is exercised on or before the expiration or termination date of this Lease and provided that Tenant, at its own cost and
	expense, shall repair any damage to the Premises caused thereby. The right granted Tenant in this Section 8.5 shall not include
	the right to remove any plumbing or electrical fixtures or equipment (with exception of generator), hot water heaters, oven hood,
	oven exhaust, heating or air-conditioning equipment, floor-coverings (including wall-to-wall carpeting) glued or fastened to the
	floors or any paneling, tile or other materials fastened or attached to the walls or ceilings, all of which shall be deemed to
	constitute a part of the freehold, and, as a matter of course, shall not include the right to remove any fixtures or machinery
	that were furnished or paid for by Landlord. The Premises and the immediate areas in front of, behind and adjacent to the Premises
	shall be left in a broom-clean condition. If Tenant shall fail to remove all of its trade fixtures or other property on or before
	the expiration or termination date of this Lease, such fixtures and other property not removed by Tenant shall be deemed abandoned
	by Tenant, and, at the option of Landlord, shall become the property of Landlord.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
</P>
<!-- FIELD: PAGE; SEQUENCE: 15 -->
<DIV STYLE="MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
	-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	11
<!-- FIELD: /SEQUENCE -->
	-
</P>
</DIV>
<A NAME="eolPage112"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<P STYLE="MARGIN: 0PT; TEXT-ALIGN: RIGHT; FONT-SIZE: 18PT">
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	ARTICLE IX
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
<U>
	INSURANCE AND INDEMNITY
</U>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	Section 9.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#9;
<U>
	Tenant&rsquo;s Insurance
</U>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Tenant covenants and agrees to procure
	and maintain, at Tenant&rsquo;s expense, prior to entry upon the Premises, in responsible companies reasonably approved by Landlord,
	combined single limit public liability insurance, insuring Landlord and Tenant, as their interests may appear, against all claims,
	demands or actions for bodily injury, including death of any person, property damage, and personal injury with limits of not less
	than $1,000,000.00 for each occurrence and $2,000,000.00 on an annual aggregate basis, and also casualty coverage insuring Landlord
	and Tenant, as their interests may appear, with a limit of not less than $300,000.00 for each occurrence. Landlord shall have the
	right to direct Tenant to increase such amounts whenever Landlord&rsquo;s insurance carrier or governing authority considers them
	inadequate. Such liability insurance shall also cover any liability from signs erected by Tenant. The policy of insurance shall
	provide that Landlord is specifically named as an additional insured therein. Tenant shall also maintain, at its own cost and expense,
	with nationally recognized companies, insurance as follows: (1) insurance commonly known as &ldquo;special all risk property insurance&rdquo;
	on property belonging to Tenant or for which Tenant is the bailee covering 100% of the replacement cost of any item of value including
	Tenant&rsquo;s property and specifically including but not limited to signs, stock, inventory, furniture and fixtures, equipment,
	and improvements and betterments installed by Tenant; (2) business interruption insurance covering 100% of Tenant&rsquo;s actual
	loss sustained for a period not exceeding twelve (12) months; and (3) insurance covering all glass forming a part of the Premises
	including plate glass in the Premises. All of said insurance shall be in form and in responsible companies licensed to do business
	in the State of Georgia and shall have an A.M. Best Rating of at least A-,VIII and shall endeavor to provide that it will not be
	subject to cancellation or termination or change except after at least thirty (30) days prior written notice to Landlord. The certificates
	of insurance shall be deposited with Landlord no later than the day Tenant opens for business. Thereafter, Tenant shall provide
	Landlord with certificates of insurance within fifteen (15) days after renewal of any such policy. In the event Tenant fails to
	obtain or maintain the insurance required hereunder, and fails to provide Landlord with the required certificates of insurance
	within thirty (30) days after demand therefore, Landlord may obtain same (but shall have no obligation to do so) and any costs
	incurred by Landlord in connection therewith shall be payable by Tenant upon demand. Tenant agrees that its insurance shall be
	primary over any insurance, which may be purchased by the Landlord. In the event of any loss of property or earnings of the Tenant
	as a result of property damage, the Tenant agrees not to subrogate against the Landlord and further agrees that it shall require
	an express waiver of any right of subrogation by its insurance company against Landlord.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	Section 9.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#9;
<U>
	Extra Hazard Insurance
	Premiums
</U>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Tenant agrees that it will not knowingly
	keep, use, sell or offer for sale in or upon the Premises any article or permit any activity, which may be prohibited by the standard
	form of fire or public liability insurance policy. Tenant agrees to pay any increase in premiums for fire and extended coverage
	or public liability insurance which may be carried by Landlord on the Premises or the building of which they are a part, resulting
	from the type of merchandise sold or services rendered by Tenant or activities in the Premises, whether or not Landlord has consented
	to the same. In determining whether increased premiums are the result of Tenant&rsquo;s use of the Premises, a schedule, issued
	by the organization making the insurance rate on the Premises, showing various components of such rate, shall be conclusive evidence
	of the several items and charges, which make up the fire and public liability insurance rate on the Premises.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Tenant shall not knowingly use or occupy
	the Premises or any part thereof, or suffer or permit the same to be used or occupied for any business or purpose deemed extra
	hazardous on account of fire or otherwise. In the event Tenant&rsquo;s use and/or occupancy causes any increase of premium for
	the fire, boiler and/or casualty rates on the Premises or any part thereof above the rate for the least hazardous type of occupancy
	legally permitted in the Premises, Tenant shall pay such additional premium on the fire, boiler and/or casualty insurance policy
	that may be carried by Landlord for its protection against rent loss through fire. Bills for such additional premiums shall be
	rendered by Landlord to Tenant at such times as Landlord may elect, and shall be due from and payable to Tenant when rendered in
	writing, but such increases in the rate of insurance shall not be deemed a breach of this covenant by Tenant. Failure to pay amounts
	due hereunder shall be a breach of the Lease.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	Section 9.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#9;
<U>
	Indemnity
</U>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Tenant during the Term hereof shall indemnify
	and save harmless Landlord, including its employees, agents, and property manager, if any, from and against any and all claims
	and demands whether for injuries to persons or loss of life, or damage to property, occurring within the Premises and immediately
	adjoining the Premises and arising out of the use and occupancy of the Premises by Tenant, or occasioned wholly or in part by any
	act or omission of Tenant, its subtenants, agents, contractors, employees, servants, lessees or concessionaires, excepting however,
	such claims and demands, whether for injuries to persons or loss of life, or damage to property, caused by the negligence of Landlord,
	its employees, agents, and property manager. If, however, any liability arises in the Common Areas because of the negligence of
	Tenant, Tenant&rsquo;s subtenants, agents, employees, contractors, invitees, customers or visitors, then in such event Tenant shall
	hold Landlord harmless. In case Landlord shall, without fault on its part, be made a party to any litigation that is covered by
	the indemnity by Tenant in the foregoing two sentences, then Tenant shall protect and hold Landlord harmless and shall pay all
	costs, expenses and reasonable attorney&rsquo;s fees incurred or paid by Landlord in connection with such litigation. The obligation
	of Tenant to indemnify Landlord under this Section 9.3 shall survive the termination of the Lease. Nothing in this Section 9.3
	shall modify or alter the Tenant&rsquo;s responsibility to purchase the insurance required by Section 9.1.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
</P>
<!-- FIELD: PAGE; SEQUENCE: 16 -->
<DIV STYLE="MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
	-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	12
<!-- FIELD: /SEQUENCE -->
	-
</P>
</DIV>
<A NAME="eolPage113"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<P STYLE="MARGIN: 0PT; TEXT-ALIGN: RIGHT; FONT-SIZE: 18PT">
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Landlord during the Term hereof shall indemnify
	and save harmless Tenant, including its employees, agents, and property manager, if any, from and against any and all claims and
	demands whether for injuries to persons or loss of life, or damage to property, occurring within the Common Areas occasioned wholly
	or in part by any act or omission of Landlord, its agents, contractors or employees, excepting however, such claims and demands,
	whether for injuries to persons or loss of life, or damage to property, caused by the negligence of Tenant including Tenant's subtenants,
	agents, employees or contractors. If any liability arises in the Premises because of the negligence of Landlord, Landlord's agents,
	employees or property manager, then in such event Landlord shall hold Tenant harmless. In case Tenant shall, without fault on its
	part, be made a party to any litigation that is covered by the indemnity by Landlord in the foregoing two sentences, then Landlord
	shall protect and hold Tenant harmless and shall pay all costs, expenses and reasonable attorney&rsquo;s fees incurred or paid
	by Tenant in connection with such litigation. The obligation of Landlord to indemnify Tenant under this Section 9.3 shall survive
	the termination of the Lease. Nothing in this Section 9.3 shall modify or alter Landlord's responsibility to purchase the insurance
	required by Section 9.4.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	Section 9.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#9;
<U>
	Tenant&rsquo;s Participation
	in Insurance
</U>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Landlord will pay all premiums for liability,
	fire, casualty and other property related insurance for the Premises, including any insurance, such as flood insurance, which in
	the reasonable judgment of Landlord is necessary (collectively, &ldquo;Insurance&rdquo;). Tenant for each Lease Year or Partial
	Lease Year during the Term of this Lease or any renewal thereof, shall pay to Landlord its Pro Rata Share of Insurance. In addition
	to the foregoing, Tenant shall also pay its Pro Rata Share of any Insurance deductible (&ldquo;Deductible Share&rdquo;) paid by
	Landlord in the event of a claim or insured loss. The Deducible Share shall be determined by multiplying the applicable deductible
	amount paid by Landlord by Tenant&rsquo;s pro rata share. The Deductible Share shall be amortized and paid by Tenant in monthly
	installments over the remaining term of the Lease beginning the month next succeeding the date on which Landlord notifies Tenant
	in writing about same.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Tenant shall pay to Landlord the Insurance
	Charge specified in Exhibit &ldquo;A&rdquo; monthly. At the end of each Lease Year (or Partial Lease Year, if applicable), Landlord
	shall determine Tenant&rsquo;s actual Pro Rata Share of Insurance for such preceding Lease Year. In the event Tenant&rsquo;s Pro
	Rata Share of Insurance exceeds the Insurance Charge paid by Tenant for such preceding Lease Year, Tenant shall pay to Landlord
	the excess amount within thirty (30) days after receipt of Landlord&rsquo;s statement invoicing the amount due by Tenant. If the
	aggregate amount of Insurance actually paid by Tenant during a given Lease Year or Partial Lease Year, as applicable, exceeds Tenant's
	actual liability for such Lease Year or Partial Lease Year, the excess shall be credited against the payment of Insurance next
	due from Tenant during the immediately subsequent Lease Year or Partial Lease Year, as applicable, except that in the event that
	such excess is paid by Tenant during the final Lease Year or Partial Lease Year, as applicable, of the Lease Term, then upon the
	expiration of the Lease Term, Landlord shall pay Tenant the then-applicable excess within fifteen (15) days after determination
	thereof. The Insurance Charge for each succeeding Lease Year may be adjusted based on Landlord&rsquo;s estimate of the Insurance
	for such succeeding Lease Year. If the Lease expires during a Partial Lease Year, Landlord shall bill Tenant, not more than sixty
	(60) days following to the Expiration Date of the Lease, for its estimated Pro Rata Share of Insurance for the Partial Lease Year.
	Tenant shall remit full payment to Landlord within fifteen (15) days of receipt of such bill. If Tenant fails to remit such payment
	to Landlord, Landlord in its sole discretion may deduct the amount due from Tenant&rsquo;s Security Deposit and/or pursue all other
	rights and remedies hereunder for Tenant&rsquo;s default.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Any Insurance policy maintained by Landlord
	shall be for the sole benefit of Landlord, and Tenant shall have no right or claim to any proceeds thereof or any other rights
	thereunder. Further, Tenant acknowledges and agrees that Tenant&rsquo;s obligation to pay its Pro Rata Share of Insurance for the
	Premises shall not give Tenant any rights under any Insurance policy maintained by Landlord, nor shall such obligation constitute
	a waiver of subrogation on the part of Landlord&rsquo;s Insurance carrier to assert claims against Tenant for damage to the Premises
	caused by Tenant&rsquo;s negligence, or for Landlord to assert any such claims against Tenant for uninsured losses. Specifically,
	nothing in this Lease shall be construed to prohibit or diminish either the subrogation rights of Landlord&rsquo;s insurance carrier
	against Tenant or Landlord&rsquo;s rights to assert claims against Tenant in its own name for damage caused by Tenant&rsquo;s negligence.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	Section 9.5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#9;
<U>
	Mutual Waiver of Claims
	and Subrogation
</U>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	LANDLORD AND TENANT HEREBY WAIVE AND RELEASE
	ANY CLAIM THAT EITHER OF THEM MAY HEREAFTER HAVE AGAINST THE OTHER ON ACCOUNT OF ANY DAMAGE TO THE PROPERTY OF THE WAIVING PARTY,
	EVEN IF SUCH DAMAGE SHALL BE DUE TO THE NEGLIGENT ACT OR OMISSION OF THE OTHER PARTY. LANDLORD AND TENANT SHALL EACH CAUSE THEIR
	RESPECTIVE PROPERTY INSURANCE POLICIES TO CONTAIN EITHER A WAIVER OF ANY RIGHT OF SUBROGATION THE INSURER OF ONE PARTY HERETO MAY
	ACQUIRE AGAINST THE OTHER PARTY HERETO BY VIRTUE OF PAYMENT OF ANY LOSS UNDER ANY SUCH INSURANCE OR AN ACKNOWLEDGMENT BY THE INSURER
	THAT THE FOREGOING WAIVER OF CLAIMS DOES NOT IMPAIR OR INVALIDATE SUCH POLICY OF INSURANCE.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
</P>
<!-- FIELD: PAGE; SEQUENCE: 17 -->
<DIV STYLE="MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
	-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	13
<!-- FIELD: /SEQUENCE -->
	-
</P>
</DIV>
<A NAME="eolPage114"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<P STYLE="MARGIN: 0PT; TEXT-ALIGN: RIGHT; FONT-SIZE: 18PT">
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	ARTICLE X
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
<U>
	DAMAGE OR DESTRUCTION BY FIRE OR OTHER
	CASUALTY AND CONDEMNATION
</U>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	Section 10.1&nbsp;&nbsp;&nbsp;&nbsp;
<U>
	Damage or Destruction by Fire or Other
	Casualty
</U>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 27PT">
	a)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Tenant shall give prompt notice to Landlord in case of fire or other damage to the Premises or
	the building(s) containing the Premises. In the event the Premises are damaged by fire, explosion, flood, Tornado or by the elements,
	or through any casualty, or otherwise, after the commencement of the Term of this Lease, the Lease shall continue in full force
	and effect. If the extent of the damage is less than Fifty Percent (50%) of the cost of replacement of the Premises, the damage
	shall promptly be repaired by Landlord at Landlord&rsquo;s expense, provided that Landlord shall not be obligated to expend for
	such repair an amount in excess of the insurance proceeds recovered or recoverable as a result of such damage, and that in no event
	shall Landlord be required to replace Tenant&rsquo;s stock in trade, fixtures, furniture, furnishings, floor coverings and equipment.
	In the event of any such damage and:
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 27.35PT">
</TD>
<TD STYLE="WIDTH: 27.35PT">
	(i)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Landlord is not required to repair as hereinabove provided; or
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 27.35PT">
</TD>
<TD STYLE="WIDTH: 27.35PT">
	(ii)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	the Premises shall be damaged to the extent of Fifty Percent (50%) or more of the cost of replacement;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 27PT">
</TD>
<TD STYLE="WIDTH: 27PT">
	(iii)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	either Landlord or Tenant may elect to terminate this Lease upon giving notice of such election
	to the other party within ninety (90) days after the occurrence of the event causing the damage.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 27PT">
	b)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	If the casualty, repairing, or rebuilding shall render the Premises untenable, in whole or in part,
	a proportionate abatement of the Fixed Minimum Rent shall be allowed from the date when the damage occurred until the date Landlord
	completes the repairing or rebuilding, said proportion to be computed on the basis of the relation which the gross square foot
	area of the space rendered untenable bears to the floor area of the Premises If Landlord is required or elects to repair the Premises
	as herein provided, Tenant shall repair or replace its stock in trade, fixtures, furniture, furnishings, floor coverings and equipment,
	and if Tenant has closed for business, Tenant shall promptly reopen for business upon the completion of such repairs.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 27PT">
	c)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	In the event the Premises shall be damaged in whole or in substantial part within the last twelve
	(12) months of the Term of this Lease, either Landlord or Tenant shall have the option, exercisable within thirty (30) days following
	such damage, of terminating this Lease, effective as of the date of receipt.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 27PT">
	d)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	by the non-terminating party of written notice from the terminating party; provided, however, that
	if Landlord elects to terminate this Lease pursuant to this Section 10.1(c), Tenant may void such termination by exercising any
	then available option to renew this Lease by giving Landlord written notice thereof within thirty (30) days of Tenant's receipt
	of Landlord's termination notice, whereupon such termination notice shall be void and Landlord will promptly and diligently repair
	the damage and restore and rebuild the Premises with reasonable dispatch to substantially the same condition as immediately prior
	to such casualty.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	Section 10.2&nbsp;&nbsp;&nbsp;&nbsp;
<U>
	Condemnation
</U>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 27PT">
	a)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Total: In the event the entire Premises shall be appropriated or taken under the power of eminent
	domain by any public or quasi-public authority (the &ldquo;Condemning Authority&rdquo;), this Lease shall terminate and expire
	as of the date of title vesting in the Condemning Authority, and Landlord and Tenant shall thereupon be released from any further
	liability, hereunder.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 27PT">
	b)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Partial: If any part of the Premises shall be taken as aforesaid and such partial taking shall
	render that portion not so taken unsuitable for the business of Tenant, as reasonably determined by Landlord and Tenant, then this
	Lease and the Term herein shall cease and terminate as aforesaid. If such partial taking is not extensive enough to render the
	Premises unsuitable for the business of Tenant, then this Lease shall continue in effect, except that the Fixed Minimum Rent shall
	be reduced in the same proportion that the floor area of the Premises taken bears to the original floor area leased and Landlord
	shall, upon receipt of the award in condemnation, make all necessary repairs or alterations to the building in which the Premises
	are located so as to constitute the portion of the building not taken a complete architectural unit, but such work shall not exceed
	the scope of the work to be done by Landlord in originally constructing said building, nor shall Landlord, in any event, be required
	to spend for such work an amount in excess of the amount received by Landlord as damages for the part of the Premises so taken.
	&ldquo;Amount received by Landlord&rdquo; shall mean that part of the award in condemnation which is free and clear to Landlord
	of any collection by mortgagee for the value of the diminished fee.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 18 -->
<DIV STYLE="MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
	-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	14
<!-- FIELD: /SEQUENCE -->
	-
</P>
</DIV>
<A NAME="eolPage115"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<P STYLE="MARGIN: 0PT; TEXT-ALIGN: RIGHT; FONT-SIZE: 18PT">
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 27PT">
	c)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Termination: If more than twenty percent (20%) of the floor area of the building in which the Premises
	are located shall be taken as aforesaid, either Landlord or Tenant may, by written notice to the other party, terminate this Lease,
	such termination to be effective as aforesaid.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 27PT">
	d)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Rent on Termination: If this Lease is terminated as provided in this Section, the Rent shall be
	paid, up to the date, that possession is so taken by the Condemning Authority and Landlord shall make an equitable refund of any
	rent paid by Tenant in advance.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 27PT">
	e)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Award: Tenant shall not be entitled to and expressly waives all claim to any condemnation award
	for any taking, whether whole or partial, and whether for diminution in value of the leasehold or to the fee although Tenant shall
	have the right, to the extent that the same shall not reduce Landlord&rsquo;s award, to claim from the Condemning Authority, but
	not from Landlord, such compensation as may be recoverable by Tenant in its own right for damage to Tenant&rsquo;s business, fixtures
	and improvements installed by Tenant at its expense.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	ARTICLE XI
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
<U>
	DEFAULT AND REMEDIES
</U>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	Section 11.1&nbsp;&nbsp; &nbsp;
<U>
	Default
</U>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	The following events shall be deemed to be Events of Default
	under this Lease:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 27PT">
	a)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Tenant shall fail to pay when due any sum of money becoming due to be paid to Landlord under this
	Lease, whether such sum be an installment of Rent under this Lease, any other amount treated as Additional Rent under this Lease,
	or any other payment or reimbursement to Landlord required by this Lease, whether or not treated as additional rent under this
	Lease, and such failure shall continue for a period of ten (10) days after the date such payment is due.;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 27PT">
	b)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Tenant shall fail to comply with any term, provision or covenant of this Lease which is not provided
	for in another Section of this Article and shall not cure such failure within thirty (30) days (immediately, if the failure involves
	a hazardous condition, improper parking under Section 3.2, or a cleanliness matter under Section 6.2) after written notice of such
	failure to Tenant; provided, however, that if such failure cannot, by its nature, be cured within such thirty (30) day period,
	but Tenant commences and diligently pursues a cure of such failure promptly within the initial thirty (30) day cure period, then
	Tenant shall not be in default under this Lease;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 27PT">
	c)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Tenant shall fail to vacate the Premises immediately upon termination of this Lease, by lapse of
	time or otherwise, or upon termination of Tenant&rsquo;s right to possession only;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 27PT">
	d)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Tenant shall become insolvent, admit in writing its inability to pay its debts generally as they
	become due, file a petition in bankruptcy or a petition to take advantage of any insolvency statute, make an assignment for the
	benefit of creditors, make a transfer in fraud of creditors, apply for or consent to the appointment of a receiver of itself or
	of the whole or any substantial part of its property, or file a petition or answer seeking reorganization or arrangement under
	the federal bankruptcy laws, as now in effect or hereafter amended, or any other applicable law or statute of the United States
	or of any state thereof;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 27PT">
	e)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	A court of competent jurisdiction shall enter an order, judgment or decree adjudicating Tenant
	bankrupt or granting bankruptcy relief, or appointing a receiver of Tenant, or of the whole or any substantial part of its property,
	without the consent of Tenant, or approving or granting relief based on a petition filed against Tenant seeking reorganization
	or arrangement of Tenant under the bankruptcy laws of the United States, as now in effect or hereafter amended, or any state thereof,
	and such order, judgment or decree shall not be vacated or set aside or stayed within sixty (60) days from the date of entry thereof;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 27PT">
	f)
</TD>
<TD>
	Tenant shall abandon or vacate any substantial portion of the Premises except as allowed in Section 7.2;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 27PT">
	g)
</TD>
<TD>
	Tenant shall assign, sublet or transfer its interest hereunder in violation of this Lease; OR
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 27PT">
	h)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Tenant does, or permits to be done, any act which creates a mechanic&rsquo;s lien or claim therefor
	against the Premises and it is not removed within thirty (30) days
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	Section 11.2&nbsp;&nbsp;&nbsp;&nbsp;
<U>
	Remedies
</U>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Upon the occurrence of any of the Events
	of Default described or referred to in Section 11.1, Landlord shall have the option to pursue any one or more of the following
	remedies without any notice or demand whatsoever, concurrently or consecutively and not alternatively:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
</P>
<!-- FIELD: PAGE; SEQUENCE: 19 -->
<DIV STYLE="MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
	-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	15
<!-- FIELD: /SEQUENCE -->
	-
</P>
</DIV>
<A NAME="eolPage116"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<P STYLE="MARGIN: 0PT; TEXT-ALIGN: RIGHT; FONT-SIZE: 18PT">
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 27PT">
	a)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Landlord may, at its election, terminate this Lease or terminate Tenant&rsquo;s right to possession
	only, without terminating the Lease.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 27PT">
	b)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Upon any termination of this Lease, whether by lapse of time or otherwise, or upon any termination
	of Tenant&rsquo;s right to possession without termination of the Lease, Tenant shall surrender possession and vacate the Premises
	immediately, and deliver possession thereof to Landlord, and Tenant hereby grants to Landlord full and free license to enter into
	and upon the Premises in such event and to repossess Landlord of the Premises as of Landlord&rsquo;s former estate and to expel
	or remove Tenant and any others who may be occupying or be within the Premises and to remove Tenant&rsquo;s signs and other evidence
	of tenancy and all other property of Tenant therefrom without being deemed in any manner guilty of trespass, eviction or forcible
	entry or detainer, and without incurring any liability for any damage resulting therefrom, Tenant waiving any right to claim damages
	for such re-entry and expulsion, and without relinquishing Landlord&rsquo;s right to Rent or any other right given to Landlord
	under this Lease or by operation of law.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 27PT">
	c)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Upon any termination of this Lease, whether by lapse of time or otherwise, or upon any termination
	of Tenant&rsquo;s right to possession without termination of the Lease, Landlord shall be entitled to recover as damages, all Rent,
	including any amounts treated as Additional Rent under this Lease, and any other sums due and payable by Tenant on the date of
	termination, plus as liquidated damages and not as a penalty, an amount equal to the sum of:
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 27.35PT">
</TD>
<TD STYLE="WIDTH: 27.35PT">
	(i)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	an amount equal to the then present value of the Rent reserved in this Lease for the residue of
	the stated Term of this Lease including any amounts treated as additional rent under this Lease and all other sums provided in
	this Lease to be paid by Tenant, minus the fair rental value of the Premises for such residue;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 27.35PT">
</TD>
<TD STYLE="WIDTH: 27.35PT">
	(ii)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	the value of the time and expense necessary to obtain a replacement tenant or tenants, and the
	estimated expenses relating to recovery of the Premises, preparation for reletting and for reletting itself, and
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 27PT">
</TD>
<TD STYLE="WIDTH: 27PT">
	(iii)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	the cost of performing any other covenants, which would have otherwise been performed by Tenant.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 27PT">
	d)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Upon any termination of Tenant&rsquo;s right to possession only without termination of the Lease:
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 27PT">
</TD>
<TD STYLE="WIDTH: 27PT">
	(i)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Neither such termination of Tenant&rsquo;s right to possession nor Landlord&rsquo;s taking and
	holding possession thereof as provided in Section 11.2(b), nor the issuance of a Writ of Possession or the lawful execution thereof,
	shall terminate the Lease or release Tenant, in whole or in part, from any obligation, including Tenant&rsquo;s obligation to pay
	the Rent, under this Lease for the full Term.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 27PT">
</TD>
<TD STYLE="WIDTH: 27PT">
	(ii)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Landlord may, but need not, relet the Premises or any part thereof for such rent and upon such
	terms as Landlord, in its sole discretion, shall determine (including the right to relet the Premises for a greater or lesser term
	than that remaining under this Lease, the right to relet the Premises as a part of a larger area, and the right to change the character
	or use made of the Premises). In connection with or in preparation for any reletting, Landlord may, but shall not be required to,
	make repairs, alterations and additions in or to the Premises and redecorate the same to the extent Landlord deems necessary or
	desirable, and Tenant shall, upon demand, pay the cost thereof, together with Landlord&rsquo;s expenses of reletting, including,
	without limitation, any commission incurred by Landlord. If Landlord decides to relet the Premises or a duty to relet is imposed
	upon Landlord by law, Landlord and Tenant agree that nevertheless Landlord shall at most be required to use only the same efforts
	Landlord then uses to lease premises generally and that in any case Landlord shall not be required to give any preference or priority
	to the showing or leasing of the Premises over any other space that Landlord may be leasing or have available and may place a suitable
	prospective tenant in any such other space regardless of when such other space becomes available. Landlord shall not be required
	to observe any instruction given by Tenant about any reletting or accept any tenant offered by Tenant unless such offered tenant
	has a credit-worthiness acceptable to Landlord and leases the entire Premises upon terms and conditions including a rate of rent
	(after giving effect to all expenditures by Landlord for tenant improvements, broker&rsquo;s commissions and other leasing costs)
	all no less favorable to Landlord than as called for in this Lease, nor shall Landlord be required to make or permit any assignment,
	or sublease for more than the current term or which Landlord would not be required to permit under the provisions of Section 13.2.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 27PT">
</TD>
<TD STYLE="WIDTH: 27PT">
	(iii)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Until such time as Landlord shall elect to terminate the Lease and shall thereupon be entitled
	to recover the amounts specified in such case in Section 11.2 (c), Tenant shall pay to Landlord upon demand the full amount of
	all rent, including any amounts treated as additional rent under this Lease and other sums reserved in this Lease for the remaining
	Term, together with the costs of repairs, alterations, additions, redecorating and Landlord&rsquo;s expenses of reletting and the
	collection of the rent accruing therefrom (including attorneys&rsquo; fees and broker&rsquo;s commissions), as the same shall then
	be due or become due from time to time, less only such consideration as Landlord may have received from any reletting of the Premises;
	and Tenant agrees that Landlord may file suits from time to time to recover any sums falling due under this Lease as they become
	due. Any proceeds of reletting by Landlord in excess of the amount then owed by Tenant to Landlord from time to time shall be credited
	against Tenant&rsquo;s future obligations under this Lease but shall not otherwise be refunded to Tenant or inure to Tenant&rsquo;s
	benefit.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 20 -->
<DIV STYLE="MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
	-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	16
<!-- FIELD: /SEQUENCE -->
	-
</P>
</DIV>
<A NAME="eolPage117"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<P STYLE="MARGIN: 0PT; TEXT-ALIGN: RIGHT; FONT-SIZE: 18PT">
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Consistent with Section 6.2 hereof, Landlord
	may, at Landlord&rsquo;s option, enter into and upon the Premises if Landlord determines in its sole discretion that Tenant is
	not acting within a commercially reasonable time to maintain, repair or replace anything for which Tenant is responsible under
	this Lease and correct the same, without being deemed in any manner guilty of trespass, eviction or forcible entry and detainer
	and without incurring any liability for any damage or interruption of Tenant&rsquo;s business resulting therefrom and bill Tenant
	the cost thereof as provided in Section 6.2. If Tenant shall have vacated the Premises, Landlord may at Landlord&rsquo;s option
	re-enter the Premises at any time during the last six months of the then current Term of this Lease and make any and all such changes,
	alterations, revisions, additions and tenant and other improvements in or about the Premises as Landlord shall elect, all without
	any abatement of any of the rent otherwise to be paid by Tenant under this Lease.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Tenant expressly waives any right to: (a)
	trial by jury; and (b) service of any notice required by any present or future law or ordinance applicable to landlords or tenants
	but not required by the terms of this Lease.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Pursuit of any of the foregoing remedies
	shall not preclude pursuit of any of the other remedies provided in this Lease or any other remedies provided by law (all such
	remedies being cumulative), nor shall pursuit of any remedy provided in this Lease constitute a forfeiture or waiver of any rent
	due to Landlord under this Lease or of any damages accruing to Landlord by reason of the violation of any of the terms, provisions
	and covenants contained in this Lease. Notwithstanding any provision of this Lease (including any provision which may provide a
	reduction in liability to Tenant for rent collected by Landlord in reletting the Premises) or in law, Landlord, in the event of
	an Event of Default, shall have no duty to mitigate damages and the same is hereby expressly waived by Tenant and disclaimed by
	Landlord.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	No act or thing done by Landlord or its
	agents during the Term shall be deemed a termination of this Lease or an acceptance of the surrender of the Premises, and no agreement
	to terminate this Lease or accept a surrender of said Premises shall be valid, unless in writing signed by Landlord. No waiver
	by Landlord of any violation or breach of any of the terms, provisions and covenants contained in this Lease shall be deemed or
	construed to constitute a waiver of any other violation or breach of any of the terms, provisions and covenants contained in this
	Lease. Landlord&rsquo;s acceptance of the payment of rental or other payments after the occurrence of an Event of Default shall
	not be construed as a waiver of such Default, unless Landlord so notifies Tenant in writing. Forbearance by Landlord in enforcing
	one or more of the remedies provided in this Lease upon an Event of Default shall not be deemed or construed to constitute a waiver
	of such Default or of Landlord&rsquo;s right to enforce any such remedies with respect to such Default or any subsequent Default.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Any and all property which may be removed
	from the Premises by Landlord pursuant to the authority of this Lease or of law, to which Tenant is or may be entitled, may be
	handled, removed, disposed of and/or stored, as the case may be, by or at the direction of Landlord but at the risk, cost and expense
	of Tenant, and Landlord shall in no event be responsible for the value, preservation or safekeeping thereof. Any such property
	of Tenant shall, at Landlord&rsquo;s option, be deemed conveyed by Tenant to Landlord under this Lease as by a bill of sale without
	further payment or credit by Landlord to Tenant.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	ARTICLE XII
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
<U>
	SECURITY DEPOSIT
</U>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-RIGHT: 0; MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-RIGHT: 0; MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	Section 12.1&nbsp;&nbsp;&nbsp;&#9;
<U>
	Security Deposit
</U>
	&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[INTENTIONALLY
	DELETED]
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	ARTICLE XIII
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
<U>
	ADDITIONAL TENANT AGREEMENTS
</U>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	Section 13.1&nbsp;&nbsp;&nbsp;&#9;
<U>
	Mortgage Financing,
	Subordination and Attornment
</U>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Provided that Tenant is provided with a
	reasonable and customary nondisturbance and attornment agreement duly executed by the holder of any mortgage, deed to secure debt,
	or deed of trust, this Lease and all of Tenant&rsquo;s rights hereunder are and shall be subordinate to any mortgage, deed of trust
	or deed to secure debt (&ldquo;Mortgage&rdquo;) upon the Premises, whether such Mortgage is in existence as of the date hereof
	or created hereafter, as well as to any existing ground lease. Subject to the foregoing, the subordination provided for in this
	section is self-operative; however, Tenant shall, upon request of either Landlord, the holder of any Mortgage now or hereafter
	placed upon the Landlord&rsquo;s interest in the Premises or future additions thereto, or the lessor under any ground lease now
	or hereafter affecting the Premises, execute and deliver upon demand, such further instruments subordinating this Lease to the
	lien of any such Mortgage or ground lease, provided such subordination shall be upon the express condition that this Lease shall
	be recognized by the mortgagees and ground lessors and that the rights of Tenant shall remain in full force and effect during the
	term of this Lease and any extension thereof, notwithstanding any default by the mortgagors with respect to the mortgages or any
	foreclosure thereof, or any default by the ground lessee, so long as Tenant shall perform all of the covenants and conditions of
	this Lease. Tenant agrees to execute within ten (10) days of Landlord&rsquo;s written request all agreements required by Landlord&rsquo;s
	mortgagee or ground lessor or any purchaser at a foreclosure sale or sale in lieu of foreclosure by which agreements Tenant will
	attorn to the mortgagee or purchaser or ground lessor without requiring Landlord to make alterations or improvements to the Premises
	or modifications to the Lease.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
</P>
<!-- FIELD: PAGE; SEQUENCE: 21 -->
<DIV STYLE="MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
	-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	17
<!-- FIELD: /SEQUENCE -->
	-
</P>
</DIV>
<A NAME="eolPage118"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<P STYLE="MARGIN: 0PT; TEXT-ALIGN: RIGHT; FONT-SIZE: 18PT">
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Section 13.2&nbsp;&nbsp;&nbsp;&#9;
<U>
	Assignment or Subletting
</U>
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	All assignments of this Lease or sublease
	or subleases of the Premises by Tenant shall be subject to and in accordance with all of the provisions of this Section.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Tenant may not assign this Lease or sublease
	the Premises, in whole or in part, without first having obtained the written consent of Landlord, which consent shall not be unreasonably
	withheld or delayed.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Any assignment or sublease by Tenant shall
	be only for the purpose specified in Section 1.1, Item 4 of the Lease, and for no other purpose, without the prior written consent
	of Landlord, and in no event shall any assignment or sublease of the Premises release or relieve Tenant from any obligations of
	this Lease.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	It shall be a condition to any consent
	by Landlord to an assignment or sublease that Tenant shall pay to Landlord a processing fee in the amount of One Thousand and 00/100
	Dollars ($1,000.00) as reimbursement to Landlord for its review and preparation of assignment or sublease-related documents, which
	may be incurred by Landlord in connection therewith. Payment of such fee shall be submitted along with Tenant&rsquo;s request for
	Landlord&rsquo;s consent. Any consent by Landlord to any assignment or sublease, or to the operation of a concessionaire or licensee,
	shall not constitute a waiver or the necessity for such consent to any subsequent assignment or sublease, or operation by a concessionaire
	or licensee.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	In the event Tenant shall sublease any
	portion of the Premises for rentals in excess of the Rent payable hereunder on a per square foot basis higher than Tenant is paying
	hereunder, Tenant shall pay to Landlord, as Additional Rent hereunder, fifty percent (50%) of such excess rentals.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Any proposed assignee or subtenant of Tenant
	shall assume Tenant&rsquo;s obligations hereunder and deliver to Landlord an assumption agreement in form satisfactory to Landlord
	no less than ten (10) days prior to the effective date of the proposed assignment.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Notwithstanding any of the foregoing provisions,
	if Tenant is in default under any of the terms of this Lease beyond any notice and cure period, Tenant may not assign or sublet
	the Premises in whole or in part.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Notwithstanding the foregoing provisions
	of this Section 13.2 or anything to the contrary in this Lease, it is agreed that Tenant shall have the right, without the prior
	consent of Landlord, to assign this Lease or sublet any part of or all of the Leased Premises to an Affiliate (as defined below)
	(a &quot;Permitted Assignment&quot;), provided that Tenant notifies Landlord within ten (10) days following any Permitted Assignment.
	Any assignee under a Permitted Assignment shall be entitled to all of Tenant&rsquo;s right, title and interest under this Lease,
	including, but not limited to, all rights to exercise any options to renew or extend the term of this Lease as provided herein.
	An &ldquo;Affiliate&rdquo; shall mean (i) a wholly owned subsidiary of Tenant, (ii) the parent of Tenant, or (iii) any corporation
	into or with which Tenant may be merged or consolidated.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Section 13.3&nbsp;&nbsp;&nbsp;&#9;
<U>
	Tenant&rsquo;s
	Notice to Landlord of Default
</U>
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Should Landlord be in default under any
	of the terms of this Lease, Tenant shall give Landlord prompt written notice thereof in the manner specified in Section 14.1, Notices,
	and Tenant shall allow Landlord a reasonable length of time in which to cure such default, which time shall not in any event be
	less than thirty (30) days from the date of such notice, provided, however, that if such failure cannot, by its nature, be cured
	within such thirty (30) day period, but Landlord commences and diligently pursues a cure of such failure promptly within the initial
	thirty (30) day cure period, then Landlord shall not be in default under this Lease. In the event Landlord is in breach of this
	Lease beyond the applicable notice and cure period, (and in addition to any other remedies provided elsewhere in this Lease), Tenant
	shall be entitled to exercise and pursue all rights and remedies available at law or in equity.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Section 13.4&nbsp;&nbsp;&nbsp;&#9;
<U>
	No Recording of
	Lease
</U>
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Tenant agrees not to record this Lease
	without the express written consent of Landlord.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Section 13.5&nbsp;&nbsp;&nbsp;&#9;
<U>
	Surrender of Premises
	and Holding Over
</U>
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Upon the expiration of the Term of this
	Lease, Tenant shall surrender the Premises in good condition, reasonable wear and tear excepted, and damage by unavoidable casualty,
	and Tenant shall surrender all keys for the Premises to Landlord at the place then fixed for the payment of rent and shall inform
	Landlord of all combinations on locks, safes and vaults, if any, in the Premises. Tenant shall remove all its trade fixtures and
	any alterations or improvements, subject to the provisions of Section 8.5, before surrendering the Premises, and shall repair,
	at its own expense, any damage to the Premises caused thereby. Any of Tenant&rsquo;s property not so removed shall be deemed abandoned
	by Tenant and may be retained or disposed of by Landlord as Landlord shall desire, without any liability to Tenant and Tenant hereby
	expressly waives and releases all claims against Landlord and its agents therefor. Tenant&rsquo;s obligations to observe or perform
	this covenant shall survive the expiration or other termination of the term of this Lease. In the event Tenant remains in possession
	of the Premises after the expiration of the tenancy created hereunder, whether or not with the consent or acquiescence of Landlord,
	and without the execution of a new lease, Tenant, at the option of Landlord, shall be deemed to be occupying the Premises as a
	tenant at will on a month-to-month tenancy. The rent during this month-to-month tenancy shall be payable monthly at one hundred
	twenty-five percent (125%) of the Fixed Minimum Rent and it shall be subject to all the other terms, conditions, covenants, provisions
	and obligations of this Lease, and no extension or renewal of this Lease shall be deemed to have occurred by such holding over.
	Tenant&rsquo;s obligations to observe or perform its obligations set forth herein, shall survive the expiration or other termination
	of the term of this Lease.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
</P>
<!-- FIELD: PAGE; SEQUENCE: 22 -->
<DIV STYLE="MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
	-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	18
<!-- FIELD: /SEQUENCE -->
	-
</P>
</DIV>
<A NAME="eolPage119"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<P STYLE="MARGIN: 0PT; TEXT-ALIGN: RIGHT; FONT-SIZE: 18PT">
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Section 13.6&nbsp;&nbsp;&nbsp;&#9;
<U>
	Estoppel Certificate
</U>
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Tenant agrees to provide at any time, within
	ten (10) business days of Landlord&rsquo;s written request, a statement certifying that this Lease is unmodified and in full force
	and effect or, if there have been modifications, that the Lease is in full force and effect as modified and stating the modifications,
	the dates to which the Fixed Minimum Rent and other charges have been paid in advance, if any, and such other information reasonably
	requested by Landlord, a prospective purchaser or mortgagee without requiring Landlord to make alterations or improvements to the
	Premises or modifications to the Lease. It is intended that any such statement delivered pursuant to this Section may be relied
	upon by any prospective purchaser or mortgagee of the Premises.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Section 13.7&nbsp;&nbsp;&nbsp;&#9;
<U>
	Compliance With
	Law, Waste
</U>
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Tenant shall comply with all governmental
	laws, ordinances and regulations applicable to the use of the Premises and shall promptly comply with all governmental orders and
	directives for the correction, prevention and abatement of nuisances in, upon, or connected with the Premises, all at Tenant&rsquo;s
	sole risk and expense. Tenant shall not commit, or suffer to be committed, any waste upon the Premises or any nuisance, other act,
	or thing. Tenant agrees that it shall be responsible for complying in all respects with the Americans With Disabilities Act of
	1990, as such Act may be amended from time to time, and all regulations promulgated therein (collectively, the &ldquo;ADA&rdquo;),
	as it affects the Premises, including but not limited to, making, to the extent required by the ADA, &ldquo;readily achievable&rdquo;
	changes to remove any architectural or communications barriers, and providing auxiliary aides and services within the Premises.
	Tenant further agrees that any and all alterations made to the Premises during the Term will comply with the requirements of the
	ADA. Tenant agrees that it will defend, indemnify and hold harmless Landlord and Landlord&rsquo;s trustees, policy holders, officers,
	employees, agents, attorneys, successors and assigns from and against any and all claims, demands, causes of action, suits, proceedings,
	liabilities, damages (including consequential and punitive damages), losses, costs and expenses, including reasonable attorneys&rsquo;
	fees, caused by, incurred, or resulting from Tenant&rsquo;s failure to comply with the obligations under this Section.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	Section 13.8&nbsp;&nbsp;&nbsp;&#9;
<U>
	Abandonment
</U>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Except as provided in 7.2, if Tenant shall
	abandon, vacate or surrender the Premises, or be dispossessed by process of law or otherwise, any personal property belonging to
	Tenant left on the Premises shall, at the option of the Landlord, be deemed abandoned.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	Section 13.9&nbsp;&nbsp;&nbsp;&#9;
<U>
	Relocation
</U>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &#9;[INTENTIONALLY
	OMITTED]
</B>
</P>
<P STYLE="MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	ARTICLE XIV
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
<U>
	MISCELLANEOUS PROVISIONS
</U>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	Section 14.1&nbsp;&nbsp;&nbsp;&#9;
<U>
	Notices
</U>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Unless expressly otherwise provided in
	this Lease, all notices required under this Lease to Landlord or Tenant shall be in writing and shall be addressed to the addresses
	and parties indicated in Item 16 of the Definitions or to any subsequent address or party which Landlord or Tenant may designate
	in writing. All notices shall be deemed to be properly served if delivered to the appropriate address and party by hand delivery,
	registered or certified mail (with postage prepaid and return receipt requested), courier or reputable overnight delivery service.
	Date of service of a notice served in accordance with this Section shall be the date of receipt or refusal of receipt.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	Section 14.2&nbsp;&nbsp;&#9;&#9;
<U>
	Entire and Binding
	Agreement
</U>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	This Lease contains all of the agreements
	between the parties hereto, and it may not be modified in any manner other than by agreement in writing signed by all parties hereto
	or their successors in interest. The terms, covenants and conditions contained herein shall inure to the benefit of and be binding
	upon Landlord and Tenant and their respective heirs, successors and assigns, except as may be otherwise expressly provided in this
	Lease.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
</P>
<!-- FIELD: PAGE; SEQUENCE: 23 -->
<DIV STYLE="MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
	-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	19
<!-- FIELD: /SEQUENCE -->
	-
</P>
</DIV>
<A NAME="eolPage120"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<P STYLE="MARGIN: 0PT; TEXT-ALIGN: RIGHT; FONT-SIZE: 18PT">
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	Section 14.3&nbsp;&nbsp;&nbsp;&#9;
<U>
	Provisions Severable
</U>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	If any term or provision of this Lease
	or the application hereof to any person or circumstance shall, to any extent, be illegal, invalid or unenforceable, the remainder
	of this Lease, or the application of such term or provision to persons or circumstances other than those to which it is held illegal,
	invalid or unenforceable shall not be affected hereby and each term and provision of this Lease shall be valid and be enforced
	to the fullest extent permitted by law.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	Section 14.4&nbsp;&nbsp;&nbsp;&#9;
<U>
	Captions
</U>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	The captions contained herein are for convenience
	and reference only and shall not be deemed as part of this Lease or construed as in any manner limiting or amplifying the terms
	and provisions of this Lease to which they relate.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	Section 14.5&nbsp;&nbsp;&nbsp;&#9;
<U>
	Relationship of the
	Parties
</U>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Nothing herein contained shall be deemed
	or construed as creating the relationship of principal and agent or of partnership or joint venture between the parties hereto;
	it being understood and agreed that neither the method of computing rent nor any other provision contained herein nor any acts
	of the parties hereto shall be deemed to create any relationship between the parties other than that of Landlord and Tenant.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	Section 14.6&nbsp;&nbsp;&nbsp;&#9;
<U>
	Accord and Satisfaction
</U>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	No payment by Tenant or receipt by Landlord
	of a lesser amount than the rental herein stipulated shall be deemed to be other than on account of the earliest stipulated rent
	nor shall any endorsement or statement on any check or any letter accompanying any check or payment as rent be deemed an accord
	and satisfaction, and Landlord may accept such check or payment without prejudice to Landlord&rsquo;s right to recover the balance
	of such rent or pursue any other remedy provided for in this Lease or available at law or in equity.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	Section 14.7&nbsp;&nbsp;&nbsp;&#9;
<U>
	Broker&rsquo;s Commission
</U>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	With the exception of Stephanie Marino
	of Avison Young &ndash; Atlanta, LLC (&ldquo;Tenant&rsquo;s Broker&rdquo;)
<B>
	,
</B>
	who shall be paid by Landlord in accordance
	with the provisions of a separate commission agreement, Landlord shall have no further obligation for payment of commissions or
	fees to any other real estate broker, finder or intermediary in connection with this Lease. Landlord and Tenant hereby covenant,
	warrant and represent that Tenant's Broker was the only broker to represent the respective parties in the negotiation of this Lease.
	Landlord and Tenant agree to and hereby do defend, indemnify and hold the other harmless against and from any other brokerage commissions
	or finder's fees or claims therefor by a party claiming to have dealt with the indemnifying party and all costs, expenses and liabilities
	in connection therewith, including, without limitation, reasonable attorneys' fees and expenses, for any breach of the foregoing.
	The foregoing indemnification shall survive the termination of this Lease for any reason.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	Section 14.8&nbsp;&nbsp;&nbsp;&#9;
<U>
	Corporate Status
</U>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	If Tenant is a corporation, Tenant&rsquo;s
	corporate status shall continuously be in good standing and active and current with the state of its incorporation and the state
	in which the Premises is located at the time of execution of the Lease and at all times thereafter and Tenant shall keep its corporate
	status active and current throughout the Term of the Lease or any extensions or renewals. Upon Landlord&rsquo;s request, Tenant
	shall provide Landlord with a copy of the Certificate of Good Standing under Seal of Tenant&rsquo;s legal entity. Failure of Tenant
	to keep its corporate status active and current shall constitute a default under the terms of the Lease. To the extent applicable,
	the same requirements shall apply to any other form of business entity that Tenant may utilize.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	Section 14.9&nbsp;&nbsp;&nbsp;&#9;
<U>
	Hazardous Substances
</U>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 27PT">
	a)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Except to the extent used in the ordinary course of Tenant's business or for the routine maintenance
	of the Premises, and provided that Tenant complies at all times with all Hazardous Materials Laws, Tenant shall not cause or permit
	any of Tenant's agents, representatives, contractors or employees (collectively, the &quot;Tenant Parties&quot;) any of the following:
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 27PT">
</TD>
<TD STYLE="WIDTH: 27PT">
	(i)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	the presence, use, generation, release, treatment, processing, storage (including storage in above
	ground and underground storage tanks), handling, or disposal of any Hazardous Materials defined as petroleum and petroleum products
	and compounds containing them, including gasoline, diesel fuel and oil; explosives; flammable materials; radioactive materials;
	polychlorinated biphenyls (&ldquo;PCBs&rdquo;) and compounds containing them; lead and lead-based paint; asbestos or asbestos-containing
	materials in any form that is or could become friable; underground or above-ground storage tanks, whether empty or containing any
	substance; any substance the presence of which on the Premises is prohibited by any federal, state or local authority; any substance
	that requires special handling; and any other material or substance now or in the future defined as a &ldquo;hazardous substance,&rdquo;
	&ldquo;hazardous material,&rdquo; &ldquo;hazardous waste,&rdquo; &ldquo;toxic substance,&rdquo; &ldquo;toxic pollutant,&rdquo;
	&ldquo;contaminant,&rdquo; or &ldquo;pollutant&rdquo; within the meaning of any Hazardous Materials Law. &ldquo;Hazardous Materials
	Laws&rdquo; means all federal, state and local laws, ordinances and regulations and standards, rules, policies and other governmental
	requirements, administrative rulings and court judgments and decrees in effect now or in the future and including all amendments,
	that relate to Hazardous Materials and apply to Tenant or to the Premises. Hazardous Materials Laws include, but are not limited
	to, the Comprehensive Environmental Response, Compensation and Liability Act, 42 U.S.C. Section 9601, et seq., the Resource Conservation
	and Recovery Act, 42 U.S.C. Section 6901, et seq., the Toxic Substance Control Act, 15 U.S.C. Section 2601, et seq., the Clean
	Water Act, 33 U.S.C. Section 1251, et seq., and the Hazardous Materials Transportation Act, 49 U.S.C. Section 5101, et seq.,);
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
</P>
<!-- FIELD: PAGE; SEQUENCE: 24 -->
<DIV STYLE="MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
	-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	20
<!-- FIELD: /SEQUENCE -->
	-
</P>
</DIV>
<A NAME="eolPage121"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<P STYLE="MARGIN: 0PT; TEXT-ALIGN: RIGHT; FONT-SIZE: 18PT">
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 27PT">
</TD>
<TD STYLE="WIDTH: 27PT">
	(ii)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	the transportation of any Hazardous Materials to, from, or across the Premises; or
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 27PT">
</TD>
<TD STYLE="WIDTH: 27PT">
	(iii)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	any occurrence or condition on the Premises which is or may be in violation of Hazardous Materials
	Laws;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	The matters described
	in clauses (a) (i) through (iii) above are referred to collectively in this Section 14.9 as &ldquo;Prohibited Activities or Conditions.&rdquo;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 27PT">
	b)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Tenant represents and warrants to Landlord that:
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 27PT">
</TD>
<TD STYLE="WIDTH: 27PT">
	(i)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Tenant will not at any time engage in or cause, or permit any of the Tenant Parties to engage in
	or cause, any Prohibited Activities or Conditions; and
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 27PT">
</TD>
<TD STYLE="WIDTH: 27PT">
	(ii)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Tenant will comply with all Hazardous Materials Laws.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 27PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0PT">
	The representations
	and warranties in this Section 14.9 shall be continuing representations and warranties that shall be deemed to be made by Tenant
	throughout the Term of the Lease including any renewals or extensions.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 27PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0PT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 27PT">
	c)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Tenant shall promptly notify Landlord in writing upon the occurrence of any of the following events:
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 27PT">
</TD>
<TD STYLE="WIDTH: 27PT">
	(i)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Tenant&rsquo;s discovery of any Prohibited Activity or Condition;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 27PT">
</TD>
<TD STYLE="WIDTH: 27PT">
	(ii)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Tenant&rsquo;s receipt of or knowledge of any complaint, order, notice of violation or other communication
	from any Government Authority or other person with regard to present or future alleged Prohibited Activities or Conditions or any
	other environmental, health or safety matters affecting the Premises; and
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 27PT">
</TD>
<TD STYLE="WIDTH: 27PT">
	(iii)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	any representation or warranty in this Section 14.9 becomes untrue after the date of this Lease.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 27PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0PT">
	Any such notice
	given by Tenant shall not relieve Tenant of, or result in a waiver of, any obligation under this Lease.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 27PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0PT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 27PT">
	d)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	If because of anything attributable to Tenant, any investigation, site monitoring, containment,
	clean-up, restoration or other remedial work (&ldquo;Remedial Work&rdquo;) is necessary to comply with any Hazardous Materials
	Law or order of any Governmental Authority that has or acquires jurisdiction over the Premises or the use, operation, or improvement
	of the Premises under any Hazardous Materials Law, Tenant shall, by the earlier of (1) the applicable deadline required by Hazardous
	Materials Law or (2) 30 days after notice from Landlord demanding such action, begin performing the Remedial Work, and thereafter
	diligently prosecute it to completion, and shall in any event complete the work by the time required by applicable Hazardous Materials
	Law. If Tenant fails to begin on a timely basis or diligently prosecute any required Remedial Work, Landlord may, at its option,
	cause the Remedial Work to be completed, in which case Tenant shall reimburse Landlord on demand for the cost of doing so.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 27PT">
	e)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Tenant shall indemnify, hold harmless, and defend Landlord from and against all proceedings, claims,
	damages, penalties and costs (whether initiated or sought by Governmental Authorities or private parties), including fees and out-of-pocket
	expenses of attorneys and expert witnesses, investigatory fees, and remediation costs, whether incurred in connection with any
	judicial or administrative process or otherwise, arising directly or indirectly from any of the following:
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 27PT">
</TD>
<TD STYLE="WIDTH: 27PT">
	(i)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	any breach of any representation or warranty of Tenant in this Section 14.9;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 27PT">
</TD>
<TD STYLE="WIDTH: 27PT">
	(ii)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	any failure by Tenant to perform any of its obligations under this Section 14.9;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 27PT">
</TD>
<TD STYLE="WIDTH: 27PT">
	(iii)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	the existence or alleged existence of any Prohibited Activity or Condition by Tenant or any of
	the Tenant Parties;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 27PT">
</TD>
<TD STYLE="WIDTH: 27PT">
	(iv)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	the presence or alleged presence of Hazardous Materials on or under the Premises caused by Tenant
	or any of the Tenant Parties; and
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 27PT">
</TD>
<TD STYLE="WIDTH: 27PT">
	(v)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	the actual or alleged violation of any Hazardous Materials Law by Tenant or any of the Tenant Parties.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 25 -->
<DIV STYLE="MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
	-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	21
<!-- FIELD: /SEQUENCE -->
	-
</P>
</DIV>
<A NAME="eolPage122"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<P STYLE="MARGIN: 0PT; TEXT-ALIGN: RIGHT; FONT-SIZE: 18PT">
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 27PT">
	f)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Tenant shall, at its own cost and expense, do all of the following:
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 27PT">
</TD>
<TD STYLE="WIDTH: 27PT">
	(i)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	pay or satisfy any judgment or decree that may be entered against Landlord in any legal or administrative
	proceeding incident to any matters against which Landlord is entitled to be indemnified under this Section 14.9;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 27PT">
</TD>
<TD STYLE="WIDTH: 27PT">
	(ii)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	reimburse Landlord for any expenses paid or incurred in connection with any matters against which
	Landlord is entitled to be indemnified under this Section 14.9; and
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 27PT">
</TD>
<TD STYLE="WIDTH: 27PT">
	(iii)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	reimburse Landlord for any and all expenses, including fees and out-of-pocket expenses of attorneys
	and expert witnesses, paid or incurred in connection with the enforcement by Landlord of its rights under this Section 14.9, or
	in monitoring and participating in any legal or administrative proceeding.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 27PT">
	g)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	If Tenant consists of more than one person or entity, the obligation of those persons or entities
	to indemnify Landlord under this Section 14.9 shall be joint and several. The obligation of Tenant to indemnify Landlord under
	this Section 14.9 shall survive the termination of the Lease.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	Section 14.10&nbsp;&nbsp;
<U>
	Inability to Perform
</U>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	If either party is delayed or prevented
	from performing any of its obligations under this Lease, with the exception of Tenant's obligation to pay Rent, by reason of such
	causes, including but not limited to, the delays by governmental and administrative agencies in granting such party&rsquo;s permits
	or approvals required for any improvements to the Premises, strikes, labor disputes, inability to procure materials, natural disaster,
	or any other cause whatsoever beyond such party&rsquo;s reasonable control, the period of such delay or such prevention shall be
	deemed added to the time herein provided for the performance of any obligation by such party.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	Section 14.11&nbsp;&#9;
<U>
	Joint and Several
	Liability
</U>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	If two or more individuals, corporations,
	partnerships or other business associations (or any combination of two or more thereof) shall sign this Lease as Tenant, the liability
	of each such individual, corporation, partnership or other business association to pay rent and perform all other obligations hereunder
	shall be deemed to be joint and several and all notices, payments and agreements given or made by, with or to anyone of such individuals,
	corporations, partnerships, or other business associations shall be deemed to have been given or made by, with or all of them.
	In like manner, if Tenant shall be a partnership or other business association, the members of which are by virtue of state or
	federal law, subject to personal liability, the liability of each such member shall be joint and several.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	Section 14.12&nbsp;&#9;
<U>
	Time of the Essence
</U>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	It is understood and agreed between the
	parties hereto that time is of the essence of all the terms, covenants and conditions of this Lease.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	Section 14.13&nbsp;&#9;
<U>
	Governing Law
</U>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	This Lease and the rights and obligations
	of the parties hereunder shall be construed in accordance with the internal substantive laws of the State of Georgia without regard
	to choice of law principles.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Section 14.14&nbsp;&#9;
<U>
	Attorney&rsquo;s
	Fees
</U>
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Tenant shall pay to Landlord all costs
	and expenses, including but not limited to attorney&rsquo;s fees, incurred by Landlord for and in connection with the review, drafting
	and negotiation of any lease amendment, modification, tenant finance or other document, or the granting of any waiver or consent
	under the Lease requested by Tenant, in respect of or related to the Lease or Tenant&rsquo;s tenancy at the Premises (each a &ldquo;Related
	Lease Matter&rdquo;) requested by Tenant, which Landlord, in its discretion determines to be of benefit to Tenant; provided, however,
	if Landlord determines in its sole reasonable discretion that the Related Lease Matter equally benefits Landlord and Tenant, Landlord
	and Tenant shall share equally in any attorney&rsquo;s fees incurred by Landlord. Notwithstanding the foregoing, Tenant shall pay
	to Landlord all costs and expenses, including reasonable attorney&rsquo;s fees, incurred by Landlord incident to the participation
	in, or in connection with, a case or proceeding under any chapter of the Bankruptcy Code, any statute or any law dealing with insolvency,
	assignment for the benefit of creditors, receivership, or similar proceeding or probate, or any successor statute thereto brought
	by or against Tenant. If either Landlord or Tenant shall commence any action or other proceeding against the other arising out
	of, or relating to, this Lease or the Premises, including the enforcement of any of the covenants and agreements of this Lease,
	the prevailing party shall be entitled to recover from the losing party, in addition to any other relief, its reasonable attorney&rsquo;s
	fees, irrespective of whether the action or other proceeding is prosecuted to judgment or other final order (without regard to
	the application of O.C.G.A. &sect; 13-1-11, or any other fee limiting statute). This shall also include reasonable attorney&rsquo;s
	fees in the event of an appeal.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
</P>
<!-- FIELD: PAGE; SEQUENCE: 26 -->
<DIV STYLE="MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
	-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	22
<!-- FIELD: /SEQUENCE -->
	-
</P>
</DIV>
<A NAME="eolPage123"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<P STYLE="MARGIN: 0PT; TEXT-ALIGN: RIGHT; FONT-SIZE: 18PT">
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	Section 14.15&nbsp;&#9;
<U>
	Signage
</U>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Landlord may erect and maintain such suitable
	signs as Landlord, in its sole discretion, may deem appropriate to advertise the Premises. Tenant may erect and maintain, at its
	sole cost and expense, signs upon the exterior of the Premises and beneath the canopy, which shall be of such size and type and
	in such locations as Landlord may approve. Tenant shall keep insured and shall maintain such signs in good condition and repair
	at all times, and such signs must be lighted at all times after sunset when the Premises is in operation, whether Tenant&rsquo;s
	Premises are open for business or not, unless Landlord shall, by written approval given to Tenant, waive such requirement. If any
	damage is done to Tenant&rsquo;s signs, Tenant shall repair same within fifteen(15) days provided if such repairs cannot reasonably
	be accomplished within such period, to begin performance within such period and to pursue performance diligently to completion
	in a reasonable time thereafter. If Tenant fails to do so, Landlord shall have the right to repair such signs and bill Tenant for
	cost of the repairs, as further provided in Section 6.2.Tenantagrees to maintain any sign, awning, canopy decoration, lettering,
	advertising matter, or other things as may be approved by Landlord, in good condition and repair at all times.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Any sign, awning, canopy or advertising
	matter or decoration of any kind, erected or placed by Tenant in violation of this Section, may be removed by Landlord without
	notice and without liability, and any expenses incurred by Landlord in such removal shall be charged to and paid by Tenant upon
	demand.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Tenant's signage must be approved by Landlord
	and provided by Tenant. Landlord hereby approves of Tenant's sign package attached hereto as Exhibit &quot;E&quot;. Landlord&rsquo;s
	approval does not constitute any assurance that Tenant&rsquo;s signage satisfies governmental regulations and requirements. All
	signs must adhere to the following sign criteria:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 27PT">
	a)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Signs shall contain only the store name. There shall be no listing of merchandise or service, and
	no slogans;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 27PT">
	b)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	The maximum letter height contained in any sign shall not exceed Twenty Percent (20%) of storefront
	height. No sign shall exceed in width Seventy-Five Percent (75%) of the storefront width;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 27PT">
	c)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Signs shall be installed within the area leased to tenants and shall not project beyond the property
	line of space leased to tenants;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 27PT">
	d)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	There shall be only one sign for each storefront, provided that any tenant having store frontage
	on more than one facade may install one sign for each elevation;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 27PT">
	e)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Signs must be illuminated. The illumination must be internal. Internal illumination by individual
	metal channel letters with neon tubing in translucent Plexiglas face, or opaque sign panel with letter cut out, backed up with
	translucent Plexiglas and illuminated with neon or fluorescent tubing from behind;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 27PT">
	f)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	The following will not be permitted in any signs:
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 27.35PT">
</TD>
<TD STYLE="WIDTH: 27.35PT">
	(i)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Exposed neon tubing;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 27.35PT">
</TD>
<TD STYLE="WIDTH: 27.35PT">
	(ii)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Animated components;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 27.35PT">
</TD>
<TD STYLE="WIDTH: 27.35PT">
	(iii)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Intermittent illumination;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 27.35PT">
</TD>
<TD STYLE="WIDTH: 27.35PT">
	(iv)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Iridescent painted sign;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 27.35PT">
</TD>
<TD STYLE="WIDTH: 27.35PT">
	(v)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Luminous sign panel;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 27.35PT">
</TD>
<TD STYLE="WIDTH: 27.35PT">
	(vi)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Back lighting (inverted metal channel letters containing exposed neon tubing);
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 27PT">
</TD>
<TD STYLE="WIDTH: 27PT">
	(vii)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Exterior signs mounted on exterior walls or rooftops except for identification signs within Tenant
	facade on main entrances of shops.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 27PT">
	g)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	All signs must comply with applicable governmental regulations and requirements.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	Section 14.16&nbsp;&#9;
<U>
	No Offer
</U>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	The submission of this Lease by Landlord
	is not an offer to lease the Premises, nor an agreement by Tenant to lease the Premises. Neither party will be bound until both
	Landlord and Tenant have duly executed and delivered an original lease to each other.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	Section 14.17&nbsp;&#9;
<U>
	Tenant&rsquo;s Representations
</U>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	In order to induce Landlord to enter into
	this Lease, Tenant represents and warrants that Tenant has full right, power and lawful authority to execute, deliver and perform
	its obligations under this Lease, in the manner and upon the terms contained herein, with no other person needing to join in the
	execution hereof in order for this Lease to be binding on Tenant.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
</P>
<!-- FIELD: PAGE; SEQUENCE: 27 -->
<DIV STYLE="MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
	-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	23
<!-- FIELD: /SEQUENCE -->
	-
</P>
</DIV>
<A NAME="eolPage124"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<P STYLE="MARGIN: 0PT; TEXT-ALIGN: RIGHT; FONT-SIZE: 18PT">
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	Section 14.18&nbsp;&#9;
<U>
	Landlord&rsquo;s
	Representations
</U>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	In order to induce Tenant to enter into
	this Lease, Landlord represents and warrants that Landlord has full right, power and lawful authority to execute, deliver and perform
	its obligations under this Lease, in the manner and upon the terms contained herein, with no other person needing to join in the
	execution hereof in order for this Lease to be binding on Landlord.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	Section 14.19&nbsp;&#9;
<U>
	Pro Rata Share
</U>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	Wherever reference is
	made to Tenant&rsquo;s &ldquo;pro rata share,&rdquo; the prorating of such share shall equal one hundred percent (100%).
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
<B>
	Section 14.20&nbsp;
</B>
	&#9;
<B>
<U>
	Tenant&rsquo;s
	Financial Records
</U>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	Landlord may divulge
	such information in any litigation or arbitration proceedings between the parties and confidential, to a prospective buyer or encumbrancer
	of the Premises. After written request from Landlord, Tenant shall make available to Landlord copies of Tenant&rsquo;s audited
	financial and quarterly financial statements for the prior five (5) years, which includes the subsidiary plasma Premises segment
	sales and financials, or the Landlord can electronically access such annual audited and quarterly financials through Tenant's website,
	www.admabiologics.com.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
<B>
	Section 14.21&nbsp;&#9;
<U>
	Pest
	Control
</U>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Tenant shall obtain at Tenant&rsquo;s sole
	cost, a pest control agreement subject to Landlord&rsquo;s reasonable approval with a reputable pest control contractor for the
	control of roaches, ants, termites, rats, mice and other miscellaneous vermin throughout the term of this Lease and all renewals
	thereafter. The agreement shall provide that the space shall be serviced at least once per quarter by the service provider. Landlord
	shall be provided with a copy of said agreement.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	Section 14.22&nbsp;&#9;
<U>
	Confidentiality
</U>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="TEXT-TRANSFORM: UPPERCASE">
	Tenant
	hereby agrees not to disclose, and to TAKE THE NECESSARY STEPS TO PREVENT its employees and agents FROM DISCLOSING to any other
	party any information regarding the terms of this Lease, including without limitation the Basic Rental rate; provided that Tenant
	may disclose such terms to its employees and agents pursuant to a legitimate need to disclose such terms.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	Section 14.23&nbsp;&#9;
<U>
	Mold
</U>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	It is generally understood that mold spores
	are part of the environment, present essentially everywhere and can grow in most moist locations. Tenant acknowledges that control
	of moisture and mold prevention is integral to its lease obligations. Emphasis is properly placed on prevention of moisture and
	on good housekeeping and ventilation practices. Tenant acknowledges the necessity of housekeeping, ventilation, and moisture control
	(especially in kitchens, janitor&rsquo;s closets, bathrooms, break rooms and around outside walls) for mold prevention. Prior to
	executing this Lease, Tenant first has inspected the Premises and certifies that Tenant has not observed mold, mildew and/or moisture
	conditions (from any source, including leaks), and shall take appropriate corrective action to remediate such condition. TENANT
	EXPRESSLY ASSUMES AND ACCEPTS ANY AND ALL RISKS INVOLVED IN OR RELATED TO, AND RELEASES LANDLORD AND LANDLORD&rsquo;S MANAGERS,
	AGENTS, EMPLOYEES AND OFFICERS FROM LIABILITY FOR ANY PERSONAL INJURY OR DAMAGES TO PROPERTY CAUSED BY OR ASSOCIATED WITH MOISTURE
	OR THE GROWTH OR OCCURRENCE OF MOLD OR MILDEW WITHIN THE PREMISES DURING THE TERM OF THIS LEASE, EXCEPT TO THE EXTENT SUCH MOLD
	OR MILDEW IS CAUSED BY LANDLORD OR LANDLORD'S MANAGERS, AGENTS, EMPLOYEES OR OFFICERS OR CAUSED BY THE BREACH BY LANDLORD OF ITS
	OBLIGATIONS UNDER THIS LEASE.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	Section 14.24&nbsp;&#9;
<U>
	Anti-Terrorism Representation
	and Warranty
</U>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	To each party's actual knowledge, Landlord
	and Tenant each represent and warrant that neither they nor the officers and directors controlling Landlord and Tenant, respectively,
	are acting, directly or indirectly, for or on behalf of any person, group, entity or nation named by the United States Treasury
	Department as a Specially Designated National and Blocked Person, or for or on behalf of any person, group, entity or nation designated
	in Presidential Executive Order 13224 as a person who commits, threatens to commit or supports terrorism; and that they are not
	engaged in this transaction or facilitating this transaction, directly or indirectly, on behalf of any such person, group, entity
	or nation. In the event the representation set forth above is not accurate, then the non-defaulting party may terminate this Lease
	on thirty (30) days&rsquo; notice, which notice must include an explanation as to why that party is terminating the Lease; provided,
	however, that such termination shall be null and void in the event the defaulting party removes the specially designated or blocked
	person from any interest in the defaulting party within such 30-day period.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
</P>
<!-- FIELD: PAGE; SEQUENCE: 28 -->
<DIV STYLE="MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
	-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	24
<!-- FIELD: /SEQUENCE -->
	-
</P>
</DIV>
<A NAME="eolPage125"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<P STYLE="MARGIN: 0PT; TEXT-ALIGN: RIGHT; FONT-SIZE: 18PT">
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	Section 14.25&nbsp;&#9;
<U>
	Limitation on Right
	of Recovery Against Landlord
</U>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="TEXT-TRANSFORM: UPPERCASE">
	Tenant
	acknowledges and agrees that the liability of Landlord under this Lease shall be limited to its interest in the Premises and any
	judgments rendered against Landlord shall be satisfied solely out of the proceeds of sale of its interest in the Premises. No personal
	judgment shall lie against Landlord upon extinguishment of its rights in the Premises and any judgment so rendered shall not give
	rise to any right of execution or levy against Landlord&rsquo;s assets. The provisions hereof shall inure to Landlord&rsquo;s successors
	and assigns including any Mortgagee. The foregoing provisions are not intended to relieve Landlord from the performance of any
	of Landlord&rsquo;s obligations under this Lease, but only to limit the personal liability of Landlord in case of recovery of a
	judgment against Landlord; nor shall the foregoing be deemed to limit Tenant&rsquo;s rights to obtain injunctive relief or specific
	performance or to avail itself of any other right or remedy which may be awarded Tenant by law or under this Lease.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="TEXT-TRANSFORM: UPPERCASE">
	If
	Tenant claims or asserts that Landlord has violated or failed to perform a covenant of Landlord not to unreasonably withhold or
	delay Landlord&rsquo;s consent or approval, Tenant&rsquo;s sole remedy shall be an action for specific performance, declaratory
	judgment or injunction and in no event shall Tenant be entitled to any money damages for a breach of such covenant and in no event
	shall Tenant claim or assert any claim for any money damages in any action or by way of set off, defense or counterclaim and Tenant
	hereby specifically waives the right to any money damages or other remedies.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	IN WITNESS WHEREOF,
	Landlord and Tenant have duly executed this Lease under seal as of the day and year first above written, each acknowledging receipt
	of an executed copy hereof.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	[SIGNATURES APPEAR ON THE FOLLOWING PAGES]
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
</P>
<!-- FIELD: PAGE; SEQUENCE: 29 -->
<DIV STYLE="MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
	-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	25
<!-- FIELD: /SEQUENCE -->
	-
</P>
</DIV>
<A NAME="eolPage126"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<P STYLE="MARGIN: 0PT; TEXT-ALIGN: RIGHT; FONT-SIZE: 18PT">
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	[LANDLORD'S SIGNATURE PAGE]
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_20"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 50%">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Signed, sealed and delivered
	in the presence of:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<U STYLE="TEXT-DECORATION: NONE">
	&nbsp;
</U>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<U STYLE="TEXT-DECORATION: NONE">
	&nbsp;
</U>
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<U>
</U>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<U>
</U>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<U>
</U>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<U>
</U>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<U>
</U>
	_____________________
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Notary Public or Witness
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<U>
</U>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	_____________________
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Name (Please Print)&nbsp;
</P>
</TD>
<TD STYLE="WIDTH: 50%">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	LANDLORD:
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	HOME CENTER PROPERTIES, LLC, a Georgia limited liability
	company
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 30.6PT; TEXT-INDENT: -30.6PT">
	By:&#9;&nbsp;MIMMS INVESTMENTS, a
	Georgia general partnership, its sole managing member
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 30.6PT; TEXT-INDENT: -30.6PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	By:
<U>
	&#9; /s/Robert C. Mimms&#9;
</U>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Name:
<U>
	&#9;Robert C. Mimms&#9;
</U>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Title:
<U>
	&#9;General Partner&#9;
</U>
</P>
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
</P>
<!-- FIELD: PAGE; SEQUENCE: 30 -->
<DIV STYLE="MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
	-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	26
<!-- FIELD: /SEQUENCE -->
	-
</P>
</DIV>
<A NAME="eolPage127"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<P STYLE="MARGIN: 0PT; TEXT-ALIGN: RIGHT; FONT-SIZE: 18PT">
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	[TENANT'S SIGNATURE PAGE]
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 50%">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Signed, sealed and delivered
	in the presence of:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<U STYLE="TEXT-DECORATION: NONE">
	&nbsp;
</U>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<U>
	/s/ Allison Kerr
</U>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Notary Public or Witness
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<U>
	Allison Kerr&#9;
</U>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Name (Please Print)
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
</P>
</TD>
<TD STYLE="WIDTH: 50%">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	TENANT:
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	ADMA BIO CENTERS GEORGIA INC., a Delaware corporation
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	By:
<U>
	&#9;/s/ Brian Lenz&#9;
</U>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Name:
<U>
	&#9;Brian Lenz&#9;
</U>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Title:
<U>
	Vice President and Chief
	Financial Officer&#9;
</U>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	&nbsp;
</B>
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
</P>
<!-- FIELD: PAGE; SEQUENCE: 31 -->
<DIV STYLE="MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
	-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	27
<!-- FIELD: /SEQUENCE -->
	-
</P>
</DIV>
<A NAME="eolPage128"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<P STYLE="MARGIN: 0PT; TEXT-ALIGN: RIGHT; FONT-SIZE: 18PT">
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	EXHIBIT &ldquo;A&rdquo;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	ADMA BIO CENTERS GEORGIA INC.
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
<U>
	SPECIAL STIPULATIONS
</U>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 27PT">
	1.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	In the event that any of the foregoing terms and conditions of the Lease shall conflict with the
	following Special Stipulations, then in such event the within and following Special Stipulations shall control.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 27PT">
	2.
</TD>
<TD>
	Fixed Minimum Rent and Additional Rent shall be as follows:
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_21"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD COLSPAN="3">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="TEXT-ALIGN: CENTER">
	Landlord's Operating
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="3" NOWRAP STYLE="TEXT-ALIGN: CENTER">
	Total Fixed Minimum Rent,
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD COLSPAN="3">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="TEXT-ALIGN: CENTER">
	Costs, Taxes and
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="3" NOWRAP STYLE="TEXT-ALIGN: CENTER">
	Landlord&rsquo;s Operating Costs,
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD COLSPAN="3">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="TEXT-ALIGN: CENTER">
	Fixed
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="TEXT-ALIGN: CENTER">
	Insurance
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="TEXT-ALIGN: CENTER">
	Taxes &amp; Insurance Charges
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD COLSPAN="3">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="TEXT-ALIGN: CENTER">
	MinimumRent
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="TEXT-ALIGN: CENTER">
	Charges Monthly*
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="TEXT-ALIGN: CENTER">
	Monthly
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD COLSPAN="3" STYLE="TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Term
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Monthly
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	(Adjustable)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	(Adjustable)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 20%; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	&#9;Months 1 &ndash; 5
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 5%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 19%; TEXT-ALIGN: RIGHT">
	0.00
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	**
</TD>
<TD STYLE="WIDTH: 5%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 19%; TEXT-ALIGN: RIGHT">
	0.00
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 5%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 19%; TEXT-ALIGN: RIGHT">
	0.00
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	&#9;Months 6
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	17,300.00
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	***
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	2,982.09
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	20,282.09
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	&#9;Months 7 &ndash; 17
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	19,300.00
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	2,982.09
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	22,282.09
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	&#9;Months 18 &ndash; 29
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	19,879.00
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	2,982.09
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	22,861.09
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	&#9;Months 30 &ndash; 41
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	20,475.00
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	2,982.09
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	23,457.09
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	&#9;Months 42 &ndash; 53
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	21,089.00
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	2,982.09
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	24,071.09
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	&#9;Months 54 &ndash; 65
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	21,722.00
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	2,982.09
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	24,704.09
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	&#9;Months 66&ndash; 77
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	22,374.00
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	2,982.09
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	25,356.09
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	&#9;Months 78 &ndash; 89
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	23,045.00
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	2,982.09
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	26,027.09
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	&#9;Months 90 &ndash; 101
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	23,736.00
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	2,982.09
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	26,718.09
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	&#9;Months 102 &ndash; 105
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	0.00
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	**
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	0.00
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	0.00
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<I>
	&nbsp;
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<I>
	[*]NOTE: Landlord's Operating Costs=
	$1,238.09/mo.;
</I>
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<I>
	Taxes = $1,632.00/mo.; Insurance = $112.00/mo.
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<I>
	[**] NOTE: Subject to the terms of Special
	Stipulation No. 4 below.
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<I>
	[***] NOTE: This sum reflects a $2,000
	credit related to Tenant&rsquo;s
</I>
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<I>
	replacement of the electrical panel in
	the FMLS portion of the Premises.
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 27PT">
	3.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Commencing on the Rent Commencement Date, Tenant hereby agrees to pay Landlord, on or before the
	first of each month, Two Thousand Nine Hundred Eighty-Two and 00/100 Dollars ($2,982.09) as Tenant&rsquo;s estimated share of Landlord's
	Operating Costs, Taxes and Insurance for the Premises. Said amount may be adjusted, as Landlord deems necessary, which shall be
	based on actual expenses incurred by Landlord.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 27PT">
	4.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="COLOR: WINDOWTEXT">
	Notwithstanding any provision to the contrary in the Lease, provided
	Tenant is not in default hereunder beyond the expiration of any applicable notice and cure period, the Ren
</FONT>
	t and Additional
	Rent
<FONT STYLE="COLOR: WINDOWTEXT">
	for the Abatement Months (as defined below) shall be conditionally excused and Tenant shall
	not be obligated to make payments of Rent and Additional Rent for the Abatement Months (the &ldquo;Conditionally Excused Rent&rdquo;).
	The &quot;Abatement Months&quot; shall refer to the first Five (5) calendar months of the Term beginning on the Lease Commencement
	Date and the last Four (4) months of the term beginning on month 102. If an uncured Event of Default occurs at any time during
	the Lease Term, then (i) if applicable,
</FONT>
	the
<FONT STYLE="COLOR: WINDOWTEXT">
	Abatement Month shall immediately cease and
	Tenant shall have no further right to the Conditionally Excused Rent
</FONT>
	and (ii) the full value of the abated Fixed Minimum
	Rent shall be immediately due and payable to Landlord
<FONT STYLE="COLOR: WINDOWTEXT">
	. If no such uncured Event of Default occurs
	during the Lease Term, then the
</FONT>
	Conditionally Excused
<FONT STYLE="COLOR: WINDOWTEXT">
	Rent will be deemed
</FONT>
	irrevocably
<FONT STYLE="COLOR: WINDOWTEXT">
	waived
</FONT>
	by Landlord.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 27PT">
	5.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Provided the Lease is in full force and effect, and provided there has been no Event of Default
	(beyond any applicable notice and cure periods) during the Term of the Lease, Tenant shall have the option to extend the Term of
	the Lease (each an &quot;Option&quot;) for two (2) additional periods of five (5) years each (each an &ldquo;Extension Term&rdquo;).
	Tenant shall give Landlord written notice of Tenant&rsquo;s desire to exercise each Option at least one hundred eighty (180) days
	prior to the expiration of the then existing Term of the Lease (the &ldquo;Extension Notice Deadline&rdquo;). If Landlord does
	not actually receive such written extension notice on or before 5:00 p.m., Atlanta, Georgia time on the Extension Notice Deadline,
	then Tenant shall be deemed to have waived its rights to exercise an Option (such Option becoming null and void no further force
	or effect) under this Special Stipulation number 5, and Landlord shall be automatically released from any and all obligations,
	and the then current Term shall expire as scheduled. If Landlord does actually receive such written extension notice on or before
	5:00 p.m., Atlanta, Georgia time on or before the Extension Notice Deadline, then, subject to the foregoing, the Term shall be
	extended for the Extension Term on the following terms and conditions:&nbsp;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 32 -->
<DIV STYLE="MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
	-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	28
<!-- FIELD: /SEQUENCE -->
	-
</P>
</DIV>
<A NAME="eolPage129"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<P STYLE="MARGIN: 0PT; TEXT-ALIGN: RIGHT; FONT-SIZE: 18PT">
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.75IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
	(i)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	The Extension Term shall be on the same terms, covenants and conditions as this Lease, except that
	the Fixed Minimum Rent payable during the applicable Extension Term shall be an amount equal to the fair market Fixed Minimum Rent
	for the Premises as of the commencement of such Extension Term.&nbsp; Landlord and Tenant shall determine and agree upon the fair
	market rate of Fixed Minimum Rent no later than the expiration of Lease term.&nbsp; If Landlord and Tenant do not agree upon the
	fair market rate of Fixed Minimum Rent by the end of the then current Lease Term, the Fixed Minimum rental rate for the applicable
	Extension Term shall be determined by appraisal pursuant to subparagraph (ii), below.&nbsp; &nbsp;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.75IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
	(ii)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	If Landlord and Tenant do not timely agree upon the aforesaid terms by the expiration of the Lease
	term, then within seven (7) days after said date, Landlord and Tenant shall mutually appoint an appraiser that has at least ten
	(10) years full-time commercial appraisal experience and is a member of the American Institute of Real Estate Appraisers.&nbsp;
	If Landlord and Tenant are unable to agree upon an appraiser, either Landlord or Tenant, after giving five (5) days&rsquo; prior
	written notice to the other party, may apply to the then president of the Atlanta Board of Realtors for the selection of an appraiser
	who meets the foregoing qualifications, which selection shall be made within fifteen (15) days after such application.&nbsp; The
	appraiser selected by the president of the Board of Realtors shall be a person who has not previously acted in any capacity for
	either party, its affiliates or leasing agents and who meets the above experience qualifications.&nbsp; Landlord and Tenant shall
	each, within seven (7) days after the appointment (either by agreement or selection) of the appraiser, submit to the appraiser
	such party&rsquo;s determination of such fair market Fixed Minimum Rent.&nbsp; Within twenty (20) days after the expiration of
	such seven-day period, the appraiser shall select one of the two submittals as the more reasonable, and the submittal so selected,
	shall be the Fixed Minimum Rent for the Extension Term.&nbsp; If, upon the expiration of such seven (7) day period, the appraiser
	shall have received one of the party&rsquo;s submittal of its proposed fair market Fixed Minimum Rent, but not both, then the appraiser
	shall select the proposal of the fair market Fixed Minimum Rent so submitted.&nbsp;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 27PT">
	6.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Tenant shall have the right to use, on a non-exclusive basis, the parking spaces on the Premises
	as delineated on Exhibit &ldquo;B-1&rdquo; for use of parking vehicles.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 27PT">
	7.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Tenant may install a panel on the pylon or monument sign, at Tenant&rsquo;s own expense, as shown
	on Exhibit &ldquo;B-5&rdquo; subject to Landlord&rsquo;s reasonable approval, local code and governmental approval. Landlord&rsquo;s
	approval of signage does not necessarily guarantee approval by local municipalities. The Landlord is responsible for removing current
	signage on the exterior of the building. Tenant may also have signage on front of the Premises facing Barrett Parkway and may also
	elect to have signage on the designated area on the side of the building facing I-575. Tenant shall also have the right to place
	signage on the front door to the Premises. All signage shall be installed by Tenant, at Tenant&rsquo;s sole cost and expense.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 27PT">
	8.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; PADDING-RIGHT: 3PT">
	Landlord acknowledges that Tenant will have biomedical waste on the Premises
	and that Landlord shall permit such activity.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 2.9PT 0PT 27PT; TEXT-ALIGN: JUSTIFY">
	Landlord represents that,
	to the best of its knowledge without inquiry, the Premises are free from hazardous substances and that there has never been environmental
	pollution to the Premises. Landlord agrees to indemnify and hold Tenant harmless from and against any and all claims, damages,
	liabilities, costs, penalties and fines which Tenant may suffer as a result of environmental pollution caused prior or subsequent
	to the occupancy of the Premises by Tenant as a result of damage or injury from hazardous substances placed in or about the Premises
	by any party other than Tenant or a Tenant party.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 2.9PT 0PT 27PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 27PT; TEXT-ALIGN: JUSTIFY">
	Notwithstanding anything to the
	contrary contained in the Lease, Tenant shall be solely responsible for complying with all federal, state and local laws, whether
	now existing or established in the future, relating in any way to the storage, containment, treatment, transfer, transportation
	and disposal of biomedical waste (including the use of licensed medical waste management companies) and shall indemnify and hold
	Landlord harmless for Tenant&rsquo;s noncompliance or violations thereof. No such biomedical waste shall be held or deposited in
	containers outside of the Premises. For purposes hereof, &ldquo;biomedical waste&rdquo; shall mean any solid, semisolid or liquid
	waste which is collected from any part of the body of human beings (this is in addition to Tenant&rsquo;s obligations under Section
	14.9 of the Lease).
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 27PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 27PT; TEXT-ALIGN: JUSTIFY">
</P>
<!-- FIELD: PAGE; SEQUENCE: 33 -->
<DIV STYLE="MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
	-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	29
<!-- FIELD: /SEQUENCE -->
	-
</P>
</DIV>
<A NAME="eolPage130"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<P STYLE="MARGIN: 0PT; TEXT-ALIGN: RIGHT; FONT-SIZE: 18PT">
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 27PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 27PT; TEXT-ALIGN: JUSTIFY">
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 27PT">
	9.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Except as provided for in the Lease (including Exhibit &quot;B-4&quot;), Tenant shall be responsible
	for all improvements to the Premises to prepare the Premises for Tenant&rsquo;s use and occupancy under this Lease (hereinafter
	referred to as &ldquo;Tenant Improvements&rdquo;). Tenant shall make all improvements with materials and workmanship of a quality
	and character at least equal to that at the Premises. All such work shall be done by Tenant or licensed contractors in accordance
	with applicable building, fire, health, sanitary and other codes, regulations and local ordinances in a good, workmanlike manner.
	Landlord shall promptly sign and execute such documents or otherwise evidence its approval, consent or grant of authority, as required
	by any public authorities having jurisdiction thereover, to facilitate issuance to Tenant of necessary licenses or permits to make
	or perform the improvements at no cost to Landlord. Tenant shall furnish Landlord a copy of the plans and specifications for all
	such improvements.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 27PT; TEXT-ALIGN: JUSTIFY">
	Landlord shall have the right
	to review and approve the interior drawings at the end of design development, whose approval shall not be unreasonably withheld,
	conditioned or delayed. Landlord and Tenant shall mutually and reasonably agree upon a schedule of delivery and review of the architectural
	and engineering plans to allow for the timely commencement of the construction.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 27PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 27PT; TEXT-ALIGN: JUSTIFY">
	Upon expiration or earlier termination
	of the Lease, ownership of the Tenant Improvements shall transfer to Landlord and they shall not be removed from the Premises except
	to the extent otherwise provided for in the Lease.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 27PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 27PT">
	10.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Tenant shall have control of the Premises HVAC on a 24/7 basis. Landlord shall warrant HVAC, electrical
	(to the exterior walls of the Premises not within the Premises), and plumbing (to the exterior walls of the Premises not within
	the Premises) for twelve (12) months from lease commencement unless necessary repair or replacements by the acts, omissions or
	negligence of Tenant. Tenant shall have the right to locate its backup electrical generator and cooling equipment condensers anywhere
	within the red line shown on Exhibit &ldquo;B-1&rdquo; attached hereto.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 27PT">
	11.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	The Adjacent Space as identified in Exhibit, &ldquo;B-2&rdquo; for 2,707 square feet is currently
	occupied by First Multiple Service Listing Service, Inc. (the Current Tenant). In the event the Landlord is unsuccessful in terminating
	the lease with the Current Tenant on or before the Lease Commencement Date, this Lease shall be amended to reflect the reduced
	square footage of the Premises until such time as the Landlord obtains possession of the Adjacent Space and delivers to the Tenant
	such Adjacent Space in the condition required by this Lease.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 27PT">
	12.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Subject to the provisions of that certain Sign Easement Agreement dated September 11, 2014, by
	and between Home Center Properties, LLC, as &ldquo;Grantor&rdquo; and Chastain Meadows 2014, LLC as &ldquo;Grantee&rdquo; as amended
	by that certain First Amendment to Sign Easement dated April 17, 2015 (&ldquo;Sign Easement&rdquo;). Tenant may use that certain
	panel on the monument sign for Home Center Village Shopping Center as indicated on Exhibit, &ldquo;B-5&rdquo; attached hereto and
	incorporated herein by reference. Tenant shall have all the benefits and obligations of Grantor under the Sign Easement.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 27PT">
	13.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Tenant shall have the right to paint the roof on the building located on the Premises, so long
	as Tenant first obtains Landlord&rsquo;s consent to color of paint to be used.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 34 -->
<DIV STYLE="MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
	-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	30
<!-- FIELD: /SEQUENCE -->
	-
</P>
</DIV>
<A NAME="eolPage131"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<P STYLE="MARGIN: 0PT; TEXT-ALIGN: RIGHT; FONT-SIZE: 18PT">
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	EXHIBIT &ldquo;B-1&rdquo;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	ADMA BIO CENTERS GEORGIA INC.
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<U>
	SITE PLAN
</U>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	[Image of Site Plan]
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
</P>
<!-- FIELD: PAGE; SEQUENCE: 35 -->
<DIV STYLE="MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
	-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	31
<!-- FIELD: /SEQUENCE -->
	-
</P>
</DIV>
<A NAME="eolPage132"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<P STYLE="MARGIN: 0PT; TEXT-ALIGN: RIGHT; FONT-SIZE: 18PT">
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	EXHIBIT &ldquo;B-2&rdquo;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	ADMA BIO CENTERS GEORGIA INC.
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<U>
	EXISTING FLOOR PLAN
</U>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	&nbsp;[Image of Floor Plan]
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
</P>
<!-- FIELD: PAGE; SEQUENCE: 36 -->
<DIV STYLE="MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
	-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	32
<!-- FIELD: /SEQUENCE -->
	-
</P>
</DIV>
<A NAME="eolPage133"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<P STYLE="MARGIN: 0PT; TEXT-ALIGN: RIGHT; FONT-SIZE: 18PT">
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	EXHIBIT &ldquo;B-3&rdquo;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	ADMA BIO CENTERS GEORGIA INC.
</B>
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
<U>
	PROPOSED FLOOR PLAN
</U>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	&nbsp;[Image of Floor Plan]&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
</P>
<!-- FIELD: PAGE; SEQUENCE: 37 -->
<DIV STYLE="MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
	-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	33
<!-- FIELD: /SEQUENCE -->
	-
</P>
</DIV>
<A NAME="eolPage134"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<P STYLE="MARGIN: 0PT; TEXT-ALIGN: RIGHT; FONT-SIZE: 18PT">
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	&nbsp;&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	EXHIBIT &ldquo;B-4&rdquo;
</B>
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	ADMA BIO CENTERS GEORGIA INC.
</B>
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
<U>
	LANDLORD&rsquo;S WORK
</U>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Prior to the Lease Commencement Date, and
	except as hereinafter provided to the contrary, Landlord, at Landlord&rsquo;s sole cost and expense and in compliance with all
	applicable codes, laws, regulations and ordinances, will perform or cause to be performed, the work described in items 1 through
	12 below (collectively, &quot;Landlord's Work&quot;):
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 27PT">
	1.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Landlord will deliver to the Tenant in good working order all existing heating, venting and air
	conditioning systems, plumbing systems (toilets, sinks), and electrical systems (panels, outlets, switches, and lighting) in place
	on the Premises (hereinafter the &ldquo;Systems&rdquo;) as of the Effective Date of this Lease. Upon taking the possession of the
	Premises by the Tenant, the Tenant shall have thirty (30) days within which to inspect, or cause said Systems to be inspected,
	to determine if any of the Systems are not in good working order. Tenant acknowledges that Tenant has a duty and an obligation
	to make such an inspection or cause such an inspection to be made and notify the Landlord within the time provided for herein of
	any non-compliance. If the Landlord shall not receive any such notice within the aforementioned thirty (30) day period, it shall
	be conclusive that the Tenant has accepted the Systems &ldquo;as-is&rdquo; &ldquo;where-is&rdquo; on the date of taking possession
	of the Premises and Landlord shall have no further obligation with regard to said Systems except as provided for in the Lease.
	Should the Tenant notify the Landlord of any system which is not in good working order, then the Landlord, at Landlord's sole cost
	and expense, shall cause the system to be operating in good working order.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 27PT">
	2.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Landlord shall repair or add metal studs, sheetrock, tape, mud, and sand all interior perimeter
	walls and support columns to a minimum height above new drop ceiling grid (which new drop ceiling grid shall be installed at Tenant&rsquo;s
	expense), or as required by code.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 27PT">
	3.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Landlord shall supply the Premises with, and/or install in the Premises, one (1) ton of HVAC per
	350 square feet of floor space. All units shall be Landlord&rsquo;s standard units. Ductwork and registers shall be designed and
	installed to distribute air throughout the Premises. Ductwork and registers shall be Landlord&rsquo;s standard fiberglass duct
	board trunk, insulated wire flex branches, and 3 tab step-down diffusers.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 27PT">
	4.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Landlord shall remove all existing floor coverings and glue to concrete slab.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 27PT">
	5.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Landlord shall provide the materials for standard commercial grade 2'-0&quot; x 4'-0&quot; white
	acoustical tile lay-in ceiling system. Tenant shall be responsible for installation.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 27PT">
	6.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Landlord&rsquo;s standard 2'-0&quot; x 4'-0&quot; (4) bulb fluorescent light fixtures shall be
	installed, one (1) per eighty (80) square feet of floor space.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 27PT">
	7.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Landlord shall install sprinkler lines and heads throughout the Premises.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 27PT">
	8.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Landlord shall pressure wash the exterior of the building
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 27PT">
	9.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Landlord shall make all repairs required pursuant to the Building Envelope Assessment Report prepared
	by BETEC, Inc., which report is attached to the Lease as Exhibit &quot;G&quot;.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 27PT">
	10.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Landlord shall repaint exterior walls of the surfaces that are currently painted on the Premises.
	Colors for paint shall be selected by the Tenant and approved by the Landlord.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 27PT">
	11.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Landlord shall install new
	mechanically fastened 45 mil TPO roof membrane over existing EPDM section of the roof that services the Premises.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 27PT; TEXT-INDENT: -27PT">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 27PT; TEXT-INDENT: -27PT">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	12.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Landlord
	will reseal and restripe the parking lot.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 27PT">
	Notwithstanding anything
	in the Lease to the contrary, the Lease Commencement Date will be the date upon which Landlord's Work has been substantially completed
	by Landlord in accordance with the provisions of the Lease (the &ldquo;Substantial Completion Date&rdquo;). The Substantial Completion
	Date is defined to be the date when (i) Landlord's Work is complete in accordance with the Lease and this Exhibit &quot;B-4&quot;,
	other than those punch-list items of work and adjustment of equipment and fixtures in the Premises, the incompleteness of which
	do not cause material and unreasonable interference with Tenant's use of or access to the Premises for the operation of Tenant&rsquo;s
	business in the entire Premises, (ii) the Premises are broom clean; (iii) Landlord has obtained a temporary or permanent certificate
	of occupancy (and if temporary then a permanent certificate of occupancy within thirty (30) days of the Substantial Completion
	Date and Tenant has delivered to Landlord the Lease Commencement Date Letter Exhibit D attached hereto) for Tenant's use of the
	Premises, and (iv) the Premises have been delivered to Tenant pursuant to notice from Landlord. In the event that the Substantial
	Completion Date has not occurred within one hundred and twenty (120) days from the date Landlord commences Landlord&rsquo;s Work,
	then Tenant shall have the right to terminate this Lease by giving Landlord written notice of such termination within ten (10)
	days following such date. Notwithstanding the foregoing, Tenant acknowledges and agrees that Landlord shall have no obligation
	to commence with performing Landlord&rsquo;s Work until the contingency set forth in Special Stipulation No. 14 on Exhibit &ldquo;A&rdquo;
	to these Lease is satisfied or waived in writing by Tenant.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 27PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 27PT">
</P>
<!-- FIELD: PAGE; SEQUENCE: 38 -->
<DIV STYLE="MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
	-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	34
<!-- FIELD: /SEQUENCE -->
	-
</P>
</DIV>
<A NAME="eolPage135"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<P STYLE="MARGIN: 0PT; TEXT-ALIGN: RIGHT; FONT-SIZE: 18PT">
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 27PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 27PT">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	As used in this Exhibit &quot;B-4&quot;,
	the term &quot;Force Majeure Delay&quot; shall mean only an actual delay resulting from fire, earthquake, explosion, flood, hurricane,
	tornado, the elements, acts of God or the public enemy, war, invasion, insurrection, rebellion, riots, industry-wide labor strikes
	or lockouts (which objectively preclude Landlord from obtaining from any reasonable source of labor or substitute materials at
	a reasonable cost necessary for completing Landlord's Work), or governmental acts. Notwithstanding anything to the contrary contained
	herein, a Force Majeure Delay shall not include any of the foregoing delays to the extent caused by the gross negligence or willful
	misconduct of Landlord, its contractors or agents. As used in this Exhibit &quot;B-4&quot;, &quot;Tenant Delay&quot; shall mean
	a delay resulting from the acts of Tenant including, but not limited to, interference or delay in approving plans, signing applications
	to authorities having jurisdiction, and the like, and failure to perform its work as stated above (e.g. Item 6) in a timely manner
	by Tenant, its agents or employees with the completion of Landlord's Work and which objectively preclude performance of Landlord&rsquo;s
	Work by any person.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	As soon as Landlord's Work has been substantially
	completed, Landlord will notify Tenant in writing. Within ten (10) days thereafter, Tenant will submit to Landlord in writing a
	punch list of items needing completion or correction. Landlord will use its reasonable diligence to complete such items within
	thirty (30) days after the receipt of such notice. Punchlist items will not cause a delay in the Lease Commencement Date, provided
	that Landlord's Work is substantially completed as defined above.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
</P>
<!-- FIELD: PAGE; SEQUENCE: 39 -->
<DIV STYLE="MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
	-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	35
<!-- FIELD: /SEQUENCE -->
	-
</P>
</DIV>
<A NAME="eolPage136"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<P STYLE="MARGIN: 0PT; TEXT-ALIGN: RIGHT; FONT-SIZE: 18PT">
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	EXHIBIT &ldquo;B-5&rdquo;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	ADMA BIO PREMISES GEORGIA INC.
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
<U>
	PYLON SIGNAGE
</U>
</B>
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	&nbsp;&nbsp;[Image of Signage]
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
</P>
<!-- FIELD: PAGE; SEQUENCE: 40 -->
<DIV STYLE="MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
	-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	36
<!-- FIELD: /SEQUENCE -->
	-
</P>
</DIV>
<A NAME="eolPage137"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<P STYLE="MARGIN: 0PT; TEXT-ALIGN: RIGHT; FONT-SIZE: 18PT">
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	EXHIBIT &ldquo;C&rdquo;
</B>
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	ADMA BIO CENTERS GEORGIA INC.
</B>
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
<U>
	RULES AND REGULATIONS
</U>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 27PT">
	1.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	All loading and unloading of goods shall be done only at such times in the areas and through the
	entrances reasonably designated for such purposes by Landlord.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 27PT">
	2.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	The delivery or shipping of merchandise, supplies and fixtures to and from the Premises shall be
	subject to such reasonable rules and regulations as in the judgment of Landlord are necessary for the proper operation of the Premises.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 27PT">
	3.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Tenant will not utilize any unethical method of business operation nor shall any space in the Premises
	be used for living quarters, whether temporary or permanent.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 27PT">
	4.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Tenant shall have full responsibility for protecting the Premises and the property located therein
	from theft and robbery and shall keep all doors and windows securely fastened when not in use.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 27PT">
	5.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	No aerial, satellite dish, or other similar device shall be erected on the roof or exterior walls
	of the Premises or on the grounds without, in each instance, the written consent of the Landlord. Any aerial, satellite dish or
	similar device so installed without such written consent shall be subject to removal without notice at any time without liability
	to Landlord and the expenses involved in said removal shall be charged to and paid by Tenant upon demand.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 27PT">
	6.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	No loudspeakers, televisions, phonographs, radios or other devices shall be used in a manner so
	as to be heard or seen outside of the Premises without the prior written consent of Landlord.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 27PT">
	7.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Tenant shall maintain the inside of the Premises at a temperature sufficiently high to prevent
	freezing of water in pipes and fixtures inside the Premises.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 27PT">
	8.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	The plumbing facilities shall not be used for any other purpose than that for which they are constructed
	and no foreign substance of any kind shall be deposited therein. The expenses of any breakage, stoppage or damage resulting from
	a violation of this provision shall be borne by Tenant.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 27PT">
	9.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Tenant shall not burn any trash or garbage of any kind in or about Premises.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 27PT">
	10.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Tenant shall not cause or permit any unusual or objectionable odors to be produced upon or permeated
	from the Premises nor shall Tenant vent any cooking fumes or odors into the interior of the Premises.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 27PT">
	11.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	The sidewalk, entrances, passages, quarters or halls shall not be obstructed or encumbered by any
	tenant or used for any purpose other than ingress or egress to and from the Premises.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 27PT">
	12.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	No sales tables, displays, signs or other articles shall be put in front of or affixed to any part
	of the exterior of the Premises nor placed in the loading or parking area without the prior written consent of the Landlord.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 27PT">
	13.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Tenant shall not create or maintain, nor allow others to create or maintain, any nuisances, including
	without limiting the foregoing general language, loud noises, sound effects, bright lights, changing, flashing, flickering or lighting
	devices or similar devices, smoke or dust, the effect of which will be visible from the exterior of the Premises.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 27PT">
	14.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Tenant shall not conduct or allow to be conducted within, on or about the leased Premises an &ldquo;adult
	massage parlor&rdquo; or spa, or the sale or viewing of lingerie modeling, nude or erotic dancing, rated X or adult videos, books,
	tapes, magazines or other &ldquo;adult fantasy products&rdquo; or other products or services which would injure the reputation
	of the Premises or Landlord.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 27PT">
	15.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Landlord shall have the right to designate employee and customer parking during the term of this
	Lease.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 27PT">
	16.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	No animals of any kind may be brought into or kept in or about the Premises, with the exception
	of licensed service/guide dogs.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 27PT">
	17.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<P STYLE="MARGIN: 0PT 0">
	Landlord reserves the right to waive any rule in any particular instance or as to any particular person
	or occurrence and further, Landlord reserves the right to amend or rescind any of these rules or make, amend and rescind reasonable
	new rules to the extent Landlord, in its sole judgment, deems suitable for the safety, care and cleanliness of the Premises and
	the conduct of high standards of merchandising and services therein. Tenant agrees to conform to such new or amended rules upon
	receiving written notice of the same, and so long as Tenant's use of the Premises (including Tenant's use of Tenant's Parking)
	is not materially and adversely infringed.
</P>
<P STYLE="MARGIN: 0PT 0">
</P>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
</P>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
</P>
<!-- FIELD: PAGE; SEQUENCE: 41 -->
<DIV STYLE="MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
	-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	37
<!-- FIELD: /SEQUENCE -->
	-
</P>
</DIV>
<A NAME="eolPage138"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<P STYLE="MARGIN: 0PT; TEXT-ALIGN: RIGHT; FONT-SIZE: 18PT">
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
</P>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
</P>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	EXHIBIT &ldquo;D&rdquo;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	ADMA BIO CENTERS GEORGIA INC.
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
<U>
	LEASE COMMENCEMENT DATE LETTER
</U>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<U>
	166 BARRETT PARKWAY MARIETTA GA 30066
</U>
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<U>
	ACKNOWLEDGMENT OF TERM
</U>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<B>
	This Acknowledgment
	of Term
</B>
	(this &ldquo;Acknowledgment&rdquo;) is attached to and made a part of the Lease Agreement, dated the _____ day of __________,
	20__, by and between _________________, a _________________, as &ldquo;Landlord&rdquo;, and __________________, a _________________,
	as &ldquo;Tenant&rdquo; (the &ldquo;Lease&rdquo;).
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
	1.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Landlord and Tenant hereby agree that:
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 1IN">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 0.5IN">
	(a)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	The
	Lease Commencement is __________________.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 1IN">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 0.5IN">
	(b)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	The
	Rent Commencement Date is ____________________.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 1IN">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 0.5IN">
	(c)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	The Expiration
	Date of the Lease Term of the Lease is ___________________
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 1IN">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 0.5IN">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	[or, if Tenant exercises its Renewal Option for the
	Option Period, the Expiration Date shall be__________, 20__ ].
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 1IN">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 0.5IN">
	(d)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	The schedule of rent and charges in Special Stipulation No.
	2 on Exhibit &ldquo;A&rdquo; to the Lease is hereby replaced with the following rent schedule:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
</P>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
</P>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
</P>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;&nbsp;
</P>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_22"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 36%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 15%; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 20%; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 29%; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	Total Fixed Minimum Rent,
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	Fixed
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	Landlord's
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	Landlord's Operating
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	Minimum
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	Operating Costs
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	Costs and
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	Rent
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	Monthly
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	Charges Monthly
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-DECORATION: UNDERLINE; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
<U>
	Term
</U>
</FONT>
</TD>
<TD STYLE="TEXT-DECORATION: UNDERLINE; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
<U>
	Monthly
</U>
</FONT>
</TD>
<TD STYLE="TEXT-DECORATION: UNDERLINE; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
<U>
	(Adjustable)
</U>
</FONT>
</TD>
<TD STYLE="TEXT-DECORATION: UNDERLINE; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
<U>
	(Adjustable)
</U>
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	_______ to________
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	_______ to________
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	_______ to________
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
	2.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Tenant hereby confirms the following:
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 1IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
	(a)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	That it has accepted possession of the Premises pursuant to the terms of the Lease;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 1IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
	(b)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	To its actual knowledge, that Landlord has fulfilled all of its obligations under the Lease required
	to be fulfilled by Landlord on or prior to the date of this Acknowledgment;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 1IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
	(c)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	That Tenant has no existing right of setoff or credits against any rentals, nor has any security
	deposit been paid except as provided by the terms of the Lease; and
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 1IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
	(d)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	That the Lease is in full force and effect as of the date of this Acknowledgment.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 42 -->
<DIV STYLE="MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
	-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	38
<!-- FIELD: /SEQUENCE -->
	-
</P>
</DIV>
<A NAME="eolPage139"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<P STYLE="MARGIN: 0PT; TEXT-ALIGN: RIGHT; FONT-SIZE: 18PT">
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 50%">
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_23"></A>
<P STYLE="MARGIN: 0PT 0">
	WITNESS:
</P>
<P STYLE="MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="MARGIN: 0PT 0">
	___________________________
</P>
<P STYLE="MARGIN: 0PT 0">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Witness
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	WITNESS:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	_____________________________
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Witness
</P>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Title:____________________________
</P>
<P STYLE="MARGIN: 0PT 0">
</P>
</TD>
<TD STYLE="WIDTH: 50%">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
	LANDLORD:
</P>
<P STYLE="MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="MARGIN: 0PT 0">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-RIGHT: 0; MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT">
	____________________,
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-RIGHT: 0; MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT">
	a
	___________________
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-RIGHT: 0; MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-RIGHT: 0; MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT">
	By:_____________________________
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-RIGHT: 0; MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-RIGHT: 0; MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Name:___________________________
<U>
</U>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Title:____________________________
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	TENANT:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-RIGHT: 0; MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT">
	____________________,
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-RIGHT: 0; MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT">
	a
	___________________
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 3IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
</P>
<P STYLE="MARGIN: 0PT 0">
	By:_____________________________
</P>
<P STYLE="MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="MARGIN: 0PT 0">
	Name:___________________________
</P>
<P STYLE="MARGIN: 0PT 0">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-RIGHT: 0; MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 3IN">
	&nbsp;
</P>
<P STYLE="MARGIN: 0PT 0">
</P>
<P STYLE="MARGIN: 0PT 0">
	&nbsp;
</P>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
</P>
<!-- FIELD: PAGE; SEQUENCE: 43 -->
<DIV STYLE="MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
	-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	39
<!-- FIELD: /SEQUENCE -->
	-
</P>
</DIV>
<A NAME="eolPage140"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<P STYLE="MARGIN: 0PT; TEXT-ALIGN: RIGHT; FONT-SIZE: 18PT">
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	EXHIBIT &ldquo;E&rdquo;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	ADMA BIO CENTERS GEORGIA INC.
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
<U>
	TENANT'S SIGN PACKAGE
</U>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	&nbsp;
</B>
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	&nbsp;&nbsp;&nbsp;[Image of Signage]
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
</P>
<!-- FIELD: PAGE; SEQUENCE: 44 -->
<DIV STYLE="MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
	-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	40
<!-- FIELD: /SEQUENCE -->
	-
</P>
</DIV>
<A NAME="eolPage141"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<P STYLE="MARGIN: 0PT; TEXT-ALIGN: RIGHT; FONT-SIZE: 18PT">
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	EXHIBIT &ldquo;F&rdquo;
</B>
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	ADMA BIO CENTERS GEORGIA INC.
</B>
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
<U>
	BUILDING ENVELOPE ASSESSMENT REPORT
</U>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	(see attached)
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	-41-
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD>
	&nbsp;
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
</EFX_EXHIBIT_10>

<DIV CLASS="eolNewPage"></DIV>
<A NAME="eolPage142"></A>
<A NAME="E615811_EX23-1_HTM"></A>
<EFX_EXHIBIT_23>
<A NAME="FIS_EXHIBIT_23"></A>
<P STYLE="MARGIN: 0">
	&nbsp;
</P>
<P STYLE="MARGIN: 0">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: RIGHT">
	Exhibit 23.1
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: RIGHT">
	&nbsp;
</P>
<EFX_EXPERTS_CONSENT>
<A NAME="FIS_EXPERTS_CONSENT"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	Consent of Independent Registered
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	Public Accounting Firm
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	We consent to the incorporation by reference
	in the registration statements on Form S-8 (File Nos. 333-193635 and 333-204590) and Form S-3 (File No. 333-200638) filed by ADMA
	Biologics, Inc. of our report, which includes an explanatory paragraph relating to the Company&rsquo;s ability to continue as a
	going concern, dated February 24, 2017, on our audits of the consolidated financial statements of ADMA Biologics, Inc. and Subsidiaries
	as of December 31, 2016 and 2015 and for the years then ended, included in this Annual Report on Form 10-K of ADMA Biologics, Inc.
	for the year ended December 31, 2016.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	/s/ CohnReznick LLP
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Roseland, New Jersey
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	February 24, 2017
</P>
</EFX_EXPERTS_CONSENT>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="MARGIN: 0">
</P>
</EFX_EXHIBIT_23>

<DIV CLASS="eolNewPage"></DIV>
<A NAME="eolPage143"></A>
<A NAME="E615811_EX31-1_HTM"></A>
<EFX_EXHIBIT_31>
<A NAME="FIS_EXHIBIT_31"></A>
<P STYLE="MARGIN: 0">
	&nbsp;
</P>
<P STYLE="MARGIN: 0">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: RIGHT">
	Exhibit 31.1
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: RIGHT">
	&nbsp;
</P>
<EFX_CERTIFICATION>
<A NAME="FIS_CERTIFICATION"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	CERTIFICATION OF THE PRINCIPAL EXECUTIVE
	OFFICER
<BR>
	PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	I, Adam S. Grossman, certify that:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 9PT">
</TD>
<TD STYLE="WIDTH: 18PT">
	1.
</TD>
<TD>
	I have reviewed this annual report on Form 10-K of ADMA Biologics, Inc. for the year ended December 31, 2016;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 9PT">
</TD>
<TD STYLE="WIDTH: 18PT">
	2.
</TD>
<TD>
	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact
	necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with
	respect to the period covered by this report;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 9PT">
</TD>
<TD STYLE="WIDTH: 18PT">
	3.
</TD>
<TD>
	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in
	all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods
	presented in this report;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 9PT">
</TD>
<TD STYLE="WIDTH: 18PT">
	4.
</TD>
<TD>
	The registrant&rsquo;s other certifying officer and I are responsible for establishing and maintaining disclosure controls
	and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined
	in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 45PT">
</TD>
<TD STYLE="WIDTH: 18PT">
	(a)
</TD>
<TD>
	Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our
	supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known
	to us by others within those entities, particularly during the period in which this report is being prepared;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 45PT">
</TD>
<TD STYLE="WIDTH: 18PT">
	(b)
</TD>
<TD>
	Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed
	under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of
	financial statements for external purposes in accordance with generally accepted accounting principles;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 45PT">
</TD>
<TD STYLE="WIDTH: 18PT">
	(c)
</TD>
<TD>
	Evaluated the effectiveness of the registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions
	about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on
	such evaluation; and
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 45PT">
</TD>
<TD STYLE="WIDTH: 18PT">
	(d)
</TD>
<TD>
	Disclosed in this report any change in the registrant&rsquo;s internal control over financial reporting that occurred during
	the registrant&rsquo;s most recent fiscal quarter (the registrant&rsquo;s fourth fiscal quarter in the case of an annual report)
	that has materially affected, or is reasonably likely to materially affect, the registrant&rsquo;s internal control over financial
	reporting; and
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 9PT">
</TD>
<TD STYLE="WIDTH: 18PT">
	5.
</TD>
<TD>
	The registrant&rsquo;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control
	over financial reporting, to the registrant&rsquo;s auditors and the audit committee of the registrant&rsquo;s board of directors
	(or persons performing the equivalent functions):
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 45PT">
</TD>
<TD STYLE="WIDTH: 18PT">
	(a)
</TD>
<TD>
	All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting
	which are reasonably likely to adversely affect the registrant&rsquo;s ability to record, process, summarize and report financial
	information; and
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 45PT">
</TD>
<TD STYLE="WIDTH: 18PT">
	(b)
</TD>
<TD>
	Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&rsquo;s
	internal control over financial reporting.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	February 24, 2017
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="BORDER-BOTTOM: BLACK 1PT SOLID">
<FONT STYLE="FONT-SIZE: 10PT">
	/s/ Adam S. Grossman
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 52%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 2%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 9%">
<FONT STYLE="FONT-SIZE: 10PT">
	Name:
</FONT>
</TD>
<TD STYLE="WIDTH: 37%">
<FONT STYLE="FONT-SIZE: 10PT">
	Adam S. Grossman
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Title:
</FONT>
</TD>
<TD>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	President and Chief Executive Officer
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	(Principal Executive Officer)
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
</P>
</TD>
</TR>
</TABLE>
</EFX_CERTIFICATION>
<P STYLE="MARGIN: 0">
</P>
</EFX_EXHIBIT_31>

<DIV CLASS="eolNewPage"></DIV>
<A NAME="eolPage144"></A>
<A NAME="E615811_EX31-2_HTM"></A>
<EFX_EXHIBIT_31>
<A NAME="FIS_EXHIBIT_31_2"></A>
<P STYLE="MARGIN: 0">
	&nbsp;
</P>
<P STYLE="MARGIN: 0">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: RIGHT">
	Exhibit 31.2
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: RIGHT">
	&nbsp;
</P>
<EFX_CERTIFICATION>
<A NAME="FIS_CERTIFICATION_2"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	CERTIFICATION OF THE PRINCIPAL FINANCIAL
	OFFICER
<BR>
	PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	I, Brian Lenz, certify that:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 9PT">
</TD>
<TD STYLE="WIDTH: 18PT">
	1.
</TD>
<TD>
	I have reviewed this annual report on Form 10-K of ADMA Biologics, Inc. for the year ended December 31, 2016;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 9PT">
</TD>
<TD STYLE="WIDTH: 18PT">
	2.
</TD>
<TD>
	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact
	necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with
	respect to the period covered by this report;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 9PT">
</TD>
<TD STYLE="WIDTH: 18PT">
	3.
</TD>
<TD>
	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in
	all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods
	presented in this report;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 9PT">
</TD>
<TD STYLE="WIDTH: 18PT">
	4.
</TD>
<TD>
	The registrant&rsquo;s other certifying officer and I are responsible for establishing and maintaining disclosure controls
	and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined
	in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 45PT">
</TD>
<TD STYLE="WIDTH: 18PT">
	(a)
</TD>
<TD>
	Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our
	supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known
	to us by others within those entities, particularly during the period in which this report is being prepared;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 45PT">
</TD>
<TD STYLE="WIDTH: 18PT">
	(b)
</TD>
<TD>
	Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed
	under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of
	financial statements for external purposes in accordance with generally accepted accounting principles;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 45PT">
</TD>
<TD STYLE="WIDTH: 18PT">
	(c)
</TD>
<TD>
	Evaluated the effectiveness of the registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions
	about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on
	such evaluation; and
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 45PT">
</TD>
<TD STYLE="WIDTH: 18PT">
	(d)
</TD>
<TD>
	Disclosed in this report any change in the registrant&rsquo;s internal control over financial reporting that occurred during
	the registrant&rsquo;s most recent fiscal quarter (the registrant&rsquo;s fourth fiscal quarter in the case of an annual report)
	that has materially affected, or is reasonably likely to materially affect, the registrant&rsquo;s internal control over financial
	reporting; and
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 9PT">
</TD>
<TD STYLE="WIDTH: 18PT">
	5.
</TD>
<TD>
	The registrant&rsquo;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control
	over financial reporting, to the registrant&rsquo;s auditors and the audit committee of the registrant&rsquo;s board of directors
	(or persons performing the equivalent functions):
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 45PT">
</TD>
<TD STYLE="WIDTH: 18PT">
	(a)
</TD>
<TD>
	All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting
	which are reasonably likely to adversely affect the registrant&rsquo;s ability to record, process, summarize and report financial
	information; and
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 45PT">
</TD>
<TD STYLE="WIDTH: 18PT">
	(b)
</TD>
<TD>
	Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&rsquo;s
	internal control over financial reporting.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	February 24, 2017
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="BORDER-BOTTOM: BLACK 1PT SOLID">
<FONT STYLE="FONT-SIZE: 10PT">
	/s/ Brian Lenz
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 52%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 2%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 9%">
<FONT STYLE="FONT-SIZE: 10PT">
	Name:
</FONT>
</TD>
<TD STYLE="WIDTH: 37%">
<FONT STYLE="FONT-SIZE: 10PT">
	Brian Lenz
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Title:
</FONT>
</TD>
<TD>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Chief Financial Officer
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	(Principal Financial Officer)
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
</P>
</TD>
</TR>
</TABLE>
</EFX_CERTIFICATION>
<P STYLE="MARGIN: 0">
</P>
</EFX_EXHIBIT_31>

<DIV CLASS="eolNewPage"></DIV>
<A NAME="eolPage145"></A>
<A NAME="E615811_EX32-1_HTM"></A>
<EFX_EXHIBIT_32>
<A NAME="FIS_EXHIBIT_32"></A>
<P STYLE="MARGIN: 0">
	&nbsp;
</P>
<P STYLE="MARGIN: 0">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: RIGHT">
	Exhibit 32.1
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: RIGHT">
	&nbsp;
</P>
<EFX_CERTIFICATION>
<A NAME="FIS_CERTIFICATION_3"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	CERTIFICATION OF THE PRINCIPAL EXECUTIVE
	OFFICER
<BR>
	PURSUANT TO 18 U.S.C. SECTION 1350,&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	AS ADOPTED PURSUANT TO SECTION 906 OF THE
	SARBANES-OXLEY ACT OF 2002
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	In connection with the annual report of
	ADMA Biologics, Inc., a Delaware corporation (the &ldquo;Company&rdquo;) on Form 10-K for the year ended December 31, 2016, as
	filed with the Securities and Exchange Commission on the date hereof (the &ldquo;Report&rdquo;), I, Adam S. Grossman, President
	and Chief Executive Officer of the Company, hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section
	906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
	(1)
</TD>
<TD>
	The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended;
	and
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
	(2)
</TD>
<TD>
	The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations
	of the Company.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	February 24, 2017
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="BORDER-BOTTOM: BLACK 1PT SOLID">
	/s/ Adam S. Grossman
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 51%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 2%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 9%">
	Name:
</TD>
<TD STYLE="WIDTH: 38%">
	Adam S. Grossman
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	Title:
</TD>
<TD>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	President and Chief Executive Officer
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	(Principal Executive Officer)
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
</P>
</TD>
</TR>
</TABLE>
</EFX_CERTIFICATION>
<P STYLE="MARGIN: 0">
</P>
</EFX_EXHIBIT_32>

<DIV CLASS="eolNewPage"></DIV>
<A NAME="eolPage146"></A>
<A NAME="E615811_EX32-2_HTM"></A>
<EFX_EXHIBIT_32>
<A NAME="FIS_EXHIBIT_32_2"></A>
<P STYLE="MARGIN: 0">
	&nbsp;
</P>
<P STYLE="MARGIN: 0">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: RIGHT">
	Exhibit 32.2
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: RIGHT">
	&nbsp;
</P>
<EFX_CERTIFICATION>
<A NAME="FIS_CERTIFICATION_4"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	CERTIFICATION OF THE PRINCIPAL FINANCIAL
	OFFICER
<BR>
	PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	In connection with the annual report of
	ADMA Biologics, Inc., a Delaware corporation (the &ldquo;Company&rdquo;) on Form 10-K for the year ended December 31, 2016, as
	filed with the Securities and Exchange Commission on the date hereof (the &ldquo;Report&rdquo;), I, Brian Lenz, Chief Financial
	Officer of the Company, hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley
	Act of 2002, that, to my knowledge:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
	(1)
</TD>
<TD>
	The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended;
	and
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
	(2)
</TD>
<TD>
	The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations
	of the Company.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	February 24 , 2017
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="BORDER-BOTTOM: BLACK 1PT SOLID">
	/s/ Brian Lenz
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 52%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 2%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 9%">
	Name:
</TD>
<TD STYLE="WIDTH: 37%">
	Brian Lenz
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	Title:
</TD>
<TD>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Chief Financial Officer
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	(Principal Financial Officer)
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
</P>
</TD>
</TR>
</TABLE>
</EFX_CERTIFICATION>
<P STYLE="MARGIN: 0">
</P>
</EFX_EXHIBIT_32>

<!-- FOOTER LOGO -->
</BODY>
</HTML>
